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Abstract – Insights into the dynamics of methicillin-resistant staphylococci in animals 
– a focus on Staphylococcus pseudintermedius in dogs 
 
Staphylococci are a group of bacteria with clinical, agricultural, and economic importance be-
cause of their wide range of virulence factors and ability to become resistant to antimicrobi-
als.  
This thesis has pursued three main objectives:  
I. Determine the frequency of methicillin-resistant S. aureus (MRSA) strains in several 
animal species, identify the characteristics of strains present in animals and compari-
son with human strains 
MRSA nasal screening was performed in 71 horses and 307 calves, and the observed fre-
quencies were 3% and 2%, respectively. Seventy-four MRSA isolated from 2001 to 2014 
were characterized: fourteen spa types, three SCCmec types and three clonal complexes 
(CC) 5, CC22 and CC398, were found. Most isolates were multidrug-resistant. Fourteen 
MRSA CC398 strains had qac genes (13 qacG and 1 qacJ), while 4 isolates (three CC5 and 
one CC22) had insertions in the norA promoter gene. MRSA linages from pets (CC5 and 
CC22) harboured specific sets of virulence genes and a lower number of resistance genes 
than CC398 from livestock-animals. 
II. Reveal antimicrobial/biocide susceptibility patterns/trends and resistance genes in 
methicillin-resistant staphylococci (MRS) 
Several antimicrobial resistance patterns and genes were found in MRS from horses. Mini-
mum bactericidal concentrations of biocides chlorhexidine acetate, benzalkonium chloride, 
triclosan and glutaraldehyde were lower than the recommended in-use concentrations for 
veterinary medicine, although two MRS carried plasmid-borne qacA and sh-fabI or qacB and 
qacH-like genes. An investigation on the evolution of resistance to 38 antimicrobials, corre-
sponding mechanisms and molecular characteristics of 644 clinical Staphylococcus spp. iso-
lates obtained from companion animals between 1999-2014 revealed resistance to the ma-
jority of antimicrobials and the number of mecA-positive strains increased significantly over 
time. Considering S. pseudintermedius, the methicillin-susceptible (MSSP) were genetically 
more diverse than methicillin-resistant (MRSP). All MRSP and two MSSP strains were multi-
drug-resistant, with several antimicrobial resistance genes identified. One MSSP isolate har-
bored a qacA and another a qacB gene. Three biocide products had high bactericidal activity 
(Otodine®, Clorexyderm Spot Gel®, Dermocanis Piocure-M®), while Skingel® failed to 
achieve a five log reduction in the bacterial counting. 
III. Study of the pathogenesis of S. pseudintermedius in dogs 
The agr type III predominated in MRSP. Five virulence genes were found in all strains and 
only spsO gene was significantly associated with MSSP. MSSP produced more biofilm on 
BHIB and BHIB+1% glucose than MRSP isolates. Several virulence genes encoding surface 
proteins and toxins were highly expressed in the MRSP strain (compared to MSSP). By 
whole proteome characterization of S. pseudintermedius through 2DE MALDI-TOF/TOF MS 
approach we were able to identify 367 unique proteins, of which 39 were surface proteins. By 
subsequent use of the serological proteome analysis (SERPA) approach we identified 4 anti-
genic proteins with promising features for vaccine development. 
These results indicate that MRS were widely disseminated in the studied animal population, 
the environment and people in contact with these animals. The resistant trends and mecha-
nisms detected in MRS strains are worrying and make animals a reservoir of important MRS 
clones and genes. Biocides are still a good therapeutic choice, even in the presence of efflux 
genes. Higher expression of virulence genes may play a role in the rapid and widespread of 
MRSP clones. Dogs are able to mount an IgG-response against S. pseudintermedius and 
the proteins identified by the immune system can in the future be used as vaccine candi-
dates.  
 




Resumo – Estudo da dinâmica de estafilococos meticilina-resistente em animais – um 
foco no Staphylococcus pseudintermedius em cães 
Os estafilococos são um grupo de bactérias com importância clínica, agrícola e económica 
devido à ampla gama de fatores de virulência e pela sua capacidade de se tornarem resis-
tentes aos antimicrobianos. 
Esta tese debruçou-se sobre três objetivos principais: 
I. Determinar a frequência de estirpes S. aureus meticilina-resistente (MRSA) em di-
versas espécies animais, identificar as características das estirpes presentes em ani-
mais e comparar com estirpes humanas 
Colhemos zaragatoas de 71 cavalos e 307 vitelos para pesquisa de MRSA, e observaram-
se frequências de 3% e 2%, respetivamente. Foram caracterizadas setenta e quatro estirpes 
MRSA isoladas entre 2001-2014: catorze tipos de spa, três tipos de SCCmec e três comple-
xos clonais (CC) 5, CC22 e CC398, foram encontrados. A maioria das estirpes (74%) eram 
multirresistentes. Catorze estirpes de MRSA CC398 tinha genes qac (13 qacG e 1 qacJ), 
enquanto 4 (três CC5 e um CC22) tinham inserções no gene promotor norA. As linhagens 
de MRSA de animais de estimação (CC5 e CC22) tinham conjuntos específicos de genes de 
virulência e um menor número de genes de resistência do que as linhagens associadas aos 
animais de produção (CC398). 
II. Revelar padrões/ tendências de suscetibilidade antimicrobiana/biocida e genes de 
resistência em estafilococos meticilina-resistente (MRS) 
Foram encontrados vários padrões e genes de resistência antimicrobiana em MRS de cava-
los. As concentrações bactericidas mínimas dos biocidas acetato de clorhexidina, cloreto de 
benzalcónio, triclosan e glutaraldeído foram menores do que as recomendadas em medicina 
veterinária, embora dois MRS tivessem os genes plasmídicos qacA e sh-fabI ou qacB e um 
qacH-semelhante. Uma investigação sobre a evolução da resistência a 38 antimicrobianos, 
mecanismos correspondentes e características moleculares de 644 Staphylococcus spp. clí-
nicos obtidos de animais de companhia entre 1999-2014 revelou resistência à maioria dos 
antimicrobianos. O número de estirpes mecA-positivo aumentou significativamente ao longo 
do tempo. Quanto aos S. pseudintermedius, os meticilina-suscetível (MSSP) eram geneti-
camente mais diversos do que os meticilina-resistente (MRSP). Todos os MRSP e 2 MSSP 
eram multirresistentes, com vários genes de resistência identificados. Um MSSP tinha um 
gene qacA e outro um qacB. Três produtos biocidas tinham elevada atividade bactericida 
(Otodine®, Clorexyderm Spot Gel®, Dermocanis Piocure-M®), enquanto Skingel® não con-
seguiu atingir uma redução de 5 log na contagem bacteriana. 
III. Estudo da patogenicidade de S. pseudintermedius em cães 
O tipo III agr predominou nos MRSP. Cinco genes de virulência foram encontrados em todas 
as estirpes e só o gene spsO foi significativamente associado com MSSP. MSSP produziu 
mais biofilme em BHIB e BHIB + 1% glucose que as estirpes de MRSP. Vários genes de vi-
rulência que codificam proteínas e toxinas de superfície foram altamente expressos na estir-
pe MRSP (em comparação com MSSP). 
Através da caracterização do proteoma total de S. pseudintermedius pela abordagem 2DE 
MALDI-TOF/TOF MS fomos capazes de identificar 367 proteínas únicas, das quais 39 eram 
proteínas de superfície. Posteriormente utilizámos a análise do proteoma serológico 
(SERPA) que identificou quatro proteínas antigénicas com características promissoras para 
o desenvolvimento de vacinas. 
Estes resultados indicam que MRS estavam amplamente disseminados na população ani-
mal estudada, no ambiente e nas pessoas em contato com esses animais. As tendências de 
resistência e os mecanismos detetados em estirpes MRS são preocupantes tornando os 
animais um reservatório de clones MRS e genes. Os biocidas ainda são uma boa opção te-
rapêutica, mesmo na presença de bombas de efluxo. Uma maior expressão de genes de vi-
rulência pode desempenhar um papel na rápida expansão de clones de MRSP. Os cães fo-
ram capazes de montar uma resposta IgG contra S. pseudintermedius e as proteínas identi-
ficadas pelo sistema imunológico podem, no futuro, ser utilizadas como candidatos vacinais. 
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SIG – Staphylococcus intermedius group 
SLST – Single-locus sequence typing 
SLV – Single locus variant 
SMR – Small multidrug resistance family 
spa – Staphylococcal protein A 
SSTIs – Skin and soft tissue infections 
ST – Sequence type 
TSS – Toxic shock syndrome 
TSST – Toxic shock syndrome toxin 
UTIs – Urinary tract infections 































1.1 The taxonomy of staphylococci 
Staphylococci are a group of Gram-positive bacteria that were first described in 1880 by Sir 
Alexander Ogston (Ogston, 1882). The Staphylococcus genus includes at least 60 species 
and subspecies, divided into 2 major groups: coagulase-positive and coagulase-negative 
staphylococci (CoPS and CoNS, respectively) (Lamers, Muthukrishnan, Castoe, Tafur, Cole 
& Parkinson, 2012). This division is based on the production of an enzyme, coagulase, which 
promotes blood clot formation (Blair, 1962). Staphylococci are part of the normal flora of an-
imals and humans, however they have an opportunistic character (Fischetti, Novick, Ferreti, 
Portnoy & Rood, 2006). What turns staphylococci so interesting is their ability to live in per-
fect commensalism with their hosts and yet their ability to infect when the opportunity arises 
(Fischetti et al., 2006). Furthermore, staphylococci are not able to cause only one type of in-
fection; on the contrary they can originate a variety of diseases that can range from a simple 
pustule to a life-threatening endocarditis (Fischetti et al., 2006). Erstwhile, only CoPS were 
believed to cause disease and CoNS were thought to be non-pathogenic (Blair, 1962). Yet in 
our days almost all Staphylococcus species are known to be able to cause infections (Fisch-
etti et al., 2006). 
To date seven species of CoPS group have been identified: S. aureus, S. intermedius, S. 
schleiferi subsp. coagulans, S. hyicus, S. lutrae, S. delphini and S. pseudintermedius (Sasa-
ki, Tsubakishita, Tanaka, Sakusabe, Ohtsuka, Hirotaki, Kawakami, Fukata & Hiramatsu, 
2010). Within these species, S. aureus is considered the most important staphylococcal spe-
cies in human medicine due to its virulence and capacity to acquire/develop antimicrobial re-
sistance (Fischetti et al., 2006) and S. aureus and S. pseudintermedius in veterinary medi-
cine (Weese and van Duijkeren, 2010). Species identification is difficult when based on phe-
notypic methods, due to a lack of unique biochemical markers. Yet this discrimination is im-
portant because there are significant differences in species-specific antimicrobial break-
points, like for example, for oxacillin (Sasaki et al., 2010). Thus, molecular identification of 
the most important species, especially S. aureus, is preferred to biochemical methods (Sa-
saki et al., 2010). Within the S. intermedius group (SIG), constituted by S. intermedius, S. 
pseudintermedius and S. delphini, discrimination can only be achieved through molecular 
identification. However, in veterinary medicine it is generally accepted that all strains belong-
ing to the SIG from dogs are identified as S. pseudintermedius, unless genomic investiga-
tions prove that the strain belongs to another related species (van Duijkeren, Catry, Greko, 
Moreno, Pomba, Pyörälä, Ružaukas, Sanders, Threlfall, Torren-Edo & Törneke, 2011). 
CoNS are normal inhabitants of skin and mucous membranes of animals and humans (Piette 
& Verschraegen, 2009). CoNS have long been disdained as culture contaminants, even in 
samples obtained from a normally sterile site by needle aspiration or surgery (Piette & 
Verschraegen, 2009). Only in 1958, Smith and colleagues published the first report on the 
potential pathogenicity of CoNS in patients with septicemia (Smith, Beals, Kingsbury & Has-
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enclever, 1958). Yet, just in the 1970s, CoNS started to be recognized as etiologic agents of 
a wide variety of infections: bacteremia, central nervous system infection, endocarditis, uri-
nary tract infection, surgical site infections, endophthalmitis, foreign body infection and many 
other infections (Piette & Verschraegen, 2009). CoNS are normally sub grouped in novobi-
ocin-resistant species (S. cohnii, S. saprophyticus, S. sciuri and S. xylosus) and novobiocin-
susceptible species (S. auricularis, S. capitis, S. caprae, S. epidermidis, S. haemolyticus, S. 
hominis, S. lugdunensis, S. pasteuri, S. saccharolyticus, S. schleiferi, S. simulans and S. 
warneri) (von Eiff, Proctor & Peters, 2001). The best species identification method is by se-
quencing the tuf gene (Heikens, Fleer, Paauw, Florijn & Fluit, 2005). The most common 
CoNS species in human clinical samples are S. epidermidis (usually accounting for 50% of 
CoNS isolates), S. haemolyticus and S. hominis (Piette & Verschraegen, 2009), but several 
other species can also be found. In horses, cats, and dogs, CoNS are also the predominant 
species isolated from the skin (Lilenbaum et al., 1998; Schnellmann, Gerber, Rossano, 
Jaquier, Panchaud, Doherr, Thomann, Straub & Perreten, 2006; Schmidt, Williams, Pinch-
beck, Corless, Shaw, McEwan, Dawson & Nuttall, 2014). One important feature of CoNS is 
their high rates of antimicrobials resistance: e.g. in humans it is generally assumed that ap-
proximately 80% of nosocomial isolates and 30-40% of isolates obtained from healthy carri-
ers from the community are resistant to methicillin (Piette & Verschraegen, 2009). Meat and 
animal products are expected to be a significant reservoir of CoNS (Bhargava & Zhang, 
2014). 
S. agnetis and S. schleiferi are two species that include both CoPS and CoNS strains and 
are considered coagulase-variable staphylococci (Lamers et al., 2012). S. schleiferi is a well 
recognized human and veterinary pathogen and two subspecies have been identified: a co-
agulase-negative, S. schleiferi subsp. schleiferi, firstly isolated from humans; and a coagu-
lase-positive subspecies, S. schleiferi subsp. coagulans, initially isolated from dogs with otitis 
externa (May, Hnilica, Frank, Jones & Bemis, 2005). More recently both subspecies were 
found in human and animal clinical samples (May et al., 2005). 
Phylogenetic analysis suggests that staphylococcal species may be separated into six major 
staphylococcal species groups comprised of 15 refined cluster groups and this is shown in 
Figure 1 (Lamers et al., 2012). After this study was published, one novel species (and sever-
al subspecies) was identified from human clinical specimens S. petrasii, with phylogenetic re-
latedness, based on 16S ribosomal ribonucleic acid (rRNA), with the Haemolyticus cluster 
group species and S. lugdunensis (Pantůček, Švec, Dajcs, Machová, Černohlávková, Šedo, 
Gelbíčová, Mašlaňová, Doškař, Zdráhal, Růžičková & Sedláček, 2013). An overview of the 




Figure 1. Staphylococcal species groups and clusters by phylogenetic analysis based on multilocus data (adapted 




























































































































































































































1.2 Staphylococci: commensals and pathogens 
1.2.1 Staphylococci in humans 
There are several staphylococcal species colonizing and infecting humans (Table 1), howev-
er S. aureus is regarded as the most important due to its pathogenic potential and ecology 
(Fischetti et al., 2006). S. aureus is a normal commensal of up to 50% of the anterior nares 
of healthy humans, either persistently or transiently (Frank, Feazel, Bessesen, Price, Janoff 
& Pace, 2010). Both healthy people and those with underlying illness are at risk for diverse 
infection types: abscesses, skin and soft tissue infections (SSTIs), endocarditis, osteomyeli-
tis, meningitis, bacteraemia, urinary tract infections (UTIs), pneumonia and surgical site in-
fections (Fischetti et al., 2006). Also, exotoxins produced by S. aureus can cause bullous im-
petigo, staphylococcal food poisoning (SFP), scalded skin syndrome, necrotizing pneumonia 
and toxic shock syndrome (Fischetti et al., 2006). Colonization of the nares is a risk factor for 
subsequent S. aureus infection, especially hospital-acquired bacteraemia (von Eiff, Becker, 
Machka, Stammer & Peters, 2001; Davis, Stewart, Crouch, Florez & Hospenthal, 2004). 
 




Type of infection 
S. aureus Both 
Abscesses, SSTIs, endocarditis, osteomyelitis, meningitis, 
bacteraemia, UTIs, pneumonia, SFP, TSS and surgical site 
infections 
S. auricularis Both Bacteraemia 
S. capitis Both Bacteraemia, UTIs, wounds, prostatitis, endocarditis 
S. caprae Both 
UTIs, SSTIs, bacteraemia, endocarditis and surgical site in-
fections 
S. cohnii Both Bacteraemia, wounds 
S. condimenti Infection Bacteraemia 
S. epidermidis Both 
Infections associated with implants, bacteraemia, UTIs, 
wounds, meningitis 
S. equorum Infection Bacteraemia, meningitis, appendicitis 
S. gallinarum Infection Bacteraemia 
S. haemolyticus Both 
Infections associated with implants, bacteraemia, UTIs, 
wounds, meningitis, otitis, prostatitis 
S. hominis Both Bacteraemia, wounds, abscesses, pneumonia 
S. kloosi Infection Wounds 
S. lugdunensis Both Endocarditis, bacteraemia 
S. massiliensis Both Abscesses, wounds 
S. nepalensis Infection UTIs 
S. pasteuri Both UTIs, bacteraemia, SFP 
S. petrasii Infection Otitis, bacteraemia 
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S. pettenkoferi Both Bacteraemia, osteomyelitis 
S. pseudintermedius Both 
Dog bite wounds, rhino sinusitis, bacteraemia, SFP, infections 
associated with implants 
S. saccharolyticus Infection Endocarditis, bacteraemia 
S. saprophyticus Both UTIs, bacteraemia, endocarditis 
S. schleiferi Infection Infections associated with implants 
S. sciuri Infection Wounds, SSTIs, abscesses, peritonitis, endocarditis, 
S. simulans Both UTIs, osteomyelitis, bacteraemia, endocarditis 
S. succinus Infection Conjunctivitis, wounds 
S. warneri Both Meningitis, wounds, endocarditis, bacteraemia 
S. xylosus Both Bacteraemia, wounds, endocarditis, pneumonia 
 
S. epidermidis, S. haemolyticus and S. hominis are the most frequently encountered CoNS 
species in human clinical samples (Piette & Verschraegen, 2009). S. epidermidis colonizes 
the skin and mucous membranes of humans and usually represents the major colonizer of 
these habitats (Vuong & Otto, 2002). As with the other staphylococci, S. epidermidis requires 
a predisposed host in order to cause infection (Vuong & Otto, 2002). An important virulence 
factor of S. epidermidis is the capacity to produce biofilm, allowing adhesion and perma-
nence of bacteria on medical devices (catheters, prosthesis, etc.) and protection against the 
action of antimicrobials and the immune system (Piette & Verschraegen, 2009). S. haemolyt-
icus is the second CoNS in its frequency of isolation from human blood cultures (Takeuchi, 
Watanabe, Baba, Yuzawa, Ito, Morimoto, Kuroda, Cui, Takahashi, Ankai, Baba, Fukui, Lee & 
Hiramatsu, 2005). S. haemolyticus is a normal commensal of the human skin microbiota, es-
pecially in areas where apocrine glands are found like the axillae, perineum and the inguinal 
area (Kloos & Bannerman, 1994). It is notorious for its multidrug resistance and historically 
early acquisition of resistance to methicillin and glycopeptide antimicrobials (Froggatt, John-
ston, Galetto & Archer, 1989). This unusual presence of antimicrobial resistance genes is 
due to the extreme plasticity of its genome, given by the presence of many insertion se-
quence elements conferring frequent genomic rearrangements (Takeuchi et al., 2005). 
S. saprophyticus is the second most frequent causative organism, after Escherichia coli, of 
uncomplicated UTI in women (Piette & Verschraegen, 2009). The vast majority of S. sapro-
phyticus infections occur in young, sexually active women, but it can also cause UTI in males 
of all ages (Raz, Colodner & Kunin, 2005; Piette & Verschraegen, 2009). The urease of S. 
saprophyticus has been shown to contribute to its uropathogenicity as a major factor for in-
vasiveness in bladder tissue (Hjelm & Lundell-Etherden, 1991). Furthermore, S. saprophyti-
cus produces slime in urine and this slime production may be a risk factor for development of 
urinary stones, especially in concentrated urine in which the urea concentration is high 
(Hjelm & Lundell-Etherden, 1991). Interestingly, S. saprophyticus can be pathogenic in low 
numbers (<105 CFU/ml) (Rupp & Archer, 1994) and is probably often missed as causative 
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organism of UTIs, because if the bacterial counts are low, then the bacteriuria is considered 
non-significant (Piette & Verschraegen, 2009). The major reservoir of S. saprophyticus is the 
gastrointestinal tract (Piette & Verschraegen, 2009).  
Several other CoNS are also associated with humans (Fischetti et al., 2006): for example S. 
auricularis, in conjunction with S. capitis, constitute the predominant Gram-positive, catalase-
positive cocci inhabiting human ears (Kloos & Bannerman, 1994); S. hominis is a normal 
commensal of the human skin microbiota, especially in the axillae, perineum and inguinal ar-
eas of humans, areas where apocrine glands are found (Kloos & Bannerman, 1994); S. lug-
dunensis is a natural colonizer of humans, and is widely distributed over the body in small 
populations (Kloos & Bannerman, 1994); and S. massiliensis was firstly isolated from a hu-
man brain abscess (Masalma, Raoult & Roux, 2010) and later was proposed as a compo-
nent of normal human skin microflora (Zong, 2012). CoNS infections in humans are becom-
ing incredibly difficult to treat due to the high levels of antimicrobial resistance (Piette & 
Verschraegen, 2009). 
Humans are not the natural host of S. pseudintermedius, but people exposed to animals, like 
owners and veterinary professionals, can become colonized/infected (Bond & Loeffler, 2012). 
The importance of this species as a zoonotic pathogen is less than that of S. aureus (Weese 
& van Duijkeren, 2010; van Duijkeren et al., 2011). However, although rare there are some 
reported cases of infection in humans, like for example, rhino sinusitis, bacteraemia and in-
fections associated with implants (Stegmann, Burnens, Maranta & Perreten, 2010; Van 
Hoovels, Vankeerberghen, Boel, Van De Beenhouwer & Vaerenbergh, 2006; Chuang, Yang, 
Hsueh & Lee, 2010; Riegel, Jesel-Morel, Laventie, Boisset, Vandenesch & Prévost, 2011). In 
these cases, the origin of the strain was unknown but the person infected had contact with 
dogs (Chuang et al., 2010; Riegel et al., 2011), but as S. pseudintermedius was not 
searched in them, the zoonotic transmission was not proven (van Duijkeren et al., 2011).  
 
1.2.2 Staphylococci in animals 
Staphylococcus species have variable relevance in veterinary medicine, however, the most 
clinically relevant are the coagulase positive S. aureus and members of the S. intermedius 
group (SIG), particularly S. pseudintermedius (Weese and van Duijkeren, 2010). 
 
1.2.2.1 Staphylococci in companion animals (dogs, cats and horses) 
S. aureus has adapted in different animal species, including companion animals (Haenni, 
Targant, Forest, Sévin, Tapprest, Laugier, Madec, 2010; Weese and van Duijkeren, 2010). 
Wound infections, surgical site infections, pyoderma, otitis and UTIs are most commonly re-
ported, but opportunistic infections at various other body sites can occur (Weese and van 
Duijkeren, 2010). In horses it can also cause sepsis, respiratory tract infections, and genital 
tract infections (Haenni et al., 2010).  
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S. pseudintermedius is a normal inhabitant of the skin and mucosa and can be isolated from 
the nares, mouth, pharynx, forehead, groin and anus of healthy dogs and cats (van Duijkeren 
et al., 2011). The anal region and the nose are colonized more frequently than other areas in 
healthy dogs (van Duijkeren et al., 2011). It is an opportunistic pathogen and a leading cause 
of pyoderma and otitis, infections of other body tissues and cavities, UTIs and post-operative 
wound infections in dogs and cats (Pomba, Couto & Moodley, 2010a; van Duijkeren et al., 
2011). S. pseudintermedius is notoriously known for its ability to cause secondary infections 
in dogs with atopic dermatitis, an allergic skin disease, which leads to skin modifications that 
predispose for secondary infections (Nuttall, Uri & Halliwell, 2013).  
S. schleiferi subsp. coagulans cause otitis and pyoderma in dogs, and rarely may be isolated 
from cats or birds (Davis, Cain, Brazil & Rankin, 2013). Prevalence from skin, nares, mouth, 
or perianal carriage in the absence of disease is low, typically ≤2%, but is higher among dis-
eased pets (Davis et al., 2013). Of concern is the propensity for clinical isolates to be methi-
cillin resistant, with many veterinary studies in the last decade reporting rates of 50% or 
higher (Davis et al., 2013).  
CoNS are also important opportunistic pathogens in companion animals. S. felis is the most 
common staphylococci isolated from the skin surface of clinically normal cats (Lilenbaum et 
al., 1998), and has been associated with a variety of infections such as external otitis, cysti-
tis, abscesses, wounds, and other skin infections (Igimi, Kawamura, Takahashi & Mitsuoka, 
1989). S. epidermidis and S. haemolyticus can also colonize and cause infections in domes-
tic mammals (Schmidt et al., 2014). S. lentus, S. fleurettii, and S. vitulinus can also be colo-
nizers of dog’s skin (Schmidt et al., 2014), while S. equorum comprises strains isolated from 
the skin of healthy horses (Schleifer, Kilpper-Bälz & Devriese, 1984). 
 
1.2.2.2 Staphylococci in food-producing animals 
Staphylococci can cause a variety of infections in food-producing animals, including bovine, 
ovine and caprine mastitis and exudative epidermitis in pigs (Fischetti et al., 2006). Bovine 
mastitis is the main cause of economic loss in milk production worldwide and S. aureus is the 
etiological agent more commonly associated with the disease and is normally related to sub-
clinical or chronic infections (Pereira, Oliveira, Mesquita, Costa & Pereira, 2011). The role of 
the CoNS in bovine mastitis has come under increased scrutiny in recent years, and CoNS 
are among the most commonly isolated bacteria from heifers before and after parturition as 
well as from lactating cows (Aarestrup, Larsen & Jensen, 1999) In general, the most com-
monly isolated CoNS species from cases of bovine mastitis worldwide seems to be S. chro-
mogenes, S. epidermidis and S. simulans (Aarestrup et al., 1999). S. chromogenes was ac-
tually the predominant CoNS species from bovine mastitis in Germany between 2003 and 
2009 (Feβler, Billerbeck, Kadlec & Schwarz, 2010). Mastitis caused by CoNS is very mild 
and usually remains subclinical (Pyörälä & Taponen, 2009). However, the significance of 
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CoNS needs to be reconsidered, as in many countries they have become the predominant 
mastitis-causing agents (Pyörälä & Taponen, 2009). 
In pigs S. hyicus is the main cause of exudative epidermitis (Tanabe, Sato, Sato, Watanabe, 
Hirano, Hirose, Kurokawa, Nakano, Saito & Maehara, 1996). Furthermore, S. hyicus has 
been isolated from animals with septic polyarthritis and bovine mastitis (Phillips, King & 
Kloos, 1980; Roberson, Fox, Hancock, Gay & Besser, 1996). Only a few cases of human in-
fection have been published, namely, a wound infection after a donkey bite and bacteraemia 
in a farmer, in which the patients’ close contact with piglets was the presumed source of in-
fection (Osterlund & Nordlund, 1997; Casanova, Iselin, von Steiger, Droz & Sendi, 2011).  
S. chromogenes is closely related to S. hyicus (Andresen, Ahrens, Daugaard & Bille-Hansen, 
2005). S. chromogenes is part of the normal skin flora of pigs, cattle and poultry and has so 
far been considered non-pathogenic to pigs however, strains of S. chromogenes producing 
exfoliative toxin type B, ExhB, have been found as a cause of exudative epidermitis in pigs 
(Andresen et al., 2005). S. aureus can also cause exudative epidermitis in pigs (Pomba, 
Baptista, Couto, Loução & Hasman, 2010b). S. rostri is a recently described Staphylococcus 
species that is present in the nasal cavity of healthy pigs alone or in combination with S. au-
reus (Stegmann & Perreten, 2010). S. rostri can carry several antimicrobial resistance genes 
similar to S. aureus (Stegmann & Perreten, 2010). 
S. caprae is the predominant species among the staphylococci recovered from mastitis-free 
goats' milk, as they colonize the healthy udder’s skin (Devriese, Poutrel, Killper-Bälz & 
Schleifer, 1983; Bedidi-Madani, Kodjo, Villard & Richard, 1998). S. gallinarum is a staphylo-
coccal species, whose natural host is birds: it was first described as a colonizer of chickens 
and a pheasant (Devriese et al., 1983), and more recently from a Buteo buteo (Sousa, Silva, 
Igrejas, Silva, Sargo, Alegria, Benito, Gómez, Lozano, Gómez-Sanz, Torres, Caniça & Po-
eta, 2014). 
 
1.2.2.3 Staphylococci in other animals 
Staphylococci can also colonize/infect several other species: S. delphini has been isolated 
from dolphins, minks, horses, cows and pigeons; S. lutrae isolated from otters; S. intermedi-
us isolated from pigeons (Foster, Ross, Hutson & Collins, 1997; Ben Zakour, Beatson, van 
den Broek, Thoday & Fitzgerald, 2012); S. muscae was obtained from the body surfaces of 
flies caught in certain cowsheds but not on flies caught in human dwellings, stables, or pig-
geries and this bacterium was regarded as a transient rather than a resident on flies (Hájek, 
Ludwig, Schleifer, Springer, Zitzelsberger, Kroppenstedt & Kocur, 1992); S. microti was iso-
lated from the common vole (Microtus arvalis) in 2010 (Nováková, Pantůcek, Hubálek, 
Falsen, Busse, Schumann & Sedlácek, 2010) and it was not reported ever since; S. simiae is 
a recently described species, isolated during an outbreak of diarrhoeal disease in squirrel 
monkeys in a zoo where staphylococcal strains with atypical features were isolated from both 
 12 
ill and healthy animals (Pantůček, Sedláček, Petráš, Koukalová, Švec, Štětina, Vancanneyt, 
Chrastinová, Vokurková, Růžičková, Doškař, Swings & Hájek, 2005); S. stepanovicii has 
been isolated from wild small mammals (Hauschild, Stepanović & Zakrzewska-Czerwińska, 
2010); and S. warneri resides in the skin epidermis of rainbow trout (Oncorhynchus mykiss) 
(Musharrafieh, Tacchi, Trujeque, LaPatra & Salinas, 2014). 
 
1.2.2.4 Staphylococci in food products 
Strains of the Simulans-Carnosus cluster group are commonly isolated from fermented foods 
(Tanasupawat, Hashimoto, Ezaki, Kozaki & Komagata, 1991). S. carnosus was originally iso-
lated from fermenting sausages (Schleifer & Fischer, 1982). It has been shown that they ex-
ert positive effects on the formation of flavour and reddening reaction and therefore strains of 
this species are used as common components in starter cultures for the production of fer-
mented sausage and cured ham (Hammes, Bosch & Wolf, 1995). S. piscifermentans was 
isolated in 1992 from fermented fish in Thailand (Tanasupawat, Hashimoto, Ezaki, Kozaki & 
Komagata, 1992). S. condimenti, can be isolated from fermented fish, shrimp sauces and 
soy sauce mash (Tanasupawat et al., 1991). S. carnosus, S. condimenti, S. piscifermentans, 
S. equorum, S. succinus and S. xylosus can be used as starter cultures for a variety of foods 
(Resch, Nagel & Hertel, 2008). S. haemolyticus and S. hominis can also be found in food of 
animal origin (Bhargavaa & Zhang, 2014). S. succinus subsp. casei has been obtained from 
the surface of ripened cheese (Nováková, Sedlácek, Pantůcek, Stetina, Svec & Petrás, 
2006b).  
S. saprophyticus has been isolated from rectal swabs taken from carcasses of cattle and 
pigs (Hedman, Ringertz, Lindstrom & Olsson, 1993). It was also found to contaminate 16% of 
various food samples in Sweden, with a high prevalence of 34% in samples of raw beef and 
pork (Hedman, Ringertz, Eriksson, Kvarnfors, Andersson, Bengtsson & Olsson, 1990). S. 
saprophyticus from food has been shown to carry qac genes (smr and qacH) and have been 
reported to produce enterotoxins (Heir, Sundheim & Holck, 1999).  
S. warneri can be isolated from bovine milk and carry a high percentage of enterotoxin genes 
(de Freitas Guimarães, Nóbrega, Richini-Pereira, Marson, de Figueiredo Pantoja & Langoni, 
2013). S. warneri and S. pasteuri isolated from milk often carry qac-efflux pumps (Bjorland, 
Steinum, Kvitle, Waage, Sunde & Heir, 2005). S. auricularis has been found in ready-to-eat 
fish and bovine milk, but usually do not carry any enterotoxin genes (de Freitas Guimarães et 
al., 2013; Sergelidis, Abrahim, Papadopoulos, Soultos, Martziou, Koulourida, Govaris, Pexa-
ra, Zdragas & Papa, 2014). S. xylosus is commonly present in raw meat and milk and is used 




1.2.2.5 Staphylococci in the environment 
S. xylosus can persist in soils and on surfaces (Shale, Lues, Venter & Buys, 2006). One of 
the reasons they can persist is explained by its ability to form biofilms and the ability to adapt 
to different environments (Planchon, Gaillard-Martinie, Dordet-Frisoni, Bellon-Fontaine, 
Leroy, Labadie, Hebraud & Talon 2006; Dordet-Frisoni et al., 2007). 
S. arlettae has two interesting properties: degrade textile azo dyes and promote plant growth 
and have been isolated from textile and tannery industrial effluents, respectively (Franciscon, 
Zille, Dias, Ragagnin, Durrant & Cavaco-Paulo, 2009; Sagar, Dwivedi, Yadav, Tripathi & 
Kaistha, 2012). 
CoNS may also colonize water destined to human consumption, even when the quality 
standards for drinking water are fulfilled (Faria, Vaz-Moreira, Serapicos, Nunes & Manaia, 
2009). The majority of the strains isolated from the drinking water distribution network belong 
to the species S. pasteuri, which has widespread distribution in food and environment, and 
may represent a relevant antimicrobial resistance reservoir, mainly in habitats with restrictive 
conditions (e.g. anaerobiosis) and reduced staphylococcal diversity (Faria et al., 2009). 
 
1.3 Staphylococal virulence factors 
Staphylococci are able to produce a wide range of virulence factors (Figure 3), enabling the-
se species to infect the host (Fischetti et al., 2006). In this thesis, only the most relevant viru-
lence factors will be reviewed. 
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The capsule is composed of capsular polysaccharides and is a cell wall bacterial component 
that protects the bacteria from being phagocyted, enhancing staphylococcal virulence (Ver-
dier, Durand, Bes, Taylor, Lina, Vandenesch, Fattom & Etienne, 2007). The capsule ham-
pers the interaction between cell wall-bound C3b or immunoglobulin and receptors for these 
molecules on the phagocytic cell, resulting in bacterial evasion to the phagocytic uptake 
(O’Riordan & Lee, 2004). In the presence of antibodies specific for the capsule, C3b and an-
tibody are deposited throughout the capsular matrix and on the bacterial surface, making 
them available for recognition by receptors on the phagocyte (Verbrugh, Peterson, Nguyen, 
Sisson & Kim, 1982). In the presence of specific capsular antibodies, mucoid strains are effi-
ciently taken up by phagocytes and killed in vitro (Verbrugh et al., 1982). There are 11 cap-
sular polysaccharide types but only two, types 5 and 8 (CP5 and CP8, respectively), are 
common in clinical isolates (Arbeit, Karakawa, Vann & Robbins, 1984; Verdier et al., 2007). 
Strains of serotypes 1 and 2, although rare, are heavily encapsulated (O’Riordan & Lee, 
2004). Strains belonging to the remaining serotypes produce non-mucoid colonies on solid 
medium in vitro, and their colony morphology is indistinguishable from that of strains lacking 
a capsule (O’Riordan & Lee, 2004). Expression of S. aureus CP5 and CP8 in vitro is highly 
sensitive to various environmental signals and is probably influenced by the in vivo environ-


















EXI directly degrades the extracellular domains of
Dsg1 in a species-specific manner
To further determine whether EXI selectively and directly
degraded the extracellular domain of canine Dsg1, recom-
binant proteins of the entire extracellular domain of
canine Dsg1 and Dsg3 produced in baculovirus were
incubated with purified EXI in vitro. Immunoblot analysis
of the mixtures was performed to detect intact and ⁄or
degraded canine Dsgs. As shown in Figure 3a, recombi-
nant canine Dsg1 was degraded to a smaller peptide
in vitro by incubation with EXI, while recombinant canine
Dsg3 was not degraded by the presence of EXI. In
contrast, SIET degraded neither cDsg1 nor cDsg3
(Figure 3a).
Whether EXI degraded Dsg1 in a species-specific













Figure 2. Recombinant EXI, but not SIET, causes intraepidermal splitting and abolishes immunofluorescence for Dsg1 in canine skin. A normal
dog was injected intradermally with recombinant EXI (a, d, g, j and m), SIET (b, e, h, k and n) or phosphate-buffered saline (PBS; c, f, i, l and o). The
skin samples were collected from injection sites and processed for routine histopathological (d–f) and immunofluorescence analyses (g–o).
Recombinant EXI causes erosion at 24 h after injection (a), and histopathology of intraepidermal splitting (d) with abolished immunofluorescence
for Dsg1 (g) at 12 h after injection. Conversely, immunofluorescence for Dsg3 was not altered by the presence (i) or absence of EXI (l). Note that
Dsg1 is expressed without co-expression of Dsg3 in superficial epidermis of canine skin (o). SIET or PBS did not cause any changes in clinical
(b and c) and histopathological findings (e and f) as well as immunofluorescence for Dsgs (h, i, k and l). Scale bar represents 25 lm. Arrowheads
(g–o) indicate basement membrane zone.
ª 2011 The Authors. Veterinary Dermatology










tract, alkaline growth conditions, and anaerobiosis (Stringfellow, Dassy, Lieb & Fournier, 
1991) but enhanced by growth of the bacterium in milk (Sutra, Rainard & Poutrel, 1990), un-
der iron limitation and on solid medium (Lee, Takeda, Livolsi & Paoletti, 1993) or in medium 
supplemented with up to 5% NaCl (Pohlmann-Dietze, Ulrich, Kiser, Doring, Lee, Fournier, 
Botzenhart & Wolz, 2000). S. aureus CP5 and CP8 are able to modulate abscess formation 
in an experimental rat model of intra-abdominal infection (Tzianabos, Wang & Lee, 2001). 
The capsule is also expressed in several models of infection, including endocarditis, subcu-
taneous infections and mastitis (Arbeit & Dunn, 1987; Lee et al., 1993; Hensen, Pavicić, Lo-
huis, de Hoog & Poutrel, 2000). 
 
1.3.2 Enterotoxins 
Enterotoxins were originally defined by their ability to cause staphylococcal food poisoning 
including emesis, and currently include the enterotoxins A, B, C, D, E, G, H, I, K, L, M, N, O, 
P, R, and T (Xu & McCormick, 2012; Omoe, Hu, Ono, Shimizu, Takahashi-Omoe, Nakane, 
Uchiyama, Shinagawa & Imanishi, 2013). The enterotoxin-like toxins, although both homolo-
gous and structurally similar to the enterotoxins, either do not induce emesis, or have not 
been formally demonstrated to induce emesis, and include the J, Q, S, U, V, and X (Xu & 
McCormick, 2012). Some enterotoxins have variants, for example SEC variants are sec1, 
sec2, sec3, secMNCopeland, sec4446, secbovine, seccanine and secovine (Marr, Lyon, Roberson, Lu-
pher, Davis & Bohach, 1993; Edwards, Deringer, Callantine, Deobald, Berger, Kapur, Stauff-
acher & Bohach, 1997; Fitzgerald, Monday, Foster, Bohach, Hartigan, Meaney & Smyth, 
2001). SIG species genomes encode another enterotoxin called Se-int (Futagawa-Saito, Su-
zuki, Ohsawa, Ohshima, Sakurai, Ba-Thein & Fukuyasu, 2004). Enterotoxins are active in 
high nanogram to low microgram quantities (Evenson, Hinds, Bernstein & Bergdoll, 1988), 
and are resistant to heat treatment and low pH that easily destroy the bacteria that produce 
them, and to proteolytic enzymes, hence retaining their activity in the digestive tract after in-
gestion (Evenson et al., 1988). The actual mechanisms behind the emetic activity are poorly 
understood, but appear to involve the serotonin pathway (Hu, Zhu, Mori, Omoe, Okada, 
Wakabayashi, Kaneko, Shinagawa & Nakane, 2007). SFP is one of the most common food-
borne diseases in the world following the ingestion of staphylococcal enterotoxins that are 
produced by enterotoxigenic strains of CoPS, mainly S. aureus (Jablonski & Bohach, 1997) 
and very occasionally by other staphylococci species such as S. intermedius (Genigeorgis, 
1989; Khambaty, Bennett & Shah, 1994). However, CoNS can also produce enterotoxins 
(Crass & Bergdoll, 1986). Fourteen countries reported 346 outbreaks caused by staphylo-
coccal toxins, representing 6% of all outbreaks reported in the European Union in 2012 
(EFSA & ECDC, 2014). Food handlers carrying enterotoxin-producing S. aureus in their nos-
es or on their hands are regarded as the main source of food contamination, via manual con-
tact or through respiratory secretions (Argudín, Mendonza & Rodicio, 2010). Symptoms of 
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SFP have a rapid onset (2-8 h), and include nausea, violent vomiting, and abdominal cramp-
ing with or without diarrhoea (Murray, 2005). The disease is usually self-limiting and typically 
resolves within 24-48 h after onset but occasionally it can be severe enough to warrant hos-
pitalization, particularly when infants, elderly or debilitated people are concerned (Murray, 
2005). 
Most genes coding for enterotoxins are located on mobile elements such as plasmids, bacte-
riophages or pathogenicity islands (Madhusoodanan, Seo, Remortel, Park, Hwang, Fox, 
Park, Deobald, Wang, Liu, Daugherty, Gill, Bohach & Gill, 2011; Suzuki, Kubota, Sato'o, 
Ono, Kato, Sadamasu, Kai & Kamata, 2015). One such element is the bovine pathogenicity 
island that encodes the three superantigens SECbovine, TSST-1 and SEL (Fitzgerald et al., 
2001). The enterotoxin gene cluster (egc) comprises the five enterotoxin genes seg, sei, sem, 
sen and seo (Jarraud, Peyrat, Lim, Tristan, Bes, Mougel, Etienne, Vandenesch, Bonneville & 
Lina, 2001). 
Staphylococcal enterotoxins and staphylococcal enterotoxin-like proteins can also be su-
perantigens (Lina, Bohach, Nair, Hiramatsu, Jouvin-Marche & Mariuzza, 2004). Superanti-
gens are secreted proteins that interact with antigen-presenting cells and T lymphocytes to 
induce cellular proliferation and high-level cytokine expression (Fast, Schlievert & Nelson, 
1988; Kotb, 1995; Pinchuk, Beswick & Reyes, 2010). This process occurs as enterotoxins in-
teract simultaneously with the major histocompatibility complex (MHC) class II molecule of 
the antigen-presenting cells and the Vβ domain of the lymphocyte T-cell receptor, forming 
trimolecular complexes (Figure 4) (Kotb, 1995). This interaction activates a much greater 
percentage of host T-cell repertoire than that induced by antigens presented in a normal 
manner (Xu & McCormick, 2012). This explains the massive cytokine expression and subse-
quent immunomodulation provided by these toxins (Xu & McCormick, 2012). 
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Figure 4. Interaction between enterotoxins and host cells (adapted from Pinchuk et al., 2010).  
 
 
Some enterotoxins can also be involved in other staphylococcal syndromes besides food 
poisoning. Enterotoxins A to E, G and I can also be involved in staphylococcal toxic shock 
syndrome and staphylococcal scarlet fever (Schlievert, 1986; Yagoob, McClelland, Murray, 
Mostafa & Ahmad, 1990; Lina, Gillet, Vandenesch, Jones, Floret & Etienne, 1997; Jarraud, 
Cozon, Vandenesch, Bes, Etienne & Lina, 1999). 
 
1.3.3 Leukocidins 
Leukocidins are bi-component toxins encoded by several genetic loci (Fischetti et al., 2006). 
Leukocidins are two synergistically acting subunits consisting of S (slow) and F (fast) poly-
peptides, named after their electrophoretic mobility (Vandenesch, Lina & Henry, 2012). De-
pending on the combination of particular S and F polypetides, a toxin is formed with varying 
leukocytolytic, erythrocytolytic, and dermonecrotic properties (Vandenesch et al., 2012). In 
addition to neutrophils, the bi-component toxins are active against monocytes and macro-
phages (Vandenesch et al., 2012). They are pore-forming toxins and include (i) γ-haemolysin 
corresponding to two combinations of an S component (HlgA or HlgC) with an F component 
T cell 
α1     β1 
α2     β2 
Enterotoxin 
αC    βC 
αV     βV 
Antigen-presenting cell 
T cell receptor 
MHC class II 
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(HlgB); (ii) the Panton-Valentine leukocidin (PVL), made of LukS-PV and LukF-PV; (iii) 
LukED; and (iv) LukGH, also known as LukAB (Vandenesch et al., 2012). PVL and γ-
hemolysin are extremely potent, while LukAB/GH and lukED are active at concentrations 
100-fold higher (Vandenesch et al., 2012). The bi-component toxins are largely considered to 
be secreted proteins (Vandenesch et al., 2012). LukGH/AB was identified both as a secreted 
protein and as one of the predominant surface protein of S. aureus, suggesting that this leu-
kotoxin might be involved in targeting immune cells when they are in direct contact with the 
bacterium, such as during phagocytosis (Vandenesch et al., 2012). While γ-hemolysin, 
LukED and LukAB/GH are highly prevalent in S. aureus strains; PVL is produced only by 2 to 
3% of the strains (Vandenesch et al., 2012). PVL is uncommonly found in methicillin-
susceptible S. aureus (MSSA) and hospital-acquired (HA)-methicillin-resistant S. aureus 
(MRSA) isolates, but is associated with community-acquired MRSA (CA-MRSA) strains, 
which explains the frequency of primary skin infections and occasionally necrotizing pneu-
monia associated with these strains (Vandenesch, Naimi, Enright, Lina, Nimmo, Heffernan, 
Liassine, Bes, Greenland, Reverdy & Etienne, 2003). Various lukS/lukF-PV-transducing 
phages have been described, making PVL genes easily horizontally transmittable 
(Vandenesch et al., 2012). 
S. pseudintermedius, S. intermedius and S. delphini may produce the bi-component leuko-
toxin Luk-I, made of LukF-I and LukS-I components (Prevost, Bouakham, Piemont & Monteil, 
1995). Luk-I shows a strong leukotoxicity on various polymorphonuclear cells, but only a 
slight haemolytic activity on rabbit erythrocytes (Prevost et al., 1995).  
 
1.3.4 Haemolysins 
α-Haemolysin, like leukocidins, is also a pore-forming toxin (Vandenesch et al., 2012). Rabbit 
erythrocytes are highly sensitive to α-haemolysin-mediated lysis, but human erythrocytes are 
much less sensitive (Vandenesch et al., 2012). Furthermore, while human lymphocytes and 
monocytes are α-haemolysin-susceptible cells, granulocytes are highly resistant to lysis by 
this protein (Vandenesch et al., 2012). 
β-Haemolysin does not form pores in the plasma cell membrane but instead is a neutral 
sphingomyelinase C hydrolysing sphingomyelin, which is a plasma membrane lipid 
(Vandenesch et al., 2012). β-haemolysin’s enzymatic activity is required for its haemolytic ac-
tivity (Vandenesch et al., 2012). S. pseudintermedius and S. delphini are also able to pro-
duce β-haemolysin (Ben Zakour et al., 2012). 
δ-Haemolysin is a small amphipathic (one hydrophobic and one hydrophilic side) peptide (26 
AA) with a α-helix structure. Belongs to a family of small cytotoxic amphipathic peptides 
termed phenol-soluble modulines (PSMs) that were first identified in S. epidermidis and sub-
sequently in S. aureus (Vandenesch et al., 2012). Two families of PSMs have been de-
scribed based on their length: PSMα, including δ-haemolysin, PSMα1–4, and PSM-mec, 
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which are 20–26 aminoacids long; and PSMβ, including PSMβ1 and PSMβ2 that are 44 ami-
noacids long (Vandenesch et al., 2012). Three different mechanisms have been proposed to 
explain its haemolytic activity: δ-haemolysin could (i) bind to the cell surface and aggregate 
to form transmembrane pores; (ii) bind to the cell surface and disturb the membrane curva-
ture, thus destabilizing the plasma membrane; or (iii) at high concentration, act as a deter-
gent to solubilize the membrane (Vandenesch et al., 2012). 
 
1.3.5 Exfoliative toxins 
Staphylococcus species produce a variety of exfoliative toxins that induce different diseases 
in humans and animals (Terauchi, Sato, Endo, Aizawa & Maehara, 2003). In humans, staph-
ylococcal scalded skin syndrome and bullous impertigo are caused by infection with S. aure-
us strains that produce exfoliative toxin A (ETA), B (ETB), or both (Kondo, Sakurai, Sarai & 
Futaki, 1975; Amagai, Yamaguchi, Hanakawa, Nishifuji, Sugai & Stanley, 2002). The gene 
encoding ETA is located on the chromosome whereas the gene encoding ETB is found on a 
large plasmid (Amagai et al., 2002). The two proteins specifically cleave desmoglein 1 as 
showed in Figure 5 (Amagai et al., 2002; Bukowski, Wladyka & Dubin, 2010). 
 
Figure 5. Schematic representation of the desmoglein distribution in (A) healthy skin and (B) skin exposed to exfo-
liative toxin (adapted from Bukowski et al., 2010). 
 
In S. hyicus four exfoliative toxins have been identified (Exfoliative Toxin Types A, B, C, and 
D). These toxins present in certain strains of S. hyicus enable the bacterium to cause a gen-
eralized skin disease named exudative epidermitis in pigs (Ahrens & Andresen, 2004). Exu-
dative epidermitis is characterized by separation of the cells in the epidermis in the upper 
stratum spinosum, exfoliation of the skin, erythema, and serous exudation (Ahrens & An-
dresen, 2004). S. pseudintermedius strains can also produce exfoliative toxins named SIET 
(Staphylococcus intermedius exfoliative toxin) and EXI (Terauchi et al., 2003; Iyori, Futaga-
wa-Saito, Hisatsune, Yamamoto, Sekiguchi, Ide, Son, Olivry, Sugai, Fukuyasu, Iwasaki & 
Nishifuji, 2011). EXI (also called ExpA), and not SIET, selectively digests canine desmoglein-
Desmoglein-1 
Normal skin Damaged skin 
Exfoliative toxin 
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1, causes subcorneal clefts in canine epidermidis and may be involved in canine impetigo 
(Iyori et al., 2011). Recently, another exfoliative toxin gene, named SPETA, was identified in 
the S. pseudintermedius genome, but its function has not been demonstrated so far (Ben 
Zakour et al., 2012). 
 
1.3.6 Other toxins 
The toxic shock syndrome toxin (TSST) is one of the causative toxins of Toxic Shock Syn-
drome (TSS), producing high fever, headache, disorientation, vomiting, diarrhea and rashes. 
In the 80s, an increased number of studies reported more cases of TSS, which were soon 
associated with tampon use in young women. It was observed that those patients showed in-
tra-vaginal colonization of S. aureus producing TSST (Torres, Kominsky, Perrin, Hobeika & 
Johnson, 2001). New animal variants were described subsequently, namely the ovine TSST 
and bovine TSST (Lee, Kreiswirth, Deringer, Projan, Eisner, Smith, Carlson, Novick & 
Schlievert, 1992).  
 
1.3.7 Surface proteins 
Surface proteins are usually anchored in the cell wall of staphylococci and interact with the 
bacterial environment (Navarre & Schneewind, 1999). Cell wall anchored proteins can be 
classified into four groups based on the presence of motifs shown in Table 2 (Foster, Geog-
hegan, Ganesh & Höök, 2014). The most prevalent group is the microbial surface compo-
nents recognizing adhesive matrix molecules (MSCRAMMs) family, but other families include 
the NEAT motif family, the three-helical bundle family and the G5-E repeat family (Foster et 
al., 2014).  
 
Table 2. Examples of staphylococcal cell wall anchored proteins. 
Protein Ligand 
Staphylococcal species where 
it can be found 
MSCRAMMs 
Clumping factor A (ClfA) 
Fibrinogen 
Complement factor I 
S. aureus 





Staphylococcus pseudintermedius surface 





Serine-aspartate repeat protein F (SdrF) Collagen type I S. epidermidis 
NEAT motif family 






Iron-regulated surface protein H (IsdH) Haemoglobin S. aureus 
Three-helical bundle family 




G5-E repeat family 
S. aureus surface protein G (SasG) Unknown ligand S. aureus 
 
These proteins fulfil a wide spectrum of functions, including binding to host tissues, interac-
tion with adhesive matrix molecules, invasion, inflammation, immune evasion, biofilm for-
mation, and binding of heme proteins for bacterial iron scavenging during infection (Foster et 
al., 2014). Interestingly, these proteins show functional plasticity, meaning several proteins 
have the same function and one protein has many functions (Foster et al., 2014). One con-
sequence of this plasticity is that knocking one single protein might only partially affect the 
bacteria (Foster et al., 2014).  
 
1.3.8 Biofilm 
A biofilm is a bacterial community of cells attached to each other or to an interface that are 
embedded in a matrix of extracellular polymeric substances (Figure 6) (Donlan & Costerton, 
2002). Biofilm formation is now recognized as an important virulence factor in several staphy-
lococcal infections, including native valve endocarditis, otitis media, cystic fibrosis pneumonia 
and infections associated with implanted biomaterials (Jain & Agarwal, 2009). Biofilms have 
increased resistance to antimicrobials, and to immune system mechanisms of defence, like 
antimicrobial peptides and neutrophil phagocytosis (Costerton, Stewart & Greenberg, 1999). 
 
Figure 6. Steps of staphylococcal biofilm formation. 




The first step of biofilm formation is attachment (Otto, 2008). Attachment to a biological sur-
face, like the body, is promoted by MSCRAMMs that have the capacity to covalently bind to 
host matrix proteins (Patti, Allen, McGavin & Hook, 1994). Other proteins not covantly bound 
to the cell wall include the autolysin (Atl) that can also govern attachment (Otto, 2008). 
Staphylococcal autolysins can also bind to plastic surfaces (Heilman, Hussain, Peters & 
Gotz, 1997).  
 
1.3.8.2 Maturation 
The second step of biofilm formation is maturation (Otto, 2008). Maturation occurs either in a 
polysaccharide intercellular adhesion (PIA)-dependent (Jabbouri & Sadovskaya, 2010) or 
PIA-independent manner (Toledo-Arana, Merino, Vergara-Irigaray, Debarbouille, Penades & 
Lasa, 2005).  
 
1.3.8.2.1 Maturation in a PIA-dependent manner 
After attachment, staphylococci start to aggregate intercellularly (Otto, 2008). In this manner 
the main molecule responsible for intercellular adhesion is the polysaccharide intercellular 
adhesion (PIA), also called poly-N-acetylglucosamine (PNAG) (Mack, Fischer, Krokotsch, 
Leopold, Hartmann, Egge & Laufs, 1996). PIA/PNAG, together with other polymers such as 
teichoic acids and proteins, form the major part of the extracellular matrix of biofilm-forming 
staphylococci, called slime (Otto, 2008). PIA/PNAG biosynthesis is determined by the prod-
ucts of the intercellular adhesion (ica) locus (Heilman, Schweitzer, Gerke, Vanittanakom, 
Mack & Gotz, 1996). Usually this type of maturation is induced by osmotic stress, like for ex-
ample when cultivating in broth medium with high concentrations of NaCl (O’Neill, Pozzi, 
Houston, Smyth, Humphreys, Robinson & O’Gara, 2007). This PIA/PNAG-mediated biofilm 
development is highly associated with MSSA and not with MRSA strains (O’Neill et al., 
2007), although the ica operon is present in the majority of these last strains (O’Gara, 2007). 
The ica operon can even be transcribed and regulated in MRSA strains grown in medium 
containing NaCl or glucose, without the production of PIA/PNAG (O’Neill et al., 2007).  
In S. epidermidis, one way of differentiating virulent from non-virulent strains is by detecting 
the ica operon (Frerbourg, Lefebvre, Baert & Lemeland, 2000). In fact, up to 80-90% of clini-
cal isolates and only 5-30% of contaminant S. epidermidis have been shown to carry the ica 
gene (Ziebuhr, Heilmann, Götz, Meyer, Wilms, Straube & Hacker, 1997).  
The ica operon has been found in other staphylococcal species like S. pseudintermedius 
(Singh, Walker, Rousseau & Weese, 2013), S. haemolyticus (Fredheim, Klingenberg, Rohde, 
Frankenberger, Gaustad, Flægstad & Sollid, 2009), S. lugdunensis (Frank & Patel, 2007), S. 
caprae (Allignet, Aubert, Dyke & El Solh, 2001), S. saprophyticus (Møretrø, Hermansen, 
Holck, Sidhu, Rudi & Langsrud, 2003), S. caseolyticus (Møretrø et al., 2003), S. condimenti 
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(Møretrø et al., 2003), S. sciuri (Møretrø et al., 2003), S. simulans (Møretrø et al., 2003), S. 
capitis (Møretrø et al., 2003) and S. cohnii (Møretrø et al., 2003).  
 
1.3.8.2.2 Maturation in a PIA-independent manner 
In cases of PIA-independent biofilm formation, adhesive proteins substitute for PIA (Otto, 
2008). These may include the accumulation-associated protein (Aap), a protein responsible 
for 27% of the biofilm formation in strains isolated from prosthetic joint infections (Rohde, Bu-
randt, Siemssen, Frommelt, Burdelski, Wurster, Scherpe, Davies, Harris, Horstkotte, Knob-
loch, Ragunath, Kaplan & Mack, 2007); the biofilm-associated protein (Bap), highly prevalent 
in S. aureus isolates from animals suffering from mastitis (Cucarella, Solano, Valle, Amore-
na, Lasa & Penades, 2001); an homolog protein named Bhp, found in human S. epidermidis 
strains and other CoNS (Zhang, Ren, Li, Wang, Fu, Yang, Qin, Miao, Wang, Chen, Shen, 
Chen, Yuan, Zhao, Qu, Danchin & Wen, 2003; Tormo, Knecht, Gotz, Lasa & Penades, 
2005); and FnBPA and FnBPB, two fibronectin-binding proteins found in S. aureus strains 
(O’Neill, Pozzi, Houston, Humphreys, Robinson, Loughman, Foster & O’Gara, 2008). 
Teichoic acids may also have a role in the biofilm PIA-independent formation (Gross, 
Cramton, Gotz & Peschel, 2001). The FnBP-mediated biofilm development is usually in-
duced by mild acid stress, like for example when isolates are grown in a medium with high 
concentrations of glucose (O’Neill et al., 2008). This biofilm phenotype is associated with 
MRSA strains (O’Neill et al., 2008). Biofilm formation by S. haemolyticus is also induced, 
when the organism is cultivated in medium with glucose, in a PIA-independent manner, how-
ever the components involved in the biofilm are not yet determined (Fredheim et al., 2009).  
 
1.3.8.3 Detachment 
Detachment is fundamental for the dissemination of bacteria to other colonization sites (Otto, 
2008). Detachment can occur as single cells or large cell aggregates (Otto, 2008). Controlled 
detachment actually maintains a certain biofilm thickness and is controlled by the quorum-
sensing system agr (Otto, 2008). The agr system regulates the expression of a class of pep-
tides, named phenol-soluble modulins (PSMs), which when up-regulated lead to the detach-
ment of cell clusters (Otto, 2008). 
 
1.4 Treatment options against staphylococci: antimicrobials and biocides 
Antimicrobials are the first-line of choice for the treatment of staphylococcal infections. Anti-
microbials are defined as naturally occurring or synthetic substances, which inhibit or destroy 
selective bacteria or other microorganisms, generally at low concentrations (Giguère, Pré-
scott & Dowling, 2013). There are several classes of antimicrobials used to treat staphylo-
cocci infections both in human and veterinary medicine (Figure 7). A brief description of 
some of the antimicrobials used to treat staphylococcal infections is reviewed here. 
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Figure 7. Antimicrobial targets in staphylococci. 
 
A large variety of antimicrobial resistance mechanisms have been described in staphylococci 
(Giguère et al., 2013). Antimicrobial resistance mechanisms can be classified into four major 
categories as shown in Figure 8. 
 
Figure 8. Summary of the antimicrobial resistance mechanisms commonly found in staphylococci. 
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1.4.1 Cell-wall synthesis inhibitors 
Cell-wall synthesis inhibitors are among the most selective antimicrobials, since they target a 
structure, the peptidoglycan, which only exists in prokaryotic and not in eukaryotes cells 
(Giguère et al., 2013). Antimicrobials affecting the cell wall synthesis include β-lactams (pen-
icillins, cephalosporins, carbapenems and monobactams) and glycopeptides (Giguère et al., 
2013). The peptidoglycan synthesis is done in four steps: 1) synthesis of the precursor in the 
cytoplasm; 2) precursor transport through the membrane; 3) deposition at the cell wall gly-
cans; and 4) binding and maturation (McDermott, Walker & White, 2003). The β-lactams and 
glycopeptides operate in stages 3 and 4 of peptidoglycan synthesis (McDermott et al., 2003). 
 
1.4.1.1 β-lactams 
β-lactam antimicrobials were the first antimicrobials to be used in the clinical setting and are 
widely used due to their selectivity, versatility and low toxicity (Giguère et al., 2013). These 
antimicrobials reach bacterial killing by binding to penicillin-binding proteins (PBP) located in 
the cytoplasmic membrane that are involved in cell-wall assembly (Lowy, 1998; Gardam, 
2000). By binding to these PBP, β-lactams consequently inhibit the crosslink of bacterial cell 
wall (Gardam, 2000). Penicillins are important antimicrobials for the treatment of infections in 
animals (Giguère et al., 2013). Penicillin G is the most commonly used antimicrobial in food-
producing animals, especially ruminants, for the treatment of several bacterial infections 
(Giguère et al., 2013). In small animals, however, there are other formulations containing fur-
ther penicillins in combination with β-lactamase inhibitors that are preferred (Giguère et al., 
2013). Amoxicillin and ampicillin alone are also widely used in food-producing animals but 
they are susceptible to staphylococcal penicillinases (Giguère et al., 2013). Cloxacillin is an-
tistaphylococcal, and is available as an intra-mammary formulation (Giguère et al., 2013). 
This penicillin is similar to methicillin and was developed to overcome the penicillinases or β-
lactamases produced by staphylococci (Giguère et al., 2013). In small animals, amoxicillin-
clavulanate (a β-lactamase inhibitor) is available to overcome these enzymes produced by 
staphylococci (Giguère et al., 2013). Ureidopenicillins, amidopenicillins and carboxypenicil-
lins do not have activity against staphylococci (Giguère et al., 2013). Cephalosporins and 
carbapenems are resistant to staphylococcal penicillinases, however, carbapenems are not 
licensed for veterinary use and its administration in animals is poorly recommended (Giguère 
et al., 2013). Cephalosporins are divided into 5 generations, with 1st generation (e.g. 
cephalexin and cefazolin) and 5th generation (e.g. ceftobiprole and ceftaroline) being the 
most active against staphylococci (Kollef, 2009; Giguère et al., 2013). First generation 
cephalosporins are useful in the treatment of chronic staphylococcal pyoderma in dogs (Hilli-
er, Lloyd, Weese, Blondeau, Boothe, Breitschwerdt, Guardabassi, Papich, Rankin, Turnidge 
& Sykes, 2014).  
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The initial mechanism of staphylococci resistance involved the production of penicillinases or 
β-lactamases, which hydrolyse the cyclic amide bond of the β-lactam ring (Gardam, 2000). 
Subsequently, after introduction of penicillinase-stable penicillins (like methicillin and oxacil-
lin), a new mechanism of resistance developed and staphylococcal strains began producing 
a unique penicillin-binding protein, PBP2a or PBP2’, which has a much lower affinity for β-
lactam antimicrobials (including penicillins, cephalosporins, carbapenems) (Gardam, 2000; 
Weese & van Duijkeren, 2010). The first recognized gene encoding for PBP2a was mecA, 
which is part of a mobile genetic element, termed staphylococcal chromosome cassette mec 
(SCCmec) (Hiramatsu, Cui, Kuroda & Ito, 2001). More recently another gene, mecC, was 
identified in human and bovine S. aureus strains conferring resistance to β-lactam antimicro-
bials (García-Álvarez, Holden, Lindsay, Webb, Brown, Curran, Walpole, Brooks, Pickard, 
Teale, Parkhill, Bentley, Edwards, Girvan, Kearns, Pichon, Hill, Larsen, Skov, Peacock, 
Maskell & Holmes, 2011). This gene is located in a specific SCCmec type XI (García-Álvarez 
et al., 2011). The mecA and mecC genes have been detected in several staphylococcal spe-
cies from humans and animals (García-Álvarez et al., 2011; Harrison et al., 2013; Harrison et 
al., 2014). S. xylosus harbour an allotype of the mecC gene, named mecC1 (Harrison, Pater-
son, Holden, Morgan, Larsen, Petersen, Leroy, Vliegher, Perreten, Fox, Lam, Sampimon, 
Zadoks, Peacock, Parkhill & Holmes, 2013). Just like in S. aureus mecC1 forms part of a 
class E mec complex (mecI-mecR1-mecC1-blaZ) located at the orfX locus as part of a likely 
SCCmec remnant, which also contains a number of other genes present on the type XI 
SCCmec (Harrison et al., 2013). Some strains harbouring the mecC1 allotype may be cefox-
itin- and oxacillin-susceptible due to inactivation of the resistance gene (Harrison et al., 
2013). S. saprophyticus can carry another allotype of mecC, named mecC2 (Matyszko, 
Schwarz & Hauschild, 2014). 
 
1.4.1.2 Glycopeptides 
Vancomycin, teicoplanin and avoparcin are glycopeptides with activity against Gram-positive 
bacteria, especially cocci (Guiguère et al., 2013). Vancomycin and teicoplanin are last-resort 
antimicrobials used for the treatment of MRSA infections in humans (Guiguère et al., 2013). 
Avoparcin was available for veterinary medicine, but since vancomycin-resistant enterococci 
started appearing in farm animals, its use was forbidden in Europe (Guiguère et al., 2013). 
These antimicrobials interact with the cell wall components, inhibiting the formation of the rig-
id backbone of the cell wall (Guiguère et al., 2013). S. haemolyticus was the first staphylo-
coccal species that acquired resistance to the glycopeptide antimicrobials teicoplanin and 
vancomycin (Froggatt et al., 1989). Studies of vancomycin-resistant CoNS showed that they 
have altered crosslinks compared to susceptible strains (Billot-Klein, Gutmann, Bryant, Bell, 
Van Heijenoort, Grewal & Shlaes, 1996.). It has been suggested that these altered cross-
links may inhibit vancomycin binding to target peptides, but this hypothesis has yet to be 
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proven (Srinivasan, Dick & Perl, 2002). Vancomycin resistance in CoNS, namely in S. hae-
molyticus is likely multifactorial, but the exact mechanisms await elucidation (Srinivasan et 
al., 2002). More recently Van proteins, first isolated in enterococci, have been described in 
human S. aureus strains, including in Portugal (Melo-Cristino, Resina, Manuel, Lito & 
Ramirez, 2013). To date, seven types of resistance (VanA, -B, -C, -D, -E, -G, and -L) in en-
terococci have been described (Périchon & Courvalin, 2009). VanA-mediated resistance, the 
only to be described in S. aureus, is characterized by high levels of resistance to glycopep-
tides, vancomycin, and teicoplanin and is mediated by transposon Tn1546 or closely related 
elements that are chromosomally- or plasmid-located (Périchon & Courvalin, 2009). 
 
1.4.2 Membrane synthesis inhibitors 
1.4.2.1 Lipopeptides 
The bactericidal, cell membrane-targeting lipopeptide antimicrobial daptomycin is an im-
portant agent for the treatment of invasive S. aureus infections, especially since the emer-
gence of vancomycin-resistant S. aureus (Bayer, Schneider & Sahl, 2013). This antimicrobial 
is only approved for the treatment of S. aureus skin and soft tissue infections, bacteraemia 
and right-sided endocarditis in human medicine (Bayer et al., 2013). However, there have 
been numerous recent reports of development of daptomycin-resistance during therapy with 
this agent (Bayer et al., 2013). The mechanism of resistance appears to be quite diverse, 
with strains often exhibiting progressive accumulation of single nucleotide polymorphisms in 
the multipeptide resistance factor gene (mprF) and the yycFG components of the yycFGHI 
operon (Bayer et al., 2013). 
 
1.4.3 Deoxyribonucleic acid (DNA) inhibitors 
1.4.3.1 Quinolones 
The first quinolone approved for use in animals in 1988 was enrofloxacin (Giguère et al., 
2013). Nowadays several others have been approved (Giguère et al., 2013). Quinolones are 
classified based on their biological activity (Andriole, 2005) as 1st generation quinolones with 
restricted antibacterial activity against Enterobacteriaceae (e.g. nalidixic acid, flumequine), 
2nd generation quinolones with added spectrum against Gram-positive and improved activity 
against Gram-negative bacteria (e.g. for human purpose – norfloxacin, ofloxacin, ciprofloxa-
cin, levofloxacin; veterinary purpose – danofloxacin, difloxacin, enrofloxacin, ibafloxacin, 
marbofloxacin, orbifloxacin [Table 3]), 3rd generation quinolones with greater potency against 
Gram-positive bacteria, particularly streptococci, and good activity against anaerobic bacteria 
(e.g. for human purpose – grepafloxacin, gatifloxacin, sparfloxacin, temafloxacin, tosufloxa-
cin, and pazufloxacin; veterinary purpose – pradofloxacin) and 4th generation quinolones with 
potent activity against anaerobes and increased activity against pneumococci (e.g. for hu-
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man purpose - trovafloxacin, clinafloxacin, sitafloxacin, moxifloxacin, and gemifloxacin) (An-
driole, 2005). 
 
Table 3. Fluoroquinolones approved for Veterinary Medicine in Europe (adapted from Giguère et al., 2013). 










Difloxacin Dogs, cats SSTI, UTI Oral 
Enrofloxacin 
Cattle, pigs, poultry, 




SSTI, UTI (pets) 
Oral, injectable 
Ibofloxacin Dogs, cats SSTI, UTI, respiratory infections Oral 
Marbofloxacin 
Cattle, pigs, calves, 
dogs, cats 
Respiratory infections 
Mastitis (cattle, pigs) 
Gastroenteritis (calves) 
SSTI, UTI, otitis (pets) 
Oral, injectable, 
topical 
Orbifloxacin Dogs, cats SSTI, UTI, otitis Oral, topical 
Pradofloxacin Dogs, cats 




Resistance to fluoroquinolones occurs by target modification (topoisomerase IV and gyrase), 
decreased permeability, efflux and/or target protection (Hooper, 2002). More than one re-
sistance mechanism can be present in one bacterial cell (Hooper, 2002). Amino acid chang-
es in critical regions of the enzyme-DNA complex, named quinolone resistance–determining 
region (QRDR), reduce quinolone affinity for both its targets (topoisomerase IV and gyrase) 
(Lowy, 2003). The GrlA subunit of topoisomerase IV and the GyrA subunit in gyrase are the 
most common sites of resistance mutations, however topoisomerase IV mutations are the 
most critical, since they are the primary fluoroquinolone targets in staphylococci (Hooper, 
2002). Single amino acid mutations are sometimes sufficient to confer clinical resistance, es-
pecially to 2nd and 3rd generation fluoroquinolones, but for the more active fluoroquinolones 
(4th generation) additional mutations are necessary (Lowy, 2003). Resistance mutations can 
accumulate in the QRDR sites, increasing the levels of resistance (Lowy, 2003) and it is very 
common that both targets, topoisomerase IV and gyrase, have mutations (Lowy, 2003). For 
example, moxifloxacin, a 4th generation fluoroquinolone with high activity against staphylo-
cocci, is active against ciprofloxacin-resistant S. aureus in vitro (Ince, Zhang & Hooper, 
2003). Topoisomerase IV is the primary target of moxifloxacin in S. aureus and single muta-
tions in the gene encoding this topoisomerase increases the MIC 4-8 times (Ince et al., 
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2003). However, only a double mutation in topoisomerase IV and gyrase increases the MIC 
125 times, enough to give resistance (Ince et al., 2003). An additional mechanism of re-
sistance in S. aureus is induction of the Nor (NorA, NorB and NorC) efflux pumps (Lowy, 
2003). Increased expression of these pumps in S. aureus can result in low-level quinolone 
resistance (Yoshida, Bogaki, Nakamura, Ubukata & Konno, 1990; Truong-Bolduc, Strahi-
levitz & Hooper, 2006; Ding, Onodera, Lee & Hooper, 2008). Overexpression of the NorA ef-
flux pump, for example, causes a two-fold increase in the MIC of moxifloxacin in S. aureus 
(Ince et al., 2003). 
As for S. aureus, ciprofloxacin resistance in CoNS is due to the combined presence of single 
mutations in each grlA and gyrA gene (Dubin, Fitzgibbon, Nahvi & John, 1999). For 
trovafloxacin resistance, a 4th generation fluoroquinolone, an additional mutation in the grlA 
gene is needed (Dubin et al., 1999). Some studies have shown a high frequency of fluoro-
quinolone resistance in S. schleiferi comparing to S. pseudintermedius (Intorre, Vanni, Di 
Bello, Pretti, Meucci, Tognetti, Soldani, Cardini & Jousson, 2007; Vanni, Tognetti, Pretti, 
Crema, Soldani, Meucci & Intorre, 2009). S. schleiferi and S. pseudintermedius fluoroquino-
lone-resistant isolates are usually resistant to 2nd and 3rd generation fluoroquinolones (en-
rofloxacin, levofloxacin, marbofloxacin, gatifloxacin) but susceptible to 4th generation fluoro-
quinolones (moxifloxacin, trovafloxacin) (Intorre et al., 2007; Vanni et al., 2009). Interestingly, 
for the same pattern of resistance, typically S. pseudintermedius shows double mutations in 
the grlA genes (positions 80 or 84) and gyrA (positions 84 or 88), while S. schleiferi only has 
a single alteration in gyrA (Intorre et al., 2007). However, until very recently none of these 
mutations were associated with resistance to 4th generation fluoroquinolones (Intorre et al., 
2007). Yet, more recent studies on methicillin-resistant S. pseudintermedius (MRSP) have 
detected resistance to moxifloxacin (Couto, Pomba, Moodley & Guardabassi, 2011).  
 
1.4.3.2 Nitrofurans 
Nitrofurantoin is a nitrofuran with broad-spectrum activity against Gram-positive and Gram-
negative bacteria (Maaland & Guardabassi, 2011). It is used for the treatment of UTIs in pets 
under the cascade (FAO/OIE/WHO 2008), since it is not approved for veterinary medicine 
however there is a lack of pharmacokinetic/pharmacodynamics studies in these species and 
there is a risk for adverse effects, including gastrointestinal irritation that may cause nausea 
and emesis in both dogs and cats (Maaland & Guardabassi, 2011). Yet, study results show 
that the use of nitrofurantoin might be indicated for the treatment of UTIs caused by staphy-
lococci, including MRSP, which are otherwise difficult to treat using conventional veterinary 




Rifampicin (also called rifampin) acts by binding to the ß-subunit of the DNA-dependent ribo-
nucleic acid (RNA) polymerase (Kadlec, van Duijkeren, Wagenaar & Schwarz, 2011). Rifam-
picin has a high degree of lipid solubility and so is effective against intracellular and extracel-
lular pathogens (Giguère er al., 2013). Interestingly, rifampicin may enter neutrophils and 
macrophages to kill intracellular bacteria, without interfering with phagocytosis (Giguère er al., 
2013). It is primarly used in veterinary medicine for the treatment of Rhodococcus equi infec-
tions in foals (Giguère er al., 2013). Rifampicin has been recently recommended for the 
treatment of MRSA and MRSP infections (Frank & Loeffler, 2012). However, resistance to 
rifampicin readily develops with monotherapy and should be used in combination with other 
antimicrobials to which the organism is also susceptible, such as clindamycin or cefalexin, to 
prevent development of resistance (Frank & Loeffler, 2012). Synergistic activity with erythro-
mycin, clarithromycin and azithromycin has also been observed (Giguère er al., 2013). 
In most bacteria, rifampicin resistance is mediated by mutations in the rifampicin resistance-
determining region (RRDR) of the rpoB gene encoding the ß-subunit of RNA polymerase 
(Aubry-Damon, Soussy & Courvalin, 1998). Such mutations have been described in S. aure-
us and S. pseudintermedius (Aubry-Damon et al., 1998; Kadlec et al., 2011). Usually rifam-
picin-resistant isolates show mutations at one or two of the amino acid positions of RRDR 
(Kadlec et al., 2011).  
 
1.4.4 Protein synthesis inhibitors 
1.4.4.1 Aminoglycosides 
Aminoglycosides are bactericidal antimicrobials with Gram-negative and Gram-positive ac-
tivity, but they are not active under anaerobic condition and against anaerobes since the bac-
terial uptake is oxygen-dependent (Giguère et al., 2013). Several compounds within this 
class are approved for use in animals (Giguère et al., 2013). Aminoglycosides can cause 
varying degrees of ototoxicity and nephrotoxicity depending on the molecule, and for this 
reason this class is usually only used for the treatment of severe infections, such as septi-
caemias, digestive tract infections (e.g. neomycin for Escherichia coli), respiratory and uri-
nary infections in many animal species (cattle, pigs, sheep, goats, horses, dogs and cats) 
(EMA, 2014). In the European Union the most frequently used aminoglycosides are neomy-
cin and dihydrostreptomycin (EMA, 2014). Other substances from the group used in food 
producing species are: apramycin (approved for use in animals only), gentamicin, kanamy-
cin, paromomycin, framycetin and streptomycin (EMA, 2014). Amikacin is an aminoglycoside 
that is not typically used in animals, however it is being used more frequently now, with the 
emergence of gentamicin-resistant MRSA and MRSP infections in dogs (Frank & Loeffler, 
2012; EMA, 2014). 
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The most common mechanisms of resistance are the production of aminoglycoside modify-
ing enzymes (Giguère et al., 2013). These resistance mechanisms are complex and differ 
between the different aminoglycoside molecules, and generally there is less cross-resistance 
when compared to other classes of antimicrobials (EMA, 2014). Enzymatic modification of 
aminoglycosides results in a chemical modification of the drug, with low affinity to bind to the 
ribosome (Mingeot-Leclercq, Glupczynski & Tulkens, 1999). Depending on the type of modi-
fications they cause, these enzymes are called acetyltransferases (AAC), adenyltransferases 
(ANT) or phosphotransferases (APH) (Fluit, Visser & Schmitz, 2001). In staphylococci, usual-
ly the genes encoding these enzymes are present in plasmids or other mobile genetic ele-
ments (Giguère et al., 2013). Often there can be more than one aminoglycoside resistance 
gene in the same element (Giguère et al., 2013; McCarthy, Harrison, Stanczak-Mrozek, Leg-
gett, Waller, Holmes, Lloyd, Lindsay & Loeffler, 2015). The bifunctional enzyme AAC(6′)-Ie-
APH(2″) (also called AacA-AphD), conferring resistance to gentamicin, tobramycin and kan-
amycin, is the most common resistance mechanism found in S. aureus and CoNS isolated 
from humans and animals (Schmitz, Fluit, Gondolf, Beyrau, Lindenlauf, Verhoef, Heinz & 
Jones, 1999; Schnellmann et al., 2006). Resistance to neomycin, kanamycin, tobramycin 
and amikacin in staphylococci is mediated by an ANT(4′)-I (also called AadD) enzyme en-
coded by the ant(4′)-Ia gene (Schmitz et al., 1999). The str gene, conferring resistance to 
streptomycin alone, has also been documented in CoNS from horses (Schnellmann et al., 
2006). In S. pseudintermedius, the aac(6′)-Ie-aph(2″), ant(4’)-Ia, ant(6’)-Ie and aph(3’)-IIIa 
genes have been identified (Kadlec & Schwarz, 2012; Gold, Cohen & Lawhon, 2014; McCar-
thy et al., 2015). In MRSP, the ant(6’)-Ie (also called aadE) and aph(3’)-IIIa (also called 
aphA) genes are co-located on a Tn5405-like transposon (McCarthy et al., 2015). In 2010, a 
novel apramycin resistance gene, apmA, was detected in a bovine MRSA ST398 strain 
(Feβler, Kadlec & Schwarz, 2011). The apmA gene coded for a protein that was related only 
distantly to acetyltransferases involved in chloramphenicol or streptogramin A resistance 
(Feβler et al., 2011). 
 
1.4.4.2 Tetracyclines 
Tetracyclines, which were discovered in the 1940s, are a family of antimicrobials that inhibit 
protein synthesis by preventing the attachment of aminoacyl-tRNA to the ribosomal acceptor 
site (Chopra & Roberts, 2001). Tetracyclines are broad-spectrum agents, exhibiting activity 
against a wide range of Gram-positive and Gram-negative bacteria, atypical organisms and 
protozoan parasites (Chopra & Roberts, 2001). The favourable antimicrobial properties of 
these agents and the absence of major adverse side effects has led to their extensive use in 
therapy of human and animal infections (Chopra & Roberts, 2001). Tetracyclines are first-line 
antimicrobials in food-producing animals, including aquaculture and honeybees, and are the 
class of antimicrobials with the highest use in veterinary medicine (Giguère et al., 2013). In 
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these animals, tetracyclines are used for a variety of infections, including respiratory infec-
tions (Giguère et al., 2013). In small animals, tetracyclines (e.g. doxycycline) are widely used 
to treat tick-born infections (Giguère et al., 2013). Minocycline was recently recommended for 
the treatment of MRSP infections in dogs, since these strains, although resistant to tetracy-
cline, maintain their susceptibility to minocycline (Maaland, Guardabassi & Papich, 2014). 
Resistance to tetracyclines can be mediated by several different mechanisms in staphylo-
cocci (Chopra & Roberts, 2001): 
a) Efflux by reducing the intracellular concentration of the antimicrobial, conferring re-
sistance to tetracycline but not minocycline (Chopra & Roberts, 2001). The genes 
tet(K) and tet(L), which confer such resistance, are generally found in small plasmids 
(Chopra & Roberts, 2001). 
b) Ribosomal protection mediated by cytoplasmic proteins conferring resistance to 
tetracycline, doxycycline and minocycline (Chopra & Roberts, 2001). The genes 
tet(M) and tet(O) are the most studied and characterized in staphylococci (Chopra & 
Roberts, 2001). 
c) Enzymatic inactivation of tetracycline, with only three genes have been identified 
so far: tet(X), tet(34) and tet(36) (Chopra & Roberts, 2001). 
In CoNS from horses, tet(K) has been the most common tetracycline resistance gene detect-
ed but tet(M) has also been found (Schnellmann et al., 2006). So far, four different tetracy-
cline resistance genes have been identified in S. pseudintermedius and SIG isolates: genes 
tet(K) and tet(L) coding for efflux pumps of the major facilitator superfamily, and the genes 
tet(M) and tet(O) coding for ribosome protective proteins (Kadlec & Schwarz, 2012). 
 
1.4.4.3 Phenicols 
Chloramphenicol is a broad-spectrum antimicrobial that has been used for several years in 
human and veterinary medicine (Schwarz, Kehrenberg, Doublet & Cloeckaert, 2006). 
Florfenicol, on the other hand, is licensed exclusively for veterinary medicine (Schwarz et al., 
2006). Both antimicrobials have great activity against Gram-positive and Gram-negative bac-
teria (Schwarz et al., 2006). Chloramphenicol causes a number of adverse effects, including 
dose-unrelated irreversible aplastic anaemia and dose-related reversible bone-marrow sup-
pression, and for this reason it is only limited to the therapy of a small number of life-
threatening infections (Schwarz et al., 2006). Chloramphenicol was banned from use in any 
food-producing animals in the European Union (Schwarz et al., 2006). In small animals, chlo-
ramphenicol is used solely for ocular infections and otitis (Guiguère et al., 2013). Florfenicol 
does not cause adverse side effects like chloramphenicol and so it is licensed for the control 
of bacterial respiratory tract infections in cattle and pigs (Schwarz et al., 2006). These antimi-
crobials are bacteriostatic, inhibiting the protein synthesis by binding to the 50S ribosomal 
subunit (Schwarz et al., 2006). Resistance to chloramphenicol in staphylococci is usually 
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mediated by enzymatic inactivation through acetylation of the antimicrobial by chlorampheni-
col acetyltransferases (Cat) (Schwarz et al., 2006). The most commonly found in staphylo-
cocci are genes catpC221 and catpC223, although catpC194 has also been described (Schwarz et 
al., 2006). Small catpC221-carrying plasmids, ranging in size, have been identified in canine S. 
pseudintermedius, including MRSP (Kadlec & Schwarz, 2012). An efflux pump, FexA gives 
resistance to chloramphenicol and florfenicol (Kehrenberg & Schwarz, 2004). This protein 
was first described in a bovine S. lentus isolate (Kehrenberg & Schwarz, 2004), but it was 
then isolated from other staphylococcal species (Kehrenberg & Schwarz, 2006). Another 
mechanism of resistance to chloramphenicol and florfenicol is the one mediated by the cfr 
gene, encoding a methyltransferase that modifies 23S rRNA at A2503 (Long, Poehlsgaard, 
Kehrenberg, Schwarz & Vester, 2006). The fexA and cfr genes can be found in the same 
mobile genetic element (Kehrenberg & Schwarz, 2006). Recently there has been a new in-
terest in the use of florfenicol as a second-line antimicrobial agent for the treatment of infec-
tions caused by MRSP (Maaland, Mo, Schwarz & Guardabassi, 2015). Yet, a novel fexA var-
iant (fexAv) that confers only chloramphenicol resistance has already been described in S. 
pseudintermedius, with potential to reverse the naturally mutated positions and restore the 
florfenicol resistance phenotype (Gómez-Sanz, Kadlec, Feβler, Zarazaga, Torres & Schwarz, 
2013). 
 
1.4.4.4 Macrolides, Lincosamides and Streptogramins 
Macrolide, lincosamide, and streptogramin (MLS) antimicrobials are widely used for the 
treatment of staphylococcal infections and are usually grouped together due to the overlap-
ping binding sites and similar resistance mechanisms (Lina, Quaglia, Reverdy, Leclercq, 
Vandenesch & Etienne, 1999). Macrolides are classified according to the number of atoms 
comprising the lactone ring (Giguère et al., 2013). They have excellent activity against im-
portant bacterial pathogens of animals, especially food-producing animals (Table 4) (Giguère 
et al., 2013). Macrolides are able to accumulate within phagocytes (Giguère et al., 2013). 
Macrolides are usually bacteriostatic but they may be bactericidal at high concentrations 
(Giguère et al., 2013). 
 
Table 4. Macrolide antimicrobials in veterinary medicine (adapted from Giguère et al., 2013). 
Macrolide Species Indication 
Route of admin-
istration 
Gamithromycin Cattle Respiratory infections Injectable 
Spiramycin 
Cattle, sheep, goats, poultry, 
pigs, dogs, cats 
Respiratory infections 
Mastitis, metritis (cattle) 





Tildipirosin Cattle, pigs Respiratory infections Injectable 









Cattle, sheep, goats, pigs, 
poultry 
Respiratory infections 
Mastitis, metritis (cattle) 
Arthritis, metritis, enteritis 
(pigs) 
Oral, injectable 





Lincosamides, comprising three different compounds used in veterinary medicine (lincomycin, 
clindamycin and pirlimycin) are active against Gram-positive bacteria, anaerobic bacteria and 
some mycoplasma (Giguère et al., 2013). The lincosamides, clindamycin and lincomycin, are 
used for the treatment of staphylococcal infections, mainly pyoderma and osteomyelitis in 
dogs and cats (Giguère et al., 2013). Lincomycin in association with neomycin can also be 
used as an intra-mammary administration for the treatment of mastitis (Giguère et al., 2013). 
Lincomycin associated to spectinomycin is approved for several animal species for the 
treatment of respiratory tract infections and lincomycin alone is frequently used in pigs to 
control dysentery and mycoplasma infections (Giguère et al., 2013). 
Streptogramins are a group of natural (virginiamycin, pristinamycin) or semisynthetic (quinu-
pristin/dalfopristin) cyclic peptides (Giguère et al., 2013). Streptogramins consist of two struc-
turally unrelated molecules: group A streptogramins and group B streptogramins (Giguère et 
al., 2013). Virginiamycin is the only streptogramin approved for veterinary use (Giguère et al., 
2013). These antimicrobials inhibit bacterial protein synthesis by binding irreversibly to the 
50S ribosomal subunit (Giguère et al., 2013). Group A and B streptogramins bind to separate 
sites on the 50S ribosomal subunit: group A streptogramins bind first inducing a conforma-
tional change that increases affinity of the ribosome for group B streptogramins (Giguère et 
al., 2013). 
Resistance to macrolides and lincosamides is prevalent among staphylococci, however, re-
sistance against streptogramins, the two types A and B together, remains infrequent (Fluit et 
al., 2001). There are three basic mechanisms of resistance: i) target-site modification by 
methylation; ii) efflux of the antimicrobials; and iii) antimicrobial inactivation (Leclerq, 2002). 
Target modification alters a site in 23S rRNA common to the binding of macrolides, lincosa-
mides and streptogramins B (MLSB) (Fluit et al., 2001). This target modification confers 
cross-resistance to MLSB antimicrobials and the genes encoding these methylases have 
been designated erm (erythromycin ribosome methylation) (Fluit et al., 2001). Strepto-
gramins A-type are unaffected by these erm genes, and so susceptibility to compounds with 
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the two types of streptogramins is maintained (Fluit et al., 2001). Expression of MLSB re-
sistance in staphylococci can be constitutive or inducible and this is due to the regulatory re-
gion upstream of the structural gene for the methylase (Werckenthin, Schwarz & Westh, 
1999). The Cfr rRNA methyltransferase, mentioned previously, also confers resistance to lin-
cosamides and streptogramins A (Long et al., 2006). 
Another mechanism of resistance is through antimicrobial modification: phosphotransferases 
(Mph) giving resistance to macrolides and lincosamide nucleotidyltransferases (Lnu) giving 
resistance to lincosamides (Leclerq, 2002). Genes mph(C) and lnu(A), encoding a phos-
photransferase and a nucleotidyltransferase respectively, are quite uncommon in S. aureus 
but are frequent in CoNS (Leclerq, 2002). Other mechanisms include enzymes that hydro-
lyse streptogramins B [vgb genes (virginiamycin factor A hydrolases)] or modify strepto-
gramins A by adding an acetyl group (acetyltransferases) [vat(A) (virginiamycin, factor A 
acetylation), vat(B), vat(C) genes] i (Roberts, Sutcliffe, Courvalin, Jensen, Rood & Seppala, 
1999). Many of these genes are plasmid borne, and often these vat-related genes are down-
stream of other genes encoding resistance to streptogramins (Roberts et al., 1999). 
The last resistance mechanism involves antimicrobial efflux through adenosine-triphosphate 
(ATP)-binding cassette (ABC) transporters (Leclerq, 2002). A specific efflux pump encoded 
by the gene msr(A) is present in staphylococci and effectively extrudes macrolides from the 
bacterial cell before they can bind to their target site on the ribosome (Lewis & Jorgensen, 
2005). This mechanism of resistance does not create resistance to lincosamides, but only to 
14-membered ring macrolides (e.g. erythromycin and clarithromycin), 15-membered ring 
macrolides or azalides (e.g., azithromycin, gamithromycin and tulathromycin), and group B 
streptogramins (e.g. quinupristin) (Lewis & Jorgensen, 2005). Resistance to streptogramins 
A and decreased susceptibility to lincosamides have also been attributed to ABC transport-
ers encoded by the vga genes, described below (Gentry, McCloskey, Gwynn, Rittenhouse, 
Scangarella, Shawar & Holmes, 2008). 
 
1.4.4.5 Pleuromutilins 
There are two pleuromutilins used in veterinary medicine, tiamulin and valnemulin that have 
great activity against anaerobic bacteria and mycoplasma and They also against staphylo-
cocci (Giguère et al., 2013). Retapamulin is approved in Europe for topical use to treat impe-
tigo, a highly contagious skin infection typically caused by S. aureus (Gentry et al., 2008). In 
Gram-positive bacteria, cross-resistance to pleuromutilins and streptogramins A and de-
creased susceptibility to lincosamides have been attributed to ABC transporters encoded by 
the vga genes (Gentry et al., 2008). To date, seven vga genes have been described in 
staphylococci: vga(A), vga(A)LC, vga(A)v, vga(B), vga(C) and vga(E) (Allignet, Loncle & El 
Sohl, 1992; Allignet & El Solh, 1997; Gentry et al., 2008; Kadlec & Schwarz, 2009; Haroche, 
Allignet, Buchrieser & El Solh, 2000; Schwendener & Perreten, 2011). These genes are very 
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common in staphylococci, especially in MRSA ST398 isolated from farm animals, and this is 
probably due to the use of antimicrobials like virginiamycin, tiamulin, valnemulin and linco-
mycin, that are administrated through medicated feed piggeries to prevent and treat bacterial 
infectious diseases (Schwendener & Perreten, 2011). Resistance to pleuromutilins can also 
be mediated by the, already mentioned, multidrug-resistance Cfr rRNA methyltransferase 
(Long et al., 2006). 
 
1.4.4.6 Oxazolidininones 
Oxazolidininones are a recently described class of antimicrobials (Giguère et al., 2013). 
Linezolid targets important functional centres of the ribosome of Gram-positive bacteria 
(Long et al., 2006). Linezolid was the first oxazolidininone to be approved in human medicine 
and it is mainly used for the treatment of MRSA and vancomycin-resistant S. aureus (VRSA) 
(Giguère et al., 2013). Treatment of MRSP infections with linezolid has been recommended 
(Papich, 2012), however this scenario represents a serious ethical dilemma, even when ap-
plying the cascade principle (Papich, 2012). 
Resistance to oxazolidininones is usually conferred by the, already stated, multidrug-
resistance Cfr rRNA methyltransferase (Long et al., 2006). The cfr gene was first described 
in 2000 in a bovine S. sciuri strain (Schwarz, Werckenthin & Kehrenberg, 2000). Since then it 
has been found in S. simulans from cows (Kehrenberg, Ojo & Schwarz, 2004) and in porcine 
S. aureus strains (Kehrenberg & Schwarz, 2006). The cfr gene is commonly detected in bac-
teria isolated from livestock, where the use of phenicols, lincosamides, and pleuromutilins 
may provide selective pressure and lead to maintenance of this gene in animal staphylococci 
(Tewhey, Gu, Kelesidis, Charlton, Bobenchik, Hindler, Schork & Humphries, 2014). Human 
S. aureus and S. epidermidis isolates can also harbour the cfr RNA methylase gene (Mendes, 
Deshpande, Castanheira, DiPersio, Saubolle & Jones, 2008; Tewhey et al., 2014). 
Modification of the ribosome, commonly by mutation of the V domain of the 23S rRNA, is al-
so associated with resistance in human clinical isolates of staphylococci (Tsiodras, Gold, Sa-
koulas, Eliopoulos, Wennersten, Venkataraman, Moellering, Ferraro, 2001; Mazzariol, Lo 
Cascio, Kocsis, Maccacaro, Fontana & Cornaglia, 2012; Tewhey et al., 2014). Multiple muta-
tions in the rRNA and associated proteins have been descibed in linezolid-resistant isolates, 
underscoring the multifocal nature of resistance to linezolid in staphylococci (Tewhey et al., 
2014). 
 
1.4.5 Folic acid synthesis inhibitors 
1.4.5.1 Sulphonamides 
Sulphonamides interfere with the biosynthesis of folic acid in bacterial cells by competitively 
inhibiting the dihydropteroate synthase (DHPS) and consequently preventing the para-
aminobenzoic acid from incorporating into the folic acid molecule (Lyon & Skurray, 1987). 
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Sulphonamides have a broad-spectrum of activity, however, resistance is very common, in-
cluding in staphylococci (Giguère et al., 2013). At least two different mechanisms of bacterial 
resistance have been reported, but it is not known whether both are operative in staphylo-
cocci (Lyon & Skurray, 1987). One consists of an increased production of the para-
aminobenzoic acid probably due to a chromosomal mutation (sulA); the other is due to a 
plasmid-encoded mechanism of resistance mediated by DHPS enzymes with much reduced 
affinity for the antimicrobial (Lyon & Skurray, 1987). So far, the molecular basis for sulphon-
amide resistance has not been identified in S. pseudintermedius (Kadlec & Schwarz, 2012).  
 
1.4.5.2 Diaminopyrimidines 
Trimethoprim is a diaminopyrimidine that interferes with folic acid synthesis by inhibiting the 
dihydrofolate reductase (Giguère et al., 2013). A synergistic and bactericidal effect is detect-
ed when a diaminopyrimidine is combined with a sulphonamide and formulations usually 
contain a combination of these antimicrobials (Giguère et al., 2013). Resistance to diamino-
pyrimidine is usually the result of synthesis of a resistant dihydrofolate reductase enzyme 
(Skold, 2001). The dfr genes encoding these enzymes are usually located on plasmids or 
transposons (Skold, 2001). Several dfr genes conferring resistance to trimethoprim have 
been described in staphylococci (Schnellmann et al., 2006). Usually the dfr genes found in 
CoPS and CoNS are different (Schnellmann et al., 2006). In CoNS dfrA and dfrD have been 
described (Schnellmann et al., 2006). In CoPS, the gene dfrG is the most common in S. 
pseudintermedius isolates, including MRSP (Kadlec & Schwarz, 2012); while the dfrK gene is 
the most common in S. aureus (Schnellmann et al., 2006). 
 
1.4.6 Topical antimicrobials 
1.4.6.1 Mupirocin 
Mupirocin is a topical antimicrobial commonly used for topical treatment of canine bacterial 
skin infections caused by staphylococci (Werner & Russel, 1999). However, the use of this 
topical antimicrobial in veterinary medicine is controversial, since mupirocin is used for de-
colonization of persistent nasal MRSA carriage in humans (Coates, Bax & Coates, 2009). 
Mupirocin is an analogue of isoleucine that competitively binds to isoleucyl-tRNA synthetase, 
inhibiting protein synthesis (Farmer, Gilbart & Elson, 1992). Mupirocin-resistance is pheno-
typically divided into two groups, low-level (minimum inhibitory concentrations [MICs], 4 to 
256 µg/ml) and high-level (MICs, ≥512 µg/ml) (Fluit et al., 2001). Low-level resistance to 
mupirocin in most cases is probably due to mutations in the host isoleucyl-tRNA synthetase, 
while isolates with high level resistance to mupirocin contain an additional biochemically dis-
tinct isoleucyl-tRNA synthetase, encoded by the mupA gene, that is less sensitive to inhibi-
tion by mupirocin (Gilbart, Perry & Slocombe, 1993). The mupA gene may be carried on 
transferable plasmids that vary in size in both S. aureus and CoNS isolates that are epidemi-
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ologically unrelated (Farmer et al., 1992; Gilbart et al., 1993). One study in 2010 evaluated 
the in vitro susceptibility of staphylococci to mupirocin and found that 94% of the staphylo-
cocci, independent of the methicillin-resistant status, isolated from dogs with superficial pyo-
derma were susceptible to mupirocin (Fulham, Lemarie, Hosgood & Dick, 2010). Interestingly 
the odds of an isolate being resistant to mupirocin were nine times higher if the isolate was 
resistant to clindamycin than if the isolate was clindamycin-susceptible, suggesting cross-
resistance (Fulham et al., 2010). In another study staphylococci from cats had statistically 
significant higher MICs for mupirocin than isolates from dogs (Loeffler, Baines, Toleman, 
Felmingham, Milsom, Edwards & Lloyd, 2008). Higher MICs of mupirocin were also signifi-
cantly associated with infection isolates (Loeffler et al., 2008). 
 
1.4.6.2 Fusidic acid 
Fusidic acid is authorized for use in dogs and cats for the treatment of skin, ear or eye infec-
tions (Loeffler et al., 2008). Fusidic acid interacts with elongation factor G, preventing its re-
lease from the ribosome and thereby inhibiting bacterial protein synthesis (Turnidge & Col-
lignon, 1999). Previously, mutations in elongation factor G encoding gene, fusA, were con-
sidered the primarily cause of resistance to fusidic acid (Turnidge & Collignon, 1999). How-
ever, in 2010, one study evaluated the fusidic acid resistance rates and resistance mecha-
nisms among 4,167 S. aureus strains and 790 CoNS from North America and Australia and 
found an overall resistance prevalence of 1.7% (MIC ≥ 2µg/ml) (Castanheira, Watters, Bell, 
Turnidge & Jones, 2010). The CoNS strains carried fusB and fusC genes while S. aureus 
carried predominantly the fusC gene (Castanheira et al., 2010). Mutations in the fusA gene 
were also detected but only in a few S. aureus strains (Castanheira et al., 2010). The fusD 
gene is responsible for intrinsic fusidic acid resistance in S. saprophyticus strains (Skov, Fri-
modt-Moller & Espersen, 2001).  
 
1.4.7 Biocides 
Biocides are active chemical molecules, usually broad-spectrum in activity, that inactivate or 
kill microorganisms (Sheldon, 2005; SCENIHR, 2009). Biocides encompass chemicals with 
antiseptic, disinfectant, and/or preservative activity (Sheldon, 2005). Antiseptics are biocides 
that destroy or inhibit the growth of microorganisms in or on living tissue (e.g. health care 
personnel hand washes and surgical scrubs); and disinfectants are similar but are biocides 
that are used on inanimate objects or surfaces (Sheldon, 2005). Preservatives, on the other 
hand, are incorporated into pharmaceutical, cosmetic, or other types of products to prevent 
microbial contamination (Sheldon, 2005). The production, use and fate of biocides are well 
regulated by the European Committee (SCENIHR, 2009). Biocides can be used in a variety 
of settings, like health care, consumer products, food production, animal husbandry, foods of 
animal origin, and in the environment (Table 5) (SCENIHR, 2009). 
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The mechanism of action of biocides is poorly understood (Sheldon, 2005), but depends on 
the chemical characteristics of the biocide as well as the microorganism (Sheldon, 2005). 
Several other factors influence the biocide activity, like concentration, pH, duration of expo-
sure and temperature (Sheldon, 2005). 
 
Table 5. Biocides commonly used in human and veterinary medicine. 












(acetate or digluconate) 
Antiseptic, disinfectant, preserva-
tive 
Halogen-releasing agents Sodium hypochlorite Antiseptic, disinfectant 
Peroxygens Hydrogen peroxyde Antiseptic, disinfectant 
Phenylethers/Bisphenols Triclosan Antiseptic, preservative 







One product or formulation may have more than one biocide (SCENIHR, 2009). Usually the 
objective is synergy, meaning the combined action of the pooled biocides is greater than the 
sum of the activities of the biocides alone (SCENIHR, 2009). However, other effects can oc-
cur: additive, when the combined action of the added biocides is not greater than the sum of 
the individual biocides; and antagonistic, when the combined effect result is lower than the 
sum of the activities of the individual biocides (SCENIHR, 2009). Other components of a 
product or formulation may have an effect on the antimicrobial activity of the biocide 
(SCENIHR, 2009). For example, surfactants have an intrinsic antibacterial activity, and when 
used in combination with biocides, they increase the overall bactericidal activity (SCENIHR, 
2009). Another example is Tris–EDTA, a chelating agent affecting permeability of the outer 
membrane in Gram-negative bacteria by removing Ca2+ and Mg2+ (Guardabassi, Ghibaudo & 
Damborg, 2009). This mechanism of action results in a synergistic effect when Tris–EDTA is 
administered together with other compounds, including antiseptics, most likely by enhancing 
their penetration into the bacterial cell (Guardabassi et al., 2009). 
 
1.4.7.1 Biocide susceptibility 
The objective of a biocide is to kill microorganisms very quickly, normally in a matter of 
minutes (SCENIHR, 2009). In this way, determination of MIC is not a good test to assess bi-
ocide susceptibility (Cerf, Carpentier & Sanders, 2010). Time is a fundamental factor to con-
sider when testing biocide susceptibility (Cerf et al., 2010). Another important factor to pon-
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der is temperature (Cerf et al., 2010). Biocides can be used in a large set of equipment, 
which are often at low temperatures (0ºC or less in refrigerators) or at high temperatures 
(100ºC in flow heat exchangers in the food industry) (Cerf et al., 2010). Furthermore, antisep-
tics used on the skin should do their activity at ± 37ºC (Cerf et al., 2010). The standardized 
methods to test for biocide susceptibility are based on the determination of the concentration 
that leads to a 5 logarithmic reduction in the number of microorganisms in a liquid suspen-
sion or deposited and dried on a carrier surface, in a given time at a given temperature, in 
the presence of interfering substances or not (Cerf et al., 2010). Interfering substances are 
proteins, carbohydrates and/or lipids, which bind to the biocides and reduce the concentra-
tion of molecules available to interact with the microorganism (Cerf et al., 2010). The Euro-
pean Committee for Standardization has 13 protocols available for the evaluation of biocides 
(CEN, 2006). 
 
1.4.7.2 Inefficacy of biocides 
The term biocide resistance is not a defined concept and is often misused (Cerf et al., 2010). 
A strain or a species is said to be “resistant” or “tolerant” or “non-susceptible” to a biocide if: 
a) The time needed to achieve the 5 logarithmic reduction at a given biocide concentra-
tion is significantly longer than expected or; 
b) The concentration needed to achieve the 5 logarithmic reduction for a given expo-
sure time is significantly higher then normal. 
This can be due to improper dilution of the in-use concentration of the biocide, to the pres-
ence of interference substances, to microorganism adhesion, to microorganism inactivation 
and/or to efflux pumps (Sheldon, 2005; Cerf et al., 2010). Improper dilution often occurs in 
places that should be but are not dry (e.g. floors or equipment) (Cerf et al., 2010). Insuffi-
ciently cleaned surfaces may contain organic matter that interferes with biocide activity (Cerf 
et al., 2010). Adherent microorganisms (in biofilms or not) are also harder to inactivate or kill 
than suspended bacteria and as a consequence the concentration needed to inactivate or kill 
a given fraction of an adherent population in a given time can be higher by more than 400-
times than the one needed for cells in suspension (McDonnell & Russell, 1999). This is the 
reason why one of the available protocol tests of European Committee for Standardization 
uses a microbial population deposited and dried on a carrier surface (Cerf et al., 2010). En-
zymatic inactivation of biocides has been described in bacteria, including staphylococci, no-
tably to heavy metals (Ug & Ceylan, 2003; Cavaco, Hasman & Aarestrup, 2011). Efflux 
pumps decrease the intracellular concentration of biocides (Paulsen, Brown & Skurray, 
1996). These efflux pumps are classified in five families according to their energy require-
ments and structure (Table 6) (Costa, Viveiros, Amaral & Couto, 2013): 
a) Major facilitator superfamily (MFS);  
b) Small multidrug resistance (SMR) family;  
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c) Multidrug and toxic compound extrusion (MATE) family;  
d) Resistance-nodulation-cell division (RND) superfamily;  
e) ATP-binding cassette (ABC) superfamily. 
Several efflux pumps have been recognized in staphylococcal species (McDonnell & Russell, 
1999; Sheldon, 2005). They can either be chromosomally- or plasmid-encoded (Costa et al., 
2013). The Nor efflux-pumps, NorA, NorB and NorC, have been extensively characterized in 
S. aureus and one important characteristic is that they are capable of extruding fluoroquin-
olones, besides biocides (Yoshida et al., 1990; Truong-Bolduc et al., 2006; Ding et al., 2008). 
MepA is an efflux pump belonging to the MATE family, which is also capable of effluxing fluo-
roquinolones and also glycylcyclines, like tigecycline (Kaatz, McAleese & Seo, 2005; 
McAleese, Petersen, Ruzin, Dunman, Murphy, Projan & Bradford, 2005). Multidrug-efflux 
pumps of the MFS are capable of extruding, besides biocides, several antimicrobials namely 
virginiamycin, novobiocin, mupirocin, fusidic acid and fluoroquinolones by MdeA (Huang, 
O'Toole, Shen, Amrine-Madsen, Jiang, Lobo, Palmer, Voelker, Fan, Gwynn & McDevitt, 
2004; Yamada, Shiota, Mizushima, Kuroda & Tsuchiya, 2006a) and oxazolidinones, phen-
icols, trimethoprim, erythromycin, kanamycin and fusidic acid by LmrS (Floyd, Smith, Kumar, 
Floyd & Varela, 2010). Both chromosomally encoded efflux systems SepA and SdrM only ef-
flux low levels of biocides (Narui, Noguchi, Wakasugi & Sasatsu, 2002; Yamada, Hideka, 
Shiota, Kuroda & Tsuchiya, 2006b). Contrary to the chromosomally-encoded efflux pumps, 
the plasmid-mediated pumps have been detected in several staphylococcal species and are 
only able to efflux biocides (Costa et al., 2013). They are often reported in staphylococcal 
strains from food products and food-producing animals (Heir et al., 1999; Bjorland, Steinum, 
Kvitle, Waage, Sunde & Heir, 2005). But these pumps, especially QacA and QacB, are also 
commonly found in clinical samples (Alam, Kobayashi, Uehara & Watanabe, 2003; Correa, 
De Paulis, Predari, Sordelli & Jeric, 2008; Smith, Gemmel & Hunter, 2008). The genes en-
coding these pumps, qacA and qacB respectively, are often carried in the same mobile ge-
netic element as the blaZ gene, encoding resistance to penicillin/ampicillin, in clinical and 
food-related staphylococci (Sidhu, Heir, Sørum & Holck, 2001; Sidhu, Heir, Leegaard, Wiger 
& Holck, 2002). Although Smr, QacG, QacH and QacJ have differences in their amino acid 
sequences, all these pumps share almost identical substrate specificities, extruding similar 
levels of benzalkonium chloride, ethidium bromide and cetyltrymethylammonium bromide 
(Costa et al., 2013).  
Triclosan is often used to control MRSA outbreaks (Sheldon, 2005) and in vitro studies have 
showed that some S. aureus and S. epidermidis strains have higher MICs than others (Suller 
& Russell, 2000; Al-Doori, Morrison, Edwards & Gemmel, 2003; Schmid & Kaplan, 2004). A 
novel mechanism with high potential for horizontal transfer of decreased susceptibility to 
triclosan was described recently (Ciusa, Furi, Knight, Decorosi, Fondi, Raggi, Coelho, Ar-
agones, Moce, Visa, Freitas, Baldassarri, Fani, Viti, Orefici, Martinez, Morrissey & Oggioni, 
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2012). The gene sh-fabI was suggested to have originated from S. haemolyticus core ge-
nome, transferred to S. aureus and from the S. aureus chromosome to plasmids (Ciusa et 
al., 2012). The fabI gene is the target of triclosan and the presence of the sh-fabI and the 
original fabI gene increases the target amount through heterologous target duplication (Ciusa 
et al., 2012). 
Although these mechanisms are capable of interfering with biocide activity, their actual clini-
cal significance remains unknown (Sheldon, 2005). Most of the times, in the literature we find 
“biocide resistance” associated with high MICs, yet the biocide in-use concentration is much 
higher than the MIC and so this is not truly resistance (Cerf et al., 2010). One study has 
evaluated the susceptibilities of MRSA isolates to seven biocides using the appropriate in-
use concentrations and time of exposure and found some strains had minimum bactericidal 
concentrations (MBCs) to some biocides higher than user concentrations but failed to relate 
this inefficacy with the presence of efflux pumps (Narui, Takano, Noguchi & Sasatsu, 2007). 
However, some of these efflux pumps are able to secrete antimicrobials as well and the wide 
availability and common misuse of biocides can lead to the counter selection of staphylococ-
ci with these mechanisms (Sheldon, 2005). Likewise, the widespread use of antimicrobials 
can lead to the selection of bacteria carrying efflux-pumps and probably selecting for biocide 
tolerance (Sheldon, 2005). 
 
1.5 Epidemiology of staphylococci 
The epidemiology of infectious diseases relies on typing methods as tools for the characteri-
zation and discrimination of isolates based on their genotypic or phenotypic characteristics, 
which may be used to establish clonal relationships between strains and to trace the geo-
graphic dissemination of bacterial clones (Faria, Carriço, Oliveira, Ramirez & de Lencastre, 
2008).  
 
1.5.1 Single-locus typing methods 
Single locus sequence typing (SLST) is used to determine the relationships among bacterial 
isolates based on the comparison of sequence variations in a single target gene (Sabat, Bu-
dimir, Nashev, Sá-Leão, van Dijl, Laurent, Grundmann & Friedrich, 2013). The most widely 
used method of the SLST group is the S. aureus protein A gene (spa)-typing, but other SLST 
are also useful (Sabat et al., 2013). 
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Table 6. Multidrug-resistant efflux pumps described in staphylococci (adapted from Costa et al., 2013). 
Pump Family Substrate specificity Staphylococcal species Reference 
Chromosomally encoded efflux pumps 
NorA MFS QACs, dyes and fluoroquinolones S. aureus Yoshida et al., 1990 
NorB MFS QACs, dyes, fluoroquinolones and tetracyclines S. aureus Ding et al., 2008 
NorC MFS Dyes, fluoroquinolones S. aureus Truong-Bolduc et al., 2006 
MepA MATE QACs, dyes, fluoroquinolones, glycylcyclines S. aureus Kaatz et al., 2005 
MdeA MFS 
QACs, dyes, fluoroquinolones, virginiamycin, no-
vobiocin, mupirocin, fusidic acid 
S. aureus Huang et al., 2004; Yamada et al. 2006a 
LmrS MFS 
QACs, dyes, oxazolidinones, phenicols, trime-
thoprim, erythromycin, kanamycin and fusidic acid 
S. aureus Floyd et al., 2010 
SepA Unknown QACs, dyes, biguanidines S. aureus Narui et al., 2002 
SdrM MFS Dyes, fluoroquinolones S. aureus Yamada et al., 2006b 
Plasmid encoded efflux pumps 
QacA MFS QACs, dyes, biguanidines, diamidines 
S. aureus, S. epidermidis, S. haemolyti-
cus, S. hominis, S. warneri 
Paulsen et al., 1996; Heir et al., 1999; Bjor-
land et al., 2005; Correa et al., 2008 
QacB MFS QACs, dyes 
S. aureus, S. epidermidis, S. haemolyti-
cus, S. hominis, S. warneri 
Paulsen et al., 1996; Heir et al., 1999; Bjor-
land et al., 2005; Correa et al., 2008 
Smr or 
QacC 
SMR QACs, dyes 
S. aureus, S. caprae, S. cohnii, S. epi-
dermidis, S. haemolyticus, S. hominis, S. 
pasteuri, S. saprophyticus, S. warneri 
Heir et al., 1999; Bjorland et al., 2005; Cor-
rea et al., 2008 
QacG SMR QACs, dyes 
S. cohnii, S. haemolyticus, S. hominis, S. 
warneri 
Heir et al., 1999; Bjorland et al., 2005; Cor-
rea et al., 2008 
QacH SMR QACs, dyes S. haemolyticus, S. saprophyticus Heir et al., 1998; Correa et al., 2008 
QacJ SMR QACs, dyes 
S. aureus, S. delphini, S. intermedius, S. 
haemolyticus, S. hominis, S. simulans 
Bjorland et al., 2003; Bjorland et al., 2005; 
Correa et al., 2008 
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1.5.1.1 spa typing 
In 1996, Frenay and colleagues developed a single-locus sequence typing method for S. au-
reus using the sequence of polymorphic X or short sequence repeat region of the spa gene 
as an alternative technique for the typing of S. aureus (Frenay, Bunschoten, Schouls, van 
Leewen, Vandenbroucke-Gauls, Verhoef & Mooi, 1996). The polymorphic X region consists 
of a variable number of 21 bp to 27 bp repeats and is located upstream of the region encod-
ing the C-terminal cell wall attachment sequence (Schneewind, Model & Fischetti, 1992). The 
diversity of the region seems to arise from deletion and duplication of the repetitive units and 
also by point mutation (Brigido, Baradi, Bonjardin, Santos, Junqueira & Brentani, 1991). The 
existence of well-conserved regions flanking the X region coding sequence in spa gene al-
lows the use of primers for polymerase chain reaction (PCR) amplification and direct se-
quence typing (Shopsin, Gomez, Montgomery, Smith, Waddington, Dodge, Bost, Riehman, 
Naidich & Kreiswirth, 1999). Moreover, the determination of spa types was simplified when 
appropriate software synchronized with an accompanying public website was developed 
(Harmsen, Claus, Witte, Rothgänger, Claus Turnwald & Vogel, 2003). A potential problem 
with spa typing is that it involves sequencing of only one small region of the chromosome, 
which is subject to recombination between unrelated clones (Cookson, Robinson, Monk, 
Murchan, Deplano, de Ryck, Struelens, Scheel, Fussing, Salmenlinna, Vuopio-Varkila, Cuny, 
Witte, Tassios, Legakis, van Leeuwen, van Belkum, Vindel, Garaizar, Haeggman, Olsson-
Liljequist, Ransjo, Muller-Premru, Hryniewicz, Rossney, O’Connell, Short, Thomas, 
O’Hanlon, & Enright, 2007). The actual mutation rate in the spa region during long-term per-
sistence has been reported to be one genetic change every 70 months (Kahl, Mellmann, 
Deiwick, Peters & Harmsen, 2005). This could result in isolates exhibiting the same spa type 
when they are unrelated by other methods (Cookson et al., 2007). Although spa-typing has a 
lower discriminatory ability than other molecular typing techniques (mainly pulsed-field gel 
electrophoresis [PFGE]) (Malachowa, Sabat, Gniadkowski, Krzyszton-Russjan, Empel, 
Miedzobrodzki, Kosowska-Shick, Appelbaum & Hryniewicz, 2005), its cost-effectiveness, 
ease of use, speed, excellent reproducibility, appropriate in vivo and in vitro stability, stand-
ardised international nomenclature, high-throughput by using a software, and full portability 
of data via the Ridom database, makes this method the currently most useful instrument for 
characterising S. aureus isolates at the local, national and international levels (Sabat et al., 
2013). 
The spa typing scheme for S. pseudintermedius was developed in 2009 and was tested 
against a collection of 31 MRSP isolates (Moodley, Stegger, Ben Zakour, Fitzgerald & 
Guardabassi, 2009). The results indicated there were two major MRSP clones: in Europe, 
clone sequence type (ST) 71-t02-III and in California, clone ST68-t06-V (Moodley et al., 
2009). Like for MRSA, the developed spa typing method seemed promising for the easy and 
rapid typing of MRSP (Moodley et al., 2009). However, some issues were detected later. 
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Some MRSP and most methicillin-susceptible S. pseudintermedius (MSSP) strains could not 
be typed by this method (Perreten, Kadlec, Schwarz, Gronlund-Andersson, Greko, Moodley, 
Kania, Frank, Bemis, Franco, Iurescia, Battisti, Duim, Wagenaar, van Duijkeren, Weese, 
Fitzgerald, Rossan & Guardabassi, 2010; Ruscher, Lübke-Becker, Semmler, Wleklinski, 
Paasch, Soba, Stamm, Kopp, Wieler & Walther, 2010). The spa PCR products of non-
typeable isolates could not be sequenced due to the presence of multiple bands that were 
found to be related to the presence of two adjacent spa genes (Perreten et al., 2010). For the 
purpose of overcoming this problem a nested PCR approach was described containing only 
the spa gene with the complete X-region (Perreten et al., 2010). However, another problem 
was that the same spa type could be found in unrelated STs and PFGE types (Perreten et 
al., 2010). This could be due to convergent evolution or genetic recombination (Perreten et 
al., 2010) and so care should be taken when interpreting variation in spa genes of S. 
pseudintermedius (Ruscher et al., 2010). 
 
1.5.1.2 agr typing 
The accessory gene regulator (agr) locus of S. aureus encodes a two-component signal 
transduction system that leads to down-regulation of surface proteins and up-regulation of 
secreted proteins during in vitro growth (Robinson, Monk, Cooper, Feil & Enright, 2005). Four 
auto-inducing peptide (AIP) variants of agr have been characterized in S. aureus (numbered 
I to IV) that generally induce agr activity within a group and inhibit agr activity between 
groups (Robinson et al., 2005). The inhibitory activity of agr groups may serve to isolate bac-
terial populations and facilitate the evolution of new strains or even species (Novick, 2003). 
This is based on the observation that a certain genetic background is usually represented by 
a given agr group; rarely is a given genetic background represented by multiple agr groups 
(Wright, Traber, Corrigan, Benson, Musser & Novick, 2005). Associations between agr group 
and certain strain characteristics may include resistance to glycopeptides (agr groups I and 
II) (Sakoulas, Eliopoulos, Moellering, Wennersten, Venkataraman, Novick & Gold, 2002; 
Verdier, Reverdy, Etienne, Lina, Bes & Vandenesch, 2004), isolation from toxic shock syn-
drome and from CA-MRSA disease (agr III) (Vandenesch et al., 2003), and isolation from 
staphylococcal scalded skin syndrome (agr IV) (Jarraud, Mougel, Thioulouse, Lina, 
Meugnier, Forey, Nesme, Etienne & Vandenesch, 2002). Epidemiological studies, however, 
generally conclude that agr groups have no obvious influence on strain colonization and 
competition dynamics in humans (van Leeuwen, van Nieuwenhuizen, Gijzen, Verbrugh & 
van Belkum, 2000; Robinson et al., 2005), questioning the proposal that agr-mediated bacte-
rial interference is an important means of isolating bacterial populations (Robinson et al., 
2005). 
Like S. aureus, the agrD locus in S. pseudintermedius has four predicted AIP variants, I to 
IV, as shown in Table 7 (Sung, Chantler & Lloyd, 2006; Bannoehr, Ben Zakour, Waller, 
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Guardabassi, Thoday, van den Broek & Fitzgerald, 2007). The AIP variants found in S. 
pseudintermedius were also found in the other members of the SIG, suggesting the exist-
ence of a conserved agr quorum-sensing system (Bannoehr et al., 2007). In contrast to S. 
aureus, studies on S. pseudintermedius suggest that recombination has frequently contribut-
ed to the association of different agr alleles with strains of S. pseudintermedius of identical 
genotypes (Bannoehr et al., 2007). Also contrary to S. aureus, no association between agr 
types and host, clinical or geographic origin has been found in S. pseudintermedius, ques-
tioning what selective pressure drives agr diversification (Bannoehr et al., 2007). 
 
Table 7. Amino acid sequences of the predicted agrD-encoded AIP identified in Staphylococcus intermedius 
group (adapted from Bannoehr et al., 2007). 






1.5.1.3 dru typing 
In 1991, a study conducted on the DNA sequence hypervariable region of the methicillin re-
sistance determinant (mec), revealed a minimal direct repeat unit (dru) of 40 bp which was 
repeated 10 times within 500 bp (Ryffler, Bucher, Kayser & Berger-Bächi, 1991). These dru 
sequences are responsible for the length and polymorphisms of mec (Ryffler et al., 1991). 
Later on, Nishi and colleagues (1995) characterized this region in other S. aureus isolates as 
well as in methicillin-resistant coagulase-negative staphylococci (MRCoNS) and found that 
the region could have between 2 and 11 repeats in S. aureus and up to 16-18 repeats in S. 
haemolyticus (Nishi, Miyanohara, Nakajima, Kitajima, Yoshinaga, Maruyama & Miyata, 
1995). Further studies using this epidemiological tool have concluded that the mec-
associated dru typing may have potential for identifying and tracking specific subtypes of 
otherwise indistinguishable epidemic MRS (Nahvi, Fitzgibbon, John & Dubin, 2001; Goering, 
Morrison, Al-Doori, Edwards & Gemmell. 2008). Identical SCCmec types can have different 
dru types and the same dru type can sometimes be found in different SCCmec types (Bar-
tels, Boye, Oliveira, Worning, Goering & Westh, 2013). The dt10a type has been proposed 
as the ancestor dru type for most MRSA lineages and the other dru types have evolved from 
this one (Bartels et al., 2013). MRCoNS have also been shown to carry dt10a (Bartels et al., 
2013). MRSA dru-negative isolates have been found and these usually belong to the ST225 
clone, which has suggested that the spread of this MRSA clone rather than several episodes 
of acquisition of an SCCmec lacking the dru region into the same genetic background has 
occurred (Bartels et al., 2013). For all these reasons, dru typing is not recommended as a 
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first line epidemiological typing method but might be informative for epidemiological subtyp-
ing and can add interesting information on the evolution of SCCmec (Bartels et al., 2013). 
 
1.5.2 Multi-locus sequence typing (MLST) 
MLST is a method of characterizing bacterial isolates on the basis of the sequences of ± 450 
bp of internal fragments of seven housekeeping genes (Maiden, Bygraves, Feil, Morelli, Rus-
sell, Urwin, Zhang, Zhou, Zurth, Caugant, Feavers, Achtmann & Spratt, 1998). For each 
gene locus, unique sequences (alleles) are assigned arbitrary numbers and, based on the 
combination of identified alleles (i.e. the 'allelic profile'), the ST is determined (Sabat et al., 
2013). MLST reveals slowly accumulating changes in conserved genes that reflect long-term 
evolutionary changes and can identify global spread of the relatively small number of suc-
cessful clones (Gomes, Vinga, Zavolan & de Lencastre, 2005). MLST has become popular 
due to the development of large-scale sequencing methodologies, ease of data transfer and 
excellent comparability of results (Aires-de-Sousa, Boye, de Lencastre, Deplano, Enright, 
Etienne, Friedrich, Harmsen, Holmes, Huijsdens, Kearns, Mellmann, Meugnier, Rasheed, 
Spalburg, Strommenger, Struelens, Tenover, Thomas, Vogel, Westh, Xu & Witte, 2006), 
however, MLST is not appropriate for routine infection control due to its limited discriminatory 
power (Cai, Kong, Wang, Tong, Sintchenko, Zeng, & Gilbert, 2007). 
In order to overcome the difficulty of comparing PFGE results and the genetic relatedness of 
the clones of MRSA described by different laboratories, Enright and colleagues (2000) de-
veloped a multilocus sequence typing for MRSA. Out of the fourteen housekeeping gene 
fragments sequenced, the seven housekeeping gene fragments that provided the greatest 
number of alleles were chosen for use in the MLST scheme and included: carbamate kinase 
gene (arcC), shikimate dehydrogenase gene (aroE), glycerol kinase (glpF), guanylate kinase 
(gmk), phosphate acetyltransferase (pta), triosephosphate isomerase (tpi) and acetyl coen-
zyme A acetyltransferase (yqiL) (Enright, Day, Davies, Peacock & Spratt. 2000).  
The first MLST scheme described for S. pseudintermedius included the following 5 house-
keeping genes: 16S rRNA (coding gene subunit ribosomal 16S rRNA), cpn60 (chaperonin 
60), tuf (elongation factor Tu), pta (acetyl phosphate) and agrD (accessory gene regulatory) 
(Bannoehr et al., 2007). However, this scheme was poorly discriminatory and was restruc-
tured to also include seven loci: purA (adenylosuccinate synthetase), fdh (formate dehydro-
genase), ack (acetate kinase), sar (sodium sulfate co-transporter) and the already described 
above pta, cpn60 and tuf genes (Solyman, Black, Duim, Perreten, van Duijkeren, Wagenaar, 
Eberlein, Sadeghi, Videla, Bemis & Kania, 2013). As for S. aureus, there is a worldwide da-
tabase for MLST S. pseudintermedius (http://pubmlst.org/spseudintermedius) easily accessi-
ble. 
Three different MLST schemes were published for S. epidermidis (Wang, Noble, Kreiswirth, 
Eisner, McClements, Jansen & Anderson, 2003; Wisplinghoff, Rosato, Enright, Noto, Craig & 
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Archer, 2003; Thomas, Vargas, Miragaia, Peacock, Archer & Enright, 2007). The first two 
described S. epidermidis MLST schemes were largely based on the scheme for S. aureus 
(Enright et al., 2000). By the use of different isolate collections, neither scheme was able to 
discriminate more than two CC (Thomas et al., 2007). A third scheme, assessed the ability of 
the 14 different loci used in these previous schemes (plus one scheme that was not pub-
lished) to discriminate between isolates of S. epidermidis and determined an MLST scheme, 
which was not as discriminatory as those developed for other species, including S. aureus 
(Enright et al., 2000), but was improved enough to provide the best discrimination of the 
MLST formats available at the time for the typing of S. epidermidis strains (Thomas et al., 
2007). 
In the MLST websites there is an algorithm available, denominated BURST (Based upon re-
lated sequence type), that allows the grouping of related in STs into clonal complexes (CC) 
(Enright, Robinson, Randle, Feil, Grundmann & Spratt, 2002). STs are considered related if 
at least five of the seven loci are equal (Enright et al., 2002). 
 
1.5.3 Pulsed-field gel electrophoresis (PFGE) 
PFGE separates DNA under conditions of alternating polarity allowing for the resolution of 
DNA fragments nearly 20-times larger than those separated by traditional agarose gel elec-
trophoresis (Leonard & Markey, 2008). PFGE is used in combination with restriction en-
zymes to give a DNA fingerprint of the bacterial genome (Tenover, Arbeit, Goering, Mickel-
sen, Murray, Persing & Swaminathan, 1995). The DNA restriction patterns of the isolates are 
then compared with one another to determine their relatedness (Tenover et al., 1995). The 
main advantage of this technique is that it provides great discrimination among strains and is 
useful in the investigation of outbreaks, by allowing differentiation of unrelated strains (Leo-
nardo & Markey, 2008). Until very recently PFGE was regarded as the molecular typing “gold 
standard” for S. aureus (Murchan, Kaufmann, Deplano, de Ryck, Struelens, Zinn, Fussing, 
Salmenlinna, Vuopio-Varkila, El Solh, Cuny, Witte, Tassios, Legakis, van Leeuwen, van 
Belkum, Vindel, Laconcha, Garaizar, Haeggman, Olsson-Liljequist, Ransjo, Coombes & 
Cookson, 2003). Disadvantages relate principally with difficulties in inter-laboratory compari-
son of results and consequently reliable comparison of strains between regions and interna-
tionally (Leonard & Markey, 2008), its time consuming and the expensive cost of the method 
(Montesinos, Salido, Delgado, Cuervo & Sierra, 2002). In 2003, Murchan et al., in a multicen-
ter study, described a consensus PFGE protocol for typing of strains of MRSA, which result-
ed in higher intercenter reproductibility, local acceptability and the establishment of a web-
based database of harmonized MRSA SmaI restriction patterns (Murchan et al., 2003). This 
protocol has been adapted, with minor modifications, for use in MRSP strains using the same 
restriction enzyme, SmaI (Perreten et al., 2010). MRSA isolates of ST398 cannot be typed 





site (Argudín et al., 2010). Yet, Cfr9I and XmaI, two SmaI-neoschizomers that cut in the 
same recognition sequence but at different positions can be used instead, allowing studies 
for outbreak investigations and traceability studies of MRSA ST398 (Argudín et al., 2010). 
 
1.5.4 SCCmec typing 
As stated before the mecA and mecC genes are carried on a genetic element, called SCC-
mec (Hiramatsu et al., 2001). This element inserts precisely into the staphylococcal chromo-
some at orfX (Hiramatsu et al., 2001). It can be found in various Staphylococcus species yet 
the original donor remains unknown (Enright, 2003). SCCmec elements are highly diverse in 
their structural organization and genetic content and have been classified into types and sub-
types (International Working Group on the Classification of the Staphylococcal Cassette 
Chromosome Elements [IWG-SCC], 2009). Types are defined by the combination of (i) the 
type of ccr gene complex (Tables 8 and 9) and (ii) the class of the mec gene complex (Table 
10) and an example is shown in Figure 9 (IWG-SCC, 2009). 
 







The ccr complex is constituted by the ccr gene(s) and surrounding open reading frames 
(IWG-SCC, 2009). Three distinct ccr genes, ccrA, ccrB and ccrC, have been identified (IWG-
SCC, 2009). In S. aureus, 4 allotypes of ccrA and ccrB have been found, however in S. 
pseudintermedius and in CoNS others have been described (IWG-SCC, 2009; Zong, Peng & 
Lü, 2011). 
Table 8. Currently classified ccr gene complexes (adapted from IWG-SCC, 2009). 
ccr gene complexes ccr genes 
SCCmec types carrying the ccr 
gene complexes 
Type 1 A1B1 I, IX 
Type 2 A2B2 II, IV 
Type 3 A3B3 III 
Type 4 A4B4 VI, VIII 
Type 5 C1 V, VII 
Type 6 A5B3 - 
Type 7 A1B6 X 
Type 8 A1B3 XI 
 





As methicillin-resistance is prevalent in CoNS, these species may serve as reservoirs of 
SCCmec (Zong et al., 2011). SCCmec elements are more diverse in CoNS, with new vari-
ants of the ccr genes continuing to be frequently identified (Zong et al., 2011). 
 
Table 9. Identified ccr genes in staphylococci (adapted from Zong et al., 2011). 
ccr genes Staphylococcal species 
A1B4 S. saprophyticus 
A5B3 S. hominis, S. cohnii, S. pseudintermedius, S. haemolyticus 
A2B2 & C1 S. epidermidis, S. haemolyticus 
A1B1 & C1 S. cohnii, S. hominis 
A4B4 & C1 S. epidermidis 
 
The mec gene complex is constituted by the mecA or mecC, its regulatory genes, and asso-
ciated insertion sequences (IS) (IWG-SCC, 2009). The class A mec gene complex is the pro-
totype, containing the mecA and the complete mecR1 and mecI regulatory genes (IWG-SCC, 
2009). Downstream of mecA there is the hypervariable region and IS431 (IWG-SCC, 2009). 
 
Table 10. Currently identified mec gene complexes in staphylococci (adapted from IWG-SCC, 2009). 
mec gene complexes Sequence 
SCCmec types carrying the 
mec gene complexes 
Class A IS431-mecA-mecR1-mecI II, III, VIII 
Class B IS431-mecA-∆mecR1-IS1272 I, IV, VI 
Class C1 IS431-mecA-∆mecR1-IS431 VII, X 
Class C2 IS431-mecA-∆mecR1-IS431 V, IX 
Class D IS431-mecA-∆mecR1 - 
Class E blaZ-mecC-mecCR1-mecCI XI 
 
Each SCCmec type has been further classified into subtypes based on the polymorphisms or 
variations in J regions within the same ccr gene complex and mec gene complex combina-
tion (IWG-SCC, 2009). 
The first MRSA isolated carried an SCCmec type I (Enright, 2003). The predominant SCC-
mec type in CA-MRSA is type IV (Vandenesch et al., 2003). The most prevalent SCCmec 
types in MRCoNS are types III, IV and V (Zong et al., 2011). SCCmec type III is the predom-
inant type in the S. sciuri group, SCCmec type IV in S. epidermidis, SCCmec type V in S. 
haemolyticus and SCCmec type VI in S. hominis (Zhang, Agidi & LeJeune, 2009; Faria, 
Conceição, Miragaia, Bartels, de Lencastre & Westh 2014). 
The first MRSP strains described in Europe and North America harboured mainly SCCmec III 
and SCCmec V, respectively (Sasaki et al., 2007; Black, Solyman Eberlein, Bemis, Woron & 
Kania, 2009). After, two other cassettes have been identified in MRSP strains, SCCmec II-III 
and SCCmec VII, which belong to class A, allotype 3, and class A, allotype 5, respectively 
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(Descloux, Rossano & Perreten, 2008). SCCmec II-III consists of a combination of S. aureus 
SCCmec III and S. epidermidis SCCmec II (Descloux et al., 2008). SCCmec IV has also 
been identified, recently, in MRSP of lineage ST261 (McCarthy et al., 2014). One SCCmec 
element from MRSP lineage CC45 was firstly identified as non-typeable and was later re-
classified as a pseudo-SCCmec element (ψSCCmec57395) due to the lack of ccr genes (Per-
reten et al., 2013).  
The mecC gene is present as part of a type XI SCCmec element inserted at orfX carrying the 
regulators mecI-mecR1, as part of a class E mec complex that shares structural similarity 
(mecI-mecR1-mecC-blaZ) with a mec gene complex, containing the mecB gene, found in 
Macrococcus caseolyticus (Tsubakishita, Kuwahara-Arai, Baba & Hiramatsu, 2010). The 
SCCmec XI element also includes the recombinase genes ccrA1B3 (type 8 ccr) and arsenic 
resistance genes (Shore, Deasy, Slickers, Brennan, O'Connell, Monecke, Ehricht & Cole-
man, 2011). 
 
1.5.5 Whole-genome sequencing (WGS) 
WGS is being considered the ultimate tool for epidemiological typing of bacteria and other 
pathogens, including staphylococci (Struelens & Brisse, 2013). This technique combines two 
major advantages compared to previous methods: maximal strain discrimination, and link to 
clinically and epidemiologically relevant phenotypes (Struelens & Brisse, 2013). Furthermore, 
WGS provides full genomic characteristics of the infectious isolates, including the set of 
genes linked to antimicrobial resistance (the resistome) and those linked to virulence of the 
isolates (the virulome) (Sabat et al., 2013; Struelens & Brisse, 2013). The main disadvantage 
of this typing is its cost, however they are continuously declining (Sabat et al., 2013). 
 
1.5.6 Epidemiology of CoPS 
1.5.6.1 Epidemiology of S. aureus 
The first MRSA described was isolated in England in 1961 and was only resistant to β-lactam 
antimicrobials (Jevons, 1961). In the following years after the identification of the first case of 
MRSA infection, this agent spread globally and it has become highly prevalent in hospitals all 
over the world (Stefani, Chung, Lindsay, Friedrich, Kearns, Westh & MacKenzie, 2012). In 
general, the highest prevalence (>50%) of MRSA is present in America and Asia and inter-
mediate prevalence (25-50%) is detected in Australia, China and Africa (Stefani et al., 2012). 
In Europe, there is an enormous variability in the prevalence (0-65%) of MRSA among coun-
tries: in the south and southeast region (e.g. Portugal, Italy, Greece, Malta and Romania) 
rates are generally higher than in the north (e.g. Netherlands, Sweden, Norway and Den-
mark) (European Antimicrobial Resistance Surveillance Network [EARS-Net], 2014). For a 
long time, these MRSA infections were limited to the hospital environment and were denomi-
nated hospital/healthcare-acquired/associated MRSA (HA-MRSA), and occurred especially 
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in patients with risk factors such as prolonged hospitalization, prolonged antimicrobial thera-
py, surgical interventions, patients with weakened immune system and/or with contact with 
MRSA positive people (Catry, van Duijkeren, Pomba, Greko, Moreno, Pyörälä, Ruzauskas, 
Sanders, Threlfall, Ungemach, Törneke, Munoz-Maduro & Torren-Edo, 2010). Only a small 
number of clones were successful in this environment (Stefani et al., 2012). The main HA-
MRSA clones belonged to CC5, CC8, CC22, CC30 and CC45 (Enright et al., 2002; Stefani et 
al., 2012.). The distribution of these clones varies geographically, with some lineages clus-
tered in specific geographical locations (Stefani et al., 2012). For example, the HA-MRSA 
dominant clones in the United States of America are the ST5-II (USA100), ST5-IV (USA800) 
and ST8-IV (USA500), in the United Kingdom and Portugal is the ST22-IV (EMRSA-15), 
while in Germany the CC5 and ST45-IV clones are the most frequent. In South America, 
Australia and Asia the ST239-III is the main clone (Stefani et al., 2012). In general, the 
clones CC5 and CC8 are the most prevalent worldwide, and the CC22 is also very spread 
(Stefani et al., 2012). 
In recent years, there have been MRSA infections in healthy young people in the community, 
without the typical risk factors associated with nosocomial infections (Stefani et al., 2012). 
The strains responsible for these types of infection are phenotypically and genotypically dis-
tinct of HA-MRSA strains; having received the designation CA-MRSA (Otter & French, 2010). 
There are several definitions for CA-MRSA, but a globally accepted definition is that the iso-
lates that are CA-MRSA are isolated from an outpatient or from a patient on the first 48 hours 
after admission to the hospital; as long as such a patient does not have history of previous 
MRSA colonization or infection, or hospitalization, surgical procedures or dialysis in the last 
year, and does not have permanent catheters (Otter & French, 2010). CA-MRSA clones are 
genetically diverse, belonging to a wide variety of lineages, and some belong to HA-MRSA 
clones (Otter & French, 2010). Similarly to nosocomial clones, CA-MRSA clones are also as-
sociated with specific geographic locations: USA300 is extremely widespread in the USA, the 
Southwest-Pacific clone (ST30-IVc) and the Queensland clone (ST93-IVa) in Australia and 
New Zealand; the Taiwan clone (ST59-IVa, ST59-V) and USA700 (ST72-IVc) in Asia; ST88-
IV in Africa and the European clone (ST80-IVc) in Europe (Rolo, Miragaia, Turlej-Rogacka, 
Empel, Bouchami, Faria, Tavares, Hryniewicz, Fluit, de Lencastre & the CONCORD Working 
Group, 2012b). However, it has been observed a spill over of S. aureus clones from the hos-
pital into the community, including ST22-IVh, ST105-II and ST5-IVc clones (Espadinha, Far-
ia, Miragaia, Lito, Melo-Cristino & de Lencastre, 2013).  
In the early 2000s a new category of MRSA emerged in humans due to exposure to livestock 
(livestock-associated MRSA [LA-MRSA]) (Armand-Lefevre, Ruimy & Andremont, 2005; Voss, 
Loeffen, Bakker, Klaassen & Wulf, 2005). These LA-MRSA strains were associated with lin-
eage ST398 and were mainly found in pigs (Armand-Lefevre et al., 2005; Voss et al., 2005). 
Since then MRSA ST398 have been detected in several species, including horses (Van den 
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Eede, Martens, Lipinska, Struelens, Deplano, Denis, Haesebrouck, Gasthuys & Hermans, 
2009), dogs (Nienhoff, Kadlec, Chaberny, Verspohl, Gerlach, Schwarz, Simon & Nolte, 
2009), cats (Weiß, Kadlec, Feßler & Schwarz, 2013), cows (Feβler, Scott, Kadlec, Ehricht, 
Monecke & Schwarz, 2010) and turkeys (Vossenkuhl, Brandt, Fetsch, Käsbohrer, Kraushaar, 
Alt & Tenhagen, 2014) around the world (Price, Stegger, Hasman, Aziz, Larsen, Andersen, 
Pearson, Waters, Foster, Schupp, Gillece, Driebe, Liu, Springer, Zdovc, Battisti, Franco, 
Żmudzki, Schwarz, Butaye, Jouy, Pomba, Porrero, Ruimy, Smith, Robinson, Weese, Arriola, 
Yu, Laurent, Keim, Skov & Aarestrup, 2012). MRSA ST398 has already been detected in 
Portugal, as colonizers and as infecting pathogens causing exsudative epidermitis in pigs 
(Pomba, Hasman, Cavaco, Fonseca & Aarestrup, 2009; Pomba et al., 2010). Three different 
SCCmec types (IV, V and VII-like) and several subtypes (IVa, IVc, Va, Vb, Vc) have been de-
tected in ST398 (Price et al., 2012; Chlebowicz, Bosch, Sabat, Arends, Grundmanna, van 
Dijla & Buist, 2013). One of these subtypes, with major structural differences in the J1 region, 
is specifically associated with ST398 PVL-positive strains (Chlebowicz et al., 2013). MRSA 
ST398 originated in humans as MSSA and then jumped from humans to livestock, loosing 
the phage-carried human virulence genes (ϕSa3 phage carrying genes sak [staphylokinase], 
chp [chemotaxis inhibitory protein] and scn [staphylococcal complement inhibitor]) and ac-
quiring tetracycline [tet(M) gene] and methicillin resistance (Price et al., 2012). Furthermore, 
a small cluster of avian CC398 strains acquired ϕAvβ prophage and two genes that belong to 
the avian-niche-specific accessory gene pool (Price et al., 2012). A rare subclass of MRSA 
ST398 strains carry the toxin Panton-Valentine leukocidin (PVL) and are tetracycline suscep-
tible (Welinder-Olsson, Florén-Johansson, Larsson, Oberg, Karlsson & Ahrén, 2008; Chle-
bowicz, Nganou, Kozytska, Arends, Engelmann, Grundmann, Ohlsen, van Dijl & Buist, 2010; 
Stegger, Lindsay, Sørum, Gould & Skov, 2010), in contrast to the vast majority of known 
livestock-associated ST398 isolates that are PVL-negative and tetracycline resistant (Wulf, 
Tiemersma, Kluytmans, Bogaers, Leenders, Jansen, Berkhout, Ruijters, Haverkate, Isken & 
Voss, 2008). 
Another MRSA clone that has jumped from humans to animals is CC5 (Lowder, Guinane, 
Ben Zakour, Weinert, Conway-Morris, Cartwright, Simpson, Rambaut, Nübel & Fitzgerald, 
2009). The clone CC5 is one of the most successful human-associated lineages of S. aure-
us, characterized by its global distribution and frequent emergence of methicillin-resistant 
strains (Nübel, Roumagnac, Feldkamp, Song, Ko, Huang, Coombs, Ip, Westh, Skov, Struel-
ens, Goering, Strommenger, Weller, Witte & Achtman, 2008). The majority of S. aureus iso-
lates from broiler chickens descend of a single human-to-poultry host jump that occurred ap-
proximately 38 years ago by a subtype of the human CC5 clonal lineage unique to Poland 
(Lowder et al., 2009). In contrast to human subtypes of CC5 that cluster geographically, the 
poultry CC5 clade is distributed in different continents (Lowder et al., 2009). Like in ST398, 
the poultry CC5 clade has undergone genetic diversification from its human progenitor strain 
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by acquisition of novel mobile genetic elements (ϕAvβ prophage) from an avian-specific ac-
cessory gene pool, and by the inactivation of several proteins important for human disease 
pathogenesis (ϕSa3 phage) (Lowder et al., 2009). Interestingly, an increase in the preva-
lence of skeletal infections of poultry, a major cause of lameness in the industry, is correlated 
with the emergence and wide dissemination of the CC5 poultry subtype (Lowder et al., 
2009). Of note, CC5 is associated with increased frequency of haematogenous infections in 
humans, including osteomyelitis (Fowler, Nelson, McIntyre, Kreiswirth, Monk, Archer, Feder-
spiel, Naidich, Remortel, Rude, Brown, Reller, Corey & Gill, 2007), consistent with the largely 
skeletal tropism of infections caused by the poultry CC5 clade (Lowder et al., 2009). In the 
United States of America MRSA from cats and dogs were mainly CC5 (USA100), and had 
genotypic and virulence profiles more similar to each other than to those of horses (Lin, 
Barker, Kislow, Kaldhone, Stemper, Pantrangi, Moore, Hall, Fritsche, Novicki, Foley & 
Shukla, 2011). This clone has also been detected in horses in the United States of America 
(Lin et al., 2011) and from bovine milk in Japan (Hata, Katsuda, Kobayashi, Uchida, Tanaka 
& Eguchi, 2010). In Japan, this lineage, uncommon among bovine isolates but common in 
human MRSA isolates, could have been introduced by humans due to the entrance of unau-
thorized personnel and ambulatory patients in dairy farms (Hata et al., 2010).  
Contrary to CC5 and ST398, MRSA lineage CC97, a major bovine S. aureus complex, 
jumped from livestock-to-human (Spoor, McAdam, Weinert, Rambaut, Hasman, Aarestrup, 
Kearns, Larsen, Skov & Fitzgerald, 2013). Methicillin resistance was acquired by human 
CC97 clones subsequent to the host jump from cows (Spoor et al., 2013). Furthermore, hu-
man CC97 clades also acquired the ϕSa3 phage and some strains had the arginine catabo-
lite mobile element (ACME), characteristic of CA-MRSA clones that contributes to enhanced 
survival during infection (Spoor et al., 2013). 
In 2011 a novel variant of mecA was identified in S. aureus from cattle (Garcia-Alvarez et al., 
2011). This variant was identified in MRSA strains of the CC130 (Shore et al., 2011). After 
the first description it has been described in humans, and a range of other animal species in 
Denmark, France, The Netherlands, Ireland, Germany, Belgium, and the United Kingdom 
(Garcia-Alvarez et al., 2011; Becker, Larsen, Skov, Paterson, Holmes, Sabat, Friedrich, 
Köck, Peters & Kriegeskorte, 2013; Loncaric, Kübber-Heiss, Posautz, Stalder, Hoffmann, 
Rosengarten & Walzer, 2013). This subtype was originally designated mecALGA251 but it has 
been renamed mecC and shares 70% nucleotide identity with the mecA gene (Becker et al., 
2013). The frequency of human infection with LA-MRSA CC130 is even lower than for LA-
MRSA ST398 (Guardabassi, Larsen, Weese, Butaye, Battisti, Kluytmans, Lloyd & Skov, 
2013). However, there are potential diagnostic problems associated with the detection of the 
mecC gene and the emergence of novel MRSA lineages in animals (Guardabassi et al., 
2013). Isolates carrying the mecC gene are not detected by conventional confirmatory tests 
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(i.e. standard mecA PCR and PBP2a latex agglutination test) thereby creating the potential 
for misdiagnosis and inappropriate therapy (Guardabassi et al., 2013). 
Several epidemiological studies have described the incidence and characteristics of MRSA in 
companion animals (Weese & van Duijkeren, 2010). Usually MRSA clones found in dogs and 
cats tend to be those that predominate in humans in a given region (Weese & van Duijkeren, 
2010). For example, Moodley and colleagues (2006) found that most MRSA strains found in 
cats and dogs in the United Kingdom and Ireland belonged to the ST22-IV (EMRSA-15) 
clone, which is, as mentioned above, one of the predominant clones in human hospitals in 
these two countries (Moodley, Stegger, Bagcigil, Baptiste, Loeffler, Lloyd, Williams, Leonard, 
Abbott, Skov, & Guardabassi, 2006). In Portugal, dogs and cats have also been showed to 
carry MRSA ST22-IV, which circulates in the human population in this country (Coelho, 
Torres, Radhouani, Pinto, Lozano, Gómez-Sanz, Zaragaza, Igrejas & Poeta, 2011; Couto, 
Pomba, Moodley & Guardabassi, 2011). MRSA ST239-III has been found in small animals in 
Australia (Malik, Coombs, O’Brien, Peng & Barton, 2006), the most frequent clone in human 
hospitals (Stefani et al., 2012). This strongly suggests that the principal origin for MRSA col-
onization and infection in companion animals is through contact with humans infected with or 
carrying MRSA (Leonard & Markey, 2008). Dogs and cats can then serve as reservoirs and 
act as a source of re-infection or re-colonization (Leonard & Markey, 2008). The distribution 
of MRSA clones in horses is a little bit different from dogs and cats (Weese & van Duijkeren, 
2010). The first MRSA strains isolated from horses belonged to ST8 and other STs within the 
CC8 (Weese & van Duijkeren, 2010). In the United States of America, CC8 was a typical eq-
uine clone (USA500), which emerged as an important HA-MRSA clone in this country de-
spite being responsible for a small percentage of infections in humans (Weese, 2010; Lin, 
Barker, Kislow, Kaldhone, Stemper, Pantrangi, Moore, Hall, Fritsche, Novicki, Foley & 
Shukla, 2011). The predominance of this human epidemic clone in horses suggested that it 
adapted to this animal species (van Duijkeren & Weese 2010). However in Europe, ST398 
was the predominant clone among horses suggesting they acquired this clone directly or in-
directly from food animals (van Duijkeren & Weese 2010). 
 
1.5.6.2  Epidemiology of S. pseudintermedius 
The first phenotypic MRSP strains were isolated in France in the mid-1980s from healthy 
dogs and dogs with pyoderma (Pellerin, Bourdeau, Sebbag & Person, 1998). However, only 
in 1999 was the first mecA-positive strain detected in United States of America from a dog 
with pyoderma (Gortel, Campbell, Kakoma, Whittem, Schaeffer & Weisiger, 1999). In Eu-
rope, only in 2005 were identified the first mecA-positive S. pseudintermedius strains (Loef-
fler, Linek, Moodley, Guardabassi, Sung, Winkler, Weiss & Lloyd, 2007). MRSP strains are 
particularly resistant to many different classes of antimicrobials, such as β-lactams, amino-
glycosides, fluoroquinolones, tetracyclines, lincosamides, macrolides, folate pathway inhibi-
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tors, and phenicols, thus limiting the therapeutic options (Frank & Loeffler, 2012). There are 
two major MRSP clones identified in Europe and North America and they are designated 
ST71-II-III (Europe) and ST68-V (North America), respectively (Black, Eberlein, Solyman, 
Wilkes, Hartmann, Rohrbach, Bemis & Kania, 2011). ST71 isolates have both the blaI/blaR1 
and mecI/mecR1 regulatory mechanisms controlling the expression of the mecA gene, lead-
ing to low levels of PBP2a (Black et al., 2011). ST68 isolates, however, only have the blaI 
and blaR1 regulating mecA expression, which results in high constitutive mecA expression 
even in the presence of only low concentrations of oxacillin (Black et al., 2011). Other clonal 
lineages have been reported to be predominant in some countries (Perreten, Chanchaithong, 
Prapasarakul, Rossano, Blum, Elad & Schwendener, 2013). In South China ST4, ST5, and 
ST95 were the dominant sequence types found in a study in 2012 (Feng, Tian, Lin, Luo, 
Zhou, Yang, Deng, Liu & Liu, 2012). In North China, on the other hand, the most prevalent 
genotypes detected were ST71-t06-II-III, followed by ST5-t19, ST126-III and ST6-t02-V 
(Wang, Yang, Logue, Liu, Cao, Zhang, Shen & Wu, 2012). In South America only recently 
MRSP strains were described, belonging to the European clone (ST71-III) (Quitoco, Ramun-
do, Silva-Carvalho, Souza, Beltrame, de Oliveira, Araújo, Del Peloso, Coelho & Figueiredo, 
2013). In Israel and Thailand, dogs and cats carried or were infected with specific MRSP 
strains that were non-typeable by SmaI PFGE and SCCmec typing using the Kondo method 
and were found to belong to a specific lineage, CC45 (ST45, ST57, ST85 and ST179), and 
carried a novel pseudo-SCCmec element with no ccr genes (Perreten et al., 2013). 
 
1.5.7 Epidemiology of CoNS 
An international study performed in Europe, Asia and Latin America revealed that approxi-
mately 70% of S. epidermidis strains circulating in the hospital environment are resistant to 
methicillin and a high percentage are also resistant to other antimicrobial classes (Sanches, 
Mato, de Lencastre, Tomasz, Nunes, Alves, Miragaia, Carriço, Couto, Bonfim, Aires de Sou-
sa, Oliveira, Gomes, Vaz, Fernandes, Verde, Ávila, Antunes, Sá-Leão, Almeida, Melter, 
Chung, Brandileone, Castañeda, Cocuzza, Echaniz-Aviles,  Heitmann,  Hortal, Hryniewicz, 
Jia, Kikuchi, Konkoly-Thege, Kristinsson, Liñares, Rossi, Savov, Schindler, Solorzano-
Santos, Totsuka, Venditti, Villari, Westh, Wu & Zanella, 2000). ST2 was identified in 13 dif-
ferent countries across 4 continents (Miragaia, Thomas, Couto, Enright & de Lencastre, 
2007). ST35 and ST57 were two lineages only found in Portugal (Miragaia et al., 2007). The 
most frequently found STs among carriage isolates was ST2, followed by ST59, ST22 and 
ST5; while among infection strains was ST2 followed by ST23 and ST59 (Miragaia et al., 
2007). There was more genetic diversity in methicillin-susceptible S. epidermidis than in 
methicillin-resistant S. epidermidis (MRSE), however CC2 was the predominant clonal line-
age in both (Miragaia et al., 2007). This genetic diversity may be due to the need for adapta-
tion to different environments in hospital and community settings, which in turn leads to in-
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creased frequency of horizontal gene transfer and dissemination of mobile genetic elements 
(Miragaia et al., 2007). Higher recombination rates were observed within CC2 due to a result 
of exclusive restriction modification systems between different S. epidermidis lineages (Mi-
ragaia et al., 2007). This mechanism, would actually favour the recombination between S. 
epidermidis strains belonging to CC2 opposed to recombination between strains of CC22 
and strains of other lineages (Miragaia et al., 2007). Hospital S. epidermidis has an epidemic 
population that evolves rapidly by means of recombination and frequent transfer of genetic 
mobile elements, including SCCmec (Miragaia et al., 2007). In fact a much higher genetic di-
versity in SCCmec was observed among hospital isolates (Rolo, de Lencastre & Miragaia, 
2012). In the hospital a large reservoir of SCCmec types exist in other CoNS, and this may 
contribute to the genetic diversity observed in S. epidermidis (Rolo et al., 2012). Specific 
physiological conditions during infection and stress imposed by the hospital environment can 
promote SCCmec excision/acquisition and dissemination in the S. epidermidis hospital popu-
lation (Rolo et al., 2012). SCCmec transfer may also be promoted during biofilm formation 
(Rolo et al., 2012). Hospital isolates, particularly those belonging to CC2, were associated 
with the presence of the ica operon and the ACME (Rolo et al., 2012). Very recently CC2 has 
been renamed CC5 (Rolo et al., 2012). CC5 is now the predominant clone in the hospital and 
community settings (Rolo et al., 2012). The great majority of these isolates carry SCCmec 
type IV, which probably confers advantages and has no fitness cost in either environment 
(Rolo et al., 2012).  
S. epidermidis has been isolated from small animals in Australia (Malik et al., 2006). Two 
STs were found, ST43 and ST60, which carried SCCmec IVb (Malik et al., 2006). Up until 
2006, those STs were unique in the MLST database and the authors suggested that those S. 
epidermidis strains were specific to cats and dogs (Malik et al., 2006). In Portugal, S. epi-
dermidis has been described in birds of prey, belonging to ST35 (CC2) (Sousa et al., 2014). 
A recent study examining S. aureus and CoNS from pig farms identified common SCCmec 
types shared in S. aureus and S. epidermidis from the same environmental niche, indicating 
the possibility of interspecies exchange of SCCmec (Tulinski, Fluit, Wagenaar, Mevius, van 
de Vijver & Duim, 2012). 
 
1.6 The problem of S. pseudintermedius 
One of the most common diseases caused by S. pseudintermedius is pyoderma in dogs 
(Figure 10) (Nuttall et al., 2013). Pyoderma is usually secondary to atopic dermatitis, a prurit-
ic allergic skin disease that results in disrupted skin barrier and predisposition for secondary 
S. pseudintermedius infections (Nuttall et al., 2013). Pyoderma is usually treated with antimi-




Figure 10. A dog with S. pseudintermedius pyoderma secondary to atopic dermatitis (original photo). 
 
 
The selective pressure imposed by the long-term administration of antimicrobials can lead to 
the development of bacterial resistance that could potentially be transmitted to human patho-
gens, like S. aureus. The recent emergence of MRSP has complicated considerably the 
treatment of infections caused by these bacteria. MRSP have become virtually resistant to all 
the antimicrobials approved for administration in companion animals, which has led to ethical 
concerns about the use of antimicrobials classified by the World Health Organization as “crit-
ically important” for human medicine (Frank et al., 2012). There has always been an interest 
in developing alternative options to antimicrobials, however since the appearance of multi-
drug-resistant S. pseudintermedius, this interest has been renewed. Several approaches can 
be chosen, like phage therapy, antivirulence drugs or vaccines. 
 
1.6.1 Phage therapy 
Bacteriophages or phages are viruses that invade bacterial cells and may disrupt bacterial 
metabolism and eventually cause lysis (Sulakvelidze, Alavidze & Morris, 2001). Recently, 
with the significant increase in the number of deaths caused by multidrug-resistant bacteria, 
including staphylococci, there was a renewed interest in phage therapy both in human and 
veterinary medicine (Thiel, 2004; Mann, 2008; Kaźmierczak, Górski & Dąbrowska, 2014). 
Phages against staphylococci belong to the Caudovirales order: phages with an icosahedral 
head, tube-like tail and linear, double-stranded DNA (Figure 11) (Ackermann, 2007). The 
members of this order are divided (Kropisinski, 2006): 
a) Morphologically, based on the length and complexity of their tales; 
b) Functionally, based on their effect upon host infection (lytic or lysogenic). 
Functionally, phages can be lytic or lysogenic/temperate (Kropisinski, 2006). Other authors 
divide further and consider phages into obligately lytic, temperate and chronic (Mann, 2008). 
Obligately lytic phages lead exclusively to cell death and release of progeny phages, since 
they can only undergo the lytic pathway (Kropisinski, 2006; Mann, 2008).  
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Figure 11. Functional characterization of the Caudovirales order (adapted from Kropisinski, 2006). 
 
The lysogenic or temperate phages may also lead to cell death, through the lytic pathway, or 
if the phage lytic functions are repressed, the virus genome coexists in a stable form (i.e. as 
a prophage) within its host (Kropisinski, 2006; Mann, 2008). In these cases, the virus DNA 
can either be integrated in the host DNA or remain separate (Kropisinski, 2006). A chronical-
ly infecting phage can release progeny into the extracellular environment without killing its 
host that can continue to grow and divide (Mann, 2008). Conventionally, lytic phages offer 
the greatest therapeutic potential since they invariably cause death of the bacterial host 
(Mann, 2008; Kaźmierczak et al. 2014). Temperate phages, on the other hand, are not suita-
ble for phage therapy because they may not kill the bacterial host (Mann, 2008). Further-
more, temperate phages may actually carry genes that turn the bacteria more virulent, in a 
process called lysogenic conversion (Kropisinski, 2006). Temperate phages encode a large 
proportion of S. aureus virulence factors (e.g. the immune evasion cluster [IEC]) and provide 
the pathogen with a large variety of toxins, allowing, for example, escaping the host immune 
system (Deghorain & Melderen, 2012). 
One of the first phage preparations against S. aureus was produced by D’Herelle’s commer-
cial laboratory in Paris and was called Bacté-staphy-phage (Sulakvelidze et al. 2001). In the 
1940s, the Eli Lilly Company (Indianapolis, Ind.) was producing therapeutic phages in the 














lysed, bacteriologically sterile broth cultures of the targeted bacteria (e.g. Staphylo-lysate) or 
the same preparations in a water-soluble jelly base (e.g. Staphylo-jel) (Sulakvelidze et al. 
2001). However, as stated before, these productions were discontinued and only institutions 
localized in Eastern Europe were actively involved in therapeutic phage research and pro-
duction (Sulakvelidze et al. 2001; Kaźmierczak et al. 2014). Indeed, in Georgia, phage prod-
ucts are available in pharmacies with a prescription (Kaźmierczak et al. 2014).  
Studies using phage therapy against staphylococcal infections seem promising. In the 1970s, 
Sakandelidze and colleagues administered phages against Staphylococcus, Streptococcus, 
and Proteus, subcutaneously or via a surgical drain daily for 5–10 days to human patients, 
leading to an improvement in 92% of the investigated cases (Sakandelidze & Meipariani, 
1974). In the 1980s, Ślopek and colleagues observed improvement in 75% of infected ulcer-
ated varicose vein cases and in 100% of cases of gastrointestinal infections, pericarditis, and 
furunculosis, caused by Staphylococcus species (Ślopek, Durlakowa, Weber-Dabrowska, 
Kucharewicz-Krukowska, Dabrowski & Bisikiewicz, 1983; Ślopek, Weber-Dabrowska, 
Dabrowski & Kucharewicz-Krukowska, 1987). Overall, in studies reported by the Hirszfeld In-
stitute of Immunology and Experimental Therapy, staphylococcal phages administered by dif-
ferent routes, topically, orally, or both, were effective in the treatment of bacterial infections 
(Sulakvelidze et al. 2001). 
Phage therapy has also been applied to animals. In fact, two companies offer phage lysates 
against Staphylococcus or phage cocktails applicable in veterinary medicine. One of them is 
a S. aureus phage lysate, which is actually a mixture of a S. aureus bacterin and a phage ly-
sate, SPL® (Delmont Laboratories Inc., Swarthmore, United States of America), which was 
used very frequently in the 80s and was considered highly effective for the treatment of idio-
pathic pyoderma caused by S. (pseud)intermedius in dogs (DeBoer, Moriello, Thomas & 
Schultz, 1990). The other is an antistaphylococcal phage lysate (Stafal®, Sevapharma, Pra-
ha, Czech Republic) recommended for topical applications in veterinary medicine, available 
in Czech Republic (Kaźmierczak et al. 2014). However, poor results were obtained in a study 
of the efficacy and pharmacokinetics of phage therapy to treat subclinical S. aureus mastitis 
in dairy cattle in a placebo-controlled multisite trial (Gill, Pacan, Carson, Leslie, Griffiths & 
Sabour, 2006a), due to an apparent inactivation of phage within the mammary gland. 
Phage therapy seems very promising, however, some scientific and logistical challenges re-
main (Thiel, 2004). Wild-type phage particles are rapidly eliminated by the body's reticulo-
endothelial (mononuclear phagocyte) system (Thiel, 2004). So in order to enhance the effi-
cacy of treatment, long-circulating mutants (Merril, Biswas, Carlton, Jensen, Creed, Zullo & 
Adhya, 1996) must be chosen, or wild-type virions must be protected with a non-
immunogenic polymer such as polyethylene glycol (Kim, Cha, Jang, Klumpp, Hagens, Hardt, 
Lee & Loessner, 2008). Some studies observed inhibitory effect of whey proteins on phage-
host interactions (Gill, Sabour, Leslie & Griffiths, 2006). The development of phage-
 61
neutralizing antibodies is another problem that has been documented after parenteral admin-
istration, which may obstruct phage effectiveness in lysing targeted bacteria (Kucharewicz-
Krukowska & Slopek, 1987). Another concern regarding the therapeutic use of lytic phages is 
development of phage resistance (Sulakvelidze et al. 2001). Bacterial resistance to phages 
will undeniably develop, although some authors state that the rate of developing resistance 
to phages is approximately 10-fold lower than that to antimicrobials (Carlton, 1999). This re-
sistance against phages can be partially avoided by using numerous phages in one prepara-
tion and/or in conjunction with antimicrobials (Sulakvelidze et al. 2001). In fact, phage thera-
py and antimicrobial therapy, given together, are synergistic (Kutateladze & Adamia, 2010). 
Moreover, like bacteria but unlike antimicrobials, phages mutate and so can develop to coun-
ter phage-resistant bacteria (Matsuzaki, Rashel, Uchiyama, Sakurai, Ujihara, Kuroda, 
Ikeuchi, Tani, Fujieda, Wakiguchi & Imai, 2005).  
 
1.6.2 Antivirulence therapy 
To infect animals, bacteria need to express certain factors, virulence determinants that allow 
them to enter and damage the host (Defoirdt, 2013). As virulence determinants are essential 
for infection, preventing bacteria from producing these factors will be a good way of control-
ling bacterial disease (Defoirdt, 2013). Antivirulence therapy is, therefore, based on the ability 
of disarming pathogens rather than killing them (Defoirdt, 2013). A thorough understanding of 
the bacterial pathogenesis is consequently needed to develop antivirulence drugs. There are 
two main ways of interfering with virulence (Defoirdt, 2013): 
 a) Inhibiting specific virulence factors, such as secretion systems or toxins; 
 b) Interfering with regulatory mechanisms that control the expression of virulence fac-
tors, such as quorum sensing and host-pathogen signalling. 
Both strategies have been used against staphylococci and some examples are present in 
Table 11 (Ragle, Karginov & Wardenburg, 2010; Qiu, Luo, Wang, Dong, Li, Leng, Zhang, 
Dai, Zhang, Niu & Deng, 2011a; Qiu, Luo, Dong, Wang, Li, Wang, Deng, Feng & Deng, 
2011b; Wang, Qiu, Dong, Li, Luo, Dai, Zhang, Leng, Niu, Zhao & Deng, 2011; Qiu, Niu, 
Wang, Xing, Leng, Dong, Li, Luo, Zhang, Dai, Luo & Deng, 2012; Dong, Qiu, Wang, Li, Dai, 
Zhang, Wang, Tan, Niu, Deng & Zhao, 2013).  
 
Table 11. Examples of antivirulence drugs tested against staphylococcal specific virulence factors. 
Compound Virulence target Model of infection Reference 
Apigenin 
(Extracted from parsley) 
Alpha-hemolysin 
In vitro A549 cells, in vi-
vo mouse model of 
pneumonia 





In vivo murine model of 
pneumonia 
Ragle et al. 
2010 
Chrysin Alpha-hemolysin In vitro A549 cells and in Wang et al. 
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(Present in honey, propolis 
and many plant extracts) 




(Present in Inula helenium – 
Compositae) 
Alpha-toxin 
In vivo mouse model of 
pneumonia 
Qiu et al. 
2011a 
Capsaicin 
(Present in red chilli - Cap-
sicum annuum) 
Alpha-toxin 
In vitro A549 cells, in vi-
vo mouse model of 
pneumonia 
Qiu et al. 
2012 
Menthol 
(Present in plants of the 
Mentha species) 
Alpha-hemolysin, enterotox-
ins A and B, toxic-shock 
syndrome toxin 1 
In vitro 
Qiu et al. 
2011b 
Note – A549 cells are human alveolar epithelial cells. 
 
Several compounds tested against S. aureus have shown promising in vitro and in vivo re-
sults. Interestingly, most of these compounds were developed against one toxin, designated 
alpha-toxin or alpha-hemolysin. Most of them inhibited the expression of alpha-toxin/alpha-
hemolysin and prevented alveolar cell injury (Qui et al. 2011a; Qui et al. 2011b; Qui et al. 
2012). Menthol was the only compound that could inhibit the expression of several virulence 
genes, α-hemolysin, enterotoxins A and B, and toxic shock syndrome toxin 1 in S. aureus 
(Qiu et al. 2011b). 
There are also several studies reporting antivirulence drugs testes against virulence regula-
tory mechanisms (Table 12) (Khodaverdian, Pesho, Truitt, Bollinger, Patel, Nithianantham, 
Yu, Delaney, Jankowsky & Shoham, 2013; Long, Mead, Hendricks, Hardy & Voyich, 2013; 
Nielsen, Mânsson, Bojer, Gram, Larsen, Novick, Frees, Frøkiær & Ingmer, 2014). 
 




Model of infection Reference 
Solonamide B 
(Isolated from the marine bacte-
rium Photobacterium halotolerans) 
agr In vitro rabbit erythro-
cytes and human neutro-
phils 
Nielsen et al. 
2014 
18β-Glycyrrhetinic acid 
(isolated from the licorice root 
Glycyrrhiza spp.) 
saeR In vivo mouse model of 
skin and soft tissue infec-
tion 
Long et al. 2013 
Diflunisal agr In vitro rabbit blood Khodaverdian et 
al. 2013 
 
Solonamide B was the first compound produced naturally by a Gram-negative marine bacte-
rium, that interfered with agr and affected both RNAIII and AgrA controlled virulence gene 
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expression in S. aureus (Nielsen et al. 2014). One the other hand, 18β-Glycyrrhetinic acid 
was isolated from a root (Glycyrrhiza spp.) and resulted in decreased expression of saeR 
and hla and significantly reduced skin lesion size in murine models (Long et al. 2013). 
Diflunisal is actually a nonsteroidal anti-inflammatory drug but also inhibits the expression of 
the regulatory mechanism agr by binding to AgrA protein (Khodaverdian et al. 2013).  
A main advantage of antivirulence therapy, comparing to antimicrobial treatment, is that there 
will be less interference with non-target organisms (i.e. the commensal microbiota), as it spe-
cifically targets virulence factors or virulence gene regulation (Khodaverdian et al. 2013). 
One other advantage is that antivirulence therapy will only pose selective pressure under 
conditions in which the virulence genes are required, therefore the tendency to develop re-
sistance and spread will probably also be lower, but not absent (Defoirdt, Boon & Bossier, 
2010). However, some resistance mechanisms that bacteria have acquired during exposure 
to antimicrobials could potentially give resistant to antivirulence agents (Defoirdt, 2013). 
 
1.6.3 Vaccines 
Vaccination is regarded as the most efficient and cost-effective method for the control of in-
fectious diseases in humans and animals and they can become immune by two methods: 
passive and active immunization (Figure 12) (Tizard, 2009).  
 







































Passive immunization is the transfer of immunity from one resistant animal to a susceptible 
one (Tizard, 2009). This type of immunization, also called therapeutic vaccination, gives im-
mediate protection against infection, however this protection declines and the animal ulti-
mately becomes susceptible again (Tizard, 2009). Active immunization on the other side in-
volves administration of an antigen to an animal, so that it builds an immune response (Tiz-
ard, 2009). The disadvantage with this immunization, also called prophylactic vaccination, is 
protection is not conferred immediately (Tizard, 2009). However, once an immune response 
is established it can be long lasting and capable of re-stimulation (Tizard, 2009). 
 
1.6.3.1 Passive Immunization 
This type of immunization requires that antibodies are produced in a donor animal by active 
immunization and then the antibodies are transferred to the recipient to confer immediate 
protection (Tizard, 2009). Serum containing these antibodies may be produced against a va-
riety of pathogens, including Staphylococcus species (Spellber & Daum, 2012). Several pas-
sive immunization vaccines against S. aureus have been tested in human clinical trails  (Ta-
ble 13) (Jansen, Girgenti, Scully & Anderson, 2013).  
 
Table 13. Overview of passive immunization vaccines against S. aureus (adapted from Otto, 2011; Proctor, 2012; 
Jansen et al. 2013). 
Name Company Target 
AltaStaph® Nabi 
Capsular polysaccharides types 5 
and 8 (CP5, CP8) 
Aurexis/Tefibazumab® Inhibitex Clumping factor A (ClfA) 
Aurograb® NeuTec/Novartis ABC Transporter 
Pagimaximab® Biosynexus Lipoteichoic acid 
ETI-211 Elusys/Pfizer Protein A (Spa) 
KBSA301 Kenta Biotech Alpha toxin 
MEDI4893 Medimmune LLC Alpha toxin 
Staphyban® Berne 
Whole cell vaccine and alpha tox-
in toxoid 
Veronate® Inhibitex 
Clumping factor A (ClfA) from S. 
aureus and Serine-aspartate re-
peat-containing protein G (SdrG) 
from S. epidermidis 
 
These vaccines were used in an attempt to help treating already established S. aureus infec-
tions, however efficacy in humans was not seen with any of the vaccines tested (Otto, 2010; 
Proctor, 2012; Jansen et al., 2013). 
The intent of passive immunotherapy is to inject enough preformed antibodies to bind and 
neutralize antigens (commonly toxins) and protect the host (Otto, 2010). So investigators aim 
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at eliminating major S. aureus virulence factors, such as toxins, instead of the whole bacteria 
(Otto, 2010). However, given the plasticity of staphylococcal toxins and virulence determi-
nants, a passive immunization vaccine should combine antibodies against several different 
virulence factors (Otto, 2010). As such, investigators should focus on the study of staphylo-
coccal pathogenesis to determine which virulence factors are essential for infection and 
therefore should be the target of passive immunotherapy (Otto, 2010). 
 
1.6.3.2 Active Immunization 
In active immunization, the immune system slowly develops its response against the antigen 
but this response is usually long lasting (Tizard, 2009). An idyllic vaccine for active immun-
ization should induce a prolonged strong immunity, without adverse side effects (Tizard, 
2009). Other characteristics must also be present (Tizard, 2009): 
 a) The antigen must be provided efficiently so that antigen-presenting cells can pro-
cess it and release the proper cytokines; 
 b) Both T and B cells should be stimulated so that memory cells are created; 
 c) The memory and effector T cells should recognize several epitopes, to avoid indi-
vidual variations in major histocompatibility complex (MHC) class II polymorphism; 
 d) The antigens should stimulate protection, through memory T cells, for as long as 
possible. 
Several human active immunization vaccines have been developed against staphylococci 
(Table 14) (Otto, 2011; Proctor, 2012; Jansen et al. 2013).  
 
Table 14. Overview of active immunization vaccines against S. aureus in humans (adapted from Otto, 2011; Proc-
tor, 2012; Jansen et al. 2013). 




Capsular polysaccharides 5 and 8 (CP5, CP8), wall 
techoic acid, non-toxic mutants of Panton-Valentine 




Adhesion protein fragment from Candida albicans with 
similar structure to Clumping factor A (CflA) 
SA3Ag Pfizer 
Capsular polysaccharides 5 and 8 (CP5, CP8), re-
combinant monoclonal antibodies against Clumping 
factor A (rmClfA) 
SA4Ag Pfizer 
Capsular polysaccharides 5 and 8 (CP5, CP8), re-
combinant monoclonal antibodies against Clumping 





Whole cell vaccine 
SAR279356 Sanofi Pasteur Polymeric N-acetylglucosamine (PNAG) 
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StaphVAX® Nabi 
Capsular polysaccharides 5 and 8 (CP5, CP8), conju-




Enterotoxin B (SEB) 
Unnamed Novartis 
Iron-regulated surface determinant A (IsdA), Iron-
regulated surface determinant B (IsdB), Serine-
aspartate repeat-containing protein D (SdrD), Serine-
aspartate repeat-containing protein E (SdrE) 
Unnamed Novartis 
Ferrichrome-binding protein (FhuD2), Ess extracellular 
A and B (EsxAB), alpha-hemolysin (Hla), Sur-2 
V710® Merck Iron-regulated surface determinant B (IsdB) 
 
All of these vaccines were efficient in protecting animal models against S. aureus infections, 
however, most failed to give significant protection in humans (Otto, 2010). There are several 
interpretations to why these vaccines failed (Proctor, 2012; Jansen et al., 2013): 
 a) Antibodies against one single antigen may not be sufficient to protect from staphy-
lococcal infections; 
 b) The antibodies developed may be opsonic but may not lead to the destruction of 
the phagocyted bacteria; 
 c) Antibody avidity has not been shown; 
 d) Competing anti-idiotype antibodies (e.g. antibodies raised against capsular poly-
saccharides and against PNAG) may interfere with the success of the vaccine; 
 e) Antibodies raised against the capsule may select for hyperadhesive strains, which 
may enhance biofilm formation and increase virulence; 
 f) Staphylococcal protein A (Spa) and Staphylococcus aureus binder of immuno-
globulin G (Sbi) proteins may interfere with antibodies; 
 g) Some staphylococcal strains do not produce virulence determinants to which the 
vaccine was developed (e.g. not all S. aureus produce capsule); 
 h) Opsonic antibodies may not give more protection than the protection already exist-
ent in non-vaccinated individuals. 
In spite of the problems found in human clinical trials, new attempts to develop vaccines 
based on active immunization are on going and will hopefully be successful (Otto, 2010). 
These vaccines try to overcome the problems found with the first vaccines developed and 
are based on research efforts in selecting the best vaccine targets (Otto, 2010). 
In animals there are also vaccines that were designed for active immunization (Table 15). 
Some of them are even commercialized although its efficacy is a matter of debate (Pereira et 
al., 2011). 
 
Table 15. Overview of active immunization commercially available vaccines against staphylococci in animals. 
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Name Company Target 





Whole-cell vaccine Bovine 
Mastivac® Laboratorios Ovejero S. A. Whole-cell vaccine Bovine 
Startvac® Laboratorios Hipra S. A. Whole-cell vaccine Bovine 
Vimco® Laboratorios Hipra S. A. Whole-cell vaccine Caprine 
SPL® Delmont Laboratories Inc. 
Whole-cell vaccine 
and phage lysate 
Canine 
 
1.6.3.3 Methods for the identification of novel staphylococcal antigens for vaccine 
development 
First generation vaccines were developed based on the Pasteur’s strategy, which was to iso-
late, inactivate or attenuate, and inject the pathogenic microorganism (Movahedi and Hamp-
son, 2008; Serruto and Rappuoli, 2006; Bagnoli, Baudner, Mishra, Bartolini, Fiaschi, Mariotti, 
Nardi-Dei, Boucher & Rappuoli, 2011; Prachi, Biagini & Bagnoli, 2012). During most of the 
20th century this was the approach used for the development of novel bacterial vaccines and 
today there are still several vaccines that are based on killed or live-attenuated microorgan-
isms (Movahedi and Hampson, 2008; Serruto and Rappuoli, 2006; Bagnoli et al., 2011; Pra-
chi et al., 2012). A second-generation of vaccines has been created based on the use of re-
combinant proteins and rationally attenuated strains (Movahedi and Hampson, 2008; Bagnoli 
et al., 2011; Prachi et al., 2012). However, novel approaches in the last decades enabled the 
identification of third-generation vaccine candidates (Movahedi and Hampson, 2008; Bagnoli 
et al., 2011; Prachi et al., 2012). This approach has been termed “Reverse Vaccinology” and 
is based in recent technologies like genomics, transcriptomics or proteomics (Movahedi and 
Hampson, 2008; Serruto and Rappuoli, 2006; Bagnoli et al., 2011; Prachi et al., 2012). There 
are limitations to these approaches and these will be discussed within each strategy. 
 
1.6.3.3.1 First-generation approach or Pasteur’s approach 
Since the development of vaccine therapy there has been an interest in the elaboration of a 
staphylococcal vaccine. Until the 1970s a variety of whole staphylococcal preparations was 
used in clinical and veterinary trials: these included cultured, attenuated, fixed or lysed or-
ganisms (Pankey, Boddie, Watts & Nickerson, 1985; Michie, 2002; García-Lara & Foster, 
2009; Pellegrino, Giraudo, Raspanti, Odierno & Bogni, 2010; Pereira et al., 2011). However, 
little benefit and common adverse reactions were seen when using these preparations (Gar-
cía-Lara & Foster, 2009). In humans, staphylococci cause a wide variety of infections, includ-
ing bacteraemia (Fischetti et al., 2006). One vaccine, SA75 developed by the Vaccine Re-
search International Plc and composed of a whole cell extract against staphylococcal infec-
tions, was evaluated in a phase I clinical trial and induced a significant immune response in 
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healthy individuals but it is still waiting for further clinical trials (Vaccine Research Interna-
tional Plc website). In food-producing animals, staphylococci, namely S. aureus, are the main 
causative agent of bovine, caprine and ovine mastitis (Wilson, Gonzalez & Das, 1997). Bo-
vine mastitis is the most prevalent disease of diary cows responsible for major economic 
losses on dairy farms worldwide (Wilson et al., 1997). The main causative agent of bovine 
mastitis is S. aureus (Pellegrino et al., 2010). In light of these facts some studies have ad-
dressed the efficacy of an avirulent S. aureus vaccine to control bovine mastitis. There are 
actually three commercially available inactivated S. aureus vaccines, Lysigin® (Boehringer 
Ingelheim Vetmedica, Inc., Ingelheim am Rhein, Germany), Mastivac® (Laboratorios Ovejero 
S.A., León, Spain) and Startvac® (Laboratorios Hipra S. A., Girona, Spain). There is also 
one inactivated S. aureus vaccine licensed for caprine and ovine mastitis, named Vimco® 
(Laboratorios Hipra S. A., Girona, Spain). Although a recent systematic review suggested 
that vaccines that employ new long-standing bacterins have achieved good results, which 
supports their use in the prevention and control of bovine mastitis caused by S. aureus, 
methodological differences and in some cases, a lack of more severe scientific criteria (such 
as double blind protocols) hinder the assessment of the effectiveness of these vaccines (Pe-
reira et al., 2011). In small animals, like dogs and cats, staphylococci, namely S. pseudinter-
medius, are the main cause of pyoderma and otitis, infections very common in daily veteri-
nary practice (DeBoer, Moriello, Thomas & Schultz, 1990). In the 80s another S. aureus vac-
cine combined with a phage lysate, SPL® (Delmont Laboratories Inc., Swarthmore, United 
States of America), was used and considered a highly effective bacterial antigen licensed for 
the treatment of idiopathic pyoderma caused by S. (pseud)intermedius in dogs (DeBoer et 
al., 1990). Although this vaccine is still commercialized nowadays, only a few reports have 
addressed the real efficacy of this bacterin/phage lysate and so it is not widely recommended 
for routine use (DeBoer & Marsella, 2001).  
Pasteur’s approach has been used also with a different objective: identification of the reper-
toire of antigens necessary to elicit a widespread antibody response against invasive staphy-
lococci by immunization with inactivated attenuated strains in animal models of S. aureus in-
fection, combined with high-throughput screening (Burnside, Lembo, Harrell, Klein, Lopez-
Guisa, Siegesmund, Torgerson, Oukka, Molina & Rajagopal, 2012). Interestingly, the results 
suggested that protection against S. aureus infections requires antibody responses to the 
wide repertoire of antigens/virulence factors (Burnside et al., 2012), which is actually one of 
the reasons appointed for the failure of single-antigen vaccines against S. aureus infections 
(Bagnoli, Bertholet & Grandi, 2012). Yet, although strategies that incorporate whole, inacti-
vated or attenuated S. aureus provide the host with an opportunity to mount a widespread 
antibody response, it is unlikely that incorporation of whole bacteria is an acceptable vaccine 
strategy (Burnside et al., 2012). 
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1.6.3.3.2 Second-generation approach 
This approach started to be used when knowledge was improved on the pathogenesis of mi-
crobial infections, the identification of virulence factors and the characterization of the im-
mune response after infection (Movahedi & Hampson, 2008). In fact most of the tested vac-
cines, including some developed against staphylococci, fall within this generation (Movahedi 
& Hampson, 2008; Otto, 2010). The antigens tested in these vaccines do not usually under-
go a specific selection process, and are obtained from the literature based on their surface 
location, participation on the pathogenesis and frequency in predominant clones (Otto, 
2010). One of the second-generation approaches against staphylococci includes active and 
passive vaccines against S. aureus capsular polysaccharides types 5 and 8 (for example 
StaphVAXTM or AltastaphTM from NABI) (Otto, 2010). These polysaccharides were selected 
based on good results obtained against other capsular pathogens and based on the high fre-
quency of these capsular types in most prominent S. aureus clinical clones (Otto, 2010). An-
other approach included the use of recombinant proteins, mainly toxins like alpha-toxin and 
PVL (PentaStaphTM from GlaxoSmithKline), based on their major role as significant virulence 
factors (Otto, 2010). Recombinant vaccines targeting S. aureus MSCRAMMs have also been 
developed due to their surface location, widespread distribution and pathogenesis involve-
ment (SA3AgTM from Pfizer) (Otto, 2010). One other vaccine, containing a recombinant Tar-
get of RNAIII Activating Protein (rTRAP), has been tested in dairy animals (Leitner, Krifucks, 
Kiran & Balaban, 2011). The rTRAP vaccine was immunogenic and caused the induction of a 
humoral immune response, preventing new udder infections by staphylococci (Leitner et al., 
2011). As TRAP is highly conserved among all strains and staphylococcal species and is 
constitutively expressed in any strain of S. aureus or CoNS, the authors considered it a uni-
versal anti-staphylococcus vaccine (Leitner et al., 2011). 
Although this approach has been successfully used to select antigens against several bacte-
rial pathogens, so far it has not been effective against staphylococci (Otto, 2010; Jansen et 
al., 2013). One of the factors associated with this failure is due to the staphylococci plasticity, 
meaning these bacteria can express several different virulence factors in vivo (Jansen et al., 
2013). For example, staphylococci can overcome the production of capsular polysaccharides 
by producing proteins with the same function (Proctor, 2012). Another problem with vaccines 
targeting toxins, for example, is that these virulence factors are produced once the infection 
has been established, and so infection prevention cannot be achieved (Jansen et al., 2013). 
More recent approaches have been helpful in understanding the role of virulence factors in 
vivo in the staphylococcal pathogenesis and the immune response after infection (Movahedi 
& Hampson, 2008). 
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1.6.3.3.3 Third-generation approach or Reverse Vaccinology 
1.6.3.3.3.1 Genomics and in silico prediction of antigens 
A complete genome sequence can be used for several purposes. One of these purposes is 
the in silico analysis, through bioinformatics algorithms, of genes that are considered to be 
the most important molecules to induce a protective immune response (Movahedi & Hamp-
son, 2008). Normally these genes of interest encode proteins or lipoproteins that are surface 
exposed, or secreted or are virulence factors (Movahedi & Hampson, 2008). In silico analysis 
can also be used to predict T cell and B cell epitopes, which will help optimize the best vac-
cine candidates (Movahedi & Hampson, 2008). The new advances in the development of 
bioinformatics tools coupled with faster recombination techniques and the knowledge on the 
host immune response will lead to new vaccines against diseases, including staphylococci 
(Soria-Guerra et al., 2014). 
 
a) In silico analysis for detection of virulence factors 
As we saw above, most of the current vaccines tested in human clinical trials so far are 
based on virulence factors. Several bioinformatic algorithms (Table 16) have been created to 
help investigators find virulence determinants based on sequence motifs (Zagursky & Rus-
sell, 2001). These bioinformatic algorithms use different models to predict the gene function, 
like Hidden Markov models (HMM) (Zagursky & Russell, 2001). Yet one should not forget 
that, ultimately, predictions need to be validated by laboratory experiments (Zagursky & Rus-
sell, 2001). One study on S. pseudintermedius used a combined genomic and proteomic ap-
proach to detect proteins with the LPXTG motif (Bannoehr et al., 2011). This motif is usually 
found in S. aureus cell-wall-associated surface proteins, which play important roles in viru-
lence: ability to bind to host extracellular matrix and plasma components promoting adhesion 
to host tissues, evasion of host defence mechanisms and invasion of epithelial and endothe-
lial cells (Roche, Massey, Peacock, Day, Visai, Speziale, Lam, Pallen & Foster, 2003). Be-
sides detecting 18 proteins with the LPXTG motif in the S. pseudintermedius genome, the 
authors also identified 3 proteins containing MSCRAMMs, which represented candidate ther-
apeutic targets for the control of bacterial pyoderma (Bannoehr et al., 2011). Another study 
employing a combined genomic approach was used to find motifs associated with virulence 
in S. epidermidis (Shahrooei, Hira, Khodaparast, Khodaparast, Stijlemans, Kucharíková, 
Burghout, Hermans & Van Eldere, 2012). After testing 5 proteins to evaluate as vaccine can-
didates in a mouse jugular vein catheter infection model, the authors found at least one pro-
tein was a promising target for antibody-mediated strategies against S. epidermidis biofilm 
formation (Shahrooei et al., 2012). 
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Table 16. Bioinformatic algorithms for prediction of virulence factors. 
Name Website Type of information Reference 
Blast http://blast.ncbi.nlm.nih.gov/Blast.cgi 
Compares nucleotide or protein sequences to sequence databases 
and calculates the statistical significance of matches 
Altschul et al., 
1990 
ScanProsite http://prosite.expasy.org/scanprosite/ 
Scans for protein domains, families and functional sites as well as 
associated patterns and profiles 
Sigrist et al., 2002; 
De Castro et al., 
2006 
InterProScan http://www.ebi.ac.uk/interpro/interproscan.html/ 
Provides functional analysis of proteins by classifying them into 
families and predicting domains and important sites 
Jones et al., 2014; 
Mitchell et al., 2015 
Pfam http://pfam.xfam.org/ Analyses your protein sequence for Pfam matches Finn et al., 2014 
ProDom http://prodom.prabi.fr/prodom/current/html/home.php 
Builds multiple alignments, phylogenetic trees and domain archi-
tectures of proteins, as well as a BLAST-based server to analyse 
new sequences for homologous domains 
Servant et al., 






Gives the familiar form of output, but modified by means f direct 
links both to the familial discriminators in PRINTS and fingerprint 
profile visualization software 
Attwood et al., 
1999; Wright et al., 
1999 
SMART http://smart.embl-heidelberg.de Identificaties and annotates signalling domain sequences Schultz et al., 1998 
HAMAP-Scan http://hamap.expasy.org/hamap_scan.html 
Uses manually built annotation templates for protein families to 
propagate annotation to all members of manually defined protein 
families, using very strict criteria 
Lima et al., 2009 
CATCH http://www.cathdb.info 
Groups protein domains into superfamilies when there is sufficient 
evidence they have diverged from a common ancestor 
Sillitoe et al., 2013 
SUPERFAMILY http://supfam.cs.bris.ac.uk/SUPERFAMILY/ 
Provides sequencing searching, multiple alignments to sequences 
of known structure, and structural assignments to all complete ge-
nomes 
Gough & Chothia, 
2002 




Relates protein sequence relationships to function relationships in 
a robust and accurate way 
Thomas et al., 
2003 
TIGRFAMs http://www.jcvi.org/cgi-bin/tigrfams/index.cgi 
Provides curated multiple sequence alignments, HMM for protein 
sequence classification, and associated information designed to 
support automated annotation of proteins 
Haft et al., 2001 
ClustalOmega http://www.ebi.ac.uk/Tools/msa/clustalo/ 
Performs multiple sequence alignment program that uses seeded 
guide trees and HMM profile-profile techniques to generate align-
ments between three or more sequence 
Sievers et al., 2011 
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b) In silico analysis for detection of surface-exposed proteins 
Another approach that has been used frequently in combination with the previous methodol-
ogy is the identification of surface-exposed proteins. In fact, for vaccine development, it has 
been previously suggested that more importantly than finding a gene function, is to find out if 
the gene encodes a surface-exposed antigen (Zagursky & Russell, 2001). In the course of an 
infection, the bacterial outer cell membrane components, as well as secreted proteins, repre-
sent the interphase of the bacterium-host interaction and are exposed to the host immune 
system (Chakravarti, Fiske, Fletcher & Zagursky, 2000; Chitlaru, Gat, Grosfeld, Inbar, Gozlan 
& Shafferman, 2007). Several bioinformatic algorithms have been developed with this pur-
pose and some are shown in Table 17. These algorithms employ different models, to detect, 
for example, transmembrane helices or signal peptides (Movahedi & Hampson, 2008). The 
two studies presented above (Bannoehr et al., 2011; Shahrooei et al., 2012), also used algo-
rithms to predict surface location. In the S. pseudintermedius genome, 60 proteins and in the 
S. epidermidis genome 64 proteins were possibly surface-localized (Bannoehr et al., 2011; 
Shahrooei et al., 2012). Surface-exposed proteins are favoured vaccine candidates since 
they are more easily accessible microbial antigens to the host’s immune system (Zagursky & 
Russell, 2001). 
 
c) In silico analysis for prediction of B cells and T cells epitopes 
In order for an antigen to be effective, it must elicit a T cell and a B cell response (Davies & 
Flower, 2007). Newly created in silico algorithms and databases can be used to identify, 
characterize or predict antigen epitopes recognized by T- and B-lymphocytes (Bambini & 
Rappuoli, 2009). These algorithms are able to recognize peptide fragments of pathogen anti-
gens exhibited by MHC proteins at the surface of antigen-presenting cells (Bambini & Rap-
puoli, 2009). B-cell epitopes are defined by the discrete surface region of an antigen bound 
by the variable domain of an antibody (Bambini & Rappuoli, 2009). While T-cell epitopes are 
short linear peptides, B-cell epitopes can be linear contiguous amino acids or they can be 
discontinuous amino acids, separated within the sequence but brought together in the folded 
protein, known as conformational epitopes (Bambini & Rappuoli, 2009). Several algorithms 
have been developed so far, from which some are described in Table 18.  
One study used this strategy to design T-cell epitope candidates against S. aureus endocar-
ditis in humans (Oprea & Antohe, 2013). By selecting and performing structural analysis, an-
tigenicity testing and identification of B cell and T cell epitopes on 10 proteins, previously 
identified as surface-exposed, the authors were able to identify five T-cell epitopes that could 
potentially be used in a vaccine (Oprea & Antohe, 2013). 
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Table 17. Bioinformatic algorithms for prediction of subcellular location. 
Name Website Type of information Reference 
PSORTb http://www.psort.org/psortb/ 
Consists of multiple analytical modules, each of which analyses one biologi-
cal feature known to influence or be characteristic of subcellular localization 
Yu et al., 2010 
ProtLock http://bioinf.uab.es/cgi-bin/trsdb/protloc.cgi 
Assigns a possible cellular localization of polypeptide sequences according 
to their amino acid frequencies against predefined sets 
Cedano et al., 1997 
SignalP http://www.cbs.dtu.dk/services/SignalP/ 
Predicts the presence and location of signal peptide cleavage sites in amino 
acid sequences from different organisms 
Petersen et al., 2011 
SecretomeP http://www.cbs.dtu.dk/services/SecretomeP/ 
Produces ab initio predictions of non-classical i.e. not signal peptide triggered 
protein secretion 
Bendtsen et al., 2006 
TatP http://www.cbs.dtu.dk/services/TatP/ 
Predicts the presence and location of Twin-arginine signal peptide cleavage 
sites in bacteria 
Bendtsen et al., 2005 




Predicts membrane proteins von Heijne, 1992 
PRED-TMR http://athina.biol.uoa.gr/PRED-TMR/ 
Predicts transmembrane domains in proteins using solely information con-
tained in the sequence itself 
Pasquier et al., 1999 
DAS http://www.sbc.su.se/~miklos/DAS/ Predicts transmembrane regions of a query sequence Cserzo et al., 1997 
PredictProtein https://www.predictprotein.org Predicts secondary structure and returning families of related proteins Yachdav et al., 2014 
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Table 18. Bioinformatic algorithms for prediction of B cells and T cells epitopes. 
Name Website Type of information Reference 
BepiPred http://www.cbs.dtu.dk/services/BepiPred/ 
Predicts the location of linear B-cell epitopes using a com-
bination of a hidden Markov model and a propensity scale 
method 
Larsen et al., 2006 
DiscoTope http://www.cbs.dtu.dk/services/DiscoTope/ 
Predicts discontinuous B cell epitopes from protein three 
dimensional structures 
Kringelum et al., 
2012 
NetMHCpan http://www.cbs.dtu.dk/services/NetMHCpan/ 
Predicts binding of peptides to any known MHC molecule 
using artificial neural networks 
Hoof et al., 2009 
NetMHCcons http://www.cbs.dtu.dk/services/NetMHCcons/ 
Predicts binding of peptides to any known MHC class I 
molecule 




More recently, in another study three important virulence factors of S. aureus were selected, 
clumping factor A (ClfA), iron-regulated surface determinant (IsdB), and gamma hemolysin 
(Hlg) to form a chimeric protein and bioinformatic tools were used to predict the chimeric pro-
tein antigenicity and linear and conformational B-cell epitopes (Delfani, Fooladi, Mobarez, 
Emaneini, Amani & Sedighian, 2015). The data indicated that epitopes of the chimeric pro-
tein, designed from ClfA, IsdB, and Hlg of S. aureus could induce B-cell–mediated immune 
responses successfully and therefore, could be used as a vaccine candidate against S. au-
reus infections (Delfani et al., 2015). 
One of the limitations of this analysis is the lack of accuracy, although T-cell epitopes are 
more accurate and comprehensive than B-cell epitopes (Movahedi & Hampson, 2008). An-
other limitation is that most algorithms so far developed only predict T-cell epitopes for hu-
mans and a few animals (Movahedi & Hampson, 2008). Finally, although this approach 
saves the investigators time before going to the laboratory, all the identified epitopes require 
subsequent experimental validation in order to ascertain the suitability of the epitopes for 
vaccine development (Oprea & Antohe, 2013). 
 
1.6.3.3.3.2 Transcriptomics 
By analysing the changes that occur in the bacterial gene expression during infection investi-
gators are able to understand which determinants are essential for bacterial pathogenesis 
and for bacterial survival (Kaushik & Sehgal, 2008). This analysis can be done at the level of 
the complete genome, for example by using complementary deoxyribonucleic acid (cDNA) 
microarrays, by the newly technique RNA-seq, or by targeting the expression of specific 
genes involved, for example in the pathogenesis of infection, by qRT-PCR (Dhiman, Bonilla, 
O’Kane & Poland, 2001).  
Transcriptomics has been used to detect changes in the expression of particular staphylo-
coccal genes. In one study, the investigators were interested in the expression of sdrG, a 
gene encoding serine-aspartate repeat-containing protein G, present in most strains of S. ep-
idermidis (Sellman, Timofeyeva, Nanra, Scott, Fulginiti, Matsuka & Baker, 2008). This gene 
was expressed early during infection in response to specific host environmental cues present 
in the bloodstream and resulted in a concomitant increase in SdrG protein levels (Sellman et 
al., 2008). The authors concluded that SdrG possessed attributes of a vaccine component 
effective against the pathogenic form of S. epidermidis (Sellman et al., 2008). In another 
study, the expression of the fhuD2 gene, encoding the ferric hydroxamate-binding lipopro-
tein, was evaluated in a murine renal abscess model of infection (Mishra, Mariotti, Fiaschi, 
Nosari, Maccari, Liberatori, Fontana, Pezzicoli, De Falco, Falugi, Altindis, Serruto, Grandi & 
Bagnoli, 2012). Using qRT-PCR, the authors detected up-regulation of the fhuD2 gene in 
bacteria recovered from infected animals, which was accompanied by up-regulation of the 
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FhuD2 protein in infected tissues and was required for staphylococcal dissemination and ab-
scess formation suggesting it could be efficacious as a vaccine target (Mishra et al. 2012). 
One of the limitations of this technique is the amount of RNA needed for the experiments, 
especially for the microarray analysis, which is not always possible when performing in vivo 
studies (Kaushik & Sehgal, 2008). However, new techniques like RNA-seq are overcoming 
this problem, and are able to do massively parallel sequencing of RNA (or, in fact, the corre-
sponding cDNA), based on next-generation sequencing (NGS) platforms (Westermann, Gor-
ski & Vogel, 2012). Apart from also being able to quantify the RNA expression like microar-
rays, RNA-seq provides possibility for the simultaneously determination of the host and path-
ogen transcriptomes providing the potential to further get insights into the host-pathogen in-
teraction (Westermann et al., 2012). Still, another major limitation that cannot be undergone 
by any of these techniques, is the simple fact that there is not a direct correlation between 
mRNA and protein expression level (Bambini & Rappuoli, 2009). In this way, higher levels of 
mRNA expression do not necessarily mean higher levels of the corresponding protein and 
further studies are needed to confirm the hypothesis (Bambini & Rappuoli, 2009). 
 
1.6.3.3.3.3 Proteomics 
Genomics and transcriptomics can give fundamental information on the potential antigens 
produced by a bacterial pathogen; however only proteomics gives evidence on the protein 
expression during the bacteria’s life and during host-pathogen interactions (Serruto & Rap-
puoli, 2006). Proteomic analysis involves protein digestion, eventually preceded by its sepa-
ration using one-dimension electrophoresis (1-DE) or two-dimension electrophoresis (2-DE) 
followed by liquid chromatography coupled to mass spectrometry/mass spectrometry (LC)-
MS/MS or matrix-assisted laser desorption/ionization-time-of-flight/time-of-flight mass spec-
trometry (MALDI-TOF/TOF MS), respectively (Nandakumar, Nandakumar, Marten & Ross, 
2005; Resch, Leicht, Saric, Pásztor, Jakob, Götz & Nordheim, 2006; Planchon, Chambon, 
Desvaux, Chafsey, Leroy, Talon & Hébraud, 2007). Proteomics allows the identification of 
post-translational modifications, differentially expressed proteins and protein-protein interac-
tions (Movahedi & Hampson, 2008). Like for genomics, in the proteomic approach to bacteri-
al vaccine development preference is given to surface proteins (Serruto & Rappuoli, 2006; 
Movahedi & Hampson, 2008). 
This approach has been used extensively to study different staphylococci in different growth 
conditions, including during biofilm formation (Kohler, Wolff, Albrecht, Fuchs, Becher, 
Büttner, Engelmann & Hecker, 2005; Nandakumar et al., 2005; Resch et al., 2006; Planchon 
et al., 2007; Bannoehr et al., 2011). Other studies identified proteins differentially produced 
during infection, like mastitis (Le Maréchal, Jardin, Briard-Bion, Rault, Berkova, Vautor, 
Thiéry, Even & Le Loir, 2013), while in others the investigators compared the proteomes of 
invasive and commensal staphylococcal strains (Yang, Li, Chen, Ou, Jin, Lu, Zhu, Qin, Qu & 
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Yang, 2006; Seyffert, Le Maréchal, Jardin, McCulloch, Rosado, Miyoshi, Even, Jan, Berkova, 
Vautor, Thiéry, Azevedo & Le Loir, 2012). 
One of the limitations of this approach is the large amount of proteins that are produced un-
der in vitro conditions that may not correspond to in vivo infection (Movahedi & Hampson, 
2008). This can be overcome by using models of in vivo infection, but this may not always be 
easy, especially in human infections (Movahedi & Hampson, 2008). Another limitation of pro-
teomics is that some proteins are poorly resolved by 2-DE, like membrane-anchored proteins 
due to its hydrophobicity (Wilkins, Gasteiger, Sanchez, Barioch & Hochstrasser, 1998; Nan-
dakumar et al., 2005) or low abundance proteins (Bröker & van Belkum, 2011). This has 
been recently overcome by the GeLC-MS/MS approach, which does not rely on 2-DE sepa-
ration (Chandramouli & Qian, 2009). More recently, shotgun approaches, which do not in-
volve any protein separation, have been developed and present a high-resolution separation 
of peptide digests (Chandramouli & Qian, 2009). Yet, this type of assays requires very ex-
pensive equipment and highly specialized apparatus (Chandramouli & Qian, 2009). The last 
limitation is that proteomics alone cannot identify the potential immunogenicity of a protein 
and so it has been combined with serological analysis (Movahedi & Hampson, 2008). 
 
1.6.3.3.3.4 Serological proteomics 
Serological proteomics, also called Immunoproteomics, is a technique that combines 2-DE, 
2-DE western blotting (also called immunoblotting) and antigens identification through MS 
(Klade, Voss, Krystek, Ahorn, Zatloukal, Pummer & Günther, 2001; Chitlaru et al., 2007). In 
this approach, the immunogenic proteins are identified using sera with antistaphylococcal an-
tibodies from healthy individuals and infected patients (Bröker & van Belkum, 2011). The pro-
tocol involves protein extraction of the microorganism of interest and subsequent protein 
separation by 2-DE (Bröker & van Belkum, 2011). The proteins are then transferred to a 
membrane and incubated with serum antibodies (Bröker & van Belkum, 2011). Following in-
cubation with a secondary antibody, the highly immunogenic proteins are visualized and 
matched with spots in the protein gels. The gel spots are then excised and identified by MS 
(Bröker & van Belkum, 2011). However, there are some limitations in serological proteomics. 
First of all, only proteins resolved by 2-DE can be subsequently identified by serum antibod-
ies (Bröker & van Belkum, 2011). However, as discussed above, in the 2-DE method several 
proteins may not be separated (Wilkins et al., 1998; Nandakumar et al., 2005) or low abun-
dance proteins may not be detected (Bröker & van Belkum, 2011). Furthermore, the in vitro 
conditions used (like bacterial growth) may not mimic the in vivo protein expression and so 
not all the relevant proteins may be present (Bröker & van Belkum, 2011). Another problem 
that may occur is that antibody binding cannot always be attributed to a single protein but to 
a group of proteins (Bröker & van Belkum, 2011). Matching the proteins in the gel and in the 
membrane may not be very easy either and since immunoblotting is more sensitive than the 
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staining for general protein detection, antibody binding to low abundance proteins may erro-
neously be attributed to a major spot in its vicinity (Bröker & van Belkum, 2011). 
In spite of its limitations, this methodology has been used to identify staphylococcal antigenic 
proteins. Vytvytska and colleagues performed the first work in S. aureus (2002). The authors 
used a S. aureus laboratory strain and two pools of selected human sera (healthy donors 
and patients) to identify highly immunogenic proteins (Vytvytska, Nagy, Blüggel, Meyer, Kur-
zbauer, Huber & Klade, 2002). The authors were able to identify very strong immunoglobulin 
G (IgG)-reactivity against multiple proteins using both pooled sera from healthy individuals 
and patients (Vytvytska et al., 2002). This led to the identification of 15 proteins including 
novel and known vaccine candidates (Vytvytska et al., 2002). Other studies have been de-
scribed after, including serological approaches with sera from ruminants with mastitis 
(Tedeschi, Taverna, Negri, Piccinini, Nonnis, Ronchi & Zecconi, 2009; Le Maréchal, Jan, 
Even, McCulloch, Azevedo, Thiéry, Vautor & Le Loir, 2009) 
 
1.6.3.3.3.5 Antigenomics 
This approach combines the advantages of full genome coverage and serological antigen 
identification (Meinke, Henics, Hanner, Minh & Nagy, 2005). It is similar to the Serological 
Proteomics approach, and the difference relies in the “protein library” preparation. In this 
method, the selection of vaccine candidates, either small linear epitopes or medium-sized 
conformational epitopes encoded by the bacterial genome are displayed on the surface of 
Escherichia coli via outer membrane proteins (Henics, Winkler, Pfeifer, Gill, Buschle, von 
Gabain & Meinke, 2003). The antigenome technology does not rely on genome annotation 
and, thus, has the potential to select proteins that are not predicted by ORF-finding algo-
rithms and does not have the problem of in vitro vs in vivo protein expression (Meinke, Hen-
ics, Hanner, Minh & Nagy, 2005). This technology has been used to identify staphylococcal 
antigens (Etz, Minh, Henics, Dryla, Winkler, Triska, Boyd, Söllner, Schmidt, von Ahsen, 
Buschle, Gill, Kolonay, Khalak, Fraser, von Gabain, Nagy & Meinke, 2002; Weichhart, Horky, 
Söllner, Gangl, Henics, Nagy, Meinke, von Gabain, Fraser, Gill, Hafner, & von Ahsen, 2003; 
Dryla et al., 2005). In one of these studies, the authors determined a total of 60 antigenic pro-
teins based on their reactivity with individual sera from patients and healthy individuals (Etz 
et al., 2002). This study was actually one of the two studies that identified the iron-regulated 
surface determinant B (IsdB) protein as an antigen and was used in vaccine V710TM from 
Merck (Kuklin, Clark, Secore, Cook, Cope, McNeely, Noble, Brown, Zorman, Wang, Pancari, 
Fan, Isett, Burgess, Bryan, Brownlow, George, Meinz, Liddell, Kelly, Schultz, Montgomery, 
Onishi, Losada, Martin, Ebert, Tan, Schofield, Nagy, Meineke, Joyce, Kurtz, Caulfield, Jan-
sen, McClements & Anderson, 2006; Harro, Betts, Orenstein, Kwak, Greenberg, Onorato, 
Hartzel, Lipka, DiNubile & Kartsonis, 2010). The authors considered the approach as having 
the potential to greatly accelerate and facilitate the formulation of novel vaccines (Etz et al., 
 80 
2002) and this approach has been used to identify vaccine candidate antigens from other 
bacterial species. However, one major limitation of this technique is that it can only detect 
linear contiguous epitopes, because conformational epitopes that are assembled as a result 


















2 Objectives  
Dynamics 












The importance of MRS has been recognized in animals and knowledge on the epidemiology 
of MRS is important since these strains pose a serious public health threat. Furthermore, the 
antimicrobial and biocide susceptibility and the molecular epidemiology of these strains can 
contribute to monitor the spread of antimicrobial/biocide resistance genes/strains and conse-
quently control its dissemination. In the first part of the study, we determined the frequency 
and characteristics of MRS isolated from different animal species. In a second part of this 
work, a focus was given to S. pseudintermedius since this bacterium has become a serious 
veterinary problem due to its multidrug resistant profile. In this way, novel strategies are 
needed for the treatment of S. pseudintermedius infections and more information on the in-
teraction of this pathogen with its host is indispensable. 
The main objectives and approaches of this study were: 
I. Determine the frequency of MRSA strains in several animal species, identify the character-
istics of MRSA present in animals and compare to human strains 
a) Determine the frequency and characteristics of MRSA colonization in horses and 
calves 
b) Characterize the clonal diversity, antimicrobial/biocide susceptibility patterns, re-
sistance genes and virulence factors of MRSA from animals, environment and hu-
mans in contact with animals 
II. Reveal antimicrobial/biocide susceptibility patterns/trends and resistance genes in MRS 
strains 
a) Identify the antimicrobial/biocide susceptibility and resistance genes in MRS strains 
from horses 
b) Compare the antimicrobial/biocide susceptibility and resistance genes between 
MRSP and MSSP strains 
c) Detect the trends of antimicrobial resistance, resistance mechanisms and molecu-
lar characteristics of MRS in companion animals 
III. Study the pathogenesis of Staphylococcus pseudintermedius infections in dogs 
a) Identify differences in the expression of virulence factors and regulatory systems 
between MRSP and MSSP 
b) Characterize the S. pseudintermedius proteome and identify antigenic proteins 
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3.1 Part 1 – Epidemiology of methicillin-resistant Staphylococcus aureus in animals 
in Portugal 
3.1.1 First Report of Methicillin-Resistant Staphylococcus aureus ST5 and ST398 
from Purebred Lusitano Horses 
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a b s t r a c t
Methicillin-resistant Staphylococcus aureus (MRSA) was first described in horses in 1996.
The frequency of MRSA colonization in horses varies among European countries, but it is
unknown in Portugal. The aim of this study was to screen for MRSA nasal carriage in
a sample of horses entering the Equine Unit, Large Animal Veterinary Teaching Hospital of
the Faculty of Veterinary Medicine, Lisbon, Portugal. Seventy-one horses were swabbed,
and MRSA was identified by selective isolation on a chromogenic medium. Two S aureus
isolates showed resistance to oxacillin (minimum inhibitory concentration>4 mg/mL) and
contained the mecA gene. Both strains were isolated from purebred Lusitano horses that
lived in farms with more than 20 equines. These MRSA strains represented two different
clones: isolate FMVA3/10 was an MRSA sequence type ST5 with a staphylococcal cassette
chromosome mec VI, coresistant to erythromycin and clindamycin; and isolate FMVA16/
10 was sequence type ST398, with a staphylococcal cassette chromosome mec IV,
coresistant to tetracycline, gentamicin, and trimethoprim. Isolate FMVA3/10 represents
a human epidemic clone not previously reported among horses in Europe, which once
again reinforces the fact that transmission of MRSA clones between horses and humans
occurs. Isolate FMVA16/10 represents the first report of the detection of MRSA ST398
among horses in Portugal. Lusitano horses can carry animal and human MRSA in the
nostrils, acting as reservoirs, which can potentially be transmitted to humans.
! 2012 Elsevier Inc. All rights reserved.
1. Introduction
Methicillin-resistant S aureus (MRSA) was first reported
in horses in 1996, as a cause of metritis in Japan [1]. Since
then, several other reports have described MRSA as a cause
of a variety of other infections, including several life-
threatening conditions such as pneumonia and blood-
stream infection [2]. The prevalence of MRSA colonization
has been studied in numerous horse populations in various
countries, with rates ranging from 0% to 10.9% [2]. Still, in
Portugal, there are no reports of equine MRSA infections,
and the rate of MRSA carriage in horses is unknown.
Portugal is one of the countries in Europe with the highest
prevalence of nosocomial invasive MRSA isolates in
humans [3], and a recent report described a prevalence of
MRSA carriage of 1.4% in cats and 0.7% in dogs [4].
The first reports of MRSA in horses described sequence
type (ST) 8 (USA500 or CMRSA-5) as the major clone pre-
dominant in this species in the North American continent
[2]. MRSA ST8 was first described in humans but accounts
only for a small percentage of human infections [2].
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This led to the suggestion that this human epidemic clone
could have adapted to horses [2]. In Europe, however,
ST398 is the main clone associated with horses both as
a cause of infection and colonization [1]. Weese and van
Duijkeren proposed that this clone could have entered
the horse population from food animals, directly or
indirectly [2].
Owing to the lack of knowledge on MRSA in horses in
Portugal, the aim of this studywas to screen a population of
horses admitted to a Veterinary Hospital to determine the
MRSA colonization frequency and the type of MRSA strains
involved. This could be a first estimation of the equine
MRSA colonization status in a country with a high preva-
lence of human hospital-acquired MRSA infection.
2. Methods
2.1. Study Population
Between March 2008 and October 2010, a total 71
horses entering the Equine Unit, Large Animal Veterinary
Teaching Hospital of the Faculty of Veterinary Medicinee
Technical University of Lisbon, were enrolled in the
study. All horses from the facility, which stayed in the
hospital for at least one night, were enrolled after owner’s
consent. Thirty horses had recurrent airway obstruction
(RAO); eight had a respiratory pathology, other than RAO;
13 had equine gastrointestinal ulcer syndrome (EGUS), and
20 were healthy horses that were admitted to either elec-
tive surgery (castration) or as part of a control group for an
RAO study (Table 1). The horses’ gender, age range, breed,
stable geographic localization, and type are summarized in
Table 1. This table also contains staging and characteriza-
tion of the equines’ diseases. Horses presenting with RAO
were classified into the following stages: stage 0eNo RAO;
stage 1elatent RAO; stage 2emild RAO; stage 3emoderate
RAO; stage 4esevere RAO. The horses were classified on the
basis of the following parameters: clinical evaluation of
cough, nostril flare, and abdominal lift; endoscopic evalu-
ation of airway mucus accumulation, apparent viscosity,
localization, and color; X-ray evaluation of interstitial
pattern, bronchial radiopacity, bronchial, and tracheal
thickening; and bronchoalveolar lavage fluid cytology
neutrophil percentage. Horses with EGUS were classified
according to the number and severity of the lesions (see
Table 1) as previously described [5].
Table 1






Portugal Region Pathology Characterization
Recurrent airway obstruction
(RAO) horses (n ¼ 30)
7-30 Maree8 Purebred
Lusitanoe16
Rurale19 Estremadurae22 RAO stages:
Geldinge6 Lusitano crosse14 Citye6 Ribatejoe8 Stage 1-4 horses
Stallione16 Towne1 Stage 2-7 horses
Villagee4 Stage 3-10 horses
Stage 4-9 horses
Other respiratory pathology
cases (n ¼ 8)
2-20 Maree2 Purebred
Lusitanoe3
Rurale4 Estremadurae7 Dorsal displacement of the soft palate
(DDSP)e3
Geldinge2 Lusitano crosse5 Citye1 Ribatejoe1 4th brachial arch defects (4-BAD)e1
Stallione4 Towne2 Grade 4 right recurrent laryngeal
neuropathy (RLN)e1
Grade 3 left RLNe2
Villagee1 Pneumoniae1
Equine gastric ulcer syndrome
(EGUS) horses (n ¼ 13)
7-20 Maree0 Purebred
Lusitanoe13
Rurale0 Estremadurae13 Number of lesions (a):
Geldinge0 Citye0 Ribatejoe0 Grade 0-0











Control group (n ¼ 20) 0.2-22 Maree7 Purebred
Lusitanoe9
Rurale8 Estremadurae12 Control group of a RAO study e10
Geldinge3 Lusitano crosse11 Citye8 Ribatejoe8 Elective surgerye9 (1 Corneal laceration;
3 Standard castrations; 2 Cryptorchid
castrations; 1 Calcinosis circumscripta;




(a) Classification according to the number of lesions (MacAllister et al., 1997): grade 0ewithout lesions; grade 1e1-2 lesions; grade 2e3-5 lesions; grade
3e6-10 lesions; grade 4 to >10 lesions or diffuse lesions or of large dimensions.
(b) Classification according to severity of lesions (MacAllister et al., 1997): grade 0ewithout lesions; grade 1esuperficial lesions only in themucosa (pink and
without raised borders); grade 2edeeper lesions than in grade 1, including deeper structures (pink crater with raised borders); grade 3emultiple lesions of
varying severity (grade 1 and 2 and at least one grade 4 lesion); grade 4elesions, including deeper structures and with an active appearance (hyperemic,
darkened, or necrotic crater); grade 5eLesion severity similar to grade 4 but with active hemorrhage or with adherent blood clot.
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2.2. Bacterial Isolates
All 71 horses were nasally swabbed after admission to
the hospital. Samples were collected by inserting a cotton
swab approximately 10 cm into one anterior nostril, and
then rolling it while removing. The swabs were placed in
modified Amies medium and stored at 4!C until processing.
Swabs were first enriched in 3 mL of MuellereHinton broth
containing 65 g/L NaCl for 24 hours at 37!C, and then
500 mL were inoculated into 3-mL tryptone soy broth with
3.5 mg/L cefoxitin and 75mg/L aztreonam. After incubation
for 24 hours at 37!C, a 10-mL loopful was then plated onto
a chromogenic agar selective for MRSA, ChromID MRSA
(bioMérieux, Marcy L’Etoile, France). Incubation was
carried out for 24 and 48 hours at 37!C, as recommended
by the manufacturer. On evaluation of the growth on the
selective medium after 24 and 48 hours, MRSA-suspicious
colonies were purified on Columbia agar plates contain-
ing 5% sheep blood (bioMérieux) for 24 hours at 37!C.
Isolates were then subjected to PCR amplification of the
mecA and S aureus specific-nuc genes [6].
2.3. Antimicrobial Susceptibility Testing
Susceptibility to oxacillin, erythromycin, tetracycline,
gentamicin, clindamycin, vancomycin, enrofloxacin, fusidic
acid, and trimethoprim was tested by broth microdilution
using customized plates (Sensititre CMV1AMAF and
BOPO6Fmicroplates, Trek Diagnostic Systems,West Sussex,
United Kingdom) and using an in-house method (trimeth-
oprim and fusidic acid). Clinical and Laboratory Standards
Institute guidelines and breakpoints were used [7,8].
2.4. Molecular Typing
Genomic DNA was isolated by the boiling method.
Briefly, a loop full of bacteria was picked from a plate and
transferred to phosphate-buffered saline. The suspension
was centrifuged, the supernatant discarded, and the pellet
resuspended in TE (Tris-EDTA buffer pH 8.0). After boiling,
it was transferred directly to ice and finally diluted in TE.
The antibiotic resistance genes ermA, ermC, dfrK, tetK, tetM,
fusB, fusC, and aac(6’)-Ie-aph(2’’)-Iawere detected by PCR as
described before [9,10]. Isolates were subjected to spa
typing, SCCmec typing, and ST398 specific-PCR amplifica-
tion [11]. They were also tested for the presence of the
Panton-Valentine leukocidin (PVL) genes by PCR [12].
3. Results
Of the 71 horses swabbed, 17 were mares (24%), 11 were
geldings (15%), and 43 were stallions (61%). More than half
were purebred Lusitano horses (58%), whereas the
remaining were Lusitano cross horses (42%). Furthermore,
a high proportion of the equines were from a rural area
(44%), followed by horses living in towns (25%), in cities
(21%) and finally in villages (10%). The stables were
distributed in two Portuguese regions, Estremadura (76%)
and Ribatejo (24%), located in the central part of the
country, not too far from each other.
MRSA was isolated from two purebred Lusitano horses:
one horse with EGUS (8%) and one healthy horse (5%). Both
MRSA isolates had minimum inhibitory concentration
(MIC) of >4 mg/mL and contained the mecA gene. The
overall MRSA colonization frequency was 3%. One MRSA
isolate (FMVA3/10) was spa type t062, which is known to
be ST5, harbored a SCCmec VI and was PVL-negative. Isolate
FMVA3/10 was coresistant to fusidic acid (MIC 24 mg/mL),
erythromycin (MIC >4 mg/mL), and clindamycin (MIC
>16 mg/mL) and was positive for the antimicrobial resis-
tance genes fusC and ermC (Table 2). This isolate can be
related to two human epidemic clones: the Pediatric clone
(ST5-IV/VI) and the New York/Japan clone (ST5-II). The
MRSA ST5-IV clone has been described in horses, cats, dogs,
and pigs in Canada (named CMRSA-2), where it is also the
most common community-associated MRSA strain in
humans [13]. In contrast, MRSA ST5-II has never been
described in horses, although it has been reported in dogs
and cats in a study conducted in the upper Midwestern and
Northeastern United States [14]. Still, it is important to
notice that none of these clones has ever been isolated in
equine samples in Europe.
The second MRSA isolate (FMVA16/10) was spa type
t011, ST398-PCR positive, harbored a SCCmec IV, and was
PVL-negative. Isolate FMVA16/10 was coresistant to tetra-
cycline (MIC >8 mg/mL), gentamicin (MIC >16 mg/mL), and
trimethoprim (MIC >256 mg/mL) and was positive for the
antimicrobial resistance genes tetM, aac(6’)-Ie-aph(2’’)-Ia,
and dfrK (Table 2). This is in accordance with previous
European reports, which have identified ST398 as the main
clone colonizing horses admitted to veterinary hospitals
[2]. This clone has also been reported in Portugal, in pigs, as
a nasal colonizer and as the causative agent of an exudative
epidermitis outbreak [12,15].
4. Discussion
In this study, we report the first isolation of MRSA
strains from nasal swabs of purebred Lusitano horses.
Although not very high (3%), the frequency of colonization
found here was within the prevalence rate found by other
authors, which ranged from 0% to 10.9% [2]. No association
between MRSA carriage and healthy/sick horses could be
made. One could expect that horses with RAO would have
Table 2
Molecular characteristics and antimicrobial resistance profiles of methicillin-resistant Staphylococcus aureus isolated from purebred Lusitano horses





SCCmec Type spa Type ST Type
FMVA3/10 Horse with EGUS FAr, Er, CLIr fusC, ermC VI t062 5
FMVA16/10 Healthy horse TETr, GENr, Wr tetM, aac(6’)-Ie-aph(2’’)-Ia, dfrK IV t011 398
CLI, clindamycin; E, erythromycin; EGUS, equine gastric ulcer syndrome; FA, fusidic acid; GEN, gentamicin; SCCmec, staphylococcal cassette chromosome
mec; ST, sequence type; W, trimethoprim.
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a higher rate of nasal MRSA colonization, as there is
a respiratory airway inflammation and horses tend to have
flared nostrils. Yet, if we look in the human medicine
literature, asthma (a disease with a similar pathophysi-
ology to RAO) has only been recognized as a risk factor for
methicillin-susceptible S aureus carriage and not for MRSA
[16]. This could indicate that the type of pathology pre-
sented by the animals is not related to the MRSA carriage.
Nevertheless, further studies are necessary to confirm this.
Considering the risk factors known for MRSA coloniza-
tion in horses [1,2], only one was recognized: both MRSA-
positive animals lived on a farm that housed more than
20 equines. Furthermore, the MRSA-colonized horses were
from different regions: one was from Alter do Chão (Alen-
tejo region) and the other one from Santo Estevão (Ribatejo
region). The two horses had no previous history of anti-
microbial therapy within the past 30 days; they had no
record of previous admission to a neonatal intensive care
unit or other hospital unit other than the surgical service.
There was no hospitalization of other horses from the
affected farm in Alter do Chão. One other horse from Santo
Estevão was simultaneously hospitalized with the MRSA-
positive horse, but was negative. However, previous colo-
nization of the horses or the presence of colonized horses
on both farms was unknown.
Isolate FMVA3/10 was clonally related to two human
epidemic clones, the Pediatric clone and the New York/
Japan clone. Pediatric MRSA clone (ST5-IV/VI) was first
described in Portugal in 1992 as the dominant strain in
a pediatric hospital in Lisbon [3]. Still in 2006, in a national
surveillance study, this clone was isolated only once from
a single patient in a hospital in the South of Portugal [17].
However, surprisingly, 4 years later in a study carried out in
the Azores archipelago, the pediatric clone appeared as the
second major clone isolated [3]. In contrast, the New York/
Japan clone (ST5-II) was detected for the first time in
a Portuguese hospital in 2005 as single isolate, but in 2006
was already accounting for 17% of the MRSA isolates and
was themajor clone in four hospitals in the Lisbon area [17].
This could induce the assumption that isolate FMVA3/10
could belong to the New York/Japan clone. Yet, the contrary
seems more likely. Isolate FMVA3/10 harbors an SCCmec
(type VI) that has only been described in the pedriatic clone
and has a spa type (t062), which has only been associated,
in Portugal, with ST5-VI [3]. Comparatively, all genome
analysis by pulsed-field gel electrophoresis could give us
some information, but only whole genome sequencing
could enable us to assess the certain phylogeny, as it has
been used to show that the ST5 clonal group emerged
through a number of independent SCCmec transfer events
in multiple geographic locations [18]. Either way, this
isolate represents a human epidemic clone not previously
reported among horses in Europe. This once again rein-
forces the fact that transmission of MRSA clones between
horses and humans occurs and that there is a risk of horses
acting as reservoirs of important resistant bacteria.
This is the first report of the detection of MRSA ST398
among horses in Portugal. It is in agreement with previous
reports from Austria, Belgium, Canada, France, and the
United Kingdom, indicating that ST398 is widespread
among horses [1,2]. Isolate FMVA16/10 shares the same spa
type (t011) as some of the previously describedMRSAST398
isolates from pigs and humans in Portugal [12,15]. Yet, this
isolate does not share the same SCCmec (type IV) as the
previous strains described (type V), which is in accordance
with the theory thatMRSA ST398 fromhorses are unrelated
to the other isolates and probably have evolved indepen-
dently by acquisition of a different SCCmec element [19].
The antimicrobial resistance patterns detected in the
equine isolates (Table 2) match the current proposed
antimicrobials in the guidelines for the treatment of
infections in horses [20]. Gentamicin, tetracycline (in the
form of oxytetracycline), erythromycin, and trimethoprim
(in the form of trimethoprim in combination with a sul-
phonamide) are first choice antimicrobials in the absence
of an antimicrobial susceptibility result or a pending
culture [20]. Clindamycin is the only systemic antimicro-
bial, which is not used in equine medicine, but to which
resistance is easily explainable because the erm genes
confer resistance not only to macrolides but also to linco-
samides. Fusidic acid, a topical antimicrobial, is often used
in equines for the treatment of skin infections. To the best
of our knowledge, this is the first report of fusC-mediated
resistance in S aureus of equine origin.
5. Conclusion
This is the first report on the detection of MRSA of
equine origin in Portugal. Horses can act as a reservoir of
both human- and animal-adapted epidemic MRSA clones
and thus influence animal-to-animal and animal-to-human
MRSA dissemination. Furthermore, horses can be reser-
voirs of resistance genes that can be transferred to other
important bacteria. Finally, equine MRSA carriage is by
itself a hazard for the development of a multidrug-resistant
animal infection.
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Letter to the Editor
First description of fexA-positive
meticillin-resistant Staphylococcus aureus
ST398 from calves in Portugal
Sir,
Meticillin-resistant Staphylococcus aureus (MRSA) primarily
causes human diseases, and food-producing animals are known to
be reservoirs of MRSA clonal complex (CC) 398 [1,2]. MRSA CC398
has become a rapidly emerging cause of human infections, most
often associated with livestock exposure [2]. A direct association
between animal and human MRSA carriage has been established
[3]. Until now, no data were available regarding MRSA in calves in
Portugal.
In this study, nasal swabs were taken from randomly selected
breeding calves at two closed-cycle farms from distinct regions of
Portugal. In total, 247 nasal swabs from Farm A and 60 from Farm B
were cultured as previously described [4]. Antimicrobial suscepti-
bility testing was performed using the broth microdilution method
[MicroScan1 PM21; Siemens, Erlangen, Germany; and VetMIC1
(Large Animals); National Veterinary Institute, Uppsala, Sweden] for
the following antibiotics: chloramphenicol; ciprofloxacin; erythro-
mycin; florfenicol; fosfomycin; fusidic acid; gatifloxacin; gentami-
cin; levofloxacin; linezolid; moxifloxacin; mupirocin; netilmicin;
oxacillin; penicillin; quinupristin/dalfopristin; rifampicin; tetracy-
cline; teicoplanin; trimethoprim/sulfamethoxazole; and vancomy-
cin. Results of susceptibility testing were interpreted according to
Clinical and Laboratory Standards Institute (CLSI) standards. The
mecA and/or mecC genes were identified by PCR (http://www.crl-
ar.eu), and MRSA isolates were subjected to staphylococcal protein A
(spa) typing (http://www.seqnet.org/), staphylococcal cassette
chromosome mec (SCCmec) typing [5] and pulsed-field gel
electrophoresis (PFGE) using ApaI restriction [4]. The results of
PFGE were interpreted using BioNumerics software v.4.6 (Applied
Maths, Sint-Martens-Latem, Belgium). The presence of fexA, tet(K),
tet(M), erm(A), erm(B) and erm(C) genes was studied by PCR. One
strain (VF30T1) was randomly chosen for characterisation using an
S. aureus Genotyping Kit 2.0 (Alere Technologies GmbH, Jena,
Germany).
Six MRSA isolates from Farm A were identified as CC398, spa
type t108 and SCCmec V (Table 1). No MRSA isolates were detected
in Farm B. All isolates were indistinguishable by PFGE. None of the
isolates carried the novel mecC gene. Susceptibility testing and PCR
revealed resistance to tetracycline attributed to tet(K) and tet(M)
genes, to chloramphenicol and florfenicol due to the presence of
the fexA gene, and to fluoroquinolones in all MRSA isolates. One
isolate (VF20T1) was also resistant to erythromycin and clinda-
mycin and carried the erm(C) gene. Microarray-based genotyping
analysis revealed that the isolate was positive for a and d
haemolysin, accessory gene regulator (agr) group 1 and capsule
type 5 and carried a set of MSCRAMM (microbial surface
components recognising adhesive matrix molecules) genes,
including clfA and clfB (clumping factors A and B), fnbA and fnbB
(fibronectin-binding proteins A and B), fib (fibrinogen-binding
protein), cna (collagen-binding protein), vwb (von Willebrand
factor-binding protein) and ebpS (elastin-binding protein). The
isolate was negative for the Panton–Valentine leukocidin genes
lukF-PV and lukS-PV, the immune evasion cluster (IEC), the toxic
shock syndrome toxin 1 gene tst, exfoliative toxin genes as well as
staphylococcal enterotoxin genes.
MRSA CC398 has been described in veal calves, cattle and
bovine mastitis in Belgium, France, Germany, The Netherlands,
Switzerland and the UK [3,5]. This is the first report of MRSA CC398
among calves in Portugal. These isolates carried the fexA gene,
which has been previously described on a non-conjugative
transposon (Tn558) in MRSA CC398 isolated from pigs and cattle
in Germany [5]. The location of this phenicol exporter gene was not
investigated in the current study. Resistance to fluoroquinolones in
MRSA CC398, however, has only been reported sporadically [2], yet
the isolates in this study were resistant to this class of
Journal of Global Antimicrobial Resistance 2 (2014) 342–343
Table 1
Molecular characteristics and antimicrobial resistance profiles of meticillin-resistant Staphylococcus aureus (MRSA) isolated in six calves in Farm A (Portugal).






spa type CC PFGE
cluster
VF97T0 Calf CHLr, FFCr, FQr, TETr fexA, tet(M), tet(K) V t108 398 A
VF2T1 Calf CHLr, FFCr, FQr, TETr fexA, tet(M), tet(K) V t108 398 A
VF10T1 Calf CHLr, FFCr, FQr, TETr fexA, tet(M), tet(K) V t108 398 A
VF20T1 Calf CHLr, CLIr, ERYr, FFCr,
FQr, TETr
erm(C), fexA, tet(M), tet(K) V t108 398 A
VF30T1 Calf CHLr, FFCr, FQr, TETr fexA, tet(M), tet(K) V t108 398 A
VF42T1 Calf CHLr, FFCr, FQr, TETr fexA, tet(M), tet(K) V t108 398 A
SCCmec, staphylococcal cassette chromosome mec; spa, staphylococcal protein A; CC, clonal complex; PFGE, pulsed-field gel electrophoresis; CHL, chloramphenicol; FFC,
florfenicol; FQ, fluoroquinolones; TET, tetracycline; CLI, clindamycin; ERY, erythromycin; r, resistant.
a The following antimicrobials were tested: chloramphenicol; ciprofloxacin; erythromycin; florfenicol; fosfomycin; fusidic acid; gatifloxacin; gentamicin; levofloxacin;
linezolid; moxifloxacin; mupirocin; netilmicin; oxacillin; penicillin; quinupristin/dalfopristin; rifampicin; tetracycline; teicoplanin; trimethoprim/sulfamethoxazole; and
vancomycin.
Contents lists available at ScienceDirect
Journal of Global Antimicrobial Resistance
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antimicrobials. Interestingly, Farm A used enrofloxacin routinely
(three times 5-day course of 10 mg/kg enrofloxacin separated by 5
days without antimicrobial) to avoid respiratory and/or gastroin-
testinal infections. Farm B, on the other hand, administered
gamithromycin for the same purpose. Fluoroquinolone adminis-
tration is known to be a risk factor for MRSA infection in
companion animals [1], so the use of enrofloxacin in Farm A could
have favoured the spread of this MRSA clone. No information was
available regarding usage of other antimicrobial agents that could
have selected (b-lactams) or co-selected (e.g. florfenicol) for the
occurrence of this multidrug-resistant clone.
Although these isolates did not carry the IEC known to be
important for human colonisation, these strains still harboured a
high number of virulence factors, which could still enable these
MRSA to colonise and subsequently infect the human host. This
fact and the multidrug resistance pattern identified in this study
enhance the importance of livestock animals as a reservoir of
antimicrobial resistance.
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Objectives: The objective of this study was to identify the Staphylococcus aureus clonal types currently circulating
in animals, humans in contact with animals and the environment in Portugal based on genetic relatedness, viru-
lence potential and antimicrobial/biocide susceptibility.
Methods: Seventy-four S. aureus isolates from pets, livestock, the environment and humans in contact with ani-
mals were characterized by SCCmec typing, spa typing, PFGE and CC398-specific PCR, by antimicrobial and biocide
susceptibility testing and by detection of resistance genes and genes for efflux pumps. Representative strains
were analysed by DNA microarray and MLST.
Results: The S. aureus isolates represented 13 spa types and 3 SCCmec types and belonged to three clonal com-
plexes (CC5, CC22 and CC398). Most of the isolates were multiresistant and harboured the resistance genes that
explained the resistance phenotype. The qacG and qacJ genes for biocide resistance were detected in 14 isolates
(all MRSA CC398), while 4 isolates (3 CC5 and 1 CC22) had insertions in the 210 motif of the norA promoter.
Isolates of the clonal lineages associated with pets (CC5 and CC22) harboured specific sets of virulence genes
and often a lower number of resistance genes than isolates of the clonal lineage associated with livestock
animals (CC398).
Conclusions: We found, for the first time in animals in Portugal, four strains belonging to CC5, including ST105-II,
a lineage that has been previously reported as vancomycin-resistant S. aureus in Portugal. Moreover, for the first
time the qacG and qacJ genes were detected in MRSA CC398 strains. Active surveillance programmes detecting
MRSA not only in livestock animals but also in companion animals are urgently needed.
Keywords: mecA, staphylococci, public health, CC5, CC398, CC22
Introduction
Staphylococcus aureus, especially MRSA, are a major problem in
the healthcare system and are also disseminated into the com-
munity.1 In Portugal, a country with a high prevalence of nosoco-
mial MRSA, MRSA of the clonal complexes CC22 and CC5 are the
main clones causing infections in people attending healthcare
centres and EMRSA-15 (ST22-IVh) accounts for more than 50%
of the total isolates in hospitals.1 The first European vancomycin-
resistant S. aureus (VRSA), a CC5 MRSA clone ST105-II, was
recently described in Portugal.2 Animals can also become colo-
nized and infected by MRSA, and might act as a reservoir for
human infections.3 In Portugal, colonization and infection with
MRSA has been described in pigs, horses, calves, dogs and
cats.4 – 7 However, little is known about the potential of these
strains to colonize/infect humans, especially those in contact
with animals. Furthermore, animal MRSA strains can harbour
antimicrobial resistance genes and/or efflux pumps that could
potentially be transmitted to human MRSA strains, limiting the
efficacy of antimicrobial/biocide treatment.3,8,9
The objective of this study was to identify and characterize the
MRSA clonal types currently circulating in animals, humans in con-
tact with animals and the environment in Portugal.
Materials and methods
Bacterial isolates
This study included all of the MRSA isolated at the Antibiotic Resistance
Laboratory (Faculty of Veterinary Medicine, University of Lisbon) from
2001 to 2014, from all over Portugal (from routine diagnostic and national
monitoring and surveillance programmes).4 – 7 Infection (i) and coloniza-
tion (c) isolates were obtained from pigs in 2008 (n¼17, 11 i + 6 c), envir-
onmental dust samples from breeding pig sheds in 2008 (n¼14), humans
# The Author 2015. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.




 Journal of Antimicrobial Chemotherapy Advance Access published June 4, 2015
 by Stefan Schw





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 by Stefan Schw








in contact with animals in 2008–12 (n¼18 c), calves in 2010 (n¼6 c),
dogs in 2008–14 (n¼10, 1 i + 9 c), cats in 2001–14 (n¼7, 5 i + 2 c)
and horses in 2010 (n¼2 c).
Antimicrobial susceptibility testing and resistance genes
The 74 isolates were routinely tested by broth microdilution for their anti-
microbial susceptibility to a panel of antimicrobials (ampicillin, amoxicillin/
clavulanic acid, chloramphenicol, ciprofloxacin or enrofloxacin, erythromycin,
florfenicol, fusidic acid, gentamicin, kanamycin, penicillin, trimethoprim, tri-
methoprim/sulfamethoxazole and tetracycline). Genes encoding resistance
tob-lactams, aminoglycosides, macrolides, lincosamides, tetracyclines, fusi-
dic acid, phenicols and trimethoprim were detected by PCR.8,9
Biocide susceptibility and efflux pump genes
Determination of ethidium bromide (EtBr) MICs was used as a simple
screening procedure for identifying strains with an increased efflux pheno-
type.9 MICs of chlorhexidine acetate, benzalkonium chloride and triclosan
were determined to further characterize the efflux phenotype. S. aureus
ATCC 29213 was used as a quality-control strain. The detection of the bio-
cide efflux pump genes norA and its promoter region, qacA/B, smr, qacG,
qacH and qacJ was performed by PCR and sequencing of strains with high
EtBr MICs (.8 mg/L).9
Molecular typing
All strains were assigned a spa type through the spa server (http://www.
ridom.de/spaserver/). The isolates were assigned to clonal complexes
according to the database of the spa server. These strains were also sub-
jected to ST398-specific PCR and SCCmec typing using primers described
previously.8 CC5 and CC22 strains were compared by SmaI PFGE, while
CC398 strains were compared by ApaI PFGE, using a previously described
protocol.8 Nine strains were subjected to MLST. Eleven strains were ran-
domly chosen for characterization using the S. aureus Genotyping Kit 2.0
(Alere Technologies GmbH, Jena, Germany).
Statistical analysis
The comparison of groups of categorical data was performed using the
Fisher’s exact test with a level of significance set at 0.05, using SPSS v20
(IBM, New York, USA).
Results
Overall, 13 spa types were identified (Table 1). According to the
spa server, four of these spa types were associated with CC398
(n¼47), six were linked to CC22 (n¼21) and three were asso-
ciated with CC5 (n¼6). These assignments were confirmed by
results from MLST and CC398-specific PCRs. The PFGE patterns of
all isolates belonging to the same clonal complex showed .80%
similarity (Figures S1 and S2, available as Supplementary data at
JAC Online). The CC22 isolates had SCCmec type IV and the CC398
isolates type V (n¼46) and type IV (n¼1). Among the CC5 iso-
lates, three had SCCmec type II, one had type IV and two carried
non-typeable SCCmec elements, which are currently sequenced.
All CC398 strains were resistant to tetracycline due to the pres-
ence of the tet(M) gene alone or in combination with tet(K) or
tet(L) genes. All CC22 and bovine CC398 strains were fluoroquino-
lone resistant. One porcine, one canine and the six bovine CC398
were resistant to chloramphenicol and florfenicol due to the pres-
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almost all porcine and environmental MRSA CC398 strains. All
strains were susceptible to vancomycin.
Eighteen strains had high MICs of EtBr: 13 (all CC398) carried a
qacG gene and had MICs of 16 mg/L, 1 strain (CC398) carried a
qacJ gene and had an MIC of 32 mg/L and in 4 strains (3 CC5
and 1 CC22) the norA gene had an insertion of sequence CAAT
(n¼3) or GTTGTAATACAAT (n¼1) in the 210 motif of the norA pro-
moter and had MICs of 32 mg/L. MICs of benzalkonium chloride
ranged from ≤0.125 to 4 mg/L and MICs of chlorhexidine acetate
ranged from ≤0.125 to 1 mg/L. All strains had low MICs of triclo-
san (≤0.125 mg/L).
The main virulence characteristics of the 11 S. aureus character-
ized by the S. aureus Genotyping Kit 2.0 are summarized in Table 2.
MRSA CC5 strains belonged to agr type II and the others to agr type I.
All strains carried the following virulence genes: isaB, isdA, hsdSx, aur,
sspA, sspB, sspP, sdrC, hysA1, setC, ssl02, cap5, icaA, icaC, icaD, vwb,
bbp, cflA, cflB, ebpS, eno, fib, fnbA, map, splA and splB. None of the
strains carried the ACME locus, the epidermal cell differentiation
inhibitor (edinA, edinB or edinC), exfoliative toxins (etA, etB or etD),
biofilm-associated protein (bap) or toxic shock syndrome toxic 1
(tsst-1). The main differences in the carriage of virulence genes
were detected in the enterotoxins, haemolysins, leukotoxins and
immune evasion cluster (IEC) (Table 2). Interestingly, the human
MRSA CC22-t032 strain carried the IEC, while the dog MRSA
CC22-t032 strain did not.
Pet-associated MRSA (CC5 and CC22) were significantly more
likely to carry enterotoxin genes [seg (P¼0.002), sei (P¼0.002),
sem (P¼0.002), sen (P¼0.002), seo (P¼0.002), seu (P¼0.002)
and enterotoxin gene cluster (egc; P¼0.002)] and staphylokinase
gene [sak; P¼0.015)], while livestock-associated MRSA CC398 were
significantly more likely to carry efflux pumps and particular anti-
microbial resistance genes [qacG (P¼0.003), dfrK (P¼0.0001),
tet(K) (P¼0.0001), tet(M) (P¼0.0001) and vga(A) (P¼0.0001)].
Discussion
During recent years, we have observed a significant increase in the
number of MRSA descriptions in animals in several countries,
including Portugal,4 – 7 despite only isolated studies describing
MRSA in animals and a single surveillance study (European
Union-wide baseline survey on MRSA conducted in 2008 in
breeding pig holdings) conducted in Portugal. Studies on the role
of animals, especially pets, in the transmission of MRSA into the
community are still lacking. In Denmark MRSA CC398 constituted
31% of all new MRSA cases in 2013 and patients in contact with
live pigs are screened for MRSA colonization when entering the
hospital setting.10,11 In contrast, livestock-associated MRSA con-
stitutes a small percentage of the overall MRSA burden in Portugal
and active screening does not include patients with animal con-
tact.12 This study showed that people in direct contact with ani-
mals (owners, handlers and veterinary personnel) carried similar
MRSA clones as the animals they were in contact with. Especially
worrying was the fact that humans in contact with companion
animals carried clones (CC5 and CC22) circulating in hospitals
and the community.1 We found, for the first time in animals in
Portugal, four strains belonging to CC5. One of these strains
belonged to ST105-II, the same lineage as the recently described
VRSA in Portugal.2 VRSA isolates from other countries also
belonged to CC5.13 In addition to the possibility of pets being a
reservoir and distributer of VRSA, companion animals can also
carry vanA-carrying VRE and thereby raise the chances of acquisi-
tion of the vanA gene cluster.14
MRSA CC22 and CC5 strains carried significantly more entero-
toxins than MRSA CC398, including egc, and at least one IEC
gene. One dog MRSA CC22-t032 strain did not carry IEC genes,
which might suggest host adaptation. Still a recent study found
no significant difference in the presence or absence of the IEC
between human and companion animal isolates when correcting
for shared evolutionary history, suggesting that IEC conferred iso-
lates with an extended host spectrum.15 Companion animals
seem to carry S. aureus clonal linages that are more virulent to
humans than livestock animals, and so active surveillance of
MRSA in companion animals seems to be urgently needed.
We found for the first time, to the best of our knowledge, the
qacG and qacJ genes in MRSA CC398 strains. The qacG gene has
been described in porcine MRSA isolates from clonal lineage ST9
in Hong Kong16 and both genes have also been detected among
staphylococci of bovine and caprine origin in Norway.17 Biocides
are extensively used in animal husbandry, including quaternary
ammonium compounds.14 The acquisition of qacG and qacJ by
MRSA CC398, usually carried on plasmids, may aid to the persist-
ence of MRSA in the environment, making the eradication of MRSA
CC398 more difficult.
Table 2. Virulence characteristics of the 11 S. aureus characterized by the S. aureus Genotyping Kit 2.0 (Alere)
Origin Clone agr group Haemolysins and leukotoxins Enterotoxins IEC
Dog (i) CC5-t002-II II hla, hlb, hld, lukF, lukS, lukD, lukE sed, seg, sei, sej, sem, sen, seo, seu, ser, egc chp, sak, scn
Human (c) CC5-t002-II II hla, hlb, hld, lukF, lukS, lukD, lukE sed, seg, sei, sej, sem, sen, seo, seu, ser, egc chp, sak, scn
Human (c) CC5-t002-IV II hla, hlb, hld, lukF, lukS, lukD, lukE sea, seg, sei, sej, sem, sen, seo, seu, ser, egc sak, scn
Horse (c) CC5-t062-nt II hla, hlb, hld, lukF, lukS, lukD, lukE seg, sei, sem, sen, seo, seu, egc chp, sak, scn
Dog (i) CC22-t032-IV I hla, hlb, hld, lukF, lukS sec, seg, sei, sel, sem, sen, seo, seu, egc —
Human (c) CC22-t032-IV I hla, hlb, hld, lukF, lukS sec, seg, sei, sel, sem, sen, seo, seu, egc chp, sak, scn
Calf (c) CC398-t108-V I hla, hld, lukF, lukS — —
Environmental dust CC398-t1255-V I hla, hld, lukF, lukS — —
Pig (i) CC398-t4571-V I hla, hld, lukF, lukS — —
Human (c) CC398-t011-V I hla, hld, lukF, lukS — —
Pig (c) CC398-t011-V I hla, hld, lukF, lukS — —
Couto et al.
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Supplementary Figure 1. Dendogram of chromosomal DNA digested with SmaI of MRSA CC5 
and CC22 strains. Pulsed-field cluster determination using a Dice similarity coefficient with an op-
timization of 1% and a band tolerance setting of 1.7%. 



















































































































































Figure 2. Dendogram of chromosomal DNA digested with ApaI of MRSA CC398 strains. Pulsed-
field cluster determination using a Dice similarity coefficient with an optimization of 1% and a band 































































































































































































































































































































3.2 Part 2 – Epidemiology, antimicrobial and biocide susceptibility of staphylococci isolated 
from animals in Portugal 
3.2.1 Biocide and antimicrobial susceptibility of methicillin-resistant staphylococcal isolates 
from horses 
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1. Introduction
Methicillin-resistant staphylococci (MRS) have been
frequently isolated from the anterior nares of healthy
animals, including horses (Moodley and Guardabassi, 2009;
Weese and van Duijkeren, 2010). These bacteria can be
transmitted from animals to humans, especially to veter-
inarians and animal handlers which are in close contact
(Moodley and Guardabassi, 2009). Although staphylococci
are a diverse group of commensals inhabiting the skin and
mucous membranes of humans and animals, some species,
like Staphylococcus aureus, are known as important human
pathogens (Weese and van Duijkeren, 2010). In horses, S.
aureus and coagulase-negative staphylococci (CoNS) are
responsible for skin/soft tissue, joint and incision infections
(Moodley and Guardabassi, 2009; Weese and van Duijkeren,
2010). These infections are usually treated with systemic
and/or topical antibiotics and/or topical antiseptic prepara-
tions (Bjorland et al., 2003; Schnellmann et al., 2006). In
contrast to antibiotics, most of the biocide preparations used
as antiseptics and disinfectants, are commercially available
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A B S T R A C T
The aim of this study was to evaluate the biocide and antimicrobial susceptibility of
methicillin-resistant staphylococcal isolates from horses. Fourteen methicillin-resistant
staphylococci (MRS) were subjected to an extensive genotype characterization, including
SCCmec, dru, spa, PFGE and MLST typing. Antimicrobial susceptibility testing was
performed and resistance genes were detected by PCR. Minimum bactericidal
concentrations (MBCs) of four biocides [chlorhexidine acetate (CHA), benzalkonium
chloride (BAC), triclosan (TCL) and glutaraldehyde (GLA)] were determined following the
recommendations of document NF EN 1040. The presence of qac and sh-fabI genes was
investigated by PCR. Several antimicrobial resistance patterns and genes were detected.
When MRS strains were exposed for a longer period of time, a lower concentration of the
biocide was needed to achieve lethality. TCL had the lowest MBC values. All MBC values
were lower than the recommended in-use concentrations for veterinary medicine. S.
haemolyticus and S. cohnii subsp. cohnii carried plasmid-borne qacA and sh-fabI or qacB and
a qacH-like genes, respectively. Biocides appear to be a reliable antiseptic option against
MRS, since even in the presence of bacterial efflux mechanisms, the recommended
concentration is much higher than the in vitro MBC.
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without prescription by a veterinarian (Bjorland et al.,
2003). This has raised concerns about the possible devel-
opment of ‘‘biocide resistance’’ and cross-resistance to
antibiotics (e.g. via mechanisms acting on both biocides and
antibiotics) (SCENIHR, 2010; Ciusa et al., 2012). Different
mechanisms to evade the toxic activity of biocides have
been recognized (Cerf et al., 2010). One of those mechan-
isms, which can be encoded on the bacterial chromosome or
on plasmids, is overexpression of efflux pumps (SCENIHR,
2010). In Staphylococcus species several efflux pumps have
been recognized, but QAC efflux proteins seem to be the
most widespread (Bjorland et al., 2003; Couto et al., 2008;
Vali et al., 2008). A recent report identified a novel
transferable mechanism of reduced biocide susceptibility
to triclosan, mediated by the sh-fabI gene (Ciusa et al., 2012).
The Scientific Committee on Emerging and Newly Identified
Health Risks (SCENIHR) has recommended the determina-
tion of minimum bactericidal concentrations (MBCs) as the
appropriate methodology that allows the comparison of
lethality in susceptible and resistant strains (SCENIHR,
2010). This determination must involve the use of a
neutralizing agent or the removal of the biocide, otherwise
it will provide an over-estimation of the lethality of the
compound (SCENIHR, 2010; Cerf et al., 2010).
In the present study, we characterized the antimicrobial
resistance and biocide susceptibility of a collection of MRS
isolates from horses and studied the genetic relatedness of
the isolates.
2. Materials and methods
2.1. Bacterial isolates
From March 2008 to October 2010, a study was
performed in horses entering the Equine Unit of the
Faculty’s Veterinary Hospital. The objective was to
determine the prevalence of MRSA nasal colonization in
horses. Twenty horses were admitted for elective surgery –
castration or as part of a control group or were admitted
with a disease other than infection (30 samples from
horses with recurrent airway obstruction (RAO), 18 from
horses with different respiratory diseases and 13 from
horses with equine gastrointestinal ulcer syndrome
(EGUS)). None of the horses had been treated with an
antibiotic or an antiseptic prior to sample collection. The
presumptive colonies were identified as staphylococci by
routine methods. All the Staphylococcus spp. strains
growing on ChromIDTM MRSA (bioMérieux, Marcy L’Etoile,
France) were stored in brain–heart infusion broth with 20%
sterile glycerol at !20 8C. For this study, the 14 MRS strains
included were classified by BBLTM CrystalTM Gram-Positive
ID Kit (Becton, Dickinson and Company, Maryland, USA).
They comprised eight Staphylococcus sciuri, two Staphylo-
coccus aureus, and single strains of Staphylococcus lentus,
Staphylococcus fleurettii, Staphylococcus haemolyticus and
Staphylococcus cohnii subsp. cohnii. Methicillin resistance
was confirmed by amplification of the mecA gene
(Schnellmann et al., 2006). Since isolates A4C/08, A7C/08
and A36B/08 could not be properly identified by this
identification system, they were subjected to 16S rDNA
gene sequencing.
2.2. Molecular typing
All MRSA strains were tested by PCR for the presence of
lukF/lukS genes encoding Panton-Valentine leukocidin
(PVL) (Febler et al., 2010) and spa types were assigned
through the Ridom web server (http://www.ridom.de/
spaserver/). These strains were also subjected to ST398
specific PCR using primers described by van Wamel and
colleagues in 2010. Multi-locus sequence typing (MLST)
was performed in the non-ST398 MRSA strains. SCCmec
and dru types were determined as described previously
(Febler et al., 2010). The S. sciuri strains were compared by
SmaI PFGE, using a previously described protocol (Febler
et al., 2010).
2.3. Antimicrobial susceptibility testing and detection of
resistance genes
Susceptibility to a range of antibiotics was determined
by broth microdilution, following CLSI standards (CLSI,
2008, 2011). EUCAST guidelines (EUCAST, 2009) were used
for fusidic acid and mupirocin minimal inhibitory con-
centration (MIC) interpretation. E-test strips (Liofilchem,
Roseto degli Abruzzi, Italy) were used for fusidic acid MIC
determination. b-Lactamase production was detected by
using the lyophilized nitrocefin SR00112 (Oxoid, Hamp-
shire, United Kingdom) broth method, using S. aureus ATCC
29213 and S. aureus ATCC 25923 as controls. Genes
previously reported for resistance to b-lactams, amino-
glycosides, macrolides, lincosamides, tetracyclines, pleur-
omutilins, fusidic acid, chloramphenicol and trimethoprim
were detected by PCR (Schnellmann et al., 2006; Febler
et al., 2010).
2.4. Biocide susceptibility and detection of qac and sh-fabI
genes
Ethidium bromide (EtBr) MIC determination was used
as a simple screening procedure for identifying strains
with an increased efflux phenotype (Couto et al., 2008).
MIC of chlorhexidine acetate (CHA), benzalkonium chlor-
ide (BAC), and triclosan (TCL) were determined to further
characterize the efflux phenotype. TCL was included
because it is used for the control of MRSA carriage among
human patients and so monitoring of susceptibility is very
important. MICs of glutaraldehyde (GLA) were not
determined since an increase in the MIC of GLA is not
related to any known mechanism of reduced susceptibility.
The determination of MBC of the four biocides (CHA, BAC,
TCL and GLA) was performed according to Narui and
colleagues (2007), and following the recommendations of
document NF EN 1040 (AFNOR, 2006). In brief, each cell
suspension was inoculated with the biocide with an
exposure time of 5, 30 and 60 min at 20 8C. Then the
bacteria-biocide mixture was transferred into the neu-
tralization medium for 5 min and finally was inoculated
into Muller–Hinton broth without biocide. Bacterial
growth was evaluated after incubation at 37 8C for 24 h.
S. aureus ATCC 29213 and S. aureus ATCC 6538 were used as
quality controls. The detection of the biocide resistance
genes qacA/B, smr, qacG, qacH and qacJ was performed by




PCR (Bjorland et al., 2005; Couto et al., 2008) and
sequencing. The presence of sh-fabI was investigated by
PCR using strain S. aureus M0091 as a positive control
(Ciusa et al., 2012).
2.5. Transformation experiments
In order to characterize the biocide susceptibility
profiles, plasmids from strains 1 and 12 (Table 1) were
transferred into S. aureus RN4220 by electrotransforma-
tion. Transformants were selected by incubation on brain–
heart infusion agar plates, supplemented with 0.5 mg/mL
TCL or 16 mg/mL EtBr. Transformants, which appeared
after 24–48 h, were screened for their plasmid content and
their antimicrobial susceptibility phenotype.
3. Results
Both MRSA isolates were PVL-negative and were
classified as either ST5-t062-SCCmec VI or ST398-t011-
SCCmec IV (Table 1). The SCCmec and dru types of all MRS
are listed in Table 1. All S. sciuri isolates showed
indistinguishable SmaI PFGE profiles, although the isolates
included in this study were from individual horses, except
for strains 8 and 9, which were isolated from the same
horse. Isolates 8 and 9 differed, however, in their
tetracycline resistance pheno- and genotype. This obser-
vation suggests that this clone of S. sciuri is widely
disseminated among the horse population in Portugal or
may be present in the veterinary hospital in which the
horses have been sampled.
The antimicrobial resistance patterns and the resis-
tance genes detected are summarized in Table 1. The three
isolates carrying the blaZ gene, expressed the b-lactamase
as detected by the nitrocefin test. None of the vga genes
tested were identified in the MRCoNS, which exhibited
high tiamulin MICs of 32 to >64 mg/mL.
The MIC values of three biocides (BAC, CHA and TCL)
and one dye (EtBr) are summarized in Table 2. Two
MRCoNS expressed an efflux phenotype and were qacA/B-
positive (Table 1). Sequencing of the qac-amplicons
identified a qacA gene in the S. haemolyticus isolate
and a qacB and a qacH-like gene in the S. cohnii subsp.
cohnii isolate. The sh-fabI gene was present only in the
Table 1
Molecular characteristics, antimicrobial resistance profiles, MICs of dyes (ethidium bromide) and biocides (benzalkonium chloride, chlorhexidine acetate
and triclosan), and genes associated with reduced biocide susceptibility of methicillin-resistant staphylococci isolated from horses.
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with reduced
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III nt ERY, TIA msr(A),
mph(C)
128 2 1 2 qacB, qacH-like
2 S. lentus Horse
with RAO
nt dt13v CHL, TIA catpC221 0.5 0.5 0.5 0.007 –
3 S. fleurettii Horse
with RAO
III dt11a TIA – 0.5 0.5 0.5 0.007 –
4 S. sciuri Horse
with RAO
III dt11a TET, TIA tet(K) 0.5 2 1 !0.003 –
5 S. sciuri Healthy
horse
III dt11a TET, TIA tet(K) 0.5 1 1 !0.003 –
6 S. sciuri Horse
with RAO
III dt11a TET, TIA tet(K) 0.5 2 1 !0.003 –
7 S. sciuri Healthy
horse
III dt11a TET, TIA tet(K) 0.5 2 1 !0.003 –
8 S. sciuri Horse
with RAO
III dt11a TIA – 0.5 2 1 !0.003 –
9 S. sciuri III dt11a TET, TIA tet(K) 0.5 2 1 !0.003 –
10 S. sciuri Horse
with EGUS
nt nt TIA – 1 1 2 !0.003 –
11 S. sciuri Healthy
horse
nt dt11a TET, TIA tet(K) 0.5 0.5 0.5 !0.003 –
12 S. haemolyticus Healthy
horse





64 2 1 4 qacA, sh-fabI
13 S. aureus Healthy
horse




2 0.5 0.5 !0.003 –
14 S. aureus Horse
with EGUS
VI nt CLI, ERY, FUS blaZ, erm(C),
fusC
8 0.5 0.5 !0.003
RN4220 S. aureus 8 1 1 0.125 –
RN4220pNCP1 S. aureus 128 2 1 0.125 qacB
RN4220pNCP2 S. aureus 64 2 1 0.125 qacA
RN4220pNCP3 S. aureus 8 1 1 4 sh-fabI
Abbreviations: BAC: benzalkonium chloride; CC: clonal complex; CHA: chlorhexidine acetate; CHL: chloramphenicol; CLI: clindamycin; EGUS: equine
gastrointestinal ulcer syndrome; ENR: enrofloxacin; ERY: erythromycin; EtBr: ethidium bromide; FUS: fusidic acid; GEN: gentamicin; KAN: kanamycin; nt:
non typeable; RAO: recurrent airway obstruction; TCL: triclosan; TET: tetracyclin; TIA: tiamulin; TMP: trimethoprim.




aforementioned S. haemolyticus isolate. The MBC values for
TCL were very low (!0.125 mg/mL) and not within the
concentration range tested (data not shown), except for
isolates 1 and 12 (2–32 mg/mL). Nevertheless, in both cases
the MBC values decreased over time, similar as was
observed with the other three biocides. The S. haemolyticus
strain had the highest MBC value to TCL at all times (32 mg/
mL at 5 min, 16 mg/mL at 10 min and 8 mg/mL at 30 min)
and carried the sh-fabI gene. Both qacB- and qacA-carrying
plasmids (pNCP1 and pNCP2, respectively) were success-
fully transformed into S. aureus RN4220, using EtBr to
select for the transformants. Transformation of S. aureus
RN4220 with a plasmid from the S. haemolyticus strain,
using TCL to select for transformants, confirmed that the
sh-fabI gene was also located on a plasmid (pNCP3). None
of the transformants was resistant to any of the antibiotics
tested, suggesting that the biocide resistance genes were
the only resistance genes on plasmids pNCP1, pNCP2 and
pNCP3.
4. Discussion
In this study, we tested the biocides CHA, BAC, GLA and
TCL against a collection of MRS isolates from horses. Two
isolates (14%) showed an efflux phenotype (higher MIC
values to EtBr compared to the wild-type S. aureus
RN4220) and were qacA/B positive. QAC efflux pumps
have been previously reported among staphylococci from
horses and other farm animals (Bjorland et al., 2003, 2005).
However, the occurrence of qacA or qacB genes among
staphylococci of equine origin has not been described so
far. In human medicine, the frequency of qac genes differs
worldwide. Yet, studies performed in the United Kingdom
found a frequency of qacAB genes of 10% to 20% among
human MRSA strains (Vali et al., 2008), which is compar-
able to that found in this study. Similarly one study
performed in MRS strains of bovine and caprine origin
detected qac genes in 21% of the 127 dairy cattle herds and
10% of the 70 dairy goat herds that were screened (Bjorland
et al., 2005). In the same study the qac-positive strains had
MICs for BAC that ranged from 1 to 5 mg/mL (Bjorland et al.,
2005), which is similar to our results.
Neither of the two qacA/B positive strains found in our
study had high MBC values to BAC, CHA or GLA.
Surprisingly the qacA/B positive strains had significantly
higher MBC values to TCL than the qac-negative strains.
The qacB-positive strain also harboured a qacH-like gene
but no additive effect in the efflux phenotype was
observed. No additive effect was also seen in a strain
carrying a qacA/B plus a smr gene in a previous study
(Bjorland et al., 2005). No cross-resistance to antibiotics
was detected either, since neither of the two transformants
harbouring the qac genes showed resistance to the
antibiotics tested. As expected, when MRS strains were
exposed for a longer period of time, a lower concentration
of the biocide was needed to achieve lethality. TCL was the
most effective biocide, since the lowest concentrations
were needed to achieve killing. Yet in a previous study with
the same methodology, TCL was the biocide with the
highest MBCs against laboratory isolates of S. aureus,
Pseudomonas aeruginosa and Candida albicans (Koburger
et al., 2010). However, colonization isolates may have
different susceptibilities than laboratory strains depending
on the selective pressure they have been subjected to in
vivo. As TCL is currently not approved for and consequently
not used in equine medicine (Ciusa et al., 2012), the
apparent lack of selective pressure may explain the high
susceptibility of the equine MRS isolates. One MRS S.
haemolyticus isolate harbored a plasmid-borne sh-fabI gene
with a TCL MIC of 4 mg/mL and an MBC of 32 mg/mL (at
5 min). This observation was in accordance with a previous
study, where the same MIC and MBC values were detected
in a S. aureus strain carrying a plasmid-borne sh-fabI gene
and in a S. haemolyticus strain harboring a chromosomal
sh-fabI gene. This gene is responsible for a novel mechan-
ism of diminished susceptibility to TCL with a high
potential for horizontal gene transfer through plasmids
(Ciusa et al., 2012). In our study the sh-fabI-gene was found
in a plasmid and not in the chromosome of S. haemolyticus,
as reported by Ciusa and colleagues (2012). The higher MIC
and MBC values in the S. cohnii subsp. cohnii strain, and the
absence of the sh-fabI gene may indicate that another
mechanism is present, probably mutations in the original
fabI gene, which have been previously described in S.
aureus (Ciusa et al., 2012).
Overall, the MBC values of BAC, CHA and GLA were lower
than the concentrations currently used in some commercial
products (Table 2) or recommended for use in veterinary
applications (Table 2). Nevertheless, when comparing the
MBC values of the isolates of the present study with the
concentration of BAC in human products (100 mg/mL)
(Narui et al., 2007), five isolates with BAC MBCs of
>128 mg/mL were detected. A few isolates with higher
MBC results for CHA and BAC than the concentration used
Table 2
Minimum and maximum user concentration and contact time of biocides normally used in veterinary medicine.
Agent User concentration (mg/mL) and contact time (min)a
Skin and wound Environment Surgical site Hand scrubs
Benzalkonium chloride 1000–2000 5–10 60–120 120 100–500 N.A. 500–1000 1–3
Glutaraldehyde N.A. N.A. 625–1250 120–240 N.A. N.A. N.A. N.A.
Chlorhexidine acetate 150–40,000 5–10 N.A. N.A. 40,000 5–10 1000–40,000 1–3
Abbreviations: min: minutes; N.A.: not applicable.
a This is based on commercial veterinary products available at the manufactures’ websites and based on documents: European Medicines Agency.
Committee for Veterinary Medicinal Products. Chlorhexidine. EMA, London, United Kingdom, 1996 (http://www.ema.europa.eu/docs/en_GB/
document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500012062.pdf); European Medicines Agency. Committee for Veterinary Medicinal
Products. Benzalkonium chloride. EMA, London, United Kingdom, 1997 (http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_-
Limits_-_Report/2009/11/WC500010967.pdf).




in human products have already been reported (Narui et al.,
2007). This is of notice, since transmission of MRS strains
between horses, humans and their environments may
occur.
Although antimicrobial therapy of MRS has become
difficult due to the antimicrobial multidrug-resistance of
many MRS isolates, biocides are still a bactericidal option
not only for treatment of skin and wound infections, but
also for decolonization purposes.
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and Biocide Susceptibility Comparative Analysis
of Methicillin-Resistant and -Susceptible
Staphylococcus pseudintermedius from Portugal
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Forty methicillin-resistant and -susceptible Staphylococcus pseudintermedius (MRSP and MSSP, respectively) from
colonization and infection in dogs and cats were characterized for clonality, antimicrobial, and biocide sus-
ceptibility. MSSP were genetically more diverse than MRSP by multi-locus sequence typing and pulsed-field gel
electrophoresis. Three different spa types (t06, t02, t05) and two SCCmec types (II-III and V) were detected in the
MRSP isolates. All MRSP and two MSSP strains were multidrug-resistant. Several antibiotic resistance genes
(mecA, blaZ, tet(M), tet(K), aac(6¢)-Ie–aph(2’)-Ia, aph(3’)-III, ant(6)-Ia, sat4, erm(B), lnu(A), dfr(G), and catpC221) were
identified by microarray and double mutations in the gyrA and grlA genes and a single mutation in the rpoB gene
were detected by sequence analysis. No differences were detected between MSSP and MRSP in the chlorhexidine
acetate (CHA) minimum inhibitory concentrations (MICs). However, two MSSP had elevated MIC to triclosan
(TCL) and one to benzalkonium chloride and ethidium bromide. One MSSP isolate harboured a qacA gene, while
in another a qacB gene was detected. None of the isolates harboured the sh-fabI gene. Three of the biocide
products studied had high bactericidal activity (Otodine!, Clorexyderm Spot Gel!, Dermocanis Piocure-M!),
while Skingel! failed to achieve a five log reduction in the bacterial counting. S. pseudintermedius have become a
serious therapeutic challenge in particular if methicillin- resistance and/or multidrug-resistance are involved.
Biocides, like CHA and TCL, seem to be clinically effective and safe topical therapeutic options.
Introduction
Methicillin-resistant Staphylococcus pseudintermedius(MRSP) has emerged recently and has become a se-
rious therapeutic challenge for veterinarians, due to multi-
drug resistance.9,12,24,30 They are a major cause of skin and
urinary tract, and hospital acquired infections in dogs and
cats.12,30 Originally, two major MRSP clones were found
to spread in Europe (ST71-t02-SCCmec II-II) and North
America (ST68-t06-SCCmec V).4,24,30 Although more recent
reports have yet identified other S. pseudintermedius line-
ages carrying the mecA gene,11,22 methicillin-susceptible S.
pseudintermedius (MSSP) tend to be genetically more diverse
than MRSP.2,4
In addition to the mecA gene, MRSP isolates usually
have mutations in the gyrase and topoisomerase genes,
conferring resistance to fluoroquinolones10 and several other
genes, which mediate resistance to gentamicin, kanamycin,
erythromycin, clindamycin, streptomycin, tetracycline and
trimethoprim.12,30 Resistance to rifampicin and chloram-
phenicol has also been reported in some MRSP strains.12,17,30
This pattern of multidrug resistance is normally in contrast to
what happens with MSSP.12 Resistance to ampicillin and
penicillin is often reported in MSSP isolates, but they are
usually susceptible to the other antimicrobial classes.12 Yet,
treatment of MRSP infections is based on the same principles
as MSSP infections, usually involving systemic and/or topic
therapy. The difference lies on the number of antimicrobial
options available for a successful treatment. While there are
several antimicrobial options for MSSP therapy, some of
the antimicrobials used for the treatment of MRSP infections
are not licensed for veterinary use and considered ‘‘critically
important’’ for human medicine by the World Health
Organization.32 Other antimicrobials, like rifampicin and
1Laboratory of Antimicrobial and Biocide Resistance, Faculty of Veterinary Medicine, Interdisciplinary Centre of Research in Animal
Health, Technical University of Lisbon (FMV-UTL), Lisboa, Portugal.
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chloramphenicol, are potentially toxic and have suboptimal
pharmacological features for small animals.12,17 For this
reason, topical therapy, especially antiseptic preparations,
has gained a renewed interest. Biocide topical therapy can be
used as solo or as an adjuvant for the treatment of skin, ear
and wound infections.12 Previous studies have assessed the
in vitro efficacy of biocides through determination of mini-
mum inhibitory concentrations (MICs) and/or minimum
bactericidal concentrations.15,27,33 Although the determina-
tion of MICs is important for the detection of efflux pheno-
types (especially through detection of the ethidium bromide
[EtBr] MICs) the in vitro efficacy of a biocide, as recommended
by the Scientific Committee on Emerging and Newly Identi-
fied Health Risks (SCENIHR), should involve the use of a
neutralising agent or by the removal of the biocide.25 This is
important to avoid an over-estimation of the lethality of the
biocide compound, since biocides are usually in contact with
the bacteria only for a brief period of time.
To date, only a few studies have determined biocide sus-
ceptibility of S. pseudintermedius. This study compares the
clonality, antimicrobial and biocide susceptibility of MSSP
and MRSP that have been isolated from the nasal cavities of
healthy animals as well as from infection sites.
Materials and Methods
Strain collection
Twenty MRSP and twenty MSSP strains isolated between
2007 and 2011 were included in the study. The isolates were
collected at the Laboratory of Antimicrobial and Biocide
Resistance, FMV-UTL, which receives samples from the
Veterinary Teaching Hospital of FMV-UTL and private
practices covering the area of the Lisbon region. Five isolates
were from cats and 35 were from dogs. These included
clinical infection (urinary tract infection, n = 6; skin infection,
n = 10; ear infection, n = 5; surgical site infection, n = 1) and
nasal colonization isolates (n = 18).
Multi-locus sequence typing, spa and SCCmec typing
Isolates were characterized by Multi-locus sequence typ-
ing (MLST) using the MLST scheme of Bannoehr et al.,2
which is based on five housekeeping genes ( pta, cpn60, tuf,
16S rRNA and agrD),24 and also by the newly described
S. pseudintermedius MLST scheme, which is based on seven
housekeeping genes (ack, cpn60, fdh, pta, purA, sar, tuf).27
MRSP isolates were also characterized by spa and SCCmec-
typing. spa-typing was performed by sequencing the poly-
morphic region of protein A gene (spa) and spa types were
assigned according to previously proposed guidelines.24
SCCmec types were determined using the multiplex PCR 1
and the multiplex PCR 2 according to Kondo and collabo-
rators.18 In multiplex PCR 1, the presence of mecA was con-
firmed and the ccr gene complex was determined. In
multiplex PCR 2, the mec class complex was assessed.18 The
combination of the type ccr and mec complex was used to
consign SCCmec types. SCCmec II-III was identified by PCR
using primers described previously.23
eBURST analysis
Predicted lines of evolutionary descent in our collection of
MRSP and MSSP isolates were identified using the eBURST
algorithm (http://eburst.mlst.net). eBURST identified groups
of related sequence types (ST) by assigning all members that
shared identical alleles at four of the five gene loci (MLST-5
scheme) or six of the seven gene loci (MLST-7 scheme) with
at least one other member of the group.2 The founding ST of
each group was determined by the ST with the greatest
number of single locus variants (SLV).28 Subgroups were
defined by the existence of at least three SLV.
Pulsed-field gel electrophoresis
The S. pseudintermedius strains were compared for their
genetic relatedness by SmaI macrorestriction, using a previ-
ously described protocol.9 The SmaI fragment patterns were
analysed with BioNumerics (Applied Maths, Kortrijk, Bel-
gium), the similarities between profiles were calculated using
the Dice coefficient with a maximum position tolerance of
1.0%. The patterns were clustered by using the unweighted
pair group method with arithmetic averages based on a
similarity cut-off value of 80%.
Antimicrobial susceptibility testing
Antimicrobial susceptibility was determined by the disk
diffusion method and according to the Clinical and Labora-
tory Standards Institute guidelines.7 The antibiotic resistance
genes were detected using the custom-made microarray
AMR + ve-2 (Alere GmbH, Cologne, Germany)24 and by
PCR.19,24 Mutations in the quinolone resistance-determining
region (QRDR) of gyrA and grlA were determined by PCR
using the following primers: gyrA_pseudFW 5¢-ATGAGTG
TTATCGTATCTCGTGC-3¢, gyrA_pseudRV 5¢-GAACCGAA
GTTACCTTGACCAT-3¢, grlA_pseudFW 5¢-AATACGTAT
GATAAACATTTTCG-3¢ and grlA_pseudRV 5¢-TCGGTAT-
CATCATAGTTCGG-3¢, respectively. Mutations in the ri-
fampicin resistance-determining region (RRDR) within the
rpoB gene of the rifampicin-resistant isolates were amplified
by PCR and sequenced as described previously.17
Biocide susceptibility
MICs were determined for the following antiseptics and
dye: chlorhexidine acetate (CHA), benzalkonium chloride
(BAC), triclosan (TCL) and EtBr. EtBr MIC determination is a
simple screening procedure for identifying strains, which
have increased expression of efflux pump genes or an efflux
phenotype.8 CHA, BAC and TCL were determined to further
characterize any efflux phenotype. The bactericidal activity (at
5 minutes and 20!C) of four commercial dermatological
preparations (Otodine", Clorhexyderm Spot Gel", Dermoca-
nis Piocure-M" and Skingel") was determined against MRSP
and MSSP according to the document NF EN 1040–Essai
quantitatif de suspension pour l’évaluation de l’activité bac-
tericide de base des antiseptiques et des désinfectants chimi-
ques.1 Both Otodine and Clorhexyderm Spot Gel contain CHA
(0.15% and 0.3%, respectively), Dermocanis Piocure-M has
TCL (0.3%) and Skingel contains zinc oxide (10%). The full
formulation of the biocide products can be found at the
manufacture’s website (www.icfpet.it). Briefly, isolates were
grown on a solid medium for 24 hours at 37!C and suspended
on a diluent to 1.5–5 · 108 colony-forming units/ml. Each cell
suspension was inoculated into water containing the biocides
and was exposed for 5 minutes, as recommended by NF1040.
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To inactivate the biocides, the bacteria-biocide mixture was
transferred into the neutralization medium (phosphate buffer
0.25 mmol/L pH 7.2) for 5 minutes. Then the mixture was
inoculated onto Tryptone-Soy agar plates without the bio-
cides. Bacteria growth was observed after incubation at 37!C
for 24 hours. Bactericidal activity was defined as a logarith-
mical reduction on bacterial cell counts of at least five loga-
rithms. S. aureus ATCC 29213 and S. aureus ATCC 6538 were
used as quality controls. The detection of efflux genes qacA/B,
smr, qacG, qacH and qacJ was performed by PCR.3,8 The qacA/B
positive amplicons were sequenced. The detection of sh-fabI
was performed by PCR using primers described recently by
Ciusa et al., using S. aureus strain M0091 as a positive control.6
Results
Strain characterization by genotyping
The epidemiological, genotypic and phenotypic traits of
the forty MRSP and MSSP isolates under study are shown in
Table 1. MLST-7 allowed a better discrimination than MLST-
5 and further distinguished among strains (Table 1). The
MSSP strains were divided into 19 or 24 different STs ac-
cording to the MLST-5 and MLST-7 schemes, respectively
(see Table 1). Two novel cpn60 alleles (alleles 43 and 44, ac-
cession numbers JX976294 and JX982108, respectively) and
four novel pta alleles (alleles 32, 34, 35 and 36, accession
numbers JX982110, KC438371, JX982112 and JX987962, re-
spectively) were found. Using the MLST-5 scheme, 17 MRSP
belonged to ST71, two belonged to ST97 and one to ST2 (Fig.
1a). When applying the new MLST-7 scheme only 14 MRSP
ST71 isolates were assigned to the ST71, and three being as-
signed to ST203; two ST97 were subdivided into ST196 and
ST213, and ST2 was assigned to ST195. Yet ST203 and ST195
belonged to the clonal complex (CC) 71, as detected by the
eBURST analysis (Fig. 1b). Likewise ST196 and ST213 differed
only by one allele and belonged to CC196 (Fig. 1b). Pulsed-field
gel electrophoresis (PFGE) analysis, based on a similarity cut-off
value of 80%, revealed two major clusters of MRSP, one con-
taining the CC71 isolates and the other cluster having the
CC196 strains (Fig. 2). The MRSP isolate ST195 was non-type-
able by SmaI restriction PFGE. Similar to MLST results, PFGE
analysis revealed that the MSSP isolates were genetically more
diverse (Fig. 3). eBURST analysis performed in our collection of
MRSP and MSSP isolates was very different when using the
MLST-5 and MLST-7 schemes. When applying the MLST-5
scheme eBURST showed that the S. pseudintermedius isolates
belonged to very similar STs, only differing in one or two of the
five loci examined (Fig. 3a). As expected, eBURST analysis us-
ing the MLST-7 scheme had very different results, with only a
few STs relating with another (Fig. 1b) and the MSSP being
singletons (data not shown).
Antimicrobial susceptibility and resistance genes
Antimicrobial resistance patterns of the S. pseudintermedius
isolates are shown in Table 1. All MRSP isolates were resis-
tant to erythromycin, clindamycin, fluoroquinolones (cipro-
floxacin, enrofloxacin, moxifloxacin, norfloxacin, ofloxacin
and pradofloxacin), trimethoprim/sulfamethoxazole, genta-
micin, tobramycin, kanamycin and streptomycin. Ad-
ditionally 17 MRSP isolates had tetracycline-resistance, one
had chloramphenicol resistance and one was resistant to ri-
fampicin. MSSP were more susceptible than MRSP strains to
the tested antibiotics. Eight strains were susceptible to all
antibiotics. All isolates were susceptible to fluoroquinolones.
Ampicillin and penicillin resistance was present in nine
MSSP strains, while eight were resistant to tetracycline. Two
MSSP strains were resistant to erythromycin, clindamycin,
kanamycin, streptomycin and chloramphenicol and one was
resistant to trimethoprim/sulfamethoxazole. Resistances
were attributed to the presence of the penicillin binding
protein gene mecA (all b-lactams), the b-lactamase gene
blaZ (penicillin), the tetracycline resistance genes tet(M)
and tet(K), aminoglycoside acetyltransferase and phospho-
transferase gene aac(6¢)-Ie–aph(2’)-Ia (all aminoglycosides
except streptomycin), phosphotransferase gene aph(3’)-III
(kanamycin, neomycin, paromomycin, amikacin, gentamicin
B), streptomycin adenyltransferase gene ant(6)-Ia, the mac-
rolide, lincosamide and streptogramin B 23S rRNA methyl-
ase gene erm(B), the lincosamide nucleotidyltransferase
lnu(A), the chloramphenicol acetyltransferase gene catpC221,
the trimethoprim-resistance dihydrofolate reductase gene
dfr(G). Two amino acid substitutions (S84L of GyrA and
S80I of GrlA) were found in the QRDR of fluoroquinolone-
resistant isolates. The rifampicin-resistant isolate had an
A522D substitution in the RRDR. One MSSP strain har-
boured a lnu(A) gene but was not resistant to clindamycin.
Biocide susceptibility, qac and sh-fabI genes
Fourteen and six MRSP isolates presented an MIC of 1 mg/L
and 2 mg/L of BAC, respectively (Table 2). Eighteen MSSP
isolates had an MIC of 0.5 mg/L to BAC (Table 2). All MRSP and
MSSP strains had an MIC of 1 mg/L to CHA. All MRSP iso-
lates and 18 MSSP had an MIC to TCL of £ 0.003 mg/L, while
one isolate had an MIC of 0.125 mg/L. None of the isolates car-
ried the recently described TCL resistance gene sh-fabI. MIC to
EtBr were £ 4 mg/L, except for one isolate, which showed an
EtBr MIC of 32 mg/L (Table 2). This MSSP isolate (FMV20A/08)
had an MIC of four to BAC and harboured the quaternary com-
pound resistance gene qacA. Another MSSP isolate (FMV750/10)
had the qacB gene but no detectable efflux mechanisms. All
MRSP isolates were negative for the efflux genes tested.
Three preparations, Otodine, Clorexyderm Spot Gel and
Dermocanis Piocure-M, had bactericidal activity against all
MRSP and MSSP isolates. However, Skingel could not
achieve a five log reduction of the bacterial count.
Discussion
Methicillin resistance have only been recently reported in
S. pseudintermedius strains, but their capacity to resist to an-
timicrobial therapy is already a worldwide concern.23,30 ST71
was the predominant clone emphasizing its spread. The use
of the new MLST scheme based on seven housekeeping
genes allowed distinguishing between some of the strains of
the CC71, revealing new ST195 and ST203. ST71 has been
previously described among MRSP colonization isolates
from dogs in Portugal;9 however, this is the first report of
MRSP ST196 and ST213 (CC196), which are not related to
CC71. MSSP isolates, instead, were more genetically diverse,
with all MSSP isolates corresponding to a single ST. These
findings are in agreement with two previous reports,2,4
where MRSP isolates were restricted to a small number of ST,
while MSSP strains revealed substantial clonal diversity.

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































However, two recent reports found the mecA gene in a
considerable high number of ST,11,22 indicating that different
lineages of S. pseudintermedius can acquire SCCmec elements.
Only two types of SCCmec elements were detected among
the MRSP from Portugal, namely SCCmec II-III in isolates of
CC71 and SCCmec V in isolates of CC196.
Antimicrobial resistance is typically very different be-
tween MRSP and MSSP. While MRSP tend to be multidrug-
resistant, MSSP are usually only resistant to ampicillin and
penicillin, due to the presence of the blaZ gene.12 Accordingly
we found a multidrug resistant pattern in all MRSP isolates.
However, two MSSP strains were also resistant to more than
three antimicrobial classes, categorizing these strains as
multidrug-resistant. Some studies have also identified mul-
tidrug-resistance among MSSP isolates.13,14,29 Nevertheless,
in the majority of the studies MSSP strains were only resis-
tant to ampicillin and one additional antimicrobial class.12,30
Several antimicrobial resistance genes have been detected in
S. pseudintermedius strains16 and our strains exhibit the same
genes as detected before. Contrary to the study of Vanni
and colleagues,31 which only detected resistance to second-
and third-generation fluoroquinolones in S. pseudintermedius
isolates, our fluoroquinolone-resistant S. pseudintermedius
strains were resistant to second (ciprofloxacin, enrofloxacin,
norfloxacin, and ofloxacin), third generation (pradofloxacin),
and fourth generation (moxifloxacin) fluoroquinolones. The
same authors argued that a single alteration in grlA would be
sufficient to confer resistance against older fluoroquinolones
but an additional mutation in gyrA was required for resis-
tance to new fluoroquinolones to develop, as it occurs in
S. aureus and coagulase-negative staphylococci isolates.31
Accordingly, our strains presented resistance to all the
fluoroquinolones tested, including moxifloxacin, due to the
presence of mutations at both the gyrA and grlA genes.
Surprisingly there was a major difference between the
mechanisms of resistance to tetracycline: tet(K) genes were
only identified among MRSP strains, while tet(M) was only
found among MSSP isolates. The tet(K) gene codes for an
efflux pump of the major facilitator superfamily and is usu-
ally found on small plasmids.16 In contrast, tet(M) codes for
ribosome protective proteins and has been identified as part
of conjugative transposons, such as Tn916 and Tn1545.16
Other studies have identified tet(M) in other MRSP strains,
yet in MRSP ST71 only tet(K) has been detected, which could
indicate that this clone has a preference for plasmid-borne
tetracycline resistance rather than tet transposon-borne
genes.
Rifampicin resistance in MRSP isolates has been described
previously.17 Mutation at rpoB codon 522 was identified in a
clinical isolate after treatment of a clinical infection with a
combination of rifampicin and tetracycline.17 Our rifampicin-
FIG. 1. Schematic diagram of the clonal relatedness of
Staphylococcus pseudintermedius sequence types (ST) predicted
by eBURST analysis using the multilocus sequence typing
(MLST)-5 (a) and the MLST-7 (b) schemes, respectively. Each
black dot represents an ST and the dot size is proportional to
the number of isolates of that ST. The square corresponds to
the predicted group founder and ST97 and ST17 represent
predicted subgroup founders (a). Single-locus variants are
linked by lines. Methicillin-susceptible S. pseudintermedius
(MSSP) singletons are not shown in this figure.
FIG. 2. Dendogram of chromosomal DNA digested with SmaI of methicillin-resistant S. pseudintermedius strains and
relatedness to ST. Pulsed-field cluster determination using a Dice similarity coefficient with an optimization of 1% and a band
tolerance setting of 1%.
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resistant MRSP isolate came from a dog with pyoderma,
with no previous recorded history of rifampicin treatment.
As stated before,17 the observed rpoB mutation could have
occurred spontaneously or the isolate could have been
transferred from a previously treated dog.
Since the discovery of multidrug-resistant S. pseudinter-
medius there has been an increasing interest in additional
bactericidal therapeutics, other than the use of antibiotics.
Susceptibility to biocides has now become an urgent matter.
In this study, we compared the in vitro efficacy of four com-
mercial biocides using the methodology recommended by the
SCENIHR.25 At the same time we performed the determina-
tion of the biocide MICs to detect decreased susceptibility
related to efflux activity. Only one strain showed higher EtBr
MIC values compared to the wild-type S. aureus ATCC6538
and harboured a qacA gene. The qacB-positive MSSP strain
(FMV750/10) did not show any decreased susceptibility re-
lated to efflux activity. The same strain also had a lnu(A)
gene but was not clindamycin-resistant. This could indicate a
failure in the regulation and/or induction mechanism of
these genes. However, further studies are needed to address
this issue. To the best of our knowledge, this is the first
description of qacA and qacB genes among S. pseudintermedius
strains.
The efficacy of chlorhexidine has been previously tested
in vitro and also in vivo. In our study we found an MIC value
of 1 mg/L for all MRSP and MSSP strains, which is lower
than the MIC range found by Valentine and colleagues29 (4–
16 mg/L) but within the range found by Murayama et al.,
(0.5–1 mg/L).20 This latter study could not detect any qacA/B
or smr genes. This MIC of 1 mg/L is lower than the clinically
used concentrations and so it is not surprising that Otodine!
and Clorexyderm Spot Gel! were efficient at killing the MSSP
and MRSP strains. There was no difference in the efficacy of
the chlorhexidine products, but previous studies have
suggested that products with higher concentrations of CHA
(3%–4%) were more effective than products with a lower
concentration (2%–2.5%).15,33 Still, an in vivo study comparing
the use of two different chlorhexidine formulations (CHA 2%
and chlorhexidine gluconate 4%) for the treatment of cepha-
lexin-resistant S. pseudintermedius pyoderma found no differ-
ences in the efficacy of the two shampoos.21
QAC efflux pumps are known to extrude BAC;8 however,
the MICs previously found in other studies are still below the
typically used concentrations of 10 g/L.29 In our study we
FIG. 3. Dendogram of chromosomal DNA digested with SmaI of MSSP strains and relatedness to ST. Pulsed-field cluster
determination using a Dice similarity coefficient with an optimization of 1% and a band tolerance setting of 1%.
Table 2. MICs of Dyes (Ethidium Bromide)
and Biocides (Benzalkonium Chloride,
Chlorhexidine Acetate and Triclosan), and Genes
Associated with Efflux Phenotype
MICs (mg/L)




10 1 1 2 £ 0.003 -
3 2 1 4 £ 0.003 -
3 2 1 2 £ 0.003 -
2 1 1 4 £ 0.003 -
1 1 1 1 0.007 -
1 1 1 2 0.007 -
MSSP
11 0.5 1 1 £ 0.003 -
6 0.5 1 2 £ 0.003
1 4 1 32 0.125 qacA
1 0.5 1 2 £ 0.003 qacB
1 1 1 2 4 -
S. aureus ATCC 6538 1 1 8 £ 0.003 -
BAC, benzalkonium chloride; CHA, clorhexidine acetate; EtBr,
ethidium bromide; MICs, minimum inhibitory concentrations;
MRSP, methicillin-resistant Staphylococcus pseudintermedius; MSSP,
methicillin-resistant S. pseudintermedius; TCL, triclosan.
COMPARATIVE ANALYSIS OF MSSP/MRSP 369
 116 
 
detected two strains harbouring qac genes but their MICs
were also below the in-use concentration. However, even if
the strains appeared susceptible in vitro in the presence of
these genes, they may challenge biocide therapy in vivo.
None of the strains with high MIC to TCL carried the
newly described plasmid-mediated TCL resistance gene sh-
fabI.6 The higher MIC values in the two MSSP strains, and the
absence of the sh-fabI gene may indicate that another mech-
anism is present, probably mutations in the original fabI
gene, which have been previously described in S. aureus and
S. haemolyticus strains.6 A recent study assessed the MIC of
TCL against MRSP and MSSP strains.29 The authors con-
cluded that TCL demonstrated excellent activity against all
bacterial isolates with a MIC £ 0.5 mg/L.29 In this study, we
detected one MSSP strain with a MIC of 4 mg/L to TCL,
which is higher compared to the wild-type S. aureus
ATCC6538 (MIC £ 0.003) and the other S. pseudintermedius
strains. However, when testing the bactericidal activity of
Dermocanis Piocure-M,! a commercial product with a TCL
concentration 750 times higher than the MIC, no bacterial
growth was observed. Likewise, the MSSP strain presenting
an efflux phenotype, when challenged with three commercial
products containing biocides was also not able to survive. This
could mean that although some strains have efflux mecha-
nisms to biocides, they will not be able to survive if the bio-
cides are used at the correct concentration and exposure time.
Skingel! is an antiphlogistic product, containing zinc ox-
ide, which is known to have antibacterial properties.26 Zinc
oxide has been shown to reduce S. aureus viability and bio-
film formation when incorporated as a nanoparticle into
films of polyvinyl chloride (endotracheal tubes and cathe-
ters).26 However, Skingel was not able to achieve a five-log
reduction in the bacterial cell number and so had no bacte-
ricidal effect on S. pseudintermedius strains. Zinc resistance
has been detected in S. aureus strains of animal origin and
has been strongly associated with methicillin resistance.5
Further studies are needed to evaluate heavy metal resis-
tance in S. pseudintermedius.
S. pseudintermedius have become a serious therapeutic
challenge and new MRSP lineages are emerging in several
countries, including Portugal. Although multidrug-resis-
tance is more common in methicillin-resistant strains, some
of the methicillin-susceptible strains also exhibited multi-
drug-resistance profile. The use of biocides, like CHA and
TCL, seems to be a clinically effective and a safe topical
therapeutic option.
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(Università di Siena, Siena, Italy) for providing the strain
S. aureus M0091, and Alexandra Rossano (Institute of Ve-
terinary Bacteriology, University of Bern) for technical as-
sistance. This work was supported by FEDER funds through
the Programa Operacional Factores de Competitividade–
COMPETE and by National funds through the FCT–Fun-
dação para a Ciência e a Tecnologia, Project PEst-OE/AGR/
UI0276/2011 and PhD grant SFRH/BD/68864/2010 from
the same institution to NC.
Disclosure Statement
This work was partially sponsored by a grant of ICF
(Cremona, Italy) and Calier (Lisbon, Portugal) to NC. The
results were analyzed, interpreted, and discussed by the
authors without any influence by the sponsors.
References
1. Association Française de Normalisation. 2006. NF EN
1040–Essai quantitatif de suspension pour l’évaluation de
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Pomba, M.C., Pyörälä, S., et al. 2011. Review on methicillin-
resistant Staphylococcus pseudintermedius. J. Antimicrob.
Chemother. 66:2705–2714.
31. Vanni, M., Tognetti, R., Pretti, C., Crema, F., Soldani, G.,
Meucci, V., et al. 2009. Antimicrobial susceptibility of Sta-
phylococcus intermedius and Staphylococcus schleiferi isolated
from dogs. Res. Vet. Sci. 87:192–195.
32. World Health Organization—Advisory Group on In-
tegrated Surveillance of Antimicrobial Resistance 2009.
http://apps.who.int/medicinedocs/documents/s16735e/
s16735e.pdf. Accessed March 16, 2012.
33. Young, R., Buckley, L., McEwan, N., and Nuttall, T. 2011.
Comparative in vitro efficacy of antimicrobial shampoos: a
pilot study. Vet. Dermatol. 23:36–40, e8.
Address correspondence to:
Constança Pomba, DVM, MSc, PhD
Faculty of Veterinary Medicine
Technical University of Lisbon




COMPARATIVE ANALYSIS OF MSSP/MRSP 371
 118 
3.2.3 Trends in antimicrobial resistance in clinical staphylococci isolated from com-
panion animals over a 16-year period 
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Objectives: To investigate the evolution of resistance to antimicrobials, corresponding mechanisms 
and molecular characteristics of Staphylococcus spp, between 1999-2014. 
Methods: Susceptibility for 38 antimicrobials were determined in 632 clinical staphylococcal isolates 
obtained from companion animals (dogs, cats, horses and other animals). Twenty antimicrobial re-
sistance genes, including mecA and mecC, were screened by PCR. Methicillin-resistant staphylococci 
(MRS) were characterized by spa (S. aureus), SCCmec, MLST and PFGE typing. Statistical analyses 
were performed using SAS v9.3 and differences were considered relevant if P≤0.05. 
Results: The mecA gene was identified in 74 staphylococcal isolates (11.7%): 11 S. aureus (MRSA, 
40.7%), 40 S. pseudintermedius (MRSP, 8.7%) and 23 coagulase-negative staphylococci (MRCoNS, 
26.7%). Resistance to the majority of antimicrobials and the number of mecA-positive isolates in-
creased significantly over time. Eighteen spa types were identified, including two new ones. MRSA 
isolates were divided into 3 PFGE clusters that included ST22-IV, ST105-II, ST398-V and ST5-VI. 
Most methicillin-resistant S. epidermidis isolates were of CC5, including a new ST, and clustered in 8 
PFGE clusters. MRSP were grouped into 5 PFGE clusters and included ST45-nt, ST71-II-III, ST195-
III, ST196-V, ST339-nt, ST342-IV and the new ST400-III. Methicillin-resistant S. haemolyticus clus-
tered in two PFGE clusters. 
Conclusions: The significant increase of antimicrobial-resistant and mecA-positive isolates in the last 
years is worrying. Furthermore, several isolates are multidrug-resistant, which complicates antimicro-
bial treatment and raises the risk of transfer to humans or human isolates. Several clonal lineages of 
MRSA and MRSE circulating in human hospitals and in the community were found, suggesting that 
companion animals can become infected with and contribute to the dissemination of highly successful 
human clones. Urgent measures, like determination of clinical breakpoints and guidelines for antimi-
crobial use are urgently needed. 
 
Keywords: mecA, staphylococci, resistance genes, antimicrobials 
 
Introduction 
Staphylococci are a group of bacteria with 
clinical, veterinary, agricultural, and eco-
nomic importance because of their wide 
range of virulence factors and ability to be-
come resistant to antimicrobials. This fea-
ture should be considered and antimicrobial 
susceptibility testing (AST) is important to 
monitor the spread of antimicrobial-resistant 
staphylococci.1 Therefore, monitoring pro-
grams may help uncover new resistance 
trends and evaluate the usefulness of the 
available antimicrobials against staphylo-
cocci. Companion animals, in particular, are 
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frequently treated with the same antimicro-
bial classes that are used in human medi-
cine.2,3 
The genus Staphylococcus causes a differ-
ent array of infections, and the most com-
mon species in companion animal practice 
are the coagulase-positive Staphylococcus 
pseudintermedius (formerly called S. inter-
medius), S. schleiferi and S. aureus. These 
are mostly found in skin samples, ear sam-
ples and as the cause of urinary tract infec-
tions (UTI).1 CoNS, on the other hand, are 
usually not considered pathogenic but they 
are often considered reservoirs of antimi-
crobial resistance genes, like the mecA 
gene.4 Presence of the mecA or mecC 
genes, is one of the most significant fea-
tures encountered in staphylococcal spe-
cies. These genes mediate resistance to ß-
lactams, which are first-line antimicrobial 
choices for the treatment of infections in 
human and veterinary medicine and are 
considered by the WHO as “critically-
important” antimicrobials.5 Furthermore, 
knowledge on the genotype of such isolates 
is important to assess the risk of transfer of 
methicillin-resistant staphylococcal (MRS) 
isolates between companion animals and 
humans.  
The main objective of this study was to in-
vestigate the trends in antimicrobial re-
sistance in clinical staphylococci isolated 
from companion animals over a 16-year pe-
riod (1999-2014). Furthermore, we identified 
the genetic mechanisms underlying the an-
timicrobial resistance. Finally, we character-
ized the genotype of the MRS to understand 
evolutionary steps driving the spread of the-
se isolates in companion animals. 
 
Materials and methods 
Isolate collection 
Six hundred and thirty-two staphylococcal 
isolates isolated from companion animals 
between 1999 and 2014 were included in 
the study. The isolates were collected at the 
Clinical Laboratory (CL) and at the Antimi-
crobial and Biocide Resistance Laboratory 
(ABRL), FMV-UL, which receive samples 
from the Veterinary Teaching Hospital of 
FMV-UL and private practices throughout 
the Lisbon region. The isolates were ob-
tained from clinical infections and sent to 
the laboratory along with a small form with 
animal data, such as species, breed, age 
and sex, clinical description of the sample 
site and suspected pathology course. Each 
isolate was considered individually, and 
cases where more than one isolate origi-
nated from the same animal (i.e., different 
staphylococci isolated at the same time 
from the same specimen or at different 
sampling times) were considered only if the 
staphylococcal species or genotype differed 
between isolates. 
 
Staphylococcal species identification 
Both the CL and ABRL laboratories use 
phenotypical tests (BD™ BBL™ Crystal 
Gram Positive ID Kit; Becton, Dickinson and 
Company, Maryland, USA) to determine the 
staphylococcal species. All species were 
confirmed by PCR (S. epidermidis-specific 
primers Se705-1, Se705-2; S. saprophyti-
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cus-specific primers Sap1, Sap2; S. xy-
losus-specific primers XYL F, XYL R; S. 
simulans-specific primers SimF, SimR) 6-10 
and/or sequencing of 16S rRNA gene. The 
sequences were then compared using the 
nucleotide basic local alignment search tool 
(http://blast.ncbi.nlm.nih.gov/). 
 
Antimicrobial susceptibility testing 
All isolates were tested by disk diffusion ac-
cording to CLSI standards and S. aureus 
ATCC29213 was used for quality control 
purposes, whenever a new antimicrobial 
batch was used.11 A total of 38 antimicrobi-
als (Oxoid, Hampshire, United Kingdom) 
were tested: amikacin (AMK, 30 µg), ampi-
cillin (AMP, 10 µg), amoxicillin/clavulanic 
acid (AMC, 30 µg), cefalotin (CEF, 30 µg), 
cefotaxime (CTX, 30 µg), cefovecin (CVN, 
30 µg), cefoxitin (FOX, 30 µg), ceftriaxone 
(CRO, 30 µg), chloramphenicol (CHL, 30 
µg), ciprofloxacin (CIP, 5 µg), clindamycin 
(CLI, 2 µg), enrofloxacin (ENR, 5 µg), eryth-
romycin (ERY, 15 µg), florfenicol (FFC, 30 
µg), fusidic acid (FUS, 10 µg), gentamicin 
(GEN, 10 µg), kanamycin (KAN, 30 µg), 
levofloxacin (LEV, 5 µg), linezolid (LZD, 30 
µg), moxifloxacin (MXF, 5 µg), mupirocin 
(MUP, 5 µg), neomycin (NEO, 30 µg), 
netilmicin (NET, 30 µg), nitrofurantoin (NIT, 
300 µg), norfloxacin (NOR, 10 µg), ofloxacin 
(OFX, 5 µg), oxacillin (OXA, 1 µg), penicillin 
G (PEN, 10 units), quinupristin/dalfopristin 
(Q/D, 15 µg), rifampicin (RIF, 5µg), strep-
tomycin (STR, 15 µg), sulphonamides (SUL, 
300 µg), teicoplanin (TEC, 30 µg), tetracy-
cline (TET, 30 µg), tobramycin (TOB, 10 
µg), trimethoprim (TMP, 5 µg), trime-
thoprim/sulfamethoxazole (SXT, 25 µg) and 
vancomycin (VAN, 30 µg). Some antimicro-
bials were included since they are clinically 
relevant antimicrobial agents and others 
were included for antimicrobial resistance 
epidemiology purposes (like linezolid, qui-
nupristin/dalfopristin, teicoplanin). Results 
were interpreted according to CLSI VET01-
S212 (oxacillin for S. pseudintermedius, en-
rofloxacin, gentamicin, clindamycin), CLSI 
M100-S2413 (ampicillin, penicillin, cefoxitin 
for S. aureus and CoNS, teicoplanin, ami-
kacin, kanamycin, netilmicin, tobramycin, 
erythromycin, tetracycline, ciprofloxacin, 
levofloxacin, norfloxacin, ofloxacin, moxi-
floxacin, nitrofurantoin, trime-
thoprim/sulfamethoxazole, sulphonamides, 
trimethoprim, chloramphenicol, rifampin, 
quinupristin/dalfopristin, linezolid), CA-SFM 
VET-1014 (neomycin) and CA-SFM 1015 
(streptomycin, mupirocin). The EUCAST 
guidelines16 were used for fusidic acid inter-
pretation. Breakpoints for amoxicil-
lin/clavulanic acid, cephalosporins and van-
comycin were recently removed from CLSI. 
However, as these antimicrobials were in-
cluded in the susceptibility panel of both la-
boratories, we used the breakpoints given 
by the last CLSI containing them (CLSI 
M100-S1617 and CLSI M100-S2218). The 
breakpoints for cefovecin were retrieved 
from the manufacturer (S≥24; I 21-23; 
R≤20). There are no breakpoints for 
florfenicol against staphylococci and we as-
sessed the distribution of the zone diame-
ters detected in our study (Supplementary 
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Figure 1), estimating a resistance break-
point of R<19. A bacterial isolate was con-
sidered multidrug-resistant (MDR) when it 
exhibited resistance to three or more anti-
microbial classes.19 Isolates with intermedi-
ate susceptibility were regarded as suscep-
tible. 
 
Detection of antimicrobial resistance genes 
The presence of the mecA and mecC genes 
was tested in all staphylococcal isolates. 
Other antimicrobial resistance genes were 
investigated only when phenotypical re-
sistance was observed. Genes previously 
reported for resistance to ß-lactams (blaZ), 
aminoglycosides [aadE, aadD, aphA3, 
aacA-aphD], macrolides/lincosamides 
[erm(A), erm(B), erm(C), msrA, mph(C)], 
tetracyclines [tet(M), tet(K)], fusidic acid 
[fusB, fusC], chloramphenicol (cat pC221), 
florfenicol (fexA) and trimethoprim [dfr(G), 
dfr(K)] were detected by PCR.20,21  
 
Molecular characterization 
All S. aureus isolates were subjected to spa 
typing and spa types were assigned through 
the Ridom web server 
(http://www.ridom.de/spaserver/). Multi-
locus sequence typing (MLST) was per-
formed in the methicillin-resistant S. aureus 
(MRSA), S. pseudintermedius (MRSP, rep-
resentative isolates determined by PFGE) 
and S. epidermidis (MRSE) isolates 
(http://www.mlst.net/databases/default.asp; 
http://pubmlst.org/databases/). The SCC-
mec types were determined as described 
previously.22 The MRS isolates were com-
pared by SmaI PFGE, using previously de-
scribed protocols.21-23 PFGE clusters were 




Statistical analyses were performed with 
SAS software version 9.3 (SAS Institute 
Inc., Cary, N.C.), and results were consid-
ered significant when p≤0.05. For the pur-
pose of statistical analyses, we defined 
staphylococcal species as: S. aureus, S. 
pseudintermedius, S. schleiferi and CoNS. 
The association between staphylococcal 
species, antimicrobial resistance and re-
sistance genes was assessed using either 
the chi-squared test or Fisher exact test 
(when n≤5).  
The importance of animal species (dog or 
cat), type of infection (pyoderma, urinary 
tract infection [UTI] or otitis) and age within 
animal species, as possible risk factors of 
resistance to the different antimicrobials 
was analysed by logistic regression, con-
sidering each factor individually. 
The evolution over time of the proportion of 
isolates resistant to different antimicrobials 
was analysed by logistic regression, using 
year as independent variable. This test was 
also used to determine if there was a signif-
icant increase in the proportion of mecA-
positive isolates over time. 
 
This research study involved a total of 632 
staphylococcal isolates from 614 animals, of 
which 537 isolates were from dogs (84.9%), 
80 from cats (12.7%), 10 from horses 
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(1.6%), 5 from other animals (0.8%). Over-
all, 252 isolates were from females (39.8%), 
346 from males (54.7%) and 34 were un-
known (5.4%). The average age was of 6.8 
years for dogs, 5.5 for cats and 11.4 for 
horses. 
Isolates were most frequently isolated from 
otitis (307 isolates, 48.6%), followed by 178 
isolates from pyoderma (28.2%), 90 from 
UTI (14.2%), 10 from surgical site infections 
(1.6%) and 47 from other types of infection 
(7.4%). The frequency of each staphylococ-
cal species is shown in Table 1, with a clear 
predominance of S. pseudintermedius, with 
446 isolates (70.6%), followed by CoNS 
species with 86 isolates (13.6%), S. schleif-
eri with 73 isolates (11.6%) and 27 isolates 
of S. aureus (4.3%).  
 
 
Table 1. Staphylococcal species distribution and frequency of the mecA gene. 
Staphylococcal species Frequency (%) 
Frequency of the mecA gene 
(%) 
S. aureus 27 (4.3) 11 (40.7) 
S. caprae 1 (0.2) 1 (100) 
S. cohnii 2 (0.3) 0 (0.0) 
S. epidermidis 20 (3.2) 11 (55.0) 
S. felis 26 (4.1) 0 (0.0) 
S. haemolyticus 13 (2.1) 8 (61.5) 
S. hominis 1 (0.2) 1 (100) 
S. kloosi 1 (0.2) 0 (0.0) 
S. lentus 2 (0.3) 1 (50.0) 
S. lugdunensis 1 (0.2) 0 (0.0) 
S. pseudintermedius 446 (70.6) 40 (8.7) 
S. saprophyticus 4 (0.6) 0 (0.0) 
S. schleiferi 73 (11.6) 0 (0.0) 
S. simulans 9 (1.4) 1 (11.1) 
S. warneri 3 (0.5) 0 (0.0) 
S. xylosus 3 (0.5) 0 (0.0) 
 
The frequencies of antimicrobial resistance 
and antimicrobial resistance genes are 
shown in Tables 2 and 3, respectively. All 
isolates were susceptible to vancomycin, 
teicoplanin, linezolid, netilmicin and quinu-
pristin-dalfopristin. About 35% of the 
staphylococci isolates were multidrug-
resistant. The mecA gene was identified in 
74 staphylococci isolates (11.7%): 11 S. au-
reus (40.7%), 40 S. pseudintermedius 
(8.7%) and 23 CoNS (26.7%) (Table 1). 
None of the isolates carried the mecC gene. 
We detected the fexA gene in 3 isolates that 
were resistant to florfenicol and chloram-
phenicol (1 S. aureus and 2 S. pseudinter-
medius). In these fexA-positive isolates we 
searched for the cfr gene, and we detected 
for the first time the cfr gene in a S. 
pseudintermedius isolate (confirmed by se-
quencing).  
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The CoNS and S. aureus isolates had high-
er probabilities of having the mecA gene 
(p<0.05) than S. pseudintermedius or S. 
schleiferi (40.7 and 26.7 versus 8.7% and 
0%, respectively; Table 3). Resistance to 
ampicillin/penicillin and the presence of the 
blaZ gene were highly associated with both 
S. aureus and S. pseudintermedius 
(p<0.001; Tables 2 and 3, respectively). S. 
aureus were more resistant to fluoroquin-
olones [enrofloxacin (p<0.03), ciprofloxacin 
(p<0.03), levofloxacin (p<0.005), norfloxacin 
(p<0.04), moxifloxacin (p<0.002)] than the 
other species (Table 2). The S. pseudinter-
medius were more likely (p<0.05) to have 
the erm(B) gene and less likely (p<0.05) to 
have the erm(C) gene than any other spe-
cies (Table 3). The streptomycin-resistance 
was more associated with S. pseudinterme-
dius (p<0.02; Table 2) and the aadE gene 
was actually only present in this species 
(Table 3). On the other hand, tetracycline-
resistance was associated with CoNS 
(p<0.02) and S. pseudintermedius 
(p<0.0003; Table 2), with the tet(K) gene 
more associated with CoNS (p<0.006), and 
the tet(M) gene with S. pseudintermedius 
(p<0.0001; Table 3). Resistance to fusidic 
acid was higher in the CoNS isolates 




Table 2. Frequency of antimicrobial resistance for the total isolates, and per staphylococcal strain. The p-value refers to the association between antimicrobial 
resistance and staphylococcal species. 
Antimicrobial Percentage of re-







sistance in S. aureus 
Percentage of resistance 
in S. pseudintermedius 
Percentage of re-
sistance in S. 
schleiferi 
p-value 
Ampicillin 58.7 [54.7-62.6] 40.7 77.8 64.4 38.4 <0.0001 
Penicillin 58.7 [54.7-62.6] 40.7 77.8 64.4 38.4 <0.0001 
Amoxicillin/clavulanic acid 7.8 [5.8-10.1] 5.8 37.0 7.6 0.0 <0.0001 
Cephalexin 6.0 [4.3-8.2] 2.3 22.2 6.7 0.0 0.0002 
Cefovecin 10.4 [8.2-13.1] 19.8 40.7 8.5 0.0 <0.0001 
Ceftriaxone 8.5 [6.5-11.0] 11.6 37.0 7.6 0.0 <0.0001 
Cefotaxime 8.5 [6.5-11.0] 10.5 37.0 7.9 0.0 <0.0001 
Cefoxitina 28.3 [20.2-37.6] 24.4 40.7 - - 0.1005 
Oxacillinb 8.7 [6.3-11.8] - - 8.7 - - 
Enrofloxacin 12.3 [9.9-15.2] 14.0 40.7 9.2 19.2 <0.0001 
Ciprofloxacin 12.3 [9.9-15.2] 14.0 40.7 9.2 19.2 <0.0001 
Levofloxacin 11.4 [9.0-14.1] 14.0 40.7 9.0 12.3 <0.0001 
Norfloxacin 12.7 [10.2-15.5] 16.3 40.7 9.2 19.2 <0.0001 
Ofloxacin 12.8 [10.3-15.7] 16.3 40.7 9.2 20.6 <0.0001 
Moxifloxacin 10.1 [7.9-12.8] 11.6 40.7 8.1 9.6 <0.0001 
Tetracycline 34.8 [31.1-38.9] 23.3 3.7 44.0 4.1 <0.0001 
Nitrofurantoin 0.5 [0.1-1.4] 0.0 0.0 0.7 0.0 0.7393 
Chloramphenicol 4.6 [3.1-6.5] 1.2 3.7 6.1 0.0 0.0450 
Florfenicol 0.5 [0.1-1.4] 0.0 3.7 0.5 0.0 0.0812 
Gentamicin 7.6 [5.7-9.9] 11.6 0.0 8.3 1.4 0.0358 
Neomycin 14.9 [12.2-17.9] 5.8 7.4 19.1 2.7 <0.0001 
Tobramycin 7.1 [5.2-9.4] 9.3 0.0 8.1 1.4 0.0735 
Amikacin 0.3 [0.0-1.1] 2.3 0.0 0.0 0.0 0.0052 
Kanamycin 18.7 [15.7-21.9] 12.8 3.7 23.3 2.7 <0.0001 
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Streptomycin 20.6 [17.5-23.9] 8.1 7.4 26.7 2.7 <0.0001 
Erythromycin 20.1 [17.0-23.4] 25.6 11.1 22.2 4.1 0.0012 
Clindamycin 17.1 [14.2-20.3] 12.8 7.4 20.6 4.1 0.0014 
Fusidic acid 4.1 [2.7-6.0] 24.4 3.7 0.9 0.0 <0.0001 
Mupirocin 0.2 [0.0-0.9] 0.0 0.0 0.0 1.4 0.0534 
Sulfamethoxazole/Trimethoprim 13.3 [10.7-16.2] 8.1 0.0 16.4 5.5 0.0034 
Sulphonamides 46.8 [43.0-50.7] 29.1 11.1 54.3 35.6 <0.0001 
Trimethoprim 16.9 [14.1-20.1] 12.8 3.7 20.0 8.2 0.0105 
Rifampicin 1.9 [1.0-3.3] 3.5 0.0 1.4 4.1 0.2272 
Resistance to at least 1 AB 79.4 [76.1-82.5] 74.4 81.5 82.7 64.4 0.0023 
Resistance to ≥ 3 AB 35.0 [31.3-38.8] 34.9 25.9 39.0 13.7 0.0003 
aUsed for S. aureus and coagulase-negative staphylococci. 
bUsed for S. pseudintermedius. 
All strains were susceptible to netilmicin, vancomycin, teicoplanin, linezolid and quinupristin/dalfopristin.  
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Table 3. Frequency of resistance genes for the total isolates and per staphylococcal strain. The p-value refers to the association between antimicrobial re-
sistance genes and staphylococcal species. 
Resistance gene 
Percentage of the 
resistance gene in 
all strains (CI) 
Percentage of the 
resistance gene in 
CoNS 
Percentage of the 
resistance gene in 
S. aureus 
Percentage of the re-
sistance gene in S. 
pseudintermedius 
Percentage of the 
resistance gene in 
S. schleiferi 
p-value 
mecA 11.6 [9.2-14.3] 26.7 40.7 8.7 0.0 <0.0001 
blaZ 59.0 [55.1-62.9] 40.7 77.8 64.6 39.7 <0.0001 
erm(A) 0.8 [0.3-1.8] 4.7 3.7 0.0 0.0 <0.0001 
erm(B) 18.2 [15.3-21.4] 12.8 3.7 22.4 4.1 0.0001 
erm(C) 2.4 [1.3-3.9] 11.6 7.4 0.2 2.7 <0.0001 
cat pC221 4.1 [2.7-6.0] 1.2 0.0 5.6 0.0 0.0335 
aphA3 18.0 [15.1-21.3] 7.0 11.1 23.3 1.4 <0.0001 
aacA-aphD 7.6 [5.7-9.9] 11.6 3.7 8.1 1.4 0.0803 
aadD 0.5 [0.0-1.0] 3.5 0.0 0.0 0.0 0.0003 
aadE 16.3 [13.5-19.4] 0.0 0.0 23.1 0.0 <0.0001 
tet(K) 9.3 [7.2-11.9] 20.9 0.0 9.2 0.0 <0.0001 
tet(M) 27.5 [24.1-31.2] 4.7 3.7 37.2 4.1 <0.0001 
dfr(K) 0.2 [0.0-0.9] 0.0 0.0 0.2 0.0 0.9366 
dfr(G) 7.0 [5.1-9.2] 3.5 3.7 9.0 0.0 0.0163 
msrA 1.9 [1.0-3.3] 9.3 3.7 0.5 1.4 <0.0001 
mph(C) 2.2 [1.2-3.7] 10.5 3.7 0.7 1.4 <0.0001 
fusB 2.1 [1.1-3.5] 12.8 0.0 0.2 1.4 <0.0001 
fusC 0.8 [0.3-1.8] 4.7 3.7 0.0 0.0 <0.0001 
Abbreviations: CoNS, coagulase negative staphylococci. 
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The variables gender and age were not 
considered risk factors (p>0.05) leading to 
more antimicrobial resistance. However, 
isolates from dogs were resistant to more 
antimicrobials (Table 4) then isolates from 
cats (p<0.05). Likewise, staphylococcal 
isolates from otitis were resistant to more 
antimicrobials than isolates from pyoder-
ma or UTI (p<0.05, Table 4). No signifi-
cant differences were found between iso-
lates from pyoderma and isolates from UTI 
(p>0.05). 
Using a logistic regression analysis, we 
assessed the trends over time in re-
sistance to the different antimicrobials. 
Among the 38 antimicrobials analysed, re-
sistance increased over the period ana-
lysed (p<0.05) in 27 antimicrobials (Figure 
1), and the number of isolates with re-
sistance to at least one antimicrobial or 
with multiple drug resistance also in-
creased over time (P<0.05, Figure 1). The 
number of mecA positive isolates also in-
creased over time (p<0.0001, Figure 2). 
The antimicrobials where resistance did 
not increase significantly (p>0.05) over the 
16-year period under analysis were ami-
kacin, florfenicol, fusidic acid, mupirocin, 
nitrofurantoin and rifampicin. The corre-
sponding OR, CI and p-values are present 
in Supplementary Table 1. 
The characteristics of all MRS isolates are 
shown in Supplementary Table 2. Eight-
een spa types were identified in S. aureus 
(t002, t025, t032, t044, t084, t085, t091, 
t105, t108, t148, t311, t1294, t1346, t1897, 
t2357, t11188), including two new spa 
types: t14112 and t14113. The MRSA iso-
lates were divided into 3 PFGE clusters 
(Supplementary Figure 2) and MLST in-
cluded ST22-IV (n=8, including t025, t032 
and t2357), ST105-II (n=1, t002), ST398-V 
(n=1, t108) and ST5-VI (n=1, t311). Iso-
lates ST5 and ST105 belonged to clonal 
complex (CC) 5.  
Most MRSE isolates were members of CC 
5: ST2-nt (n=2), ST5-nt (n=2), ST20-nt 
(n=1), ST23-IV (n=1), ST35-nt (n=1), 
ST57-IV (n=1), ST190-nt (n=1) and a new 
ST (n=1), which carried an SCCmec II. 
The MRSE isolates were divided into 8 
PFGE clusters (Supplementary Figure 2), 
with the two MRSE ST2 isolates having 
<80% similarity by PFGE. 
 MRSP were grouped into 5 PFGE clus-
ters (Supplementary Figure 2) and includ-
ed ST45 (n=1), ST71 (n=13), ST195 
(n=1), ST196 (n=1), ST203 (n=1), ST339 
(n=1), ST342 (n=2) and the new ST, as-
signed ST400 (n=3). The ST71, ST195 
and ST203 belonged to CC71, while 
ST342 belonged to CC261, ST45 to 
CC45, ST196 to CC196 and ST339 to 
CC84. The isolates for which the MLST 
was not performed, grouped in the same 
PFGE cluster and so we assumed they 
belonged to CC71. The MRSP ST45 strain 
was non-typeable by SCCmec typing and 
by PFGE SmaI-macrorestriction.  
Methicillin-resistant S. haemolyticus 
(MRSH) were divided into two PFGE clus-
ters (Supplementary Figure 2) and SCC-
mec V (n=5) was the most frequent type, 
followed by nt (n=3). 
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Table 4. Risk factors and corresponding OR, CI and p-value for the occurrence of individual antimi-
crobial resistance and mecA gene, from logistic regression. 
Risk factor Antimicrobial/gene Odds Ratio Confidence Interval p-value 
Dogsa     
 OXA 6.4 2.2-18.4 0.0006 
 ENR 2.8 1.6-4.9 0.0005 
 CIP 2.8 1.6-4.9 0.0005 
 LEV 3.1 1.7-5.6 0.0001 
 NOR 3.1 1.8-5.5 <0.0001 
 OFX 3.1 1.8-5.4 <0.0001 
 MXF 3.1 1.7-5.7 0.0002 
 TET 0.3 0.2-0.6 0.0005 
 GEN 2.8 1.4-5.5 0.0036 
 TOB 3.0 1.5-6.0 0.0017 
 FUS 3.9 1.6-9.6 0.0026 
 mecA 3.1 1.7-5.4 0.0002 
Otitisb     
 FOX 3.7 1.2-11.1 0.0191 
 OXA 4.8 2.0-11.7 0.0006 
 ENR 2.3 1.3-4.1 0.0051 
 CIP 2.3 1.3-4.1 0.0051 
 LEV 2.6 1.4-4.7 0.0024 
 NOR 2.1 1.2-3.7 0.0109 
 OFX 2.0 1.1-3.6 0.0154 
 MXF 2.8 1.5-5.5 0.0020 
 mecA 4.8 2.5-9.2 <0.0001 
Otitisc     
 ENR 2.3 1.1-4.6 0.0241 
 CIP 2.3 1.1-4.6 0.0241 
 LEV 2.4 1.1-5.1 0.0200 
 NOR 2.1 1.0-4.2 0.0421 
 OFX 2.0 1.0-4.0 0.0543 
 MXF 2.8 1.3-6.1 0.0109 
 KAN 0.5 0.2-0.9 0.0458 
 FUS 4.2 1.4-12.9 0.0116 
 mecA 2.9 1.3-6.6 0.0116 
aOR relative to isolates from cats. 
bOR relative to isolates from pyoderma. 








Figures 1. Significant evolution of antimicrobial resistance over the 16 years studied (p<0.05): a) β-
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Recent studies have evaluated antimicrobial 
resistance in S. pseudintermedius.2,24,25 
However, none of these studies combined 
all staphylococcal species found in clinical 
specimens, susceptibility for several antimi-
crobials, corresponding resistance mecha-
nisms and, most importantly, molecular epi-
demiology of MRS. Moreover, we studied a 
large period of time, 16 years, to establish 
trends in antimicrobial resistance and 
changes in genotypes.  
The overall prevalence of clinical MRS iso-
lates found in this study was 11.7%, which 
is higher than the prevalence found in a 
similar study made in Lithuania (5.3%).26 
This difference could be due to a higher 
consumption of first and second generation 
cephalosporins in Portugal compared to 
Lithuania.27 However, the prevalence of 
MRSA within S. aureus isolates (40.7%) 
and MRSP within S. pseudintermedius 
(8.7%) was similar to two studies made in 
Germany (ranging from 41.3% to 62.7% 
MRSA in S. aureus of canine, feline and 
equine origin; and 6.3% of MRSP within iso-
lates belonging to the S. intermedius 
group).28,29 In Italy, a much higher preva-
lence of MRSP was found in clinical sam-
ples (21% of MRSP within isolates belong-
ing to the S. intermedius group).30 Interest-
ingly, Germany and Portugal have similar 
consumptions of first and second genera-
tion cephalosporins, but in Italy it is higher.27 
We could speculate that cephalosporins 
may select for methicillin-resistant isolates, 
but further studies are needed. 
Most of our isolates were characterized as 
S. pseudintermedius, which was expected 
since most isolates were from dogs, where 
this species is the most frequently found.1 
Recently, two studies evaluated antimicro-
bial resistance in S. pseudintermedius over 
time and detected trends of increasing re-
sistance for ampicillin/amoxicillin/penicillin, 
cefovecin, cephalexin, enrofloxacin, 
clindamycin and sulfamethoxa-
zole/trimethoprim.24,25 In our study, trends of 
increasing resistance to these antimicrobi-
als were also observed, but we detected 
other trends of increasing resistance, in-
cluding cefoxitin in S. aureus and CoNS, 
oxacillin in S. pseudintermedius, ciprofloxa-
cin, norfloxacin, ofloxacin, moxifloxacin, tet-
racycline, chloramphenicol, gentamicin, ne-
omycin, tobramycin, kanamycin, streptomy-
cin, erythromycin, sulphonamides and tri-
methoprim in all staphylococcal groups ana-
lysed. Moreover, increasing trends of re-
sistance to at least 1 antimicrobial and mul-
tidrug-resistance were also identified, such 
that almost 35% of the staphylococcal iso-
lates were multidrug-resistant. The most 
common multidrug-resistant pattern among 
the methicillin-susceptible isolates was am-
picillin/penicillin-tetracycline-sulphonamides 
and in methicillin-resistant isolates it was ß-
lactams-fluoroquinolones-tetracycline. The-
se resistance profiles are in accordance 
with the antimicrobial usage patterns in 
companion animal practice in Portugal.27 In 
fact, penicillins+beta-lactamase inhibitors, 
1st and 2nd generation cephalosporins, fluo-
roquinolones and tetracyclines are among 
the antimicrobials most used (in this order) 
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by companion animal practitioners in this 
country.27 
Isolates from otitis were more resistant to 
several antimicrobials and carried more of-
ten the mecA gene than isolates from pyo-
derma or UTI. This finding suggests that 
these antimicrobials are probably being 
used inappropriately for the treatment of oti-
tis. The recommended treatment option for 
otitis externa is antiseptics however, in 
some cases (e.g. ulceration and/or tympan-
ic membrane rupture) there is a need for the 
administration of systemic antimicrobial 
therapy, and the first-line antimicrobials are 
ß-lactams or fluoroquinolones.31-33 However, 
antimicrobials that are used systemically for 
otitis are unlikely to achieve therapeutic 
concentrations within the fluid and waxy ex-
udates of the external canals in which the 
infectious organisms are harboured. 26 Our 
study, probably, reflects the selective pres-
sure imposed on staphylococci in the ear by 
the use of these antimicrobials, including 
the higher frequency of mecA-positive 
staphylococci, further supporting the urgent 
need for more studies on the efficacy of 
systemic antimicrobials on ear infections. 
There are no cefoxitin or oxacillin recom-
mended breakpoints for S. schleiferi subsp. 
coagulans. However, these breakpoints are 
important for diagnostic purposes, since this 
species is very common in companion ani-
mals. Although we did not find mecA-
positive isolates, there are already descrip-
tions of methicillin-resistant S. schleiferi 
subsp. coagulans isolates27 and so it is ur-
gent to determine appropriate breakpoints 
for this species. Moreover, with the increas-
ing frequency of multidrug-resistant strains, 
some antimicrobials are being suggested as 
second-line antimicrobial agents, namely 
florfenicol, amikacin, minocycline, doxycy-
cline, nitrofurantoin, topical fusidic acid or 
mupirocin.34-36 Even some antimicrobials 
that are used daily in companion animal 
practice, like ampicillin, cefovecin or sulfa-
methoxazole/trimethoprim do not have clini-
cal breakpoints determined for these spe-
cies. Thus, updated and species-specific 
clinical breakpoints are essential for the ap-
propriate selection of antimicrobials. 
Interestingly, the first mecA-positive isolate 
detected in our study was an MRSA isolat-
ed in 2001. The ST22-IV, which represents 
the EMRSA-15, was the most common 
MRSA lineage found in this study. This is in 
agreement with previous reports, which 
show that there is a shared population of 
this lineage infecting/colonizing humans and 
companion animals.37 The ST22-t032-
SCCmec IV isolates were negative for the 
erm(C), while the other ST22-IV non-t032 
(t2357 and t025) isolates carried the erm(C) 
gene. It is assumed that the loss of this 
gene is associated with isolates coming 
from companion animals,37 which suggests 
that the MRSA ST22 non-t032 isolates 
found in our study were acquired from hu-
mans very recently, and they have thus 
maintained the erm(C) gene. 
Only one MRSA strain was ST398-t108-V, a 
livestock-associated MRSA, and it was iso-
lated from a dog. This strain had 93% ApaI-
PFGE similarity to previously isolated 
MRSA isolates from calves in Portugal (data 
not shown).38 Surprisingly, all these isolates 
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(from dog and calves) carried the fexA gene 
and were resistant to fluoroquinolones, 
which suggests that they had a similar 
source of infection/colonization.38 However, 
the dog in our study had no history of con-
tact with farms or farm animals, so this re-
mains to be elucidated. The MRSA ST5-
t311-VI isolated from a cat was resistant to 
FUS and carried the fusC gene, as was re-
ported for one MRSA ST5-t062-VI isolated 
from a horse in a previous study.22 Compar-
ing the SmaI-PFGE profiles of these two 
isolates (data not shown) they had 86% 
similarity. As the cat’s strain was isolated in 
2001 we could not determine if there was 
any history of contact with horses and so 
we could not define the source of infec-
tion/colonization. However, it is interesting 
to notice that several MRSA lineages are 
disseminated in different animal species.  
The first MRSP strain was identified in Por-
tugal in 2007, but only in 2010 we detected 
an increase in the number of isolates. The 
first MRSP isolates in Europe were detected 
in 2005,39 and were ST71-II-III. Interesting-
ly, the first MRSP strain in Portugal, isolated 
in 2007, was ST196-V. Only in 2009 the first 
ST71-II-III appeared in Portugal. Between 
2009 and mid-2012, MRSP CC71-II-III was 
the only lineage detected. Yet, in 2013-2014 
we observed a higher genetic diversity 
among the MRSP isolates isolated, with 
other MRSP lineages appearing, including a 
new ST (ST400) carrying the mecA gene. 
The ST45-nt, ST339-III and ST342-IV line-
ages were already described in recent stud-
ies.2,40 The ST45 was the predominant 
MRSP clonal lineage in Thailand and Israel, 
and was not typeable by SmaI-PFGE and 
SCCmec typing.40 This lineage carried a 
novel pseudo-SCCmec element, ΨSCC-
mec57395 that, besides mecA, also carried 
determinants of resistance to heavy metals, 
such as arsenic, cadmium, and copper.40 It 
seems that this ST has also been intro-
duced in Europe, as the MLST database 
reports that ST45 has been detected in 
England, The Netherlands and now in Por-
tugal. The new ST, ST400, does not belong 
to any of the previous mecA-positive clonal 
complexes, which suggests that SCCmec 
has been acquired by this ST. Two of the 
MRSP ST400 isolates were isolated from 
two dogs that lived in the same kennel. 
However, the third dog had no connection 
to these dogs or to the kennel, which could 
mean that this lineage is already spreading 
through the dogs’ population in Portugal. 
The fexA gene was detected in 3 isolates (2 
S. pseudintermedius and 1 S. aureus). The 
animals (three dogs) infected with these iso-
lates had been previously diagnosed with 
an infection caused by a multidrug-resistant 
MRSA or MRSP strain and so florfenicol 
(25-50mg/kg q12h SC, Nuflor®, Merck Ani-
mal Health, USA) was being used as a last-
resort antimicrobial. The use of florfenicol 
was very recently suggested, as a second-
line antimicrobial agent in dogs.34 However, 
it seems that the use of this antimicrobial 
can lead to additional acquisition of antimi-
crobial resistance genes or isolates. Fur-
thermore, one of these isolates (an S. 
pseudintermedius), also carried the cfr gene 
and, to the best of our knowledge, this is the 
first description the cfr gene in a S. 
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pseudintermedius strain isolated from a dog 
under flofenicol treatment. Although the 
strain did not exhibit resistance to linezolid, 
this is a worrisome finding, since it shows S. 
pseudintermedius could be carriers of im-
portant resistance genes.  
The MRSE STs found in this study were 
identical to the ones isolated in humans in 
Portugal (community- and hospital-acquired 
isolates).41 This means that MRSE isolates 
can circulate between humans and animals, 
making these a reservoir of important 
MRSE lineages. Unfortunately, there is no 
MLST database for S. haemolyticus, which 
makes it impossible to compare our isolates 
to other animal or even human isolates. Ei-
ther way, it is important to notice that 
MRCoNS were more frequently isolated 
than could be expected from previous stud-
ies, and the presence of the mecA gene 
was highly associated with these isolates. 
Furthermore, several MRCoNS exhibited a 
multidrug-resistance pattern, suggesting 
that they are reservoirs of antimicrobial re-
sistance genes. 
The results here reported might be a biased 
representation of the reality found in com-
panion animals in Portugal, as they were 
obtained from a reference laboratory that 
receives samples from complicated infec-
tions observed in private practices. This 
suggests that our results only represent a 
small part of the staphylococci isolates that 
in reality infect companion animals. Howev-
er, since our laboratory has been collecting 
samples since 1999, the increased frequen-
cy of antimicrobial resistance over time re-
ported here probably reflects what is hap-
pening in the staphylococci population in 
general. Additionally, the observed time-
trend for the various antimicrobials reflects 
the development of new resistant strains but 
also the spread of resistant organisms over 
time. 
This study highlights the importance of 
companion animals as reservoirs of im-
portant antimicrobial-resistant pathogens. In 
2005, Heuer and colleagues underlined that 
the use of antimicrobial drugs in companion 
animals had received little attention and that 
monitoring programs had focused solely on 
antimicrobial drug consumption in food ani-
mals.42 Ten years later, the European Sur-
veillance of Veterinary Antimicrobial Con-
sumption (ESVAC) group reports infor-
mation on the sales of tablets by veterinary 
antimicrobial class for companion animals.27 
Yet, no alteration or restrictions in antimi-
crobial prescription in companion animals 
have been imposed so far (especially con-
sidering critically important antimicrobials). 
International and national guidelines on an-
timicrobial use for companion animal prac-
tice are urgently needed and in fact they 
have been published more frequently. An-
other problem that requires immediate at-
tention is updated and species-specific clin-
ical breakpoints. Together these features 
will hopefully improve antimicrobial stew-
ardship and prevent the development of an-
timicrobial resistance. 
The significant increase of antimicrobial-
resistant and mecA-positive isolates in the 
last years is worrying. Furthermore, several 
isolates are multidrug-resistant, which com-
plicates antimicrobial treatment and raises 
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the risk of transfer to humans or human iso-
lates. Several clonal lineages of MRSA and 
MRSE circulating in human hospitals and in 
the community were found in this study, 
suggesting that companion animals can be-
come infected with and contribute to the 
dissemination of highly successful human 
clones. Thus, companion animals can act 
as reservoirs of important human clones, 
perpetuating the transmission cycle of MRS 
between humans and companion animals.  
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Supplementary Table 1. Odds ratio, confidence intervals and p-value for the evolution over time of 
the proportion of isolates resistant to different antimicrobials and mecA. 
Antimicrobial Odds ratio Confidence Interval p-value 
Ampicillin 1.104 1.060-1.150 <0.001 
Penicillin 1.104 1.060-1.150 <0.001 
Amoxicillin/clavulanic acid 1.487 1.341-1.648 <0.001 
Oxacillin 1.851 1.558-2.199 <0.001 
Cefoxitin 1.202 1.080-1.377 <0.001 
Cefovecin 1.491 1.362-1.632 <0.001 
Cefotaxime 1.444 1.315-1.585 <0.001 
Ceftriaxone 1.419 1.296-1.552 <0.001 
Cephalexin 1.607 1.401-1.843 <0.001 
Enrofloxacin 1.382 1.284-1.486 <0.001 
Ciprofloxacin 1.382 1.284-1.486 <0.001 
Levofloxacin 1.413 1.306-1.528 <0.001 
Norfloxacin 1.373 1.278-1.475 <0.001 
Ofloxacin 1.374 1.280-1.476 <0.001 
Moxifloxacin 1.420 1.306-1.544 <0.001 
Gentamicin 1.357 1.243-1.482 <0.001 
Neomycin 1.090 1.034-1.149 0.001 
Tobramycin 1.350 1.234-1.476 <0.001 
Kanamycin 1.109 1.056-1.164 <0.001 
Streptomycin 1.057 1.009-1.106 0.020 
Sulfamethoxazole/trimethoprim 1.218 1.149-1.293 <0.001 
Sulphonamides 1.037 0.999-1.078 0.058 
Trimethoprim 1.145 1.088-1.205 <0.001 
Tetracycline 1.050 1.009-1.092 0.016 
Chloramphenicol 1.151 1.052-1.259 0.002 
Erythromycin 1.120 1.068-1.174 <0.001 
Clindamycin 1.110 1.056-1.167 <0.001 
Resistance to at least 1 AB 1.101 1.047-1.159 <0.001 
Resistance to ≥ 3 AB 1.083 1.040-1.127 <0.001 
mecA 1.496 1.371-1.631 <0.001 
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Supplementary Table 2. Characteristics of the methicillin-resistant staphylococci found in this study. 















Cat S. epidermidis nt - 20 5 FQ, STR, ERY, RIF blaZ, mecA, msrA 
FMV850B/02 Otitis Cat S. epidermidis nt - 2 5 
CIP, ENR, NOR, OFX, LEV, 
GEN, NEO, TOB, AMK, KAN, 
STR, SXT, TMP, SUL 
blaZ, mecA, aacA-aphD, 
aadD 
FMV2985/02 Otitis Dog S. haemolyticus V - - - FQ, TET, GEN, KAN, ERY 





Cat S. epidermidis IV - 23 5 
FQ, GEN, NEO, TOB, AMK, 
KAN, STR, ERY, CLI, FUS, 
RIF 
blaZ. mecA, erm(A), 
aacA-aphD, aadD, fusB 
FMV3951/04 Otitis Dog S. haemolyticus nt - - - NEO, KAN blaZ, mecA, aphA3 




Cat S. lentus III - - - 
FQ, TET, ERY, CLI, SXT, 
TMP, SUL 
blaZ, mecA, erm(A), 





Cat S. epidermidis nt - 2 5 GEN, TOB, KAN 





Cat S. pseudintermedius V - 196 196 
FQ, GEN, NEO, TOB, KAN, 
STR, ERY, CLI, SXT, TMP, 
SUL 
blaZ, mecA, erm(B), 
aacA-aphD, aphA3, aa-
dE, dfr(G) 
FMV5628/07 Otitis Dog S. haemolyticus V - - - FQ, GEN, NEO, KAN, ERY, blaZ, mecA, aacA-aphD, 
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FUS, SXT, TMP, SUL aphA3, msrA, mph(C), 
fusC, dfr(G) 




Cat S. epidermidis nt - 35 5 FQ, STR, ERY, FUS, SUL blaZ, mecA, erm(B), fusB 
FMV3021/09 Otitis Cat S. haemolyticus nt - - - 
FQ, GEN, NEO, TOB, KAN, 
FUS, SXT, TMP, SUL 
blaZ, mecA, aacA-aphD, 




Cat S. pseudintermedius II-III - 71 71 
FQ, TET, GEN, NEO, TOB, 
KAN, STR, ERY, CLI, SXT, 
TMP, SUL 
blaZ, mecA, erm(B), 
tet(K), aacA-aphD, 
aphA3, aadE, dfr(G) 
FMV1860/10 Otitis Cat S. pseudintermedius II-III - 71 71 
FQ, TET, GEN, N, TOB, KAN, 
STR, ERY, CLI, SXT, TMP, 
SUL 
blaZ, mecA, erm(B), 
tet(K), aacA-aphD, 
aphA3, aadE, dfr(G) 
FMV3008/10 Otitis Dog S. pseudintermedius II-III - 203 71 
FQ, GEN, NEO, TOB, KAN, 
STR, ERY, CLI, SXT, TMP, 
SUL 






Cat S. pseudintermedius II-III - 71 71 
FQ, TET, CHL, GEN, NEO, 
TOB, KAN, STR, ERY, CLI, 
SXT, TMP, SUL 
blaZ, mecA, cat pC221, 
erm(B), tet(K), aacA-
aphD, aphA3, aadE, 
dfr(G) 
FMV4877/10 Pyoderma Dog S. pseudintermedius II-III - 71 71 
FQ, TET, GEN, NEO, TOB, 
KAN, STR, ERY, CLI, SXT, 
TMP, SUL 
blaZ, mecA, erm(B), 
tet(K), aacA-aphD, 
aphA3, aadE, dfr(G) 
FMV5819/10 Pyoderma Dog S. pseudintermedius II-III - 71 71 
FQ, TET, GEN, NEO, TOB, 
KAN, STR, ERY, CLI, SXT, 
TMP, SUL, RIF 
blaZ, mecA, erm(B), 
tet(K), aacA-aphD, 
aphA3, aadE, dfr(G),  
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FMV6096B/10 Pyoderma Dog S. pseudintermedius II-III - 71 71 
FQ, TET, GEN, NEO, TOB, 
KAN, STR, ERY, CLI, SXT, 
TMP, SUL 
blaZ, mecA, erm(B), 
tet(K), aacA-aphD, 
aphA3, aadE, dfr(G) 
FMV981/11 Pyoderma Dog S. pseudintermedius II-III - 71 71 
FQ, TET, GEN, N, TOB, KAN, 
STR, ERY, CLI, SXT, TMP, 
SUL 
blaZ, mecA, erm(B), 
tet(K), aacA-aphD, 
aphA3, aadE, dfr(G) 
FMV7/2011 Pyoderma Dog S. pseudintermedius II-III - 71 71 
FQ, TET, CHL, FFC, GEN, 
NEO, TOB, KAN, STR, ERY, 
CLI, FUS, SXT, TMP, SUL, RIF 
blaZ, mecA, fexA, 
erm(B), tet(K), aacA-
aphD, aphA3, aadE, 
fusB, dfr(G) 
FMV9/2011 Pyoderma Dog S. haemolyticus V - - - FQ, TET, ERY, FUS 
blaZ, mecA, erm(B), 





Dog S. pseudintermedius II-III - 195 71 
FQ, GEN, NEO, TOB, KAN, 
STR, ERY, CLI, SXT, TMP, 
SUL 






Dog S. pseudintermedius II-III - nd 71 
FQ, TET, GEN, NEO, TOB, 
KAN, STR, ERY, CLI, SXT, 
TMP, SUL 
blaZ, mecA, erm(B), 
tet(K), aacA-aphD, 




Dog S. pseudintermedius nt - nd 71 
FQ, GEN, NEO, TOB, KAN, 
STR, ERY, CLI, SXT, TMP, 
SUL 






Dog S. pseudintermedius II-III - nd 71 
FQ, TET, GEN, N, TOB, KAN, 
STR, ERY, CLI, SXT, TMP, 
SUL 
blaZ, mecA, erm(B), 
tet(K), aacA-aphD, 
aphA3, aadE, dfr(G) 
FMV24/2011 Synovitis Dog S. pseudintermedius II-III - nd 71 FQ, TET, GEN, NEO, TOB, blaZ, mecA, erm(B), 
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KAN, STR, ERY, CLI, SXT, 
TMP, SUL 
tet(K), aacA-aphD, 
aphA3, aadE, dfr(G) 
FMV4465/12 Pyoderma Dog S. aureus IV t032 22 22 FQ blaZ, mecA 
FMV1/2012 Wound Cat S. aureus IV t032 22 22 FQ blaZ, mecA 
FMV2/2012 Wound Cat S. aureus IV t032 22 22 FQ blaZ, mecA 
FMV14/2012 Pyoderma Dog S. pseudintermedius II-III - nd 71 
FQ, NEO, TOB, KAN, STR, 
SXT, TMP, SUL 
blaZ, mecA, erm(B), 
aphA3, aadE, dfr(G) 
FMV21/2012 Pyoderma Dog S. haemolyticus nt - - - FQ, TET, ERY, FUS 
blaZ, mecA, erm(B), 
erm(C), tet(M), fusB 




Cat S. pseudintermedius II-III - 71 71 
FQ, GEN, NEO, TOB, KAN, 
STR, ERY, CLI, SXT, TMP, 
SUL 
blaZ, mecA, erm(B), 
aacA-aphD, aphA3, aa-
dE, dfr(G) 
FMV34/2012 Pyoderma Dog S. pseudintermedius nt - 45 45 
FQ, TET, CHL, GEN, N, TOB, 
KAN, STR, ERY, CLI, SXT, 
TMP, SUL 
blaZ, mecA, cat pC221, 
erm(B), tet(M), aacA-
aphD, aphA3, aadE, 
dfr(G) 
FMV41/2012 Rhinitis Cat S. pseudintermedius II-III - nd 71 
FQ, TET, GEN, NEO, TOB, 
KAN, STR, ERY, CLI, SXT, 
TMP, SUL 
blaZ, mecA, erm(B), 
tet(K), aacA-aphD, 
aphA3, aadE, dfr(G) 
FMV47/2012 Otitis Dog S. epidermidis nt - 5 5 TET, SXT, TMP, SUL blaZ, mecA 
FMV48/2012 Pyoderma Dog S. pseudintermedius II-III - 71 71 
FQ, TET, GEN, NEO, TOB, 
KAN, STR, ERY, CLI, SXT, 
TMP, SUL 
blaZ, mecA, erm(B), 
tet(K), aacA-aphD, 




Dog S. epidermidis II -   ERY 
blaZ, mecA, mph(C), 
msrA 
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FMV54/2012 Synovitis Dog S. pseudintermedius nt - nd 71 
FQ, TET, GEN, NEO, TOB, 
KAN, STR, ERY, CLI, SXT, 
TMP, SUL 
blaZ, mecA, erm(B), 
tet(K), aacA-aphD, 
aphA3, aadE, dfr(G) 
FMV58/2012 Pyoderma Dog S. pseudintermedius II-III - nd 71 
FQ, TET, GEN, NEO, TOB, 
KAN, STR, ERY, CLI, SXT, 
TMP, SUL 
blaZ, mecA, erm(B), 
tet(K), aacA-aphD, 
aphA3, aadE, dfr(G) 
FMV59/2012 Pyoderma Dog S. pseudintermedius II-III - nd 71 
FQ, TET, GEN, NEO, TOB, 
KAN, STR, ERY, CLI, SXT, 
TMP, SUL 
blaZ, mecA, erm(B), 
tet(K), aacA-aphD, 
aphA3, aadE, dfr(G) 
FMV60/2012 Pyoderma Dog S. epidermidis IV - 5 5 
CIP, ENR, LEV, NOR, OFX, 
TET, GEN, TOB, KAN, ERY, 
CLI, FUS, SUL 
blaZ, mecA, erm(C), 




Dog S. epidermidis IV - 57 5 SUL mecA 
FMV62/2012 Otitis Cat S. epidermidis nt - 5 5 
NOR, OFX, TET, GEN, TOB, 
KAN, ERY, CLI 
blaZ, mecA, erm(C), 
tet(K), aacA-aphD,  
FMV64/2012 Pyoderma Dog S. pseudintermedius nt - nd 71 
FQ, TET, CHL, GEN, TOB, 
KAN, STR, ERY, CLI, SXT, 
TMP, SUL 
blaZ, mecA, cat pC221, 
erm(B), tet(K), aacA-
aphD, aphA3, aadE, 
dfr(G) 
FMV71/2012 Pyoderma Dog S. pseudintermedius II-III - 71 71 
FQ, TET, GEN, NEO, TOB, 
KAN, STR, ERY, CLI, SXT, 
TMP, SUL 
blaZ, mecA, erm(B), 
tet(K), aacA-aphD, 




Dog S. aureus II t002 105 5 FQ, ERY, CLI blaZ, mecA, erm(A) 
FMV22/2013 Pyoderma Dog S. pseudintermedius II-III - 71 71 FQ, TET, GEN, NEO, TOB, blaZ, mecA, erm(B), 
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KAN, STR, ERY, CLI, SXT, 
TMP, SUL 
tet(K), aacA-aphD, 
aphA3, aadE, dfr(G) 
FMV25/2013 Meningitis Dog S. hominis nt - - - FUS, SUL blaZ, mecA, fusB 
FMV29/2013 Pyoderma Dog S. pseudintermedius II-III - nd 71 
FQ, TET, GEN, NEO, TOB, 
KAN, STR, ERY, CLI, SXT, 
TMP, SUL 
blaZ, mecA, erm(B), 
tet(K), aacA-aphD, 
aphA3, aadE, dfr(G) 
FMV30/2013 Pyoderma Dog S. aureus V t108 398 398 FQ, TET, CHL, FFC blaZ, mecA, tet(M), fexA 
FMV37/2013 Pyoderma Dog S. pseudintermedius II-III - nd 71 
FQ, TET, GEN, NEO, TOB, 
KAN, STR, ERY, CLI, SXT, 
TMP, SUL 
blaZ, mecA, erm(B), 
tet(K), aacA-aphD, 
aphA3, aadE, dfr(G) 
FMV52/2013 Pyoderma Dog S. pseudintermedius IV - 342 261 
TET, NEO, KAN, STR, ERY, 
CLI, SXT, TMP, SUL 
blaZ, mecA, erm(B), 





Dog S. pseudintermedius II-III - nd 71 
FQ, TET, GEN, NEO, TOB, 
KAN, STR, ERY, CLI, SXT, 
TMP, SUL 
blaZ, mecA, erm(B), 
tet(K), aacA-aphD, 




Dog S. pseudintermedius II-III - nd 71 
FQ, TET, GEN, NEO, TOB, 
KAN, STR, ERY, CLI, SXT, 
TMP, SUL 
blaZ, mecA, erm(B), 
tet(K), aacA-aphD, 
aphA3, aadE, dfr(G) 
FMV56/2013A Pyoderma Dog S. pseudintermedius III - 400 400 
CIP, ENR, LEV, NOR, OFX, 
TET, CHL, NEO, KAN, STR, 
ERY, CLI 
blaZ, mecA, cat pC221, 
erm(B), tet(M), aphA3, 
aadE 
FMV56/2013B Pyoderma Dog S. haemolyticus V - - - TET, ERY, CLI, FUS 
blaZ, mecA, erm(C), 
tet(K), fusB 
FMV56/2013C Pyoderma Dog S. haemolyticus V - - - TET, SUL blaZ, mecA, tet(K) 
FMV57/2013A Pyoderma Dog S. pseudintermedius III - 400 400 CIP, ENR, LEV, NOR, OFX, blaZ, mecA, cat pC221, 
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TET, CHL, NEO, KAN, STR, 
ERY, CLI 
erm(B), tet(M), aphA3, 
aadE 
FMV57/2013B Pyoderma Dog S. simulans III - - - TET blaZ, mecA, tet(K) 
FMV74/2013 Unknown Dog S. pseudintermedius II-III - nd 71 
FQ, TET, GEN, NEO, TOB, 
KAN, STR, ERY, CLI, SXT, 
TMP, SUL 
blaZ, mecA, erm(B), 
tet(K), aacA-aphD, 




Dog S. pseudintermedius III - 400 400 
FQ, TET, CHL, NEO, KAN, 
STR, ERY, CLI 
blaZ, mecA, cat pC221, 
erm(B), tet(M), aphA3, 
aadE 
FMV9/2014 Pyoderma Dog S. aureus IV t2357 22 22 FQ, ERY, CLI blaZ, mecA, erm(C) 
FMV10/2014 Otitis Dog S. pseudintermedius nt - 71 71 
CIP, ENR, LEV, NOR, OFX, 
TET, GEN, NEO, TOB, KAN, 
STR, ERY, CLI, SXT, TMP, 
SUL 
blaZ, mecA, erm(B), 
tet(K), aacA-aphD, 
aphA3, aadE, dfr(G) 
FMV12/2014 Pyoderma Dog S. pseudintermedius IV - 342 261 
TET, N, KAN, STR, SXT, TMP, 
SUL 
blaZ, mecA, tet(M), 
aphA3, aadE, dfr(G) 
FMV19/2014 Pyoderma Dog S. aureus IV t032 22 22 FQ blaZ, mecA 
FMV28/2014 Otitis Dog S. pseudintermedius nt - nd 71 
FQ, TET, GEN, NEO, TOB, 
KAN, STR, ERY, CLI, SXT, 
TMP, SUL 
blaZ, mecA, erm(B), 
tet(K), aacA-aphD, 




Dog S. caprae nt - - - GEN, KAN, SUL blaZ, mecA, aacA-aphD 
FMV42/2014 Pyoderma Dog S. pseudintermedius nt - 339 84 
FQ, NEO, KAN, STR, ERY, 
CLI, SXT, TMP, SUL, RIF 
blaZ, mecA, erm(B), 
aphA3, dfr(G) 
FMV48/2014 Otitis Dog S. pseudintermedius II-III - nd 71 
FQ, GEN, TOB, KAN, STR, 
SXT, TMP, SUL 
blaZ, mecA, aacA-aphD, 





Dog S. aureus IV t025 22 22 FQ, ERY blaZ, mecA, erm(C) 
Abbreviations: AMK, amikacin; CHL, chloramphenicol; CIP, ciprofloxacin; CLI, clindamycin; ERY, erythromycin; FFC, florfenicol; FQ, fluoro-
quinolones; FUS, fusidic acid; GEN, gentamicin; KAN, kanamycin, MXF, moxifloxacin; NEO, neomycin; NOR, norfloxacin; OFX, ofloxacin; RIF, 
rifampicin; STR, streptomycin; SUL, sulphonamides; SXT, trimethoprim/sulfamethoxazole; TET, tetracycline; TMP, trimethoprim; TOB, tobra-
mycin.
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Supplementary Figure 1. Distribution of the florfenicol zone diameters (in milimeters) identi-




Supplementary Figure 2. Dendograms showing the similarity between (a) MRSA strains; (b) 
MRSP strains, (c) MRSE strains; and (d) MRSH strains. Clusters were defined as ≥ 80% sim-

















































































































































































































































































































































































































































































































































































































































































































3.3 Part 3 – The interaction between Staphylococcus pseudintermedius and dogs 
3.3.1 Comparative analysis of the virulence characteristics of methicillin–resistant 
and –susceptible Staphylococcus pseudintermedius strains isolated from small 
animals: a RNA-Seq-based transcriptome analysis 
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tive RNA-seq-Based Transcriptome Analysis of the Virulence Characteristics of Methicillin-
Resistant and -Susceptible Staphylococcus pseudintermedius Strains Isolated from Small 




















































Comparative RNA-seq-Based Transcriptome Analysis of the Virulence
Characteristics of Methicillin-Resistant and -Susceptible Staphylococcus
pseudintermedius Strains Isolated from Small Animals
Natacha Couto,a Adriana Belas,a Manuela Oliveira,a Paulo Almeida,b Carla Clemente,b Constança Pomba a
CIISA, Faculdade de Medicina Veterinária, Universidade de Lisboa (FMV-UL), Lisbon, Portugala; STABvida, Caparica, Portugalb
Staphylococcus pseudintermedius is often associated with pyoderma, which can turn into a life-threatening disease. The dissemi-
nation of highly resistant isolates has occurred in the last 10 years and has challenged antimicrobial treatment of these infections
considerably. We have compared the carriage of virulence genes and biofilm formation between methicillin-resistant and methi-
cillin-susceptible S. pseudintermedius (MRSP and MSSP, respectively) isolates and their in vitro gene expression profiles by
transcriptome sequencing (RNA-seq). Isolates were relatively unevenly distributed among the four agr groups, and agr type III
predominated in MRSP. Five virulence genes were detected in all isolates. Only the spsO gene was significantly associated with
MSSP isolates (P ! 0.04). All isolates produced biofilm in brain heart infusion broth (BHIB)– 4% NaCl. MSSP isolates produced
more biofilm on BHIB and BHIB–1% glucose media than MRSP isolates (P ! 0.03 and P ! 0.02, respectively). Virulence genes
encoding surface proteins and toxins (spsA, spsB, spsD, spsK, spsL, spsN, nucC, coa, and luk-I) and also prophage genes (encoding
phage capsid protein, phage infection protein, two phage portal proteins and a phage-like protein) were highly expressed in the
MRSP isolate (compared with the MSSP isolate), suggesting they may play a role in the rapid and widespread dissemination of
MRSP. This study indicates that MRSP may upregulate surface proteins, which may increase the adherence of MRSP isolates (es-
pecially sequence type 71 [ST71]) to corneocytes. MSSP isolates may have an increased ability to form biofilm under acidic cir-
cumstances, through upregulation of the entire arc operon. Complete understanding of S. pseudintermedius pathogenesis and
host-pathogen signal interaction during infections is critical for the treatment and prevention of S. pseudintermedius infections.
Methicillin-resistant Staphylococcus pseudintermedius (MRSP)isolates have emerged as one of the leading causes of infec-
tious diseases (including pyoderma, otitis and urinary tract infec-
tions) in companion animals, accounting for 20% to 47% of all
clinical S. pseudintermedius isolates from dogs and cats (1). More-
over, some MRSP isolates are resistant to the antimicrobials reg-
ularly used for treatment (!-lactams, fluoroquinolones, tetracy-
clines, lincosamides, and potentiated sulfonamides) in small
animal practice (1, 2). The mecA gene, encoding resistance to
!-lactams, has been acquired by several S. pseudintermedius clonal
lineages on independent occasions; however, two clones, MRSP
ST68-SCCmec V and MRSP ST71-SCCmec II-III, are the domi-
nant ones and have spread globally (1, 3, 4). This dissemination
was rapid, but the reasons for the fast emergence and success of
these lineages are not fully understood (2). Genomic and pro-
teomic studies conducted in the last few years are giving the first
clues on the pathways by which MRSP isolates have become suc-
cessful. A recent genomic report suggested that multidrug resis-
tance evolved rapidly in MRSP due to the acquisition of a very
limited number of mobile genetic elements and mutations (1).
Thus, the use of different antimicrobial classes coselected for the
spread and emergence of the multidrug-resistant MRSP isolates
(1). The frequent carriage of prophages in the MRSP sequence
type 71 (ST71) and ST68 genomes suggested they have a role in the
fitness of MRSP and that the predominant transfer of genetic ma-
terial in these isolates is through bacteriophage transduction,
rather than plasmid conjugation, as happens in methicillin-resis-
tant Staphylococcus aureus (MRSA) (1). MRSP isolates are able to
produce biofilm, and MRSP ST71 isolates, in particular, are better
biofilm producers than other MRSP clones (5, 6). The icaA gene
can be significantly upregulated in biofilm samples, suggesting a
role in the biofilm production by S. pseudintermedius (7). The
ability to form biofilm may play an important role in the patho-
physiology of bacterial infections and can be related to survival
and persistence of S. pseudintermedius, namely, MRSP, in the
environment (5, 6). The MRSP ST71 isolates also show greater
adherence to corneocytes than MRSP non-ST71 and methicillin-
susceptible S. pseudintermedius (MSSP) isolates, and thus it has
been suggested that the enhanced adherence of ST71 might be a
factor contributing to the epidemiological success of this MRSP
lineage (2). Furthermore, an MRSP ST71 isolate of human origin
adhered evenly well to canine and human corneocytes, implying
that MRSP ST71 may also be capable of adapting to human skin
(2). Two proteins, SpsD and SpsO, can mediate adherence to
canine corneocytes (8); however, the genetic factors responsible
for the enhanced in vitro adherence of MRSP ST71 are not yet
known (2).
In order to understand the epidemiological success of MRSP
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isolates, our goal was to understand if the phenotypes (biofilm)
and genotypes (virulence genes) related to virulence factors were
different between MRSP and methicillin-susceptible S. pseudin-
termedius (MSSP) isolates. Furthermore, we compared the in vitro
transcriptional profiles by transcriptome sequencing (RNA-seq)
of one MRSP isolate and one MSSP isolate to test the hypothesis
that MRSP could have altered expression of virulence genes, by
comparison with MSSP, which could have contributed to its rapid
spread.
MATERIALS AND METHODS
Genotypic characterization of the MRSP and MSSP isolates. Twenty-
one consecutive methicillin-resistant S. pseudintermedius (MRSP) isolates
obtained over a 7-year period from 2007 to 2014 were included in the
study. Twenty-one methicillin-susceptible S. pseudintermedius (MSSP)
isolates matched in terms of isolation year, isolation site, and host were
also included. These isolates were from 18 asymptomatic carriers (9 with
MRSP and 9 with MSSP), 12 patients with pyoderma (6 with MRSP and 6
with MSSP), 6 patients with urinary tract infection (3 with MRSP and 3
with MSSP), 5 patients with otitis (2 with MRSP and 3 with MSSP), and 1
patient with a surgical site infection (MRSP). Five isolates were from cats,
and 37 were from dogs. Isolates were characterized by multilocus se-
quence typing (MLST) (9). The eBURST algorithm identified groups of
related sequence types (ST) (10).
Specific sequences for virulence genes involved in biofilm formation
(bap, icaA, icaB, icaC, and icaD), enterotoxin production (se-int, seccanine,
and seh), host adherence (ebpS, spsD, spsL, and spsO), and toxin produc-
tion (lukS, lukF, siet, speta, expA, and expB) were detected by PCR on a
Mastercycle thermocycler (Eppendorf, New York) with the primers,
product sizes, and annealing temperatures shown in Table S1 in the sup-
plemental material (11–16). The primers designed in this study were gen-
erated using the Primer-BLAST tool from NCBI. All PCR products were
analyzed by electrophoresis through 1.2% agarose gels (NZYTech, Lis-
bon, Portugal). The primers agrD-F (5=-GGG GTA TTA TTA CAA TCA
TTC -3=) and agrD-R (5=-CTG ATG CGA AAA TAA AGG ATT G -3=)
(STABvida, Monte da Caparica, Portugal) were used as previously de-
scribed to amplify a 300-bp agr fragment encompassing the 3= end of agrB,
all of agrD, and the 5= end of agrC. Amplification was carried out on a
Mastercycler thermocycler (Eppendorf) under the following condi-
tions: an initial 5-min denaturation step at 94°C, followed by 30 cycles
of 1 min of denaturation at 94°C, 1 min of annealing at 45°C, and 1 min
of extension at 72°C, and a final extension step at 72°C for 10 min. The
PCR products were purified by using NZYGelpure (NZYTech) and
sequenced with the same primers used for the PCRs (STABvida). The
42 isolates were assigned to one of the four agr groups by comparing
the predicted product of the agrD gene and the N-terminal half of the
AgrC with those of four control isolates (GenBank accession no.
EU157336, EU157366, EU157334, and EU157330).
Biofilm-producing ability on polystyrene. The capacity of the iso-
lates to form biofilm was investigated by a method described by
Stepanovic and colleagues (17) and Pettit and colleagues (18) with minor
modifications, and was determined by the ability of S. pseudintermedius
isolates to adhere to 96-well polystyrene microtiter plates (Greiner bio-
one, Frickenhausen, Germany). In brief, the study was carried out using
brain heart infusion broth (BHIB [Biokar]), BHIB with 4% NaCl, and
BHIB with 1% glucose as the growth media. The plates were incubated at
37°C for 24 h. Following incubation, the alamarBlue solution was added
to each well. After 30 min at room temperature, the optical densities at 570
nm (OD570) were measured. Staphylococcus epidermidis strain RP62A
(ATCC 35984) was used as a positive control. We defined the cutoff OD
(ODC) for the microtiter plate test as 3 standard deviations (SD) above the
mean OD of the negative control as described previously (17). All isolates
were classified into the following categories based upon the ODs of bac-
terial films (17): nonadherent, OD ! ODC; weakly adherent, ODC ! OD
! 2" ODC; moderately adherent, 2" ODC ! OD ! 4" ODC; or strongly
adherent, OD " 4" ODC.
RNA isolation, sequencing and gene expression analyses. To test the
hypothesis that MRSP and MSSP isolates differ in their expression of
virulence genes, we compared the in vitro transcriptional profiles of a
clinical MRSP isolate and a clinical MSSP isolate using RNA-seq. We
attempted to choose 2 representative isolates from the S. pseudintermedius
collection. The isolates were obtained from skin swabs of dogs with pyo-
derma (the most frequent clinical specimen from which S. pseudinterme-
dius was isolated), they were obtained during the same period of time,
were agr type III (the most frequent agr type found in this study), at least
one was ST71 (the most frequent ST found in this study), and they had
similar virulence profiles (considering virulence genes tested by PCR).
Bacterial cells were grown until the mid-log-phase of growth (OD600 of
0.5), since it has been shown that the majority of surface proteins are
produced during this phase (19). RNA was isolated using the RNeasy kit
from Qiagen (Hilden, Germany). Briefly, 2 " 108 cells were removed from
growing cultures, 2 volumes of RNAprotect bacterial reagent (Qiagen)
was added, and the mixture was incubated for 5 min at room temperature.
Cells were then centrifuged and incubated with TE buffer (30 mM Tris-Cl,
1 mM EDTA, pH 8.0 [Sigma]) containing 0.5-mg/ml lysostaphin (Sigma)
and 15-mg/ml lysozyme (Sigma) for 20 min at 37°C. Proteinase K (20
mg/ml [Sigma]) was added, and the mixture was incubated for 10 min.
After this, the procedure was carried out according to the manufacturer’s
specifications. The purified RNA was quantified using a NanoDrop spec-
trometer (ThermoScientific). RNA quality was assessed by visualization
on an agarose gel. The rRNA was removed using the MICROBExpress kit
(Ambion). RNA quality was then evaluated on a ByoAnalyzer (Agilent).
Bacterial mRNA was fragmented (yield fragments were in the size range of
200 to 250 bp), and the double-stranded cDNA was generated using the
Ion Total RNA-seq kit v2 (Life Technologies, Thermo Fisher Scientific)
according to the manufacturer’s instructions. The samples were se-
quenced using the Ion PGM (Life Technologies, Thermo Fisher Scientific)
sequencer at STABvida.
Mapping to the reference genomes and normalization of gene expres-
sion were performed by CLC Genomics Workbench v8.0.1. RNA-seq
reads were aligned with the three available S. pseudintermedius reference
genomes ED99 (ST25, agr type III, lacks spsF, spsO, and spsQ), HKU10-03
(ST308, agr type III, lacks nanB), and E140 (ST71, agr type III, lacks
nanB, lukF, and lukS) (RefSeq accession no. CP002478, CP002439 and
ANOI01000001, respectively). Gene expression was normalized by calcu-
lating reads per kilobase per million mapped reads (RKPM), given by
dividing the total number of reads by the number of mapped reads (in
millions) " the length in kilobases (20).
Differentially expressed genes were identified using Baggerly’s test (bi-
nomial test), which compares the proportions of counts in a group of
samples against those of another group of samples (21) with a false dis-
covery rate (FDR) correction applied (22). Genes with an adjusted P value
of !0.05 were identified as being differentially expressed. This study fo-
cused particularly in the expression of virulence genes, but expression of
other relevant genes (e.g., antimicrobial resistance genes) was also evalu-
ated.
Statistical analysis. All data analysis was carried out using IBM SPSS
Statistics version 20.0 (IBM, New York). Differences between the two
groups MRSP and MSSP were calculated by Fisher’s exact test for categor-
ical comparisons and Student’s t test for continuous outcome. A P value of
!0.05 was considered statistically significant.
RESULTS
The results of MLST are shown in Table 1. The MSSP isolates were
divided into 21 different STs, while 15 MRSP isolates were as-
signed to ST71, 3 to ST203, 1 to ST196, 1 to ST213, and 1 to ST195.
Yet ST203 and ST195 belonged to clonal complex 71 (CC71), as
detected by eBURST analysis. Equally, ST196 and ST213 differed
by only one allele and belonged to CC196.
Couto et al.
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All isolates were classified as part of one of the four agr groups,
and the distribution was highly uneven, with 2 isolates belonging
to agr group I, 7 belonging to group II, 30 belonging to group III,
and 3 belonging to group IV (Table 1). There was a significant
difference in the agr groups’ distribution between MRSP and
MSSP (P ! 0.025), with allele III being significantly more associ-
ated with MRSP than with MSSP (P ! 0.014).
The virulence genes detected in the MRSP and MSSP isolates
are detailed in Table 2. Genes se-int, speta, siet, spsL, and ebpS were
present in all 42 isolates. The genes lukF and lukS, encoding leu-
kocidin Luk-I, were found in all isolates except for two MRSP
isolates (ST196 and ST213). Gene expB was detected in only 3
isolates. Only two MSSP isolates carried the enterotoxin gene
seccanine. No isolates harbored genes seh and expA. Eight isolates
carried the spsO gene, and by statistical analysis, this gene was
significantly more associated with MSSP than with MRSP (P !
0.04). No differences were found between clinical isolates and iso-
lates from carriage.
Results related to the biofilm-forming ability on polystyrene
are shown in Table 3. All isolates produced biofilm in the
BHIB– 4% NaCl medium. Two isolates did not produce biofilm
on BHIB, and nine isolates did not produce biofilm on BHIB–1%
glucose. Biofilm production in the BHIB and BHIB–1% glucose
media was significantly higher in MSSP than in MRSP isolates
(P ! 0.03 and P ! 0.02, respectively), but there were no differ-
ences between clinical isolates and isolates from carriage. The ica
genes were detected in all 42 isolates.
The numbers of mapped reads assigned by using each reference
genome (ED99, HKU10-30, and E140) are shown in Table S2 in
the supplemental material. Of these mapped reads, the number of
S. pseudintermedius genes with altered expression also varied
when using the three different reference genomes, as shown in Fig.
1. The MSSP isolate had higher expression in transcription of
regulatory genes agrB and agrD. On the other hand, the MRSP
isolate had higher transcription of regulatory genes sigB, srrA,
sarA, rot, and the saeRS system. The signal transduction protein
TRAP gene (traP) was also highly expressed. Considering genes
encoding surface proteins, only one, spsC, encoding an autolysin,
was highly expressed in the MSSP isolate, while 6, spsA, spsB, spsD,
spsK, spsL, and spsN, were highly expressed in the MRSP isolate.
The gamma-hemolysin component B gene (hlgB), both subunits
of the luk-I gene (lukF-I and lukS-I), and the coagulase and ther-
monuclease genes (coa and nucC, respectively) were upregulated
in the MRSP isolate. The arc genes (arcA, arcB, arcC, and arcD)
were upregulated in the MSSP isolate. Several genes associated
with antimicrobial resistance were highly expressed in the MRSP
isolate: the norA, gyrA and gyrB genes associated with quinolone
resistance, the aadE and the bifunctional aacA-aphD genes asso-
ciated with aminoglycoside resistance, the mecA, mecR1, and blaI
genes associated with "-lactam resistance, and the tet(M) gene
associated with tetracycline resistance. The MRSP isolate upregu-
lated several phage-associated genes (encoding phage capsid pro-
tein, phage infection protein, two phage portal proteins, and a
phage-like protein), and an integrase gene located in the superan-
tigen-encoding pathogenicity island SaPI (SPSINT_0063).
DISCUSSION
In the last 10 years, MRSP isolates have become highly frequent in
clinical samples from infected animals and as colonizers of healthy
ones (1). However, it is still not clear why MRSP isolates, especially
certain lineages like ST71, have spread so quickly. To understand
the rapid evolution that led to the dissemination of MRSP isolates,
we assessed the virulence determinants present in a collection of
MSSP and MRSP isolates and compared their abilities to form
biofilm in 3 different media. Finally, we performed in vitro gene
expression analysis and compared the levels of expression of one
MSSP isolate and one MRSP isolate.
Analysis of the virulence genotype of the MRSP and MSSP
isolates revealed a strong conservation of genes: five genes (ebpS,
se-int, siet, speta, and spsL) were carried by all S. pseudintermedius
isolates, and five genes (expB, luk-I, seccanine, spsD, and spsO) were
only present in some isolates. Two studies have reported the exis-
tence of some specific toxin genes (e.g., coa, lip, geh, htrA, nuc,
clpX, hlb, se-int, speta, spsA, spsB, and spsC) present in several S.
pseudintermedius isolates that might be important for the canine
host tropism, in particular the skin (1, 23). However, variation was
found in others (e.g., spsF, spsO, spsP, spsQ, luk-I, and nanB),
suggesting that a difference in virulence factors in the core genome
was probably lineage associated (1). For example, in one of these
studies, the five ST71 isolates lacked the nanB and lukF and -S
genes (1). Still, in our study and in a previous study conducted in
Spain (24), all of the ST71 isolates carried the lukF and -S genes,
suggesting that variation may also be related to the region of iso-
lation. It would be interesting to collect a large collection of ST71
isolates from different countries to study these variations. In other
lineages, however, this will be difficult to ascertain, since only a
few isolates in each lineage have been reported so far.
The capacity of bacteria to form biofilms is an important viru-
TABLE 2 Virulence traits of the MRSP and MSSP isolates
Virulence
genea








expA 0 0 0 #0.05
expB 3 0 3 #0.05
luk-I 40 19 21 #0.05
seccanine 2 0 2 #0.05
seh 0 0 0 #0.05
spsD 4 1 3 #0.05
spsO 8 1 7 0.04
a The genes ebpS, se-int, siet, speta, and spsL and the ica operon were positive in all
isolates and were not included in this table.
TABLE 1 Epidemiological characteristics of the MRSP and MSSP
isolates used in this study
agr
type
ST (no. of isolates)
P valueaMSSP (21) MRSP (21)
All 0.025
I ST207 (1), ST215 (1) No STs #0.05
II ST201 (1), ST205 (1), ST206 (1),
ST209 (1), ST217 (1)
ST196 (1), ST213 (1) #0.05
III ST17 (1), ST197 (1), ST199 (1),
ST200 (1), ST202 (1), ST204
(1), ST210 (1), ST211 (1),
ST212 (1), ST214 (1), ST379
(1)
ST71 (15), ST195 (1),
ST203 (3)
0.014
IV ST198 (1), ST208 (1), ST216 (1) No STs #0.05
a Shown are P values for differences between MRSP and MSSP.
S. pseudintermedius Transcriptome Analysis by RNA-seq
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lence factor not only in the development of device-related infec-
tions but also in a range of chronic infections (23). This capacity
might further complicate the treatment of already challenging in-
fections due to the decrease in effectiveness of antimicrobials on
biofilms (5). In one study, all S. pseudintermedius isolates pro-
duced biofilms, suggesting that biofilm production might be es-
sential for the pathogenicity of S. pseudintermedius (6). Yet, the
study failed to find differences in the biofilm formation between
MRSP and MSSP isolates. The number of MSSP isolates that was
studied was low, and the authors suggested that further experi-
ments with a larger number of isolates were warranted (6). By
using a larger set of isolates, we observed that biofilm production
in the BHIB and BHIB–1% glucose media was significantly higher
in MSSP than in MRSP isolates. This is a phenomenon that has
been observed in S. aureus, when comparing methicillin-resistant
and methicillin-susceptible isolates, and is due to different trigger-
ing mechanisms leading to biofilm formation, including ica-de-
pendent and -independent mechanisms (25). In our study, all
isolates produced biofilm, and all were positive for the ica genes,
suggesting this operon has a crucial role in biofilm formation.
However, the mechanisms triggering the higher biofilm produc-
tion in the BHIB and BHIB–1% glucose media by MSSP strains
remain unknown. One clue to this occurrence may be related to
the upregulation of the entire arc operon in the MSSP isolate stud-
ied here. A similar operon has been found in other staphylococcal
species, and in S. aureus, arcA (which belongs to the arc operon)
encodes an arginine deaminase, which allows for enhanced sur-
vival in acidic environments (26). The upregulation of this operon
may improve survival and promote biofilm formation of MSSP in
acidic circumstances, such as in BHIB medium with glucose
(which has a more acidic pH than BHIB medium alone or with
NaCl).
During the early emergence of community-acquired MRSA,
the USA300 (ST8) lineage disseminated rapidly and was consid-
ered hypervirulent, compared with lineages like MRSA USA400
(ST1) (26). However, USA300 does not contain many more viru-
lence genes than USA400, but it does have an alteration in the
expression of regulatory genes and increased expression of certain
virulence genes (26). By microarray analysis, USA300 displayed an
increased expression of genes encoding cell envelope proteins (in-
cluding lipoproteins and superantigen-like proteins), genes resid-
ing in the prophage !Sa3usa, several genes contained in pathoge-
nicity islands vSA" and vSAß, genes encoding proteases, and the
gene encoding the IgG binding protein Sbi (26). Interestingly our
MRSP isolate also had increased expression of several genes, in-
cluding spsK, which encodes the IgG binding protein Sbi, the toxin
genes nucC and coa, prophage genes, and several virulence regu-
latory genes, including saeRS. The higher expression of the pro-
phage genes might be one of the factors contributing to the rapid
dissemination of MRSP, particularly ST71 isolates. The higher
TABLE 3 Overall results of the microtiter plate test according to the pattern of methicillin resistance in S. pseudintermedius
Medium Mean OD570 # SD










BHIB 0.50 # 0.052 1 5 15 0
BHIB $ 1% glucose 0.28 # 0.038 3 18 0 0
BHIB $ 4% NaCl 0.44 # 0.055 0 18 3 0
MSSP
BHIB 0.57 # 0.082 1 6 14 0
BHIB $ 1% glucose 0.35 # 0.081 6 15 0 0
BHIB $ 4% NaCl 0.45 # 0.098 0 13 8 0
FIG 1 Number of S. pseudintermedius genes with altered expression identified by Baggerly’s test with the FDR correction applied, using the three different
reference genomes available ED99 (ST25, agr III), HKU10-30 (ST308, agr III), and E140 (ST71, agr III).
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expression of the genes spsD and spsL (encoding fibronectin-bind-
ing proteins able to adhere to the extracellular matrix) found in
this study may explain the higher adherence of MRSP ST71 iso-
lates to corneocytes previously detected (2). We observed a very
different expression of virulence regulatory genes between the two
isolates, with agr highly expressed in MSSP and saeRS highly ex-
pressed in MRSP. This may explain the differences observed in the
expression of the genes encoding surface proteins and toxins.
Among the most important bacterial defenses against uptake
of foreign DNA are the restriction-modification (R-M) systems
(27). These systems, comprising restriction endonucleases and
methyltransferases, recognize and modify specific DNA se-
quences, protecting “own” DNA from restriction while eliminat-
ing potentially harmful foreign DNA (27). In S. pseudintermedius,
type I R-M systems have been recognized, including one that was
carried on all SCCmec II and III elements of MRSP ST71 (1). One
study suggested that MRSP isolates were not more efficient or
inefficient than MSSP isolates in acquiring mobile genetic ele-
ments due to the wide distribution of the type I and type II R-M
systems in S. pseudintermedius isolates (1). In our study, however,
we found that the type I restriction-modification system restric-
tion subunit R (hsdR) was highly expressed in the MSSP isolate,
suggesting it blocks DNA horizontal gene transfer into methicil-
lin-susceptible isolates. Lower expression of subunit R in the
MRSP isolate could also suggest a more efficient way of acquiring
mobile genetic elements. In fact, it has been shown that MRSP
genomes carry more prophages than MSSP isolates. Our results
showed that the MRSP isolate also upregulates several phage-as-
sociated genes, which could be linked to the upregulation of the
integrase located in the superantigen-encoding pathogenicity is-
land, SaPI. The upregulation of prophage particles is also concor-
dant with the suggestion that transfer in MRSP is predominantly
made by transduction (1).
In summary, this is the first study to document the global tran-
scription differences between the MSSP and MRSP isolates during
in vitro growth. This study indicates that MRSP may upregulate
surface proteins, which may increase the adherence of MRSP iso-
lates (especially ST71) to corneocytes. Although MRSP and MSSP
have the capacity to form biofilm, MSSP may have an increased
ability to form biofilm under acidic circumstances, through up-
regulation of the entire arc operon. Complete understanding of S.
pseudintermedius pathogenesis and host-pathogen signal interac-
tion during infections is critical for the treatment and prevention
of S. pseudintermedius infections.
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The recent emergence of methicillin-resistant Staphylococcus pseudintermedius (MRSP) has complicated consid-
erably the treatment of infections caused by these bacteria. Therefore new treatment strategies are urgently
needed, namely through the development of vaccines towards the control of bacterial infections. Our study
describes an extensive characterization of the proteome of S. pseudintermedius through a 2-DE MALDI-TOF/TOF
approach, followed by SERological Proteome Analysis (SERPA) to identify potential vaccine candidate antigens.
Wewere able to identify 361 unique proteins, ofwhich 39 are surface proteins. In order to assess the immunogenic
potential of S. pseudintermedius proteins, a Western blot analysis of two-dimensional gels was carried out with
serum from healthy dogs, dogs with atopic dermatitis infected and not infected with S. pseudintermedius. Only
immunogenic areas detected by ≥50% of the dogs with atopic dermatitis infected with S. pseudintermedius sera
and by b50% of the healthy dogs sera were excised and identified from Coomassie-colloidal stained gels. The
areas identified by IgE were not considered as vaccine targets, because those proteins could induce hypersensitiv-
ity.Wewere able to identify 13 unique proteins after in-gel digestion of selected protein gel spots, with 4 antigenic
proteins showing promising features for vaccine development. No specific antibodies were identified in the dogs
with atopic dermatitis not infected with S. pseudintermedius sera that could contribute to prevention of infection.
The SERPA approach employed in this study revealed novel candidate therapeutic targets for the control of
S. pseudintermedius infections.








Staphylococcus pseudintermedius is a Gram-positive coccus, which
belongs to the Staphylococcus intermedius group (SIG) [1]. Like Staphylo-
coccus aureus, S. pseudintermedius are normally harmless and colonize
the skin and mucous membranes of animals [1]. However, they can
also be pathogenic by overcoming the hosts' immune system and of
clinical interest because they cause a variety of infections among small
animals, especially dogs, causing high morbidity [1]. One of the most
common diseases caused by S. pseudintermedius is pyoderma in dogs.
Pyoderma is usually secondary to atopic dermatitis, a pruritic allergic
skin disease that results in disrupted skin barrier and predisposition
for secondary S. pseudintermedius infections [2]. S. pseudintermedius
produces a wide range of virulence factors, especially proteins. However,
notmuch is known about the role of these proteins during infection [3]. In
S. aureus, homologue proteins are produced in a cell density-dependent
manner, through the agr system [4]. To initiate infection, S. aureus synthe-
sizes surface proteins, like adhesins, that bind extracellular-matrix
molecules and promote colonization [4]. Once colonization has been
established the bacteriamultiply, activating a density-sensingmechanism
that stimulates the production of exoproteins, like exfoliative toxins and
leukocidins, therefore promoting the spread of bacteria to other sites
[4]. It has been hypothesized that the agr system of S. pseudintermedius
mayplay a comparable role in thepathogenesis of these bacteria in canine
pyoderma [3].
Pyoderma is usually treated with antimicrobials [1]. The selective
pressure imposed by the long-term administration of antimicrobials
can lead to the development of bacterial resistance that could potentially
be transmitted to humanpathogens, like S. aureus. The recent emergence
of methicillin-resistant S. pseudintermedius (MRSP) has complicated
considerably the treatment of infections caused by these bacteria.
MRSP have become virtually resistant to all the antimicrobials approved
for administration in companion animals, which has led to ethical
concerns about the use of antimicrobials classified by the World Health
Organization as “critically important” for human medicine [1]. In this
way new treatment strategies are urgently needed and one way of
controlling bacterial infections is through the development of vaccines.
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The “omics” era (genomics, transcriptomics and proteomics) has
brought new tools that provide information about cell's genetic back-
ground, their potential regulatory mechanisms and biological activity
of proteins [5]. Proteomics has the advantage of dealing directly with
proteins, which are the main players of life processes [6]. Proteome
characterization of bacterial species, especially of their surface-exposed
protein fractions, can lead to the identification of vaccine candidates,
which can then be tested for their ability to induce protective immunity
or as passive immunization targets [5,7,8]. This can be accomplished
in silico, using bioinformatics tools, and/or by combining proteomics
with serological analysis (SERPA — SERological Proteome Analysis)
[7–14]. This approach has enabled the identification of vaccine candi-
dates against S. aureus [12–14].
The aim of this study was to characterize the proteome of
S. pseudintermedius through the 2-DE MALDI-TOF/TOF approach and
subsequently use a SERPA approach, using immunoblots followed by
MS protein identification, to depict potential vaccine candidate anti-
gens. To design potent and generally applicable subunit vaccines, it is
necessary to identify those antigens that are recognizable on a wide
patient population during infection [9]. For this reason we used serum
from dogs with atopic dermatitis and recurrently infected with
S. pseudintermedius (ADI) and discarded those proteins identified by
healthy dogs (H), to detect proteins only expressed during infection.
We used a third group, dogs with atopic dermatitis and not recurrently
infected with S. pseudintermedius (ADH), in an attempt to identify
antigenic proteins for which specific antibodies were missing or under-
represented in infected patients that could contribute to prevention of
infection.
2. Material and methods
2.1. Bacterial strain and culture conditions
S. pseudintermedius strain FMV5819/10was isolated from a dogwith
deep pyoderma presented to the Dermatology Service of the Teaching
Hospital FMV-UL. This strain belongs to sequence type 71 and has an
SCCmec II–III, representing the European MRSP clone ST71-II–III [16].
An overnight culture was inoculated into brain–heart infusion broth
(BHIB, Biokar® Solabia Group, Pantin, France) until the mid-exponential
phase was reached, corresponding to an OD600 of 0.4–0.5.
2.2. Protein fractionation
The fractionation protocol was optimized based on previously
published protocols [12,17] and is summarized in Fig. 1. Briefly, cells
were harvested by centrifugation at 8000 ×g for 5 min at 4 °C. Cells
were washed twice with isotonic buffer (10 mM Tris–HCl pH 7.4,
1.5 mMMgCl2, 10 mMKCl, 0.5 mMDTE, 1.1 M saccharose and protease
inhibitors; Sigma, St. Louis, United States of America), followed by
resuspension in isotonic buffer with 100 μg/ml of lysostaphin (Sigma).
The suspension was incubated at 37 °C for 35 min. Then protoplasts
were sedimented by centrifugation at 8000 ×g for 30 min at 4 °C. The
supernatant containing cell wall proteins (S1) was precipitated with
trichloroacetic acid 20% (v/v) with 2-mercaptoethanol 0.14% (v/v)
(Sigma) for 1 h at 4 °C and harvested at 13,000 ×g for 30 min at 4 °C.
The precipitate was rinsed two times with acetone and centrifuged at
13,000 ×g for 9 min at 4 °C.
Unbroken protoplasts were re-suspended in DNase I (20 μg/ml)
and RNase A (20 μg/ml) (Sigma) for 10 min at room temperature and
then centrifuged at 3500 ×g for 30 min at 4 °C. The pellet containing
cellular debris was discarded and the supernatant was centrifuged at
100,000 ×g for 9 min at 4 °C. From this centrifugation, we recovered pro-
teins in the pellet (P) and in the supernatant (S2), whichwere precipitat-
ed in 50mMammoniumbicarbonate (Sigma) and 2,2,2-trifluoroethanol/
chloroform (TFE/CHCl3) 1:1 (v/v)mixture (Sigma) andmaintained at 0 °C
for 1 h with periodic vortexing. A final centrifugation at 10,000 ×g for
4 min at 4 °C allowed the separation of both mixtures (P and S2) into
three phases: aqueous, insoluble and chloroformed. For both mixtures,
aqueous (PFA and S2FA) and insoluble (PFI and S2FI) phases were
recovered for further analysis. Chloroform phases were discarded due to
the low amount of protein present. All protein fractions (S1, PFI, PFA,
S2F1 and S2FA) were dried using a speedvac (ThermoFisher) and
stored at−20 °C until use. The obtained pellets were resuspended in a
buffer containing 7 M urea (Sigma), 2 M thiourea (Sigma), 30 mM Tris
(Sigma) and 4% CHAPS (Sigma).
Fig. 1. Protein fractionation procedure applied to S. pseudintermedius FMV5819/10.
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2.3. 2-DE and image analysis
The S. pseudintermedius proteins were separated in five different
cellular fractions. Fraction I was enriched with cell wall proteins (S1),
insoluble Fraction IIa enriched with membrane insoluble proteins
(PFI), aqueous Fraction IIb enriched with membrane water-soluble
proteins (PFA), insoluble Fraction IIIa enriched with cytoplasmic insolu-
ble proteins (S2FI), and finally, aqueous Fraction IIIb enriched with
cytoplasmatic water-soluble proteins (S2FA). The total protein of three
biological replicates of all the fractions was quantified with 2D-Quant
kit (GE healthcare Europe GmbH, Freiburg, Germany) and separated by
two-dimensional electrophoresis.
For fractions I, IIa and IIIa, the first-dimension was performed using
24 cm immobilized 3–10NL pH gradient (GE healthcare). The IPG strips
were loadedwith 500 μg of protein and submitted to active rehydration,
in a rehydration buffer containing 0.5% (w/v) ampholytes (Amersham)
and 50 mM DTE (Sigma), for 20 h at low voltage (30 V). Isoelectric fo-
cusing (IEF) was carried out with IPGphor system (GE healthcare)
using the following program: 2 h 100 V, 1 h 300 V, 2 h 500 V, 2 h
1000 V, gradient from 1000 V to 3000 V, 3 h 3000 V, 3.5 h gradient
from 3000 V to 8000 V and 8 h 8000 V, completing the run to a total
voltage of 98.4 kVh, 101.1 kVh and 98.5 kVh for fractions I, IIa and IIIa,
respectively. The first dimensional run was performed at 20 °C with
a maximum current of 50 μA/strip. Immediately after the first-
dimension run, the sampleswere reduced at room temperature by gen-
tle agitation for 9 min in equilibration buffer (6 M Urea, 2% (w/v) SDS,
50 mM Tris pH 8.8, 0.02% (w/v) bromophenol blue, 30% (v/v) glycerol;
Sigma) supplemented with 2% (w/v) DTE (Sigma), followed by
alkylation for 9 min in equilibration buffer supplemented with 3% (w/v)
iodoacetamide. SDS-PAGE was done using 12.5% polyacrylamide gels
and the separation was run following program: 1 h at 100 V, 10 mA/gel
and 1W/gel, and 4 h at 600 V, 38 mA/gel and 17W/gel. For less complex
protein samples, namely the water-soluble proteins' fractions (IIb and
IIIb), the isoelectric focusing was performed using 7 cm immobilized 3–
10 NL pH gradient (GE healthcare). The IPG strips were submitted to ac-
tive rehydration for 12 h at low voltage (30 V) and then loaded with
50 μg of protein. The first dimensional running followed program: 2 h
100 V, 1 h 300 V, 2 h 500 V, 2 h 1000 V, gradient from 1000 V to
3000 V, 3 h 3000 V, 3.5 h gradient from 3000 V to 8000 V and 8 h
8000 V, completing the run at a total voltage of 22.0 kVh.
The gels were stainedwith Coomassie-colloidal (Sigma). The images
were acquired in the Laser-based scanner FLA-5100 (FujiFilm, Valhalla,
United States of America) using 532 nm-excitation laser, and were
analyzed using Progenesis SameSpots v4.5 (NonLinear Dynamics,
Newcastle, United Kingdom). The three images, each for one biological
triplicate, were aligned automatically and a spot list was generated.
The operator made the spot detection and filtering, and only spots
found at least in two out of the three gelswere considered. No statistical
restriction analysis was done. Selected spots were excised from these
gels, washed with water and 50% acetonitrile, dehydrated with 100%
acetonitrile and vacuum-dried. Proteins were in-gel digested with
6.7 ng/μL of trypsin (Promega, Madison, United States of America).
The tryptic peptides were acidified with 5% (v/v) formic acid, concen-
trated with POROS R2 microcolumns (GELoader tip, Eppendorf,
Hamburg, Germany) and co-crystallized onto MALDI-TOF/TOF sample
plates using the α-cyano-4-hydroxycinnamic acid (Sigma) matrix.
2.4. Protein identification by MALDI-TOF/TOF MS
Peptide mass spectra were acquired using a MALDI-TOF/TOF 4800
plus MS/MS (Applied Biosystems® Life Technologies, Carlsbad, United
States of America). Data were acquired in positive MS reflector using a
PepMix1 (LaserBio Labs, Sophia-Antipolis, France) to calibrate the instru-
ment. Each reflector MS spectrumwas collected in a result-independent
acquisition mode; using 750 shots per spectra in 800–4000 m/z range
and fixed laser intensity to 3100 V. Fifteen of the strongest precursors
were selected for MS/MS. MS/MS analyses were performed using CID
(Collision Induced Dissociation) assisted with a collision energy of 1 kV
and a gas pressure of 1 × 10−6 Torr. For each MS/MS spectrum, 1400
laser shots were collected, using fixed laser intensity of 4400 V. Process-
ing and interpretation of MS and MS/MS spectra were performed with
the 4000 Series Explored™ Software (Applied Biosystems® Life Technol-
ogies, Carlsbad, United States of America).
Protein identificationwas performedusing tandemmass spectral data
andMASCOT search engine using theMOWSE algorithm (Matrix Science,
version 2.2.07, Boston, United States of America) on S. pseudintermedius
database (5029 sequences; 1,481,467 residues) retrieved from NCBI
(downloaded in August 2013). Searches included trypsin as digesting
enzyme; peptide mass tolerance of 50 ppm; fragment mass tolerance of
0.5 Da and possible oxidation, carbomidomethylation or deaminidation
as variable amino acid modifications with one missed cleavage. Peptides
were only considered if the ion score indicated extensive homology
(p b 0.05). Proteins were considered if the protein score indicated signif-
icant statistical confidence (p b 0.05). Protein identifications with only
one matched peptide were considered if they were identified with
N95% confidence.
2.5. Immunoblotting
The surface cellular proteins (cell wall and membrane protein frac-
tions) were separated by 2-DE. The first dimension was performed in
7 cm immobilized 4–7 pH gradient loaded with 20 μg of protein, until a
total voltage between 18 and 22 kVh was reached. All samples were
then reduced in 2% (w/v) DTE, followed by alkylation with 3% (w/v)
iodoacetamide. SDS-PAGE was done using 12% polyacrylamide gels
(NuPAGE Bis–Tris Precast gels, Life Technologies® Thermo Fisher
Scientific,Waltham, United States of America). Proteins were transferred
onto PVDFmembranes in a Xcell II TMBlotModule (Invitrogen® Thermo
Fisher Scientific) at 30 V for 65 min. Membranes were washed and
blocked for 1 h, with 10% for IgG and for IgE (w/v) Dry Non-Fat Milk
(BioRad)/0.5% (v/v) Tween 20, and incubated with dogs' sera (1:10
000) overnight at 4 °C. Dog's serum fromwhich S. pseudintermedius strain
FMV5819/10 was isolated was used as a reference. Other sera were
collected from healthy donors — H (n = 13) and atopic donors both
with S. pseudintermedius recurrent pyoderma — ADI (n = 16) and
without — ADH (n = 8). Each serum was incubated individually. The
attending veterinarian diagnosed dogs with atopic dermatitis according
to accepted criteria and after ruling out other causes of pruritus: a
compatible history; clinical criteria strongly associated with the disease;
exclusion of other pruritic skin diseases, with no response to an 8 week
minimum trial consisting of either home-cooked single protein or
commercial hydrolyzed protein diets and water, an 8 week veterinary-
approved flea control regimen, and exclusion of sarcoptic mange by trial
therapy and/or negative serology; and at least one positive reaction to a
perennial allergen on intradermal or serological testing. Pyoderma was
diagnosed by compatible cytology (neutrophils, cocci and neutrophils
with phagocyte cocci) and isolation of S. pseudintermedius. Pyoderma
was considered recurrent if the animal presented at least with two
episodes.
After washing, specific binding of sera IgG and IgE was visualized by
incubation with an anti-dog-IgG peroxidase conjugate (1:20 000)
(Santa Cruz Biotechnology, Texas, United States of America) and anti-
dog-IgE peroxidase conjugate (1:1000) (AbD Serotec® BioRad, Oxford,
United Kingdom), respectively, and revealed in a ChemiDoc XRS+
system (BioRad). Membranes were also stained with 0.1% (v/v) Ponceau
S (Sigma). Highly immunogenic areas were compared between groups.
Only immunogenic areas identified by ≥50% of the ADI sera and identified
by b50% of the H sera were excised and identified from Coomassie-
colloidal stained gels. The ADH sera were used in an attempt to identify
antigenic proteins for which specific antibodies were missing or under-
represented in infected patients that could contribute to prevention of
infection. Matching signals from immunoblots and protein spots were
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done by comparing films with the image of the Ponceau S stained
membrane and the Coomassie-colloidal stained preparative gel. Proteins
were digested and identified as stated above.
2.6. Bioinformatic analysis
Bioinformatic analyses were performed using web-based servers.
The functional role categories assigned were the ones used in the
S. aureus NCTC 8325 annotation proposed by The Institute for Genomic
Research [18]. Blast2go was used to find homologous sequences, when
proteins were characterized as unknown. PSORTb v3.0 [19] was used to
predict cellular localization of a protein. The programTMPred in ExPASy
[20] identified the predicted transmembrane regions for proteins.
Cleavable signal peptide predictions were performed from SignalP
v4.1 trained on Gram-positive bacteria [21], PrediSi trained on Gram-
positive [22] andTargetP v1.1 [23,24]. Prediction of non-classical secreted
proteins, lacking a signal peptide, was performed using SecretomeP v2.0
[25].
3. Results and discussion
3.1. Fractionation of S. pseudintermedius FMV5819/10 proteins
To better characterize the proteins from S. pseudintermedius
strain FMV5819/10, we performed a fractionation procedure based on
previous protocols used in other Staphylococcus species. Fig. 2 and
Supplementary Fig. 1 (with the Spots ID) show the 2-DE patterns of
S. pseudintermedius FMV5819/10 protein fractions: cell wall associated,
membrane and cytoplasmatic. The first fraction was obtained after
lysostaphin treatment. This enzyme cleaves specifically the cross
bridges of the staphylococcal peptidoglycan, maintaining the cellular
membrane intact [26]. In this way, conceptually, only cell wall compo-
nents are extracted, turning fraction I enriched in these proteins.
However, it is unavoidable to have some degree of contamination
with proteins from other cell compartments. In our study, most of the
proteins, determined as cell wall associated or secreted, were found in
Fraction I (Table 1), but several membrane and cytoplasmatic proteins
were also detected. This could be due to lysostaphin concentration or
incubation timeused.We selected a concentration of 5 U and an incuba-
tion time of 30minbased on thefindings of Nandakumar and colleagues
for S. aureus [26]. However, different Staphylococcus species have
different susceptibilities to lysostaphin, and so, lysostaphin may need
less concentration and/or incubation time to lyse the peptidoglycan
of S. pseudintermedius. Furthermore, the identification of intracellular
proteins on the cell surface has been reported in S. aureus,
S. pseudintermedius and other coagulase-negative staphylococci, and is
due to alternative functions associated with the cell surface described
for some cytoplasmatic proteins [27].
Fractions II and III were separately enriched in membrane and
cytoplasmatic proteins, respectively, after separation of the two frac-
tions by ultracentrifugation. From fraction II we recovered membrane
proteins, lipoproteins, proteins interactingwithmembrane components
and subunits of membrane-associated complexes (Table 1). Most
proteins identified in fraction III were cytoplasmatic, however we
found at least 5 proteins thatwere associatedwith the surface proteome
(2 cell wall associated, 2 extracellular and 1 membrane protein), which
could indicate that they have multiple subcellular locations or that they
can transit between the cytosol and the surface compartments, depend-
ing on the physiological and/or environmental conditions.
Although a complete fractionation of the proteins could not be
achieved, their identifications revealed that enrichment on the proteins
of each cellular fraction was succeeded, which indicates that the
established fractionation protocol was efficient and adequate for the
characterization of S. pseudintermedius proteome.
3.2. Protein identification and in silico analysis of the cell wall associated,
extracellular and membrane proteins encoded by S. pseudintermedius
FMV5819/10
From a total 1317 gel spots excised we identified 361 unique
proteins. The parameter values for the identification and subcellular
localization predicted by PSORTb, TMPred, PrediSi, SignalP, SecretomeP
and/or TargetP of all proteins are present in Supplementary Tables 1 and
2. As expected, most proteins were cytoplasmatic (72.2%), followed by
proteins with unknown location (9.5%), ribosomal proteins (7.6%),
membrane proteins (6.5%), extracellular proteins (2.5%) and finally
proteins from the cell wall (1.6%). Yet 6 of these last proteins (17.1%)
had detectable peptide signal cleavage sites identified by SignalP and
SecretomeP and/or TargetP (Table 1). Ten proteins with unknown
location were identified as secreted via unknown secretion system by
SecretomeP, while one protein was also detected as secreted by
SecretomeP and TargetP and had a predicted cleavage site at position
25 identified by PrediSi, but not by SignalP. All proteins identified as
extracellular by PSORTb had predicted cleavage sites identified by all
algorithms, except for one protein, whichwas only identified as secreted
via unknown secretion system by SecretomeP.
Three proteins had sequenced motifs relevant for vaccine develop-
ment. Three cell wall associated proteins (Fibronectin binding protein
FnbB [SpsD], Uncharacterized protein (LPXTG-motif cell wall anchor
domain protein) [SpsN], Immunoglobulin G binding protein A spa1
[SpsQ]) had a C-terminal LPXTG motif (Pfam: PF00746) and a concur-
rent YSIRK motif (Pfam: PF04650). The LPXTG motif is a hydrophobic
domain, which is recognized and cleaved by an enzyme present in the
staphylococcal membrane, sortase A (SrtA), and then attached to the
peptidoglycan [28]. Since numerous microbial surface components
recognizing adhesivematrixmolecules (MSCRAMMS),which are usually
proteins involved in tissue adhesion and immune evasion, have the
LPXTG motif, SrtA has a fundamental role in the staphylococcal patho-
genesis. The LPXTG motif or the SrtA could be potential targets to mini-
mize strain's expression of adhesins and so inhibit the establishment of
infection. The YSIRK motif is usually positioned within signal peptides
and is required for the secretion of cell wall anchored surface proteins
[29]. Although also regarded as a motif required for cell wall anchoring
of surface proteins, it has been shown that this motif plays a much
more efficient role in the secretion of these proteins, like protein A,
then for the anchoring itself [29]. However, blocking this motif could
inhibit the secretion of important immune evasion proteins, like the
already mentioned protein A, which could in turn lead to an enhanced
response by the cells of the immune system. As one would expect,
the proteins with the LPXTG and YSIRK motifs also exhibited a Sec-
dependent signal peptide. One protein classified as “with unknown
subcellular location”, SpsK (predicted IgG-binding protein Sbi), has
been previously described as cell wall associated in S. pseudintermedius
[27], however PSORTb and InterProScan failed to identify any cell wall
associated domains or motifs. Sbi in S. aureus also lacks the typical
Gram-positive cell wall anchoring sequence LPXTG [30]. In fact this pro-
tein ismainly described as secreted in S. aureus [31], although it has been
suggested that Sbi is associated with the bacterial surface through elec-
trostatic interactions, or because it does have a predicted proline-rich
cell wall-spanning segment normally found within cell-wall-spanning
domains [30]. The Immunoglobulin G binding protein A spa1 (SpsQ)
also had a Lysin motif (LysM) (Pfam: PF01476), a binding domain that
allows non-covalent binding to the cell wall [17]. The LysM sequence is
present singly or repeatedly in a large number of proteins of prokaryotes
and eukaryotes [32]. This motif has been extensively studied due to the
possibilities of employing the LysM domains for cell immobilization, for
the display of peptides, proteins, or enzymes on (bacterial) surfaces as
well as their utility in the development of novel vaccines [32]. The
LysMmotif has been used to produce antigen-to-LysM fusions, including
bacterial, viral and parasitic antigens, which have been successfully
attached to Gram-positive bacteria Lactococcus lactis [32]. This is how
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the novel adjuvant Gram-positive enhancer matrix (GEM) particles are
produced [32]. The GEM particles produced by heating the L. lactis in
acid are non-living, deprived of intact surface proteins and intracellular
content, however the thick peptidoglycan cell wall remains intact
and provides the structural rigidity to constitute the bacterial-shaped
peptidoglycan spheres, referred to as GEM particles. Studies have
demonstrated that antigens displayed on GEM particles induce higher
immune response than antigen alone [32]. This is important when
considering the development of a S. pseudintermedius vaccine.
The biological functions of unique identified proteins are described
in Fig. 3. Proteins were mostly related with the energy metabolism
(19.0%), with purines, pyrimidines, nucleosides and nucleotides
(10.0%) and protein synthesis (10.0%). These biological functions are
all related to the cell's basic metabolism. However, we also identified
2.0% of proteins associated with pathogenesis. Three main areas of
S. aureus pathogenesis – iron scavenging, coagulation and immune
evasion – have been extensively studied for vaccine development [33,
34]. In our study we found proteins associated with at least two of
Fig. 2. 2-DE patterns of S. pseudintermedius FMV5819/10 protein fractions: a) cell wall associated; b) membrane (insoluble subfraction); c) cytoplasmatic (insoluble subfraction);
d) membrane (soluble subfraction) and e) cytoplasmatic (soluble subfraction).
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these areas: iron scavenging — Iron compound ABC transporter (IsdE)
and Siderophore staphylobactin ABC transporter (SirA) and immune
evasion— IgG-binding protein SBI (SpsK) and Immunoglobulin G bind-
ing protein A spa1 (SpsQ). IsdE is a protein of the iron-regulated surface
determinant (Isd) pathway, which represents the main heme trans-
porter of S. aureus [33]. Interestingly IsdE and SirA of S. aureus are
lipoproteins strongly immunogenic, which induce an inflammatory
response through recognition by Toll-like receptor (TLR) 2-MyD88
[35]. Since iron-acquisition is essential for staphylococcal survival and
these lipoproteins are highly immunogenic, it seems like they are a
good choice of targets for vaccine development. Moreover targeting
multiple iron uptake systems seems to be a good formulation to maxi-
mize efficacy. This is due to the plasticity of staphylococci, meaning
they have the ability to remain pathogenic when only limited antigens
are neutralized because they have so many virulence factors, including
iron uptake systems [36].
SpsK and SpsQ are two immunoglobulin-binding molecules, which
prevent opsonization [33]. In S. aureus these proteins' homologues, Sbi
and Spa respectively, severely limit host immunoglobulin mediated im-
mune clearance of the pathogen [33]. Despite being very abundant
staphylococcal surface proteins for potential interaction with the host
immune surveillance system, these proteins are not good candidates
for a vaccine due to its toxicity and B cell super-antigen activity [33].
However, slightly modified proteins could be of potential use without
its deleterious effects.
Vaccines composed of single or multiple antigens are more favorable
compared to attenuated or killed whole bacteria vaccines, since many
components of staphylococcimay cause adverse effects [12]. Usually sur-
face proteins have higher probability of interaction with host's immune
system and therefore are usually chosen for the purpose of vaccine de-
velopment. Using the proteome characterization approach we identified
several proteins (Table 1), which could be potentially included in
a multivalent vaccine against S. pseudintermedius. We then used the
SERPA approach to further select potential vaccine candidate antigens.
3.3. Characterization of highly immunogenic proteins identified by SERPA
In order to assess the immunogenic potential of the previously iden-
tified proteins, a Western blot analysis of the two-dimensional gels was
carried out with serum from healthy dogs, dogs with atopic dermatitis
infected and not infected with S. pseudintermedius. As expected, the
dog's serum from which S. pseudintermedius strain FMV5819/10 was
isolated was the one that recognized more proteins. Several highly
immunogenic areas (containing more than one spot) were detected in
the cell wall fraction (Fig. 4a), and in the membrane associated fraction
(Fig. 4b). Table 2 shows which immunogenic areas each type of serum
identified. For the cell wall fraction areas A, C, D and E were identified
by more than 50% of the ADI sera and less than 50% of the H sera. In
themembrane fraction only areas C, E and Fmet the established criteria.
S. pseudintermedius is an opportunistic pathogen and it resides as part of
the normal flora of most dogs and does not cause any disease unless the
resistance of the host is lowered and the skin barrier altered by predis-
posing factors, such as atopic dermatitis [37]. However, not all dogswith
atopic dermatitis develop infection by S. pseudintermedius and remain
solely colonized by this bacterium. We used the sera from the ADH
group, in an attempt to identify antigenic proteins for which specific
antibodies were missing or underrepresented in infected patients
that could contribute to prevention of infection, however we could
not detect spots more associated with these non-infected dogs than
with infected dogs. This suggests the anti-staphylococcal antibody
repertoires from patients with atopic dermatitis with or without
S. pseudintermedius pyoderma overlap, meaning that in dogs with
atopic dermatitis, S. pseudintermedius expresses similar proteins
during invasive disease and during colonization.
For the purpose of knowing if the proteins identified could potentially
induce an undesirable IgE response, we also identified highly immuno-
genic areas after incubation with anti-dog-IgE peroxidase conjugate. The
IgE immunogenic areas are shown in Fig. 5. These areas corresponded
to area B in the cell wall associated fraction and areas C, D and E in the
Fig. 3. Functional role category assignments for each of the 361 unique proteins based on Gillaspy et al. [18] and Blast2go.
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Fig. 4. Representative SERPA of cell wall associated fraction (a) and membrane fraction (b) from S. pseudintermedius FMV5819/10 using the dog's serum from which the strain was
collected (dog with atopic dermatitis and pyoderma by S. pseudintermedius) and the anti-dog-IgG peroxidase conjugate. The highly immunogenic areas are represented inside the
circles. Dotted circles were further studied since they met the criteria of areas identified by ≥50% of the ADI sera and identified by b50% of the H sera.
Table 2
Number of sera in each group that detected the different highly immunogenic areas of S. pseudintermedius FMV5819/10.
Immunogenic area Number of sera (%)
Healthy dogs (n = 13) Dogs with atopic dermatitis with recurrent
S. pseudintermedius infections (n = 17)
Dogs with atopic dermatitis
without infections (n = 8)
Cell wall fraction
A 6 (46%) 17 (100%) 6 (75%)
B 10 (77%) 16 (94%) 8 (100%)
C 6 (46%) 16 (94%) 6 (75%)
D 2 (9%) 13 (76%) 5 (63%)
E 3 (23%) 9 (53%) 2 (25%)
F 0 (0%) 4 (24%) 0 (0%)
G 0 (0%) 5 (29%) 2 (25%)
Membrane fraction
A 6 (50%) 12 (71%) 5 (63%)
B 6 (50%) 13 (76%) 5 (63%)
C 3 (23%) 9 (88%) 6 (75%)
D 3 (23%) 6 (35%) 1 (13%)
E 2 (9%) 13 (76%) 3 (38%)
F 1 (8%) 8 (50%) 3 (38%)
G 4 (31%) 6 (35%) 1 (13%)
Areas in bold were further studied since they met the criteria of areas identified by ≥50% of the ADI sera and identified by b50% of the H sera.
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lipoproteins are a major class of cell surface-exposed proteins in many
bacterial pathogens and play critical roles in nutrient uptake, antibiotic
resistance, adhesion, protein secretion, and other functions [40]. These
molecules have been the targets of vaccine research formanypathogen-
ic bacteria. A putative lipoprotein of S. aureus was identified as highly
immunogenic [12]. However, much of these lipoproteins, as in the
case of our lipoprotein, do not have an annotated function and we
cannot anticipate the result of blocking this protein in vivo.
AtpA participates in the synthesis of ATP by driving the flow of pro-
tons into the cell, generating a proton motive force, which energizes
processes such as motility and active transport [41]. In Salmonella
Typhimurium, an atpA deletion was responsible for the attenuation
of the bacterial in vivo growth and furthermore was found to offer sig-
nificant protection against subsequent challenge [41]. These mutants
were attenuated for virulence and effectively protected mice against
Salmonella infection [41]. In staphylococcal species, one study showed
that knocking down the ATP synthase expression strongly suppressed
the growth of S. aureus, revealing a crucial role of this target in bacterial
growth and metabolism [42]. These studies together really suggest
that ATP synthase proteins may be good targets of vaccines against
staphylococci.
The Enoyl-[acyl-carrier-protein] reductase [NADPH] FabI protein has
been described as essential for the S. aureus fatty acid biosynthesis and,
hence, serves as an attractive drug target [43]. In fact there are several
compounds that successfully inhibit FabI, such as the first-line tubercu-
losis pro-drug isoniazid and the FabI diphenyl ether inhibitor triclosan,
which is recommended as topical antiseptic to reduce methicillin-
resistant S. aureus skin colonization [43]. Combined with the fact
that this protein is located in the cellular membrane makes FabI an
approachable target candidate.
By using whole proteome characterization or serological proteomic
analyses we were able to identify 39 and 13 proteins with potential to
be used as vaccine candidates, respectively. Interestingly the 4 proteins
considered as highly promising candidate therapeutic targets were
identified by both strategies.
In this approach we were able to identify several new antigens with
potential for vaccine development. Further studies are now needed to
evaluate the presence of these proteins in other S. pseudintermedius
strains and so determine their frequency in clinical isolates. This will
allow determining a combination of the appropriate antigens as a
potential vaccine against S. pseudintermedius.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jprot.2015.12.017.
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Staphylococci are a group of bacteria with clinical, agricultural, and economic importance be-
cause of their wide range of virulence factors and ability to become resistant to antimicrobi-
als. Monitoring programs may help uncover new resistance trends and evaluate the useful-
ness of the available antimicrobials, in veterinary medicine, against staphylococci. 
In particular, the recent emergence of MRSP has complicated considerably the treatment of 
infections caused by these bacteria (Frank & Loeffler, 2012). MRSP have become virtually 
resistant to all the antimicrobials approved for administration in companion animals, which 
has led to ethical concerns about the use of antimicrobials classified by the World Health Or-
ganization as “critically important” for human medicine (Frank & Loeffler, 2012). 
 
4.1 MRSA in animals, environment and humans in close contact with animals 
MRSA is of significant concern in human and veterinary medicine (Weese and van Duijkeren, 
2010). The aim of this part of the study was to get information on the frequency and charac-
teristics of MRSA from colonization and infection samples. Previous studies had been con-
ducted in pigs and companion animals in Portugal (Pomba et al., 2009; Pomba et al., 2010a; 
Couto et al., 2011) and so a primary focus on studies in calves and horses was performed. 
The frequency of MRSA nasal colonization was 2% in calves and 3% in horses. The fre-
quency found in horses was within the prevalence rate found in other studies, which range 
between 0% and 12% depending on the country of isolation (Weese and van Duijkeren, 
2010). Interestingly the two MRSA strains from horses were from two different lineages: one 
belonged to ST398, which is the predominant clone among horses in Europe (Weese and 
van Duijkeren, 2010) and the other was ST5, a clone that has only been identified in horses 
sporadically (Vincze, Stamm, Kopp, Hermes, Adlhoch, Semmler, Wieler, Lubke-Becker & 
Walther, 2014). Both strains were multidrug-resistant and carried several antimicrobial re-
sistance genes.  
On the other hand, the six MRSA isolates obtained from calves were all ST398 and were iso-
lated from only one of the two farms studied (Farm A). The six strains were also resistant to 
fluoroquinolones, tetracyclines and phenicols. This farm was using enrofloxacin routinely to 
avoid respiratory and/or gastrointestinal infections. Previous administration of fluoroquin-
olones is an identified risk factor for MRSA infection in companion animals (Weese and van 
Duijkeren, 2010). So, the use of enrofloxacin in Farm A could have imposed a selective 
pressure that led to the spread of the MRSA strains found. Farm B, on the other hand, was 
using gamithromycin for the same purpose and it seems this antimicrobial did not select for 
MRSA. The mecC gene was not detected in any S. aureus strains, which was unexpected 
since mecC-carrying MRSA have been detected in several cows throughout Europe (Garcia-
Alvarez et al., 2011; Becker et al., 2013; Loncaric et al., 2013).  
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Although the frequency of MRSA colonization was low in both species, horses and calves 
can still be considered important reservoirs of MRSA strains, which can be disseminated 
from these animals to the environment, to other animals and eventually to humans. 
After the first two studies on colonization in horses and calves, the next step was to charac-
terize all the MRSA isolated at the Antibiotic Resistance Laboratory from 2001 to 2014. The-
se included strains from animals, humans in close contact with animals and environmental. 
Overall, fourteen spa types were identified and according to the spa server, five of these 
were associated with CC398 (n=47); six were hinted to CC22 (n=21) and three were associ-
ated with CC5 (n=6). All MRSA from livestock-animals (pigs and calves) were CC398 and 
most strains from companion animals (dogs, cats and horses) were CC5 and CC22. The ma-
jority of the isolates (74%) were multidrug-resistant. One MRSA ST398 strain was also iso-
lated from a clinical sample from one dog. This MRSA ST398 strain had 93% ApaI-PFGE 
similarity to the MRSA CC398 strains from calves (Figure 13). 
 
Figure 13. Dendogram of chromosomal DNA digested with ApaI of MRSA ST398 strains from six calves and one 
dog. 
Species spa type MLST Source 
 
Surprisingly all these strains (from the dog and calves) carried the fexA gene and were re-
sistant to fluoroquinolones, which suggests they had a similar source of infec-
tion/colonization. However, the dog had no history of contact with farms or farm animals and 
so the route of transmission remains to be elucidated.  
As expected, all CC22 strains were SCCmec IV. The ST22-IV was the most common MRSA 
lineage found in companion animals. This is in agreement with previous reports, which show 
that there is a shared population of this lineage infecting/colonizing humans and companion 
animals (Harrison et al., 2014). The ST22-t032-SCCmec IV strains were negative for the 
erm(C) gene, while the other ST22-IV non-t032 (t2357 and t025) strains carried this gene. It 
is assumed that the loss of this gene occurs in companion animals (Harrison et al., 2014), 
and this suggests that the MRSA ST22 non-t032 strains found in our study were acquired 
from humans very recently, and they have thus maintained the erm(C) gene. 
The other MRSA strains isolated from companion animals belonged to CC5 (ST5 and 
ST105), the second human epidemic MRSA clone most commonly isolated in Portugal (Es-
padinha et al., 2013). This suggests that CC5 is spread in the animal population, and in hu-











































first Portuguese, and also European, VRSA human strain isolated in 2013 was ST105-II (Me-
lo-Cristino et al., 2013; Friães, Resina, Manuel, Lito, Ramirez & Melo-Cristino, 2014). VRSA 
isolates from other countries also belonged to CC5 (Friães et al., 2014). In addition to the 
possibility of companion animals being a reservoir and distributer of VRSA, companion ani-
mals can also carry vanA-carrying vancomycin-resistant enterococci (Poeta et al., 2005) and 
thereby raise the chance for the acquisition of the vanA gene by staphylococci.  
Pets-associated (PA)-MRSA (CC5 and CC22) were significantly more likely to carry entero-
toxin genes (seg [p=0.002], sei [p=0.002], sem [p=0.002], sen [p=0.002], seo [p=0.002], seu 
[p=0.002], egc [p=0.002]) and staphylokinase gene (sak [p=0.015]) than MRSA CC398. This 
supports the previous observation that companion animals, share a population of an im-
portant and globally disseminated lineages of MRSA, namely ST22-IV that can infect both 
humans and other companion animals without undergoing host adaptation (Harrison et al., 
2014). Companion animals seem to carry S. aureus clonal linages more virulent to humans 
then livestock-animals and so active surveillance including companion animals seems ur-
gently needed.  
 
4.2 Epidemiology, antimicrobial and biocide susceptibility of staphylococci isolated 
from animals in Portugal 
Knowledge on the antimicrobial and biocide susceptibility and molecular epidemiology of 
MRS strains, other than MRSA, is important to monitor the spread of antimicrobial/biocide 
resistance genes/strains and consequentely control its dissemination. 
 
4.2.1 Antimicrobial susceptibility 
The staphylococci isolated from livestock-animals in this study were almost all multidrug-
resistant. In fact, MRSA CC398 were significantly more likely to carry particular antimicrobial 
resistance genes (dfrK [p=0.0001], tet(K) [p=0.0001], tet(M), [p=0.0001], vga(A) [p=0.0001]), 
when compared to the other MRSA clonal complexes (CC5 and CC22). The high selective 
pressure imposed by the consumption of antimicrobials in food-producing animals may lead 
to the acquisition of these genes by MRSA CC398. Furthermore these antimicrobial re-
sistance genes are usually carried in the same mobile genetic elements (Wendlandt, Shen, 
Kadlec, Wang, Li, Zhang, Feßler, Wu & Schwarz, 2015) and so are co-selected by the use of 
differente antimicrobials, aiding to the persistence of MRSA in the environment. 
The MRS isolates from horses were resistant to one other antimicrobial (mainly tiamulin and 
tetracycline) besides ß-lactams, although the corresponding mechanisms of resistance were 
not always identified. In staphylococci isolated from companion animals, there were increas-
ing resistance trends for ampicillin, penicillin, amoxicillin/clavulanic acid, cefoxitin in S. aure-
us and CoNS, oxacillin in S. pseudintermedius, cefovecin, cephalexin, cefotaxime, ceftriax-
one, ciprofloxacin, enrofloxacin, norfloxacin, ofloxacin, moxifloxacin, tetracycline, chloram-
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phenicol, gentamicin, neomycin, tobramycin, kanamycin, streptomycin, erythromycin, 
clindamycin, sulfamethoxazole/trimethoprim sulphonamides and trimethoprim. Moreover, in-
creasing trends of resistance to at least one antimicrobial and multidrug-resistance were also 
identified, such that almost 35% of the staphylococci strains were multidrug-resistant. All 
MRSP and several MRCoNS strains were multidrug-resistant. The finding of multidrug-
resistant MRSP and MRCoNS strains in Portugal is not surprising since there have been 
several reports describing this observation (Schnellmann et al., 2006; Fitzgerald, 2009; 
Weese and van Duijekeren, 2010; Frank & Loeffler, 2012). However, some methicillin-
susceptible strains also exhibited a multidrug-resistant profile, suggesting a spread of antimi-
crobial resistance genes in the animal staphylococcal population.  
An important finding was the detection of the fexA gene, conferring resistance to florfenicol 
and chloramphenicol, in 2 S. pseudintermedius strains. In S. pseudintermedius, only a fexA 
variant named fexAv, had been previously reported and conferred resistance only to chlo-
ramphenicol (Gómez-Sanz et al., 2013). The animals infected with these strains were being 
treated with florfenicol (25-50mg/kg q12h SC, Nuflor®, Merck Animal Health, USA) because 
they had been previously diagnosed with an infection caused by a multidrug-resistant MRSP 
strain and so florfenicol was being used as a last-resort antimicrobial. The use of florfenicol 
was very recently suggested, as a second-line antimicrobial agent in dogs (Maaland et al., 
2015). However, it seems that the use of this antimicrobial can lead to the acquisition of an-
timicrobial resistance genes or strains. Furthermore, one of these strains also carried the cfr 
gene. This is the first description the cfr gene in a S. pseudintermedius strain. Although the 
strain did not exhibit resistance to linezolid, this is a worrisome finding since it shows S. 
pseudintermedius could be carriers of important resistant genes. Although direct selective 
pressure by the use of the linezolid was not applied, it seems florfenicol may co-select for 
linezolid-resistance genes due to co-location in the same mobile genetic elements. So the 
use of florfenicol as a second-line antimicrobial agent in dogs should be reconsidered. 
 
4.2.2 Biocide susceptibility 
Considering biocides, several susceptibility patterns and mechanisms of biocide tolerance 
were found in different staphylococcal species. In fact, numerous efflux pumps have been 
recognized in staphylococci, but QAC efflux proteins seem to be the most widespread (Bjor-
land et al., 2003; Costa et al., 2013). In this study, the qacG and qacJ genes were described 
for the first time in MRSA CC398 strains. The qacG gene had been described in porcine 
MRSA isolates from clonal lineage ST9 in Hong Kong (Wong, Zhang, O'Donoghue & Boost, 
2013) and both genes have also been detected among staphylococci of bovine and caprine 
origin in Norway (Bjorland et al., 2005). Biocides are extensively used in animal husbandry, 
including quaternary ammonium compounds (Bjorland et al., 2005). The acquisition of these 
efflux-pump genes by MRSA CC398, mainly carried on plasmids, may aid to the persistence 
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of MRSA in the environment, making the eradication of MRSA CC398 more difficult. Two 
MRS strains from horses, one S. haemolyticus and one S. cohnii subsp. cohnii also carried 
plasmid-borne qac genes: a qacA and sh-fabI in S. haemolyticus and qacB and a qacH-like 
in S. cohnii subsp. cohnii. However, none of the two qac-positive strains had high MBC val-
ues to benzalkonium chloride, chlorhexidine or gluteraldehyde. Indeed, all MBC values were 
lower than the recommended in-use concentrations for veterinary medicine (SCENIHR, 
2009). This means that biocides are still a reliable antiseptic option against MRS in horses. 
Nevertheless, when comparing the MBC values of the isolates of the present study with the 
concentration of BAC in human products (100mg/mL) (Narui et al., 2007), five isolates with 
benzalkonium chloride MBCs of >128mg/mL were detected. This is of notice, since transmis-
sion of MRS strains between horses, humans and their environments may occur (Weese and 
van Duijkeren, 2010). Similarly, one MSSP isolate harboured a qacA gene, while in another a 
qacB gene was detected. Three of the biocide products studied had high bactericidal activity, 
even against the qac-positive strains (Otodine®, Clorexyderm Spot Gel®, Dermocanis Pio-
cure-M®), although Skingel® failed to achieve a five log reduction in the bacterial counting. 
S. pseudintermedius has become a serious therapeutic challenge in particular if methicillin-
resistance and/or multidrug-resistance are involved, yet biocides, like chlorhexidine acetate 
and triclosan, seem to be clinically effective and safe topical therapeutic options against S. 
pseudintermedius, including MRSP. Finally, four MRSA strains (three CC5 and one CC22) 
did not carry qac genes but instead had insertion of sequences CAAT (n=3) or 
GTTGTAATACAAT (n=1) in the -10 motif of the norA promoter. These insertions could in-
duce a higher expression of the NorA efflux pump, which could lead to extrusion of certain 
biocides, namely benzalkonium chloride and also low-levels of fluoroquinolones (Yoshida et 
al., 1990). 
 
4.2.3 Epidemiology of MRSP 
The first MRSP strain appeared in 2007 in Portugal, but only in 2010 we observed an in-
crease in the number of strains. The first MRSP strains in Europe were detected in 2005 
(Perreten et al., 2010), and were ST71-II-III. Interestingly, our first MRSP strain isolated in 
2007 was ST196-V, and only in 2009 the first ST71-II-III appeared. Between 2009 and mid-
2012, MRSP CC71-II-III was the only lineage detected. Yet, in 2013-2014 we observed a 
higher genetic diversity among the MRSP strains isolated, with other MRSP lineages appear-
ing and actually a new ST, ST400, with the mecA gene. The ST45-nt, ST339-III and ST342-
IV lineages were already described in recent studies (Perreten et al., 2013; McCarthy et al., 
2014).  ST45 was the predominant MRSP clonal lineage in Thailand and Israel, and was not 
typeable by SmaI-PFGE and SCCmec typing (Perreten et al., 2013).  This lineage carried a 
novel pseudo-SCCmec element, ΨSCCmec57395 that besides mecA also carried determi-
nants of resistance to heavy metals, such as arsenic, cadmium, and copper (Perreten et al., 
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2013). It seems that this ST has also been introduced in Europe (according to the MLST da-
tabase ST45 has been detected in England, The Netherlands and now Portugal). The new 
ST, ST400 does not belong to any of the previous mecA-positive clonal complexes, and it 
suggests that this ST has acquired SCCmec. Two of the MRSP ST400 strains were isolated 
from two dogs that lived in the same kennel. However, the third dog had no connection to 
these dogs or to the kennel, which could mean this lineage is already spreading through the 
dogs’ population. S. pseudintermedius have become a serious therapeutic challenge and 
new MRSP lineages are emerging in several countries, including Portugal.  
 
4.2.4 Epidemiology of MRCoNS 
All S. sciuri isolates from horses showed indistinguishable SmaI PFGE profiles, although the 
isolates were from individual horses, except for two strains, which were isolated from the 
same horse. These two isolates differed, however, in their tetracycline resistance pheno- and 
genotype. This observation suggests that this clone of S. sciuri is widely disseminated 
among the horse population in Portugal. 
The MRSE STs found in companion animals were identical to the ones previously isolated in 
humans (community- and hospital-acquired isolates) in Portugal (Rolo et al., 2012a). This 
means MRSE strains can also circulate in animals, making them a reservoir of important 
MRSE lineages. Unfortunately there is no MLST database for S. haemolyticus, which makes 
it impossible to compare our strains to other animal or even human strains. Either way, it is 
important to notice that MRCoNS were more frequently isolated then predicted and the pres-
ence of the mecA gene was highly associated with these strains. Furthermore several 
MRCoNS exhibited a multidrug-resistance pattern, suggesting they are reservoirs of antimi-
crobial resistance genes. So, there is a possibility that MRCoNS are being neglected as im-
portant sources of antimicrobial resistant strains/genes. 
 
4.3 Pathogenesis of S. pseudintermedius infections in dogs 
This dissemination was incredibly rapid but the reasons for the fast emergence and success 
of these lineages are not fully understood (Latronico, Moodley, Nielsen & Guardabassi, 
2014). The “omics” era (genomics, transcriptomics and proteomics) has brought new tools 
that provide information about cell’s genetic background, their potential regulatory mecha-
nisms and biological activity of virulence determinants (Adamczyk-Poplawska, Markowicz & 
Jagusztyn-Krynicka, 2011). Genomic and proteomic studies, conducted in the last few years, 
are giving the first clues on the pathways by which MRSP have become successful (McCar-
thy et al., 2015). In this study a transcriptome analysis of the in vitro transcriptional profiles of 
a clinical MRSP isolate (ST71) and a clinical MSSP isolate (ST379) was done using RNA-
seq. Several genes encoding virulence factors were highly expressed in the MRSP strain: 
spsA, spsB, spsD, spsK, spsL, spsN, gamma-hemolysin component B gene (hlgB), both 
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subunits of luk-I gene (lukF-I and lukS-I), the coagulase and thermonuclease genes (coa and 
nucC, respectively). The higher expression of genes encoding proteins able to adhere to the 
extracellular matrix, like for example spsD (encoding a fibronectin-binding protein) and spsL 
(encoding another fibronectin-binding protein) might explain the previous observation that 
MRSP ST71 strains have higher adherence to corneocytes than non-ST71 strains (Latronico 
et al., 2014). The differences observed in the expression of virulence factors could be ex-
plained by the different expression of virulence regulatory genes between the 2 strains, with 
agr highly expressed in MSSP and saeRS in MRSP. Differences in the expression of regula-
tory genes have been detected in two MRSA clonal lineages, USA300 (ST8) and USA400 
(ST1), which have different virulence characteristics (Jones, Montgomery, Boyle-Vavra, 
Shatzkes, Maybank, Frank, Peterson & Daum, 2014). In fact, USA300 has been considered 
hypervirulent, compared with lineage USA400, however, USA300 does not contain much 
more virulence genes than USA400, but it does have an alteration in the expression of regu-
latory genes and an increased expression of toxins (Jones et al., 2014). Furthermore, the 
lower expression of the subunit R in the MRSP strain could also suggest that MRSP are 
more efficient in acquiring mobile genetic elements than MSSP. Indeed it has been shown 
that MRSP genomes carry more prophages than MSSP strains (McCarthy et al., 2015). Be-
sides carrying more prophages, the results found in this study suggest the MRSP strain also 
upregulates several phage-associated genes, which could be linked to the upregulation of 
the integrase and other genes with unknown function (might encode not yet known virulence 
factors) located in the superantigen-encoding pathogenicity islands (SaPIs). The upregula-
tion of prophage particles is also concordant with the suggestion that transfer in MRSP is 
predominantly made by bacteriophage transduction (McCarthy et al., 2015). Overall, MRSP 
isolates seem to highly express a number of virulence genes that could explain its high and 
fast adaptation. 
Since the emergence of MRSP strains, virtually resistant to all the antimicrobials approved 
for administration in companion animals (Frank & Loeffler, 2012), researchers have focused 
on the development of new treatment strategies, namely vaccines (Fitzgerald, 2009). One 
way of identifying potential vaccine candidates is through proteomics (Adamczyk-Poplawska 
et al., 2011). Proteomics has the advantage of dealing directly with proteins, which are the 
main players of life processes (Hecker, Becher, Fuchs & Engelmann, 2010). Proteome char-
acterization of bacterial species, especially of their surface-exposed protein fractions, can 
lead to the identification of vaccine candidates, which can then be tested for their ability to 
induce protective immunity or as passive immunization targets (Adamczyk-Poplawska et al., 
2011). This can be accomplished in silico, using bioinformatics tools, and/or by combining 
proteomics with serological analysis (SERPA – SERological Proteome Analysis) (Movahedi 
& Hampson, 2008). This approach has enabled the identification of vaccine candidates 
against S. aureus (Vytvytska et al., 2002). Usually surface exposed proteins are preferred for 
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vaccine development since these proteins are more likely to interact with the host immune 
system (Fitzgerald, 2009). Moreover, to design potent and generally applicable subunit vac-
cines, it is necessary to identify those antigens that are recognizable on a wide patient popu-
lation during infection (Etz et al., 2002). For this reason, serum from dogs with atopic derma-
titis and recurrently infected with S. pseudintermedius (ADI) was used to detect proteins only 
expressed during infection and the proteins identified by healthy dogs (H) were discarded. A 
third group was used, dogs with atopic dermatitis and not recurrently infected with S. 
pseudintermedius (ADH), in an attempt to identify antigenic proteins for which specific anti-
bodies were missing or underrepresented in infected patients that could contribute to infec-
tion prevention. There was a clear difference in the immune response of healthy dogs and 
dogs with atopic dermatitis with or without S. pseudintermedius recurrent infections. Howev-
er, the immune reponse of dogs with atopic dermatitis either with S. pseudintermedius recur-
rent infections or without was the same and was independent from the colonization/infection 
status (ADI versus ADH). No protective proteins were identified in dogs with atopic dermatitis 
but without S. pseudintermedius recurrent infections (ADH) that could potentially induce an 
IgG-mediated response against S. pseudintermedius infection. 
By proteomics, 361 unique proteins were identified, of which 39 were surface-located. These 
included proteins that have been extensively studied for vaccine development in S. aureus 
(DeDent, Kim, Missiakas & Schneewind, 2012): iron scavenging - Iron compound ABC 
transporter (IsdE) and Siderophore staphylobactin ABC transporter (SirA); and immune eva-
sion - IgG-binding protein SBI (SpsK) and Immunoglobulin G binding protein A spa1 (SpsQ). 
SpsK and SpsQ are two immunoglobulin-binding molecules, which prevent opsonisation 
(DeDent et al., 2012). In S. aureus these proteins’ homologues, Sbi and Spa respectively, 
severely limit host immunoglobulin mediated immune clearance of the pathogen (DeDent et 
al., 2012). Despite these proteins abundancy, they are not good candidates for a vaccine due 
to its toxicity and B cell super-antigen activity unless slight modifications are introduced in the 
proteins that could be of potential use without its deleterious effects (DeDent et al., 2012).  
In order to assess the immunogenic potential of the previously identified proteins, a Western 
blot analysis of the two-dimensional gels was carried out with serum from healthy dogs, dogs 
with atopic dermatitis infected and not infected with S. pseudintermedius. Thirteen unique 
proteins after in-gel digestion of the areas of interest were identified. However, only four 
seem promising candidate therapeutic targets (Table 19): the selection of these proteins was 
made on the basis of the predicted surface localization and/or crucial function in bacterial 
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One of these highly immunogenic proteins identified was SpsD, which has already been de-
scribed by another study as a candidate therapeutic target (Bannoehr et al., 2011). The gene 
encoding this protein was also highly transcribed by the MRSP strain as detected by RNA-
seq. This could mean SpsD is essential for the pathogenesis of MRSP infections. The pre-
dicted lipoprotein had an unknown location however it has a predicted cleavage site, mean-
ing that it may be secreted via the Sec pathway. Furthermore, lipoproteins are a major class 
of cell surface-exposed proteins in many bacterial pathogens and play critical roles in nutrient 
uptake, antimicrobial resistance, adhesion, protein secretion, and other functions (Sutcliffe & 
Russell, 1995). These molecules have been the targets of vaccine research for many patho-
genic bacteria, including S. aureus (Vytvytska et al., 2002). The other two proteins, AtpA and 
FabI, were associated with metabolism and seem to have crucial roles in bacterial growth 
(Balemans, Vranckx, Lounis, Pop, Guillemont, Vergauwen, Mol, Gilissen, Motte, Lançois, 
Bolle, Bonroy, Lill, Andries, Bald & Koul, 2012; Schiebel, Chang, Lu, Baxter, Tonge & Kisker, 


























The main findings of this thesis were:  
a) Horses and calves can carry MRSA in their nostrils, acting as reservoirs of these bacteria, 
which can potentially be transmitted to humans and companion animals. 
b) There was a clear dissemination of specific MRSA clones (CC5, C22 and CC398) be-
tween animals, the environment and humans in close contact. Furthermore, isolates of the 
clonal lineages associated with pets (CC5 and CC22) harboured specific sets of virulence 
genes and a lower number of resistance genes than isolates of the clonal lineage associated 
with livestock-animals (CC398). Active surveillance programs, not only detecting MRSA in 
livestock-animals, but also in companion animals, are urgently needed. 
c) Biocides appear to be a reliable antiseptic option against MRS from horses and MRSP 
from small animals. Even in the presence of bacterial efflux determinants, like qac genes, the 
in-use recommended concentrations of the biocides were much higher than the in vitro MBC. 
d) The increase over time of mecA-positive and multidrug-resistant staphylococcal strains is 
worrying. Several MRS clonal lineages circulating in human hospitals and in the community 
were found in this study, suggesting that companion animals can become accidently infected 
with highly successful human MRS clones or that these clones are not host specific. Thus, 
companion animals can act as reservoirs of important bacterial clones and genes of human 
origin, perpetuating the transmission cycle of MRS. 
e) An MRSP isolate highly expressed a number of virulence and regulatory genes when 
compared to MSSP that could explain its high and fast adaptation. Biofilm formation appears 
to have an important role in S. pseudintermedius pathogenesis, although there were differ-
ences in the mechanisms triggering biofilm production in MSSP and MRSP. 
f) Thirteen unique proteins were identified after in-gel digestion of highly IgG immunogenic 
areas, with four antigenic proteins showing promising features for vaccine development 


























1. Establish national surveillance programs, not only detecting MRSA in livestock-animals, 
but also in companion animals. 
The trends of antimicrobial resistance in animals is worrying, especially in small animals. Ac-
tive surveillance programs, not only detecting MRSA in livestock-animals, but also in com-
panion animals, are urgently needed. 
2. Study the dynamics of methicillin-resistant coagulase-negative staphylococci in the human, 
animal and environmental communities as reservoirs of virulence and antimicrobial re-
sistance mechanisms. 
Other staphylococci, especially MRCoNS are neglected as important pathogens and reser-
voirs of antimicrobial resistance genes in human and veterinary medicine. Studies on 
MRCoNS in people, animals and environment will give an oversight on the prevalence of 
these bacteria. Molecular epidemiology will provide insights into the dynamics of MRCoNS in 
the human, animal and environmental communities and will also give information on pheno-
typic characteristics, such as virulence and antimicrobial resistance mechanisms. Compari-
son of SCCmec elements of MRCoNS and MRSA could give comprehension on how often 
does SCCmec transfer occurs. These studies could help understand the epidemiology of 
MRCoNS and therefore lead to the implementation of control strategies to prevent the dis-
semination of these bacteria in the animal and human population. 
3. Assess virulence determinants as prognostic factors of S. pseudintermedius infection in 
the dog. 
Despite the multitude of studies on virulence factors, there are only a few studies correlating 
these with clinical characteristics in vivo. In human infections caused by S. aureus there are 
studies conducted that identified certain virulence factors as more often associated with cer-
tain clinical characteristics such as persistence or morbidity (Jarraud et al., 2002). In animals, 
and in particular in S. pseudintermedius in dogs, this has not been studied thoroughly. Fur-
ther studies using the novel “omic” approaches could help identify these crucial virulence fac-
tors for a better treatment regimen against S. pseudintermedius infections as well as for bet-
ter prognosis.  
4. Determine the efficacy of the S. pseudintermedius tetravalent vaccine in experimental and 
natural infection in the dog. 
With the four proteins that were identified we could include them in a tetravalent vaccine to 
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